nct_id,nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at,sponsor_name,agency_class,drug_name,intervention_type
NCT04251182,"ClinicalTrials.gov processed this data on January 31, 2020",2020-01-24,,,2020-01-29,2020-01-29,2020-01-31,Estimate,,,,,,,2020-01-29,2020-01-31,Estimate,"February 5, 2020",Anticipated,2020-02-05,January 2020,2020-01-31,"August 13, 2021",Anticipated,2021-08-13,"August 13, 2021",Anticipated,2021-08-13,,Interventional,,,Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects,"A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease",Not yet recruiting,,Phase 2,256,Anticipated,"T3D Therapeutics, Inc.",,4,,,,,,,True,True,False,,,,,,,,,No,A Clinical Study Report (CSR) will be generated within 9 months after database lock. Aggregate study data will be made available in this report.,2020-02-04 05:09:35.057386,2020-02-04 05:09:35.057386,"T3D Therapeutics, Inc.",Industry,15mg T3D-959,Drug
NCT03289143,"ClinicalTrials.gov processed this data on January 31, 2020",2017-09-18,,,2020-01-06,2017-09-18,2017-09-20,Actual,,,,,,,2020-01-06,2020-01-09,Actual,"October 4, 2017",Actual,2017-10-04,January 2020,2020-01-31,"September 20, 2022",Anticipated,2022-09-20,"June 24, 2020",Anticipated,2020-06-24,,Interventional,,,A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease,"A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Prodromal to Mild Alzheimer's Disease","Active, not recruiting",,Phase 2,457,Actual,"Genentech, Inc.",,4,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:45:33.720811,2020-02-01 08:45:33.720811,"Genentech, Inc.",Industry,[18F]GTP1,Drug
NCT03828747,"ClinicalTrials.gov processed this data on February 06, 2020",2019-01-29,,,2020-02-04,2019-01-31,2019-02-04,Actual,,,,,,,2020-02-04,2020-02-06,Estimate,"January 30, 2019",Actual,2019-01-30,February 2020,2020-02-29,"June 2, 2023",Anticipated,2023-06-02,"May 7, 2021",Anticipated,2021-05-07,,Interventional,,,A Study of Semorinemab in Patients With Moderate Alzheimer's Disease,"A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Moderate Alzheimer's Disease",Recruiting,,Phase 2,260,Anticipated,"Genentech, Inc.",,2,,,False,,,,True,True,False,,,,,,,,,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)",2020-02-07 05:56:24.743317,2020-02-07 05:56:24.743317,"Genentech, Inc.",Industry,[18F]GTP1,Drug
NCT02168920,"ClinicalTrials.gov processed this data on January 31, 2020",2014-06-18,,,2017-10-13,2014-06-18,2014-06-20,Estimate,,,,,,,2017-10-13,2017-10-16,Actual,"June 11, 2014",Actual,2014-06-11,October 2017,2017-10-31,"March 18, 2016",Actual,2016-03-18,"March 18, 2016",Actual,2016-03-18,,Interventional,,,Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole in the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type",Terminated,,Phase 3,150,Actual,"Otsuka Pharmaceutical Co., Ltd.",,4,,It was difficult to secure enrollment of the targeted number of subjects.,False,,,,True,,,,,,,,,,,,,2020-02-01 12:37:21.845361,2020-02-01 12:37:21.845361,"Otsuka Pharmaceutical Co., Ltd.",Industry,2 mg/day,Drug
NCT04251182,"ClinicalTrials.gov processed this data on January 31, 2020",2020-01-24,,,2020-01-29,2020-01-29,2020-01-31,Estimate,,,,,,,2020-01-29,2020-01-31,Estimate,"February 5, 2020",Anticipated,2020-02-05,January 2020,2020-01-31,"August 13, 2021",Anticipated,2021-08-13,"August 13, 2021",Anticipated,2021-08-13,,Interventional,,,Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects,"A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease",Not yet recruiting,,Phase 2,256,Anticipated,"T3D Therapeutics, Inc.",,4,,,,,,,True,True,False,,,,,,,,,No,A Clinical Study Report (CSR) will be generated within 9 months after database lock. Aggregate study data will be made available in this report.,2020-02-04 05:09:35.057386,2020-02-04 05:09:35.057386,"T3D Therapeutics, Inc.",Industry,30 mg T3D-959,Drug
NCT02168920,"ClinicalTrials.gov processed this data on January 31, 2020",2014-06-18,,,2017-10-13,2014-06-18,2014-06-20,Estimate,,,,,,,2017-10-13,2017-10-16,Actual,"June 11, 2014",Actual,2014-06-11,October 2017,2017-10-31,"March 18, 2016",Actual,2016-03-18,"March 18, 2016",Actual,2016-03-18,,Interventional,,,Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole in the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type",Terminated,,Phase 3,150,Actual,"Otsuka Pharmaceutical Co., Ltd.",,4,,It was difficult to secure enrollment of the targeted number of subjects.,False,,,,True,,,,,,,,,,,,,2020-02-01 12:37:21.845361,2020-02-01 12:37:21.845361,"Otsuka Pharmaceutical Co., Ltd.",Industry,3 mg/day,Drug
NCT04251182,"ClinicalTrials.gov processed this data on January 31, 2020",2020-01-24,,,2020-01-29,2020-01-29,2020-01-31,Estimate,,,,,,,2020-01-29,2020-01-31,Estimate,"February 5, 2020",Anticipated,2020-02-05,January 2020,2020-01-31,"August 13, 2021",Anticipated,2021-08-13,"August 13, 2021",Anticipated,2021-08-13,,Interventional,,,Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects,"A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease",Not yet recruiting,,Phase 2,256,Anticipated,"T3D Therapeutics, Inc.",,4,,,,,,,True,True,False,,,,,,,,,No,A Clinical Study Report (CSR) will be generated within 9 months after database lock. Aggregate study data will be made available in this report.,2020-02-04 05:09:35.057386,2020-02-04 05:09:35.057386,"T3D Therapeutics, Inc.",Industry,45 mg T3D-959,Drug
NCT02168920,"ClinicalTrials.gov processed this data on January 31, 2020",2014-06-18,,,2017-10-13,2014-06-18,2014-06-20,Estimate,,,,,,,2017-10-13,2017-10-16,Actual,"June 11, 2014",Actual,2014-06-11,October 2017,2017-10-31,"March 18, 2016",Actual,2016-03-18,"March 18, 2016",Actual,2016-03-18,,Interventional,,,Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole in the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type",Terminated,,Phase 3,150,Actual,"Otsuka Pharmaceutical Co., Ltd.",,4,,It was difficult to secure enrollment of the targeted number of subjects.,False,,,,True,,,,,,,,,,,,,2020-02-01 12:37:21.845361,2020-02-01 12:37:21.845361,"Otsuka Pharmaceutical Co., Ltd.",Industry,6 mg/day,Drug
NCT01193608,"ClinicalTrials.gov processed this data on January 31, 2020",2010-08-19,2016-06-15,,2017-01-03,2010-08-30,2010-09-02,Estimate,2017-01-03,2017-02-23,Actual,,,,2017-01-03,2017-02-23,Actual,September 2010,,2010-09-30,January 2017,2017-01-31,October 2013,Actual,2013-10-31,October 2013,Actual,2013-10-31,,Interventional,,All participants who were randomized.,Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease,"A Phase 1, Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptive, Multiple Ascending Dose Study Of The Safety, Tolerability And Pharmacokinetics Of Aab-003 (Pf-05236812) In Subjects With Mild To Moderate Alzheimer's Disease",Completed,,Phase 1,88,Actual,Pfizer,,6,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:54:41.851869,2020-02-01 16:54:41.851869,Pfizer,Industry,AAB-003 (PF-05236812),Drug
NCT02880956,"ClinicalTrials.gov processed this data on January 31, 2020",2016-08-24,,,2020-01-14,2016-08-24,2016-08-26,Estimate,,,,,,,2020-01-14,2020-01-18,Actual,"October 17, 2016",Actual,2016-10-17,January 2020,2020-01-31,"July 28, 2021",Anticipated,2021-07-28,"April 30, 2021",Anticipated,2021-04-30,,Interventional,,,A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease,"A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease","Active, not recruiting",,Phase 2,453,Actual,AbbVie,,4,,,True,,,,True,True,False,,,False,,,"Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.","Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.",https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html,Yes,"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.",2020-02-01 10:02:59.856443,2020-02-01 10:02:59.856443,AbbVie,Industry,ABBV-8E12,Drug
NCT03712787,"ClinicalTrials.gov processed this data on January 31, 2020",2018-10-18,,,2020-01-30,2018-10-18,2018-10-19,Actual,,,,,,,2020-01-30,2020-01-31,Estimate,"March 22, 2019",Actual,2019-03-22,January 2020,2020-01-31,"August 11, 2026",Anticipated,2026-08-11,"August 11, 2026",Anticipated,2026-08-11,,Interventional,,,An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD),An Extension Study of ABBV-8E12 in Early Alzheimer's Disease,Enrolling by invitation,,Phase 2,360,Anticipated,AbbVie,,2,,,True,,,,True,True,False,,,False,,,"Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.","Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.",https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html,Yes,"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.",2020-02-04 05:13:51.142442,2020-02-04 05:13:51.142442,AbbVie,Industry,ABBV-8E12,Drug
NCT00555204,"ClinicalTrials.gov processed this data on January 31, 2020",2007-11-07,,2011-08-19,2011-08-19,2007-11-07,2007-11-08,Estimate,,,,2011-08-19,2011-08-23,Estimate,2011-08-19,2011-08-23,Estimate,November 2007,,2007-11-30,August 2011,2011-08-31,,,,June 2009,Actual,2009-06-30,,Interventional,,,Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled Study Using a Bayesian Adaptive Design to Evaluate the Efficacy and Safety of ABT-089 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors",Terminated,,Phase 2,337,Actual,Abbott,,7,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:06:30.241600,2020-02-01 20:06:30.241600,Abbott,Industry,ABT-089,Drug
NCT01018875,"ClinicalTrials.gov processed this data on January 31, 2020",2009-11-20,,2012-02-01,2018-06-01,2009-11-23,2009-11-24,Estimate,,,,2012-02-01,2012-02-03,Estimate,2018-06-01,2018-06-06,Actual,December 2009,,2009-12-31,January 2013,2013-01-31,February 2011,Actual,2011-02-28,February 2011,Actual,2011-02-28,,Interventional,,,Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Active- and Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease",Completed,,Phase 2,242,Actual,AbbVie,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:45:00.201179,2020-02-01 17:45:00.201179,"AbbVie (prior sponsor, Abbott)",Industry,ABT-288,Drug
NCT02220738,"ClinicalTrials.gov processed this data on January 31, 2020",2014-08-18,,,2016-06-14,2014-08-18,2014-08-20,Estimate,,,,,,,2016-06-14,2016-06-16,Estimate,September 2014,,2014-09-30,June 2016,2016-06-30,March 2016,Actual,2016-03-31,March 2016,Actual,2016-03-31,,Interventional,,,"Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors","A Multiple-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors",Terminated,,Phase 1,19,Actual,AbbVie,,2,,Slow subject enrollment,False,,,,False,,,,,,,,,,,,,2020-02-01 12:24:40.493365,2020-02-01 12:24:40.493365,AbbVie,Industry,ABT-957,Drug
NCT03113812,"ClinicalTrials.gov processed this data on January 31, 2020",2017-04-04,,,2017-04-10,2017-04-10,2017-04-14,Actual,,,,,,,2017-04-10,2017-04-14,Actual,"January 1, 2014",Actual,2014-01-01,April 2017,2017-04-30,"July 30, 2015",Actual,2015-07-30,"July 30, 2015",Actual,2015-07-30,,Interventional,,,Repeated Subcutaneous Administration of ABvac40 in Mild to Moderate Alzheimer's Disease Patients,"A Randomized, Placebo-controlled, Parallel Group, Double-blinded, Single-center Phase-I, Pilot Study to Assess Tolerability and Safety of Repeated Subcutaneous Administration of ABvac40 in Patients With Mild to Moderate Alzheimer's Disease.",Completed,,Phase 1,24,Actual,Araclon Biotech S.L.,,2,,,False,,,,True,False,False,,,,,,,,,No,,2020-02-01 09:16:52.146443,2020-02-01 09:16:52.146443,Araclon Biotech S.L.,Industry,ABvac40,Drug
NCT00955409,"ClinicalTrials.gov processed this data on January 31, 2020",2009-08-04,,,2014-01-29,2009-08-07,2009-08-10,Estimate,,,,,,,2014-01-29,2014-01-31,Estimate,November 2009,,2009-11-30,January 2014,2014-01-31,December 2013,Actual,2013-12-31,December 2013,Actual,2013-12-31,,Interventional,,,"Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease","A Phase IIa, Multicenter, Randomized, Third-Party Unblinded, Long-Term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of ACC-001 With QS-21 Adjuvant In Subjects With Mild To Moderate Alzheimer's Disease",Completed,,Phase 2,50,Actual,Pfizer,,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:08:14.718450,2020-02-01 18:08:14.718450,Pfizer,Industry,ACC-001,Drug
NCT00955409,"ClinicalTrials.gov processed this data on January 31, 2020",2009-08-04,,,2014-01-29,2009-08-07,2009-08-10,Estimate,,,,,,,2014-01-29,2014-01-31,Estimate,November 2009,,2009-11-30,January 2014,2014-01-31,December 2013,Actual,2013-12-31,December 2013,Actual,2013-12-31,,Interventional,,,"Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease","A Phase IIa, Multicenter, Randomized, Third-Party Unblinded, Long-Term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of ACC-001 With QS-21 Adjuvant In Subjects With Mild To Moderate Alzheimer's Disease",Completed,,Phase 2,50,Actual,Pfizer,,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:08:14.718450,2020-02-01 18:08:14.718450,Pfizer,Industry,ACC-001 + QS21,Drug
NCT00955409,"ClinicalTrials.gov processed this data on January 31, 2020",2009-08-04,,,2014-01-29,2009-08-07,2009-08-10,Estimate,,,,,,,2014-01-29,2014-01-31,Estimate,November 2009,,2009-11-30,January 2014,2014-01-31,December 2013,Actual,2013-12-31,December 2013,Actual,2013-12-31,,Interventional,,,"Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease","A Phase IIa, Multicenter, Randomized, Third-Party Unblinded, Long-Term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of ACC-001 With QS-21 Adjuvant In Subjects With Mild To Moderate Alzheimer's Disease",Completed,,Phase 2,50,Actual,Pfizer,,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:08:14.718450,2020-02-01 18:08:14.718450,Pfizer,Industry,ACC-001+ QS21,Drug
NCT01608217,"ClinicalTrials.gov processed this data on January 31, 2020",2012-05-25,,,2014-06-26,2012-05-25,2012-05-31,Estimate,,,,,,,2014-06-26,2014-06-30,Estimate,June 2012,,2012-06-30,June 2014,2014-06-30,June 2014,Actual,2014-06-30,June 2014,Actual,2014-06-30,,Interventional,,,Delta-THC in Dementia,Efficacy and Safety of Delta-9-tetrahydrocannabinol (∆9-THC) in Behavioural Disturbances and Pain in Dementia,Completed,,Phase 2,50,Actual,Radboud University,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:02:26.242272,2020-02-01 15:02:26.242272,Radboud University,Other,Acetaminophen,Drug
NCT01614886,"ClinicalTrials.gov processed this data on January 31, 2020",2012-06-06,2015-04-16,,2016-06-30,2012-06-07,2012-06-08,Estimate,2015-04-16,2015-05-12,Estimate,,,,2016-06-30,2016-08-01,Estimate,July 2012,,2012-07-31,June 2015,2015-06-30,May 2014,Actual,2014-05-31,May 2014,Actual,2014-05-31,,Interventional,,"Randomized set (RAN) The RAN consisted of all randomized patients. Patients were analyzed according to the treatment group they were assigned to at randomization. A patient was diagnosed of dementia with Lewy Bodies, different from AD, after randomization and was excluded from all analysis (SAF and FAS).","Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)","A 24-week, Multicenter, Parallel-group, Randomized,Double-blind Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Methods of Rivastigmine Patch (ENA713D/ONO-2540) in Patients With Mild to Moderate Alzheimer's Disease (MMSE 10-20)",Completed,,Phase 3,216,Actual,Novartis,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:00:51.368993,2020-02-01 15:00:51.368993,Novartis Pharmaceuticals,Industry,Active Comparator,Drug
NCT01230853,"ClinicalTrials.gov processed this data on January 31, 2020",2010-10-27,,,2013-05-20,2010-10-28,2010-10-29,Estimate,,,,,,,2013-05-20,2013-05-22,Estimate,August 2010,,2010-08-31,February 2013,2013-02-28,February 2013,Actual,2013-02-28,October 2012,Actual,2012-10-31,,Interventional,,,"A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study","A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacodynamic Response, and Pharmacokinetics of Intravenous Infusions of BAN2401 in Subjects With Mild to Moderate Alzheimer?s Disease",Completed,,Phase 1,80,Actual,Eisai Inc.,,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 16:43:04.642093,2020-02-01 16:43:04.642093,Eisai Inc.,Industry,Active Comparator: A,Drug
NCT01230853,"ClinicalTrials.gov processed this data on January 31, 2020",2010-10-27,,,2013-05-20,2010-10-28,2010-10-29,Estimate,,,,,,,2013-05-20,2013-05-22,Estimate,August 2010,,2010-08-31,February 2013,2013-02-28,February 2013,Actual,2013-02-28,October 2012,Actual,2012-10-31,,Interventional,,,"A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study","A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacodynamic Response, and Pharmacokinetics of Intravenous Infusions of BAN2401 in Subjects With Mild to Moderate Alzheimer?s Disease",Completed,,Phase 1,80,Actual,Eisai Inc.,,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 16:43:04.642093,2020-02-01 16:43:04.642093,Eisai Inc.,Industry,Active Comparator B,Drug
NCT03493282,"ClinicalTrials.gov processed this data on February 06, 2020",2018-02-14,,,2020-01-30,2018-04-03,2018-04-10,Actual,,,,,,,2020-01-30,2020-02-05,Actual,"April 20, 2018",Actual,2018-04-20,January 2020,2020-01-31,"March 1, 2021",Anticipated,2021-03-01,"January 31, 2021",Anticipated,2021-01-31,,Interventional,,,Effect of CT1812 Treatment on Brain Synaptic Density,A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants With Mild to Moderate Alzheimer's Disease,"Active, not recruiting",,Phase 1/Phase 2,23,Actual,Cognition Therapeutics,,3,,,,,,,True,True,False,,,,,,,,,Undecided,,2020-02-07 06:03:03.394019,2020-02-07 06:03:03.394019,Cognition Therapeutics,Industry,Active Treatment- CT1812 100 mg,Drug
NCT03493282,"ClinicalTrials.gov processed this data on February 06, 2020",2018-02-14,,,2020-01-30,2018-04-03,2018-04-10,Actual,,,,,,,2020-01-30,2020-02-05,Actual,"April 20, 2018",Actual,2018-04-20,January 2020,2020-01-31,"March 1, 2021",Anticipated,2021-03-01,"January 31, 2021",Anticipated,2021-01-31,,Interventional,,,Effect of CT1812 Treatment on Brain Synaptic Density,A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants With Mild to Moderate Alzheimer's Disease,"Active, not recruiting",,Phase 1/Phase 2,23,Actual,Cognition Therapeutics,,3,,,,,,,True,True,False,,,,,,,,,Undecided,,2020-02-07 06:03:03.394019,2020-02-07 06:03:03.394019,Cognition Therapeutics,Industry,Active Treatment- CT1812 300 mg,Drug
NCT03639987,"ClinicalTrials.gov processed this data on January 31, 2020",2018-08-17,,,2019-11-07,2018-08-17,2018-08-21,Actual,,,,,,,2019-11-07,2019-11-12,Actual,"December 20, 2018",Actual,2018-12-20,November 2019,2019-11-30,"July 30, 2019",Actual,2019-07-30,"July 30, 2019",Actual,2019-07-30,,Interventional,EVOLVE,,A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities,"A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Blind, Controlled Study of Aducanumab (BIIB037) in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Subjects With Asymptomatic Amyloid-Related Imaging Abnormalities",Terminated,,Phase 2,500,Actual,Biogen,,2,,"Study was discontinued based on futility analysis conducted on Phase 3 trials (NCT02477800 and
    NCT02484547) and not based on safety concerns.",False,,,,True,True,False,,,,,,,,,,,2020-02-01 07:47:53.971667,2020-02-01 07:47:53.971667,Biogen,Industry,Aducanumab,Drug
NCT02477800,"ClinicalTrials.gov processed this data on January 31, 2020",2015-06-18,,,2019-11-07,2015-06-18,2015-06-23,Estimate,,,,,,,2019-11-07,2019-11-12,Actual,"August 31, 2015",Actual,2015-08-31,November 2019,2019-11-30,"August 8, 2019",Actual,2019-08-08,"August 8, 2019",Actual,2019-08-08,,Interventional,ENGAGE,,221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease",Terminated,,Phase 3,1647,Actual,Biogen,,2,,"Study was discontinued based on futility analysis done and not based on safety concerns.
    Follow-up visits and closing out study activities are completed",False,,,,True,,,,,,,,,,,,,2020-02-01 11:26:54.149156,2020-02-01 11:26:54.149156,Biogen,Industry,Aducanumab (BIIB037),Drug
NCT02484547,"ClinicalTrials.gov processed this data on January 31, 2020",2015-06-18,,,2019-11-07,2015-06-26,2015-06-29,Estimate,,,,,,,2019-11-07,2019-11-12,Actual,"September 30, 2015",Actual,2015-09-30,November 2019,2019-11-30,"August 5, 2019",Actual,2019-08-05,"August 5, 2019",Actual,2019-08-05,,Interventional,EMERGE,,221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease",Terminated,,Phase 3,1638,Actual,Biogen,,2,,"Study was discontinued based on futility analysis done and not based on safety concerns.
    Follow-up visits and closing out study activities are completed",False,,,,True,,,,,,,,,,,,,2020-02-01 11:25:35.474212,2020-02-01 11:25:35.474212,Biogen,Industry,Aducanumab (BIIB037),Drug
NCT03486938,"ClinicalTrials.gov processed this data on February 06, 2020",2018-03-28,,,2020-01-31,2018-04-02,2018-04-03,Actual,,,,,,,2020-01-31,2020-02-05,Actual,"January 15, 2019",Actual,2019-01-15,January 2020,2020-01-31,November 2022,Anticipated,2022-11-30,November 2021,Anticipated,2021-11-30,,Interventional,HOPE4MCI,,Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease",Recruiting,,Phase 3,830,Anticipated,AgeneBio,,2,,,False,,,,True,True,False,,,,,,,,,No,,2020-02-07 06:03:07.574413,2020-02-07 06:03:07.574413,AgeneBio,Industry,AGB101 220 mg tablet,Drug
NCT02221622,"ClinicalTrials.gov processed this data on January 31, 2020",2014-07-02,,,2019-07-02,2014-08-18,2014-08-20,Estimate,,,,,,,2019-07-02,2019-07-05,Actual,August 2014,,2014-08-31,May 2018,2018-05-31,February 2018,Actual,2018-02-28,February 2018,Actual,2018-02-28,,Interventional,Allo,,Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD,Allopregnanolone Regenerative Therapeutic for MCI/AD: Dose Finding Phase 1,Completed,,Phase 1,24,Actual,University of Southern California,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:24:27.622064,2020-02-01 12:24:27.622064,University of Southern California,Other,Allopregnanolone injection (intravenous solution),Drug
NCT04157712,"ClinicalTrials.gov processed this data on January 31, 2020",2019-11-04,,,2019-11-15,2019-11-06,2019-11-08,Actual,,,,,,,2019-11-15,2019-11-19,Actual,"September 26, 2015",Actual,2015-09-26,November 2019,2019-11-30,"July 4, 2016",Actual,2016-07-04,"July 4, 2016",Actual,2016-07-04,,Interventional,,,Multiple Ascending Dose Study of ALZ-801,"A Phase I, Single Centre, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics in Plasma and Urine of Multiple Ascending Doses of ALZ-801 in Healthy Elderly Subjects",Completed,,Phase 1,48,Actual,Alzheon Inc.,,4,,,False,,,,False,True,False,,,False,,,,,,No,,2020-02-01 06:32:20.379077,2020-02-01 06:32:20.379077,Alzheon Inc.,Industry,ALZ-801 or matching placebo,Drug
NCT02547818,"ClinicalTrials.gov processed this data on January 31, 2020",2015-09-10,,,2019-12-04,2015-09-10,2015-09-11,Estimate,,,,,,,2019-12-04,2019-12-05,Actual,September 2015,Actual,2015-09-30,July 2019,2019-07-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,,Interventional,COGNITE,,Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease,A Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease,"Active, not recruiting",,Phase 3,620,Actual,"AZTherapies, Inc.",,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:10:48.336799,2020-02-01 11:10:48.336799,"AZTherapies, Inc.",Industry,ALZT-OP1a,Drug
NCT02547818,"ClinicalTrials.gov processed this data on January 31, 2020",2015-09-10,,,2019-12-04,2015-09-10,2015-09-11,Estimate,,,,,,,2019-12-04,2019-12-05,Actual,September 2015,Actual,2015-09-30,July 2019,2019-07-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,,Interventional,COGNITE,,Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease,A Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease,"Active, not recruiting",,Phase 3,620,Actual,"AZTherapies, Inc.",,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:10:48.336799,2020-02-01 11:10:48.336799,"AZTherapies, Inc.",Industry,ALZT-OP1b,Drug
NCT03533257,"ClinicalTrials.gov processed this data on January 31, 2020",2018-04-30,,,2020-01-15,2018-05-10,2018-05-23,Actual,,,,,,,2020-01-15,2020-01-18,Actual,"August 27, 2018",Actual,2018-08-27,January 2020,2020-01-31,"September 1, 2020",Anticipated,2020-09-01,"July 1, 2020",Anticipated,2020-07-01,,Interventional,PEGASUS,,Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease,"Phase II Study to Assess the Safety, Tolerability, and Target Engagement of AMX0035, a Fixed Combination of Sodium Phenylbutyrate and Tauroursodeoxycholic Acid for the Treatment of Alzheimer's Disease",Recruiting,,Phase 2,100,Anticipated,Amylyx Pharmaceuticals Inc.,,2,,,,,,,False,True,False,,,,,,,,,Undecided,,2020-02-01 08:04:53.807069,2020-02-01 08:04:53.807069,Amylyx Pharmaceuticals Inc.,Industry,AMX0035,Drug
NCT03806478,"ClinicalTrials.gov processed this data on January 31, 2020",2019-01-04,,,2019-01-15,2019-01-15,2019-01-16,Actual,,,,,,,2019-01-15,2019-01-16,Actual,June 2021,Anticipated,2021-06-30,January 2019,2019-01-31,December 2022,Anticipated,2022-12-31,September 2022,Anticipated,2022-09-30,,Interventional,,,Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease,"Safety, Tolerability and Efficacy Assessment of Intranasal Nanoparticles of APH-1105, A Novel Alpha Secretase Modulator For Mild to Moderate Cognitive Impairment Due to Alzheimer's Disease(AD)",Not yet recruiting,,Phase 2,60,Anticipated,Aphios,,4,,,False,,,,True,False,False,,,True,,,,,,No,,2020-02-01 07:23:10.105396,2020-02-01 07:23:10.105396,Aphios,Industry,APH-1105,Drug
NCT03625622,"ClinicalTrials.gov processed this data on January 31, 2020",2018-08-08,,,2019-03-28,2018-08-08,2018-08-10,Actual,,,,,,,2019-03-28,2019-04-01,Actual,"January 15, 2019",Actual,2019-01-15,March 2019,2019-03-31,"August 1, 2020",Anticipated,2020-08-01,"June 1, 2020",Anticipated,2020-06-01,,Interventional,,,Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease,"A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease",Recruiting,,Phase 2,210,Anticipated,"AriBio Co., Ltd.",,3,,,,,,,False,True,False,,,,,,,,,,,2020-02-01 07:50:16.488873,2020-02-01 07:50:16.488873,"AriBio Co., Ltd.",Industry,AR1001,Drug
NCT01438060,"ClinicalTrials.gov processed this data on January 31, 2020",2011-09-02,2012-02-01,,2013-11-07,2011-09-20,2011-09-21,Estimate,2012-02-01,2012-03-05,Estimate,,,,2013-11-07,2013-12-02,Estimate,August 2000,,2000-08-31,November 2013,2013-11-30,July 2010,Actual,2010-07-31,July 2010,Actual,2010-07-31,,Interventional,,,Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type,"A Multicenter, Randomized, Double-Blind, Placebo Controlled Flexible Dose Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type",Completed,,Phase 3,232,Actual,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Limitations of the study, such as early termination leading to small numbers of subjects analyzed and technical problems with measurement leading to unreliable or uninterpretable data",2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:46:23.659143,2020-02-01 15:46:23.659143,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Industry,Aripiprazole (BMS-337039),Drug
NCT01406145,"ClinicalTrials.gov processed this data on January 31, 2020",2011-07-06,,,2019-01-28,2011-07-28,2011-08-01,Estimate,,,,,,,2019-01-28,2019-01-30,Actual,"June 16, 2011",Actual,2011-06-16,January 2019,2019-01-31,"November 4, 2011",Actual,2011-11-04,"November 4, 2011",Actual,2011-11-04,,Interventional,,,A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil,"A Phase 1b, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Sequential Dose Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease on Donepezil",Completed,,Phase 1,60,Actual,Astellas Pharma Inc,,4,,,False,,,,False,,,,,,,,Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.,"Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.",https://www.clinicalstudydatarequest.com/,Yes,"Access to anonymized individual participant level data collected during the trial, in addition to study-related supporting documentation, is planned for trials conducted with approved product indications and formulations, as well as compounds terminated during development. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.",2020-02-01 15:54:20.292494,2020-02-01 15:54:20.292494,Astellas Pharma Inc,Industry,ASP0777,Drug
NCT03117738,"ClinicalTrials.gov processed this data on January 31, 2020",2017-04-10,,,2019-12-30,2017-04-12,2017-04-18,Actual,,,,,,,2019-12-30,2020-01-02,Actual,"April 3, 2017",Actual,2017-04-03,December 2019,2019-12-31,"June 26, 2019",Actual,2019-06-26,"January 30, 2019",Actual,2019-01-30,,Interventional,,,A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease,"A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AstroStem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells, in Patients With Alzheimer's Disease",Completed,,Phase 1/Phase 2,21,Actual,Nature Cell Co. Ltd.,,2,,,False,,,,False,True,False,,,,,,,,,Undecided,,2020-02-01 09:16:10.503546,2020-02-01 09:16:10.503546,Nature Cell Co. Ltd.,Industry,AstroStem,Drug
NCT00890890,"ClinicalTrials.gov processed this data on January 31, 2020",2009-04-29,,2015-09-23,2015-09-23,2009-04-29,2009-04-30,Estimate,,,,2015-09-23,2015-10-12,Estimate,2015-09-23,2015-10-12,Estimate,May 2009,,2009-05-31,September 2015,2015-09-30,July 2013,Actual,2013-07-31,July 2013,Actual,2013-07-31,,Interventional,,,"A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease","Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients With Prodromal Alzheimer's Disease",Terminated,,Phase 2,263,Actual,Bristol-Myers Squibb,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:27:25.082950,2020-02-01 18:27:25.082950,Bristol-Myers Squibb,Industry,Avagacestat,Drug
NCT02442765,"ClinicalTrials.gov processed this data on January 31, 2020",2015-05-11,,,2019-03-04,2015-05-11,2015-05-13,Estimate,,,,,,,2019-03-04,2019-03-06,Actual,September 2015,,2015-09-30,March 2019,2019-03-31,"February 27, 2019",Actual,2019-02-27,"January 30, 2019",Actual,2019-01-30,,Interventional,,,"Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",Completed,,Phase 3,410,Actual,Avanir Pharmaceuticals,,3,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 11:35:00.526050,2020-02-01 11:35:00.526050,Avanir Pharmaceuticals,Industry,AVP-786,Drug
NCT02442778,"ClinicalTrials.gov processed this data on January 31, 2020",2015-05-11,,,2019-10-13,2015-05-11,2015-05-13,Estimate,,,,,,,2019-10-13,2019-10-15,Actual,September 2015,,2015-09-30,October 2019,2019-10-31,"September 9, 2019",Actual,2019-09-09,"August 14, 2019",Actual,2019-08-14,,Interventional,,,"Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type.",Completed,,Phase 3,522,Actual,Avanir Pharmaceuticals,,3,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 11:34:59.205605,2020-02-01 11:34:59.205605,Avanir Pharmaceuticals,Industry,AVP-786,Drug
NCT02446132,"ClinicalTrials.gov processed this data on January 31, 2020",2015-05-11,,,2020-01-24,2015-05-14,2015-05-18,Estimate,,,,,,,2020-01-24,2020-01-27,Actual,December 2015,,2015-12-31,January 2020,2020-01-31,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,,Interventional,,,"Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type","A Phase 3, Multicenter, Long Term, Extension Study of the Safety and Efficacy of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",Recruiting,,Phase 3,1000,Anticipated,Avanir Pharmaceuticals,,3,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 11:34:14.339484,2020-02-01 11:34:14.339484,Avanir Pharmaceuticals,Industry,AVP-786,Drug
NCT03393520,"ClinicalTrials.gov processed this data on January 31, 2020",2018-01-03,,,2020-01-24,2018-01-03,2018-01-08,Actual,,,,,,,2020-01-24,2020-01-27,Actual,"October 13, 2017",Actual,2017-10-13,January 2020,2020-01-31,June 2021,Anticipated,2021-06-30,June 2021,Anticipated,2021-06-30,,Interventional,,,"Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",Recruiting,,Phase 3,412,Anticipated,Avanir Pharmaceuticals,,3,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:27:50.083519,2020-02-01 08:27:50.083519,Avanir Pharmaceuticals,Industry,AVP-786,Drug
NCT01584440,"ClinicalTrials.gov processed this data on January 31, 2020",2012-04-23,,2018-01-08,2018-01-08,2012-04-24,2012-04-25,Estimate,,,,2018-01-08,2018-01-11,Actual,2018-01-08,2018-01-11,Actual,June 2012,,2012-06-30,January 2018,2018-01-31,September 2014,Actual,2014-09-30,July 2014,Actual,2014-07-31,,Interventional,,,"Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients","A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.",Completed,,Phase 2,220,Actual,Avanir Pharmaceuticals,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:08:45.066700,2020-02-01 15:08:45.066700,Avanir Pharmaceuticals,Industry,AVP-923 (dextromethorphan/quinidine),Drug
NCT02167256,"ClinicalTrials.gov processed this data on January 31, 2020",2014-06-12,2019-06-19,,2019-07-25,2014-06-16,2014-06-19,Estimate,2019-07-25,2019-08-14,Actual,,,,2019-07-25,2019-08-14,Actual,December 2014,Actual,2014-12-31,July 2019,2019-07-31,"February 27, 2018",Actual,2018-02-27,"February 27, 2018",Actual,2018-02-27,,Interventional,,,"A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease","A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease",Completed,,Phase 2,159,Actual,Yale University,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:37:40.784913,2020-02-01 12:37:40.784913,Yale University,Other,AZD0530 100mg daily,Drug
NCT02167256,"ClinicalTrials.gov processed this data on January 31, 2020",2014-06-12,2019-06-19,,2019-07-25,2014-06-16,2014-06-19,Estimate,2019-07-25,2019-08-14,Actual,,,,2019-07-25,2019-08-14,Actual,December 2014,Actual,2014-12-31,July 2019,2019-07-31,"February 27, 2018",Actual,2018-02-27,"February 27, 2018",Actual,2018-02-27,,Interventional,,,"A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease","A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease",Completed,,Phase 2,159,Actual,Yale University,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:37:40.784913,2020-02-01 12:37:40.784913,Yale University,Other,AZD0530 125mg daily,Drug
NCT00501111,"ClinicalTrials.gov processed this data on January 31, 2020",2007-07-12,,,2014-07-22,2007-07-12,2007-07-13,Estimate,,,,,,,2014-07-22,2014-07-23,Estimate,July 2007,,2007-07-31,July 2014,2014-07-31,August 2008,Actual,2008-08-31,August 2008,Actual,2008-08-31,,Interventional,Sirocco,,Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease,"A Multi-centre, Double-blind, Double-dummy, Placebo Controlled Parallel Group Randomized Phase IIb Proof of Concept Study With 3 Oral Dose Groups of AZD3480 or Donepezil During 12 Weeks Treatment in Patients With Alzheimer's Disease",Completed,,Phase 2,659,Actual,AstraZeneca,,3,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:24:11.554357,2020-02-01 20:24:11.554357,AstraZeneca,Industry,AZD3480,Drug
NCT01466088,"ClinicalTrials.gov processed this data on January 31, 2020",2011-11-02,,2015-05-11,2015-05-11,2011-11-04,2011-11-06,Estimate,,,,2015-05-11,2015-06-03,Estimate,2015-05-11,2015-06-03,Estimate,October 2011,,2011-10-31,July 2014,2014-07-31,May 2014,Actual,2014-05-31,May 2014,Actual,2014-05-31,,Interventional,,,"Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)","Double-Blind, Positive Comparator, Randomized, Parallel Study of Efficacy, Safety, and Tolerability of AZD3480 (TC-1734-226) as Monotherapy in Patients With Mild to Moderate Dementia of the Alzheimer's Type",Completed,,Phase 2,386,Actual,Targacept Inc.,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:38:14.385865,2020-02-01 15:38:14.385865,Targacept Inc.,Industry,AZD3480,Drug
NCT01548287,"ClinicalTrials.gov processed this data on January 31, 2020",2012-03-05,2015-01-26,,2016-12-14,2012-03-05,2012-03-08,Estimate,2016-10-12,2016-12-05,Estimate,,,,2016-12-14,2017-02-07,Estimate,April 2012,,2012-04-30,December 2016,2016-12-31,January 2013,Actual,2013-01-31,January 2013,Actual,2013-01-31,,Interventional,,,A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment,"A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Placebo-Controlled",Completed,,Phase 2,164,Actual,AstraZeneca,,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:17:18.548184,2020-02-01 15:17:18.548184,AstraZeneca,Industry,AZD5213,Drug
NCT02080364,"ClinicalTrials.gov processed this data on January 31, 2020",2014-02-25,,2019-05-08,2019-05-13,2014-03-04,2014-03-06,Estimate,,,,2019-05-13,2019-05-17,Actual,2019-05-13,2019-05-17,Actual,April 2015,Actual,2015-04-30,May 2019,2019-05-31,"June 1, 2018",Actual,2018-06-01,"June 1, 2018",Actual,2018-06-01,,Interventional,STEADFAST,,Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease,"Randomized, Double-blind, Placebo Controlled, Multi-center Registration Trial to Evaluate the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine",Terminated,,Phase 3,880,Actual,vTv Therapeutics,,2,,Not due to safety but due to a lack of efficacy at the 5 mg azeliragon dose.,False,,,,True,True,False,,,,,,,,,,,2020-02-01 12:58:28.399182,2020-02-01 12:58:28.399182,vTv Therapeutics,Industry,Azeliragon,Drug
NCT03980730,"ClinicalTrials.gov processed this data on January 31, 2020",2019-05-31,,,2020-01-13,2019-06-06,2019-06-10,Actual,,,,,,,2020-01-13,2020-01-14,Actual,"June 27, 2019",Actual,2019-06-27,January 2020,2020-01-31,July 2023,Anticipated,2023-07-31,April 2023,Anticipated,2023-04-30,,Interventional,Elevage,,Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance,"Randomized, Double-blind, Placebo-controlled, Multicenter Studies to Evaluate the Safety and Efficacy of Azeliragon as a Treatment for Subjects With Mild Alzheimer's Disease and Impaired Glucose Tolerance",Recruiting,,Phase 2/Phase 3,300,Anticipated,vTv Therapeutics,,2,,,False,,,,True,True,False,,,,,,,,,No,,2020-02-01 06:57:16.531793,2020-02-01 06:57:16.531793,vTv Therapeutics,Industry,Azeliragon,Drug
NCT02467413,"ClinicalTrials.gov processed this data on January 31, 2020",2015-06-04,,,2019-07-29,2015-06-05,2015-06-10,Estimate,,,,,,,2019-07-29,2019-07-31,Actual,"December 1, 2019",Anticipated,2019-12-01,July 2019,2019-07-31,December 2021,Anticipated,2021-12-31,June 2021,Anticipated,2021-06-30,,Interventional,,,BAC in Patient With Alzheimer's Disease or Vascular Dementia,"A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia",Withdrawn,,Phase 2,0,Actual,Charsire Biotechnology Corp.,,2,,At sponsor's decision,False,,,,False,True,False,,,,,,,,,,,2020-02-01 11:28:58.960261,2020-02-01 11:28:58.960261,Charsire Biotechnology Corp.,Industry,BAC,Drug
NCT03887455,"ClinicalTrials.gov processed this data on January 31, 2020",2019-03-21,,,2019-07-10,2019-03-21,2019-03-25,Actual,,,,,,,2019-07-10,2019-07-12,Actual,"March 27, 2019",Actual,2019-03-27,March 2019,2019-03-31,"March 7, 2024",Anticipated,2024-03-07,"February 24, 2022",Anticipated,2022-02-24,,Interventional,Clarity AD,,A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer's Disease,"A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease",Recruiting,,Phase 3,1566,Anticipated,Eisai Inc.,,3,,,False,,,,True,True,False,,,False,,,,,,Yes,Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.,2020-02-01 07:11:13.548680,2020-02-01 07:11:13.548680,Eisai Inc.,Industry,BAN2401,Drug
NCT00112073,"ClinicalTrials.gov processed this data on January 31, 2020",2005-05-27,,2012-03-12,2012-03-12,2005-05-27,2005-05-30,Estimate,,,,2012-03-12,2012-03-14,Estimate,2012-03-12,2012-03-14,Estimate,April 2005,,2005-04-30,March 2012,2012-03-31,December 2008,Actual,2008-12-31,November 2008,Actual,2008-11-30,,Interventional,,,AAB-001 in Patients With Mild to Moderate Alzheimer's Disease,"A Phase IIA, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of AAB-001 in Patients With Mild to Moderate AD",Completed,,Phase 2,234,Actual,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",,8,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:14:07.780680,2020-02-01 22:14:07.780680,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Industry,bapineuzumab,Drug
NCT00667810,"ClinicalTrials.gov processed this data on January 31, 2020",2008-04-24,2013-10-22,,2015-12-04,2008-04-25,2008-04-28,Estimate,2015-12-04,2016-01-08,Estimate,,,,2015-12-04,2016-01-08,Estimate,June 2008,,2008-06-30,December 2015,2015-12-31,August 2013,Actual,2013-08-31,October 2012,Actual,2012-10-31,,Interventional,,Safety population included all randomized participants who received at least one infusion or portion of an infusion of study drug.,Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers",Terminated,,Phase 3,901,Actual,Pfizer,"The impact of study termination, the shorter observational periods and the resulting small sample size coupled with not having enough participants with post baseline assessments for various reasons were limiting factors for data interpretation.",3,,"The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical
    benefit. This decision was not based on any new safety concerns.",False,,,,True,,,,,,,,,,,,,2020-02-01 19:33:15.927565,2020-02-01 19:33:15.927565,Pfizer,Industry,bapineuzumab,Drug
NCT00676143,"ClinicalTrials.gov processed this data on January 31, 2020",2008-05-02,2013-10-14,,2016-05-03,2008-05-09,2008-05-12,Estimate,2016-05-03,2016-06-10,Estimate,,,,2016-05-03,2016-06-10,Estimate,January 2008,,2008-01-31,May 2016,2016-05-31,November 2012,Actual,2012-11-30,October 2012,Actual,2012-10-31,,Interventional,,Safety population included all randomized participants who received at least one infusion or portion of an infusion of study drug.,Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients,"A Phase Iii, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Efficacy And Safety Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Mild To Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Carriers",Terminated,,Phase 3,1100,Actual,Pfizer,,2,,"The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical
    benefit. This decision was not based on any new safety concerns.",False,,,,True,,,,,,,,,,,,,2020-02-01 19:31:07.517307,2020-02-01 19:31:07.517307,Pfizer,Industry,bapineuzumab,Drug
NCT00937352,"ClinicalTrials.gov processed this data on January 31, 2020",2009-07-07,,2013-10-30,2013-11-26,2009-07-09,2009-07-13,Estimate,,,,2013-10-30,2013-11-25,Estimate,2013-11-26,2013-12-20,Estimate,July 2009,,2009-07-31,November 2013,2013-11-30,September 2012,Actual,2012-09-30,September 2012,Actual,2012-09-30,,Interventional,,,A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease,"A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer's Disease Who Participated in Study ELN115727-301 or Study ELN115727-302.",Terminated,,Phase 3,896,Actual,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",,2,,,False,,,,,,,,,,,,,,,,,2020-02-01 18:13:59.478829,2020-02-01 18:13:59.478829,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Industry,Bapineuzumab,Drug
NCT00574132,"ClinicalTrials.gov processed this data on January 31, 2020",2007-12-10,,2013-09-27,2013-10-30,2007-12-13,2007-12-17,Estimate,,,,2013-09-27,2013-10-28,Estimate,2013-10-30,2013-11-25,Estimate,December 2007,,2007-12-31,October 2013,2013-10-31,June 2012,Actual,2012-06-30,June 2012,Actual,2012-06-30,,Interventional,,,Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier),"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Non- Carriers.",Completed,,Phase 3,1331,Actual,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",,3,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:00:25.535905,2020-02-01 20:00:25.535905,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Industry,Bapineuzumab 0.5 mg/kg,Drug
NCT00575055,"ClinicalTrials.gov processed this data on January 31, 2020",2007-12-10,,2013-09-27,2013-10-30,2007-12-13,2007-12-17,Estimate,,,,2013-09-27,2013-10-28,Estimate,2013-10-30,2013-11-25,Estimate,December 2007,,2007-12-31,October 2013,2013-10-31,April 2012,Actual,2012-04-30,April 2012,Actual,2012-04-30,,Interventional,,,Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier),"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Carriers.",Completed,,Phase 3,1121,Actual,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",,3,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:00:04.969013,2020-02-01 20:00:04.969013,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Industry,Bapineuzumab 0.5 mg/kg,Drug
NCT00996918,"ClinicalTrials.gov processed this data on January 31, 2020",2009-10-14,2013-11-12,,2013-11-12,2009-10-15,2009-10-16,Estimate,2013-11-12,2014-01-01,Estimate,,,,2013-11-12,2014-01-01,Estimate,December 2009,,2009-12-31,November 2013,2013-11-30,November 2012,Actual,2012-11-30,November 2012,Actual,2012-11-30,,Interventional,,,A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients,"A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety And Tolerability Trial Of Bapineuzumab (AAB-001, ELN115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E e4 Noncarriers And Participated In Study 3133K1-3000",Terminated,,Phase 3,198,Actual,Pfizer,Bapineuzumab program was discontinued prematurely. Efficacy results obtained after Week 78 are not presented due to the very small number of participants after this time point.,2,,"The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical
    benefit. This decision was not based on any new safety concerns.",False,,,,True,,,,,,,,,,,,,2020-02-01 17:51:41.515235,2020-02-01 17:51:41.515235,Pfizer,Industry,Bapineuzumab 0.5 mg/kg,Drug
NCT00574132,"ClinicalTrials.gov processed this data on January 31, 2020",2007-12-10,,2013-09-27,2013-10-30,2007-12-13,2007-12-17,Estimate,,,,2013-09-27,2013-10-28,Estimate,2013-10-30,2013-11-25,Estimate,December 2007,,2007-12-31,October 2013,2013-10-31,June 2012,Actual,2012-06-30,June 2012,Actual,2012-06-30,,Interventional,,,Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier),"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Non- Carriers.",Completed,,Phase 3,1331,Actual,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",,3,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:00:25.535905,2020-02-01 20:00:25.535905,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Industry,Bapineuzumab 1.0 m/kg,Drug
NCT00575055,"ClinicalTrials.gov processed this data on January 31, 2020",2007-12-10,,2013-09-27,2013-10-30,2007-12-13,2007-12-17,Estimate,,,,2013-09-27,2013-10-28,Estimate,2013-10-30,2013-11-25,Estimate,December 2007,,2007-12-31,October 2013,2013-10-31,April 2012,Actual,2012-04-30,April 2012,Actual,2012-04-30,,Interventional,,,Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier),"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Carriers.",Completed,,Phase 3,1121,Actual,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",,3,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:00:04.969013,2020-02-01 20:00:04.969013,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Industry,Bapineuzumab 1.0 m/kg,Drug
NCT00996918,"ClinicalTrials.gov processed this data on January 31, 2020",2009-10-14,2013-11-12,,2013-11-12,2009-10-15,2009-10-16,Estimate,2013-11-12,2014-01-01,Estimate,,,,2013-11-12,2014-01-01,Estimate,December 2009,,2009-12-31,November 2013,2013-11-30,November 2012,Actual,2012-11-30,November 2012,Actual,2012-11-30,,Interventional,,,A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients,"A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety And Tolerability Trial Of Bapineuzumab (AAB-001, ELN115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E e4 Noncarriers And Participated In Study 3133K1-3000",Terminated,,Phase 3,198,Actual,Pfizer,Bapineuzumab program was discontinued prematurely. Efficacy results obtained after Week 78 are not presented due to the very small number of participants after this time point.,2,,"The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical
    benefit. This decision was not based on any new safety concerns.",False,,,,True,,,,,,,,,,,,,2020-02-01 17:51:41.515235,2020-02-01 17:51:41.515235,Pfizer,Industry,Bapineuzumab 1.0 m/kg,Drug
NCT02292238,"ClinicalTrials.gov processed this data on January 31, 2020",2014-11-10,,,2019-02-27,2014-11-14,2014-11-17,Estimate,,,,,,,2019-02-27,2019-02-28,Actual,November 2014,,2014-11-30,February 2019,2019-02-28,November 2019,Anticipated,2019-11-30,November 2019,Anticipated,2019-11-30,,Interventional,Benfotiamine,,Benfotiamine in Alzheimer's Disease: A Pilot Study,Benfotiamine in Alzheimer's Disease: A Pilot Study,"Active, not recruiting",,Phase 2,76,Anticipated,Burke Medical Research Institute,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:08:28.303175,2020-02-01 12:08:28.303175,Burke Medical Research Institute,Other,Benfotiamine,Drug
NCT00160147,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-08,,2015-01-29,2015-01-29,2005-09-08,2005-09-12,Estimate,,,,2015-01-29,2015-02-09,Estimate,2015-01-29,2015-02-09,Estimate,December 2005,,2005-12-31,June 2009,2009-06-30,January 2008,Actual,2008-01-31,January 2008,Actual,2008-01-31,,Interventional,,,Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type,"A Randomized, Double-Blind, Placebo-controlled, Efficacy, Safety, and Tolerability Study of Bifeprunox in the Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type",Terminated,,Phase 3,60,Actual,Solvay Pharmaceuticals,,2,,The study was discontinued prematurely on 25 February 2008 due to slow enrollment,False,,,,,,,,,,,,,,,,,2020-02-01 21:59:51.819507,2020-02-01 21:59:51.819507,Solvay Pharmaceuticals,Industry,bifeprunox,Drug
NCT03352557,"ClinicalTrials.gov processed this data on January 31, 2020",2017-11-21,,,2020-01-20,2017-11-21,2017-11-24,Actual,,,,,,,2020-01-20,2020-01-22,Actual,"May 3, 2018",Actual,2018-05-03,January 2020,2020-01-31,"March 26, 2024",Anticipated,2024-03-26,"March 26, 2024",Anticipated,2024-03-26,,Interventional,TANGO,,Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease","Active, not recruiting",,Phase 2,654,Actual,Biogen,,4,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:34:31.539157,2020-02-01 08:34:31.539157,Biogen,Industry,BIIB092,Drug
NCT01492374,"ClinicalTrials.gov processed this data on January 31, 2020",2011-12-13,,,2014-07-23,2011-12-13,2011-12-15,Estimate,,,,,,,2014-07-23,2014-07-24,Estimate,February 2012,,2012-02-29,October 2013,2013-10-31,October 2013,Actual,2013-10-31,October 2013,Actual,2013-10-31,,Interventional,,,"Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease","A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease",Completed,,Phase 1,40,Actual,Bristol-Myers Squibb,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:31:09.583952,2020-02-01 15:31:09.583952,Bristol-Myers Squibb,Industry,BMS-241027,Drug
NCT00810147,"ClinicalTrials.gov processed this data on January 31, 2020",2008-12-16,,2012-03-24,2015-09-23,2008-12-16,2008-12-17,Estimate,,,,2015-09-23,2015-10-12,Estimate,2015-09-23,2015-10-12,Estimate,February 2009,,2009-02-28,September 2015,2015-09-30,June 2010,Actual,2010-06-30,June 2010,Actual,2010-06-30,,Interventional,,,"A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease","Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,209,Actual,Bristol-Myers Squibb,,5,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:51:11.554481,2020-02-01 18:51:11.554481,Bristol-Myers Squibb,Industry,BMS-708163,Drug
NCT01747213,"ClinicalTrials.gov processed this data on January 31, 2020",2012-12-08,,,2019-05-15,2012-12-08,2012-12-11,Estimate,,,,,,,2019-05-15,2019-05-16,Actual,"January 1, 2013",,2013-01-01,"May 7, 2019",2019-05-07,"January 8, 2019",Actual,2019-01-08,"January 8, 2019",Actual,2019-01-08,,Interventional,,,Bisnorcymserine in Healthy Adult Volunteers,"Phase I, Double-Blind, Placebo-Controlled, Ascending, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of Bisnorcymserine (BNC), a Highly Selective Inhibitor of Butyrylcholinesterase, in Healthy Adult Volunteers",Completed,,Phase 1,75,Actual,National Institutes of Health Clinical Center (CC),,2,,,False,,,,,True,False,,,,,,,,,,,2020-02-01 14:26:05.148752,2020-02-01 14:26:05.148752,National Institute on Aging (NIA),NIH,BNC,Drug
NCT03817684,"ClinicalTrials.gov processed this data on January 31, 2020",2019-01-18,,,2019-10-30,2019-01-23,2019-01-25,Actual,,,,,,,2019-10-30,2019-10-31,Actual,"April 30, 2019",Actual,2019-04-30,October 2019,2019-10-31,February 2020,Anticipated,2020-02-29,February 2020,Anticipated,2020-02-29,,Interventional,,,Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects,"A Randomized , Double Blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients With Early Stage Alzheimer's Disease","Active, not recruiting",,Phase 2,255,Actual,Tetra Discovery Partners,,3,,,False,,,,True,True,False,,,,,,,,,No,,2020-02-01 07:21:36.297810,2020-02-01 07:21:36.297810,Tetra Discovery Partners,Industry,BPN14770,Drug
NCT03548584,"ClinicalTrials.gov processed this data on January 31, 2020",2018-05-07,,,2019-11-08,2018-06-05,2018-06-07,Actual,,,,,,,2019-11-08,2019-11-13,Actual,"May 16, 2018",Actual,2018-05-16,November 2019,2019-11-30,December 2020,Anticipated,2020-12-31,November 2020,Anticipated,2020-11-30,,Interventional,,,"A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type","A Phase 3, 12-Week, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-Arm, Fixed-dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type",Recruiting,,Phase 3,225,Anticipated,"Otsuka Pharmaceutical Development & Commercialization, Inc.",,3,,,False,,,,,True,False,,,,,,,,,,,2020-02-01 08:02:22.001085,2020-02-01 08:02:22.001085,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Industry,Brexpiprazole,Drug
NCT03594123,"ClinicalTrials.gov processed this data on January 31, 2020",2018-07-11,,,2019-11-08,2018-07-11,2018-07-20,Actual,,,,,,,2019-11-08,2019-11-13,Actual,"October 12, 2018",Actual,2018-10-12,November 2019,2019-11-30,August 2021,Anticipated,2021-08-31,August 2021,Anticipated,2021-08-31,,Interventional,,,A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type,"A 12-week, Multicenter, Active-treatment Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type",Recruiting,,Phase 3,250,Anticipated,"Otsuka Pharmaceutical Development & Commercialization, Inc.",,2,,,False,,,,,True,False,,,,,,,,,,,2020-02-01 07:55:08.643083,2020-02-01 07:55:08.643083,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Industry,Brexpiprazole,Drug
NCT03620981,"ClinicalTrials.gov processed this data on January 31, 2020",2018-08-05,,,2019-07-09,2018-08-05,2018-08-08,Actual,,,,,,,2019-07-09,2019-07-11,Actual,"August 20, 2018",Actual,2018-08-20,July 2019,2019-07-31,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,,Interventional,,,Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type,"A Phase 2/3 Multicenter, Placebo-controlled, Randomized, Double-blind, Parallel-group Comparison Trial to Evaluate the Efficacy and Safety of Brexpiprazole (OPC-34712) in the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type",Recruiting,,Phase 2/Phase 3,407,Anticipated,"Otsuka Pharmaceutical Co., Ltd.",,3,,,False,,,,True,False,False,,,,,,,,,Undecided,,2020-02-01 07:51:00.823260,2020-02-01 07:51:00.823260,"Otsuka Pharmaceutical Co., Ltd.",Industry,Brexpiprazole,Drug
NCT01862640,"ClinicalTrials.gov processed this data on January 31, 2020",2013-05-22,,2018-01-22,2019-03-11,2013-05-22,2013-05-24,Estimate,,,,2018-01-22,2018-01-26,Actual,2019-03-11,2019-03-14,Actual,July 2013,,2013-07-31,March 2019,2019-03-31,March 2017,Actual,2017-03-31,March 2017,Actual,2017-03-31,,Interventional,,,Safety and Tolerability Study of Two Fixed-doses of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type,"A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type",Completed,,Phase 3,433,Actual,"Otsuka Pharmaceutical Development & Commercialization, Inc.",,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:56:29.292305,2020-02-01 13:56:29.292305,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Industry,"Brexpiprazole, OPC-34712",Drug
NCT01922258,"ClinicalTrials.gov processed this data on January 31, 2020",2013-08-12,,2018-05-15,2018-05-15,2013-08-12,2013-08-14,Estimate,,,,2018-05-15,2018-05-17,Actual,2018-05-15,2018-05-17,Actual,September 2013,Actual,2013-09-30,May 2018,2018-05-31,March 2017,Actual,2017-03-31,March 2017,Actual,2017-03-31,,Interventional,,,Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type,"A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Flexible Dosing of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type",Completed,,Phase 3,270,Actual,"Otsuka Pharmaceutical Development & Commercialization, Inc.",,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:40:30.244190,2020-02-01 13:40:30.244190,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Industry,"Brexpiprazole, OPC-34712",Drug
NCT03560245,"ClinicalTrials.gov processed this data on January 31, 2020",2018-06-06,,,2019-08-19,2018-06-06,2018-06-18,Actual,,,,,,,2019-08-19,2019-08-20,Actual,"June 20, 2018",Actual,2018-06-20,August 2019,2019-08-31,"July 25, 2019",Actual,2019-07-25,"July 25, 2019",Actual,2019-07-25,,Interventional,,,A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment",Completed,,Phase 2,108,Actual,"Neurotrope Bioscience, Inc.",,2,,,False,,,,,True,False,,,,,,,,,No,,2020-02-01 08:00:22.661683,2020-02-01 08:00:22.661683,"Neurotrope Bioscience, Inc.",Industry,Bryostatin,Drug
NCT02221947,"ClinicalTrials.gov processed this data on January 31, 2020",2014-07-02,2016-03-21,,2017-10-03,2014-08-20,2014-08-21,Estimate,2016-03-21,2016-04-21,Estimate,,,,2017-10-03,2017-11-06,Actual,June 2014,,2014-06-30,October 2017,2017-10-31,December 2014,Actual,2014-12-31,December 2014,Actual,2014-12-31,,Interventional,,,"Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Preliminary Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bryostatin 1 in Patients With Alzheimer's Disease",Terminated,,Phase 1/Phase 2,9,Actual,"Neurotrope Bioscience, Inc.",,2,,"Part 2 of study replaced by NTRP-101-202, assessing 3 doses of bryostatin.",False,,,,False,,,,,,,,,,,No,,2020-02-01 12:24:20.790879,2020-02-01 12:24:20.790879,"Neurotrope Bioscience, Inc.",Industry,Bryostatin 1,Drug
NCT02431468,"ClinicalTrials.gov processed this data on January 31, 2020",2015-04-22,2018-04-30,,2018-06-06,2015-04-27,2015-05-01,Estimate,2018-06-06,2018-07-06,Actual,,,,2018-06-06,2018-07-06,Actual,November 2015,,2015-11-30,June 2018,2018-06-30,February 2017,Actual,2017-02-28,February 2017,Actual,2017-02-28,,Interventional,,,A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease,"A Randomized, Double-Blind,Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease",Completed,,Phase 2,147,Actual,"Neurotrope Bioscience, Inc.",,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:37:32.174698,2020-02-01 11:37:32.174698,"Neurotrope Bioscience, Inc.",Industry,Bryostatin 1,Drug
NCT00606164,"ClinicalTrials.gov processed this data on January 31, 2020",2008-01-21,,,2008-01-21,2008-01-21,2008-02-01,Estimate,,,,,,,2008-01-21,2008-02-01,Estimate,April 2008,,2008-04-30,January 2008,2008-01-31,December 2008,Anticipated,2008-12-31,December 2008,Anticipated,2008-12-31,,Interventional,,,"Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin 1 in Patients With Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Parallel Groups, Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bryostatin 1 in Patients With Mild to Moderate Alzheimer's Disease",Unknown status,Not yet recruiting,Phase 2,9,Anticipated,Blanchette Rockefeller Neurosciences Insitute,,3,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:51:23.445840,2020-02-01 19:51:23.445840,Blanchette Rockefeller Neurosciences Insitute,Other,Bryostatin for Injection,Drug
NCT02646982,"ClinicalTrials.gov processed this data on January 31, 2020",2016-01-04,,,2019-02-15,2016-01-04,2016-01-06,Estimate,,,,,,,2019-02-15,2019-02-18,Actual,June 2016,,2016-06-30,February 2019,2019-02-28,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,,Interventional,CEDAR,,Candesartan's Effects on Alzheimer's Disease And Related Biomarkers,Candesartan's Effects on Alzheimer's Disease And Related Biomarkers,Recruiting,,Phase 2,72,Anticipated,Emory University,,2,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 10:48:22.473223,2020-02-01 10:48:22.473223,Emory University,Other,Candesartan,Drug
NCT01211782,"ClinicalTrials.gov processed this data on January 31, 2020",2010-09-24,,,2012-12-03,2010-09-28,2010-09-30,Estimate,,,,,,,2012-12-03,2012-12-04,Estimate,,,,December 2012,2012-12-31,,,,,,,,Interventional,ALERT,,AC-1204 Long-term Efficacy Response Trial (ALERT Protocol),"A Phase 2-3, 6-12 Month, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Subjects With Mild to Moderate Alzheimer's Disease Who Are APOE4(-)",Withdrawn,,Phase 2/Phase 3,0,Actual,Cerecin,,2,,Study never started. Study was redesgined.,False,,,,False,,,,,,,,,,,,,2020-02-01 16:49:09.095841,2020-02-01 16:49:09.095841,Cerecin,Industry,caprylic triglyceride,Drug
NCT00876863,"ClinicalTrials.gov processed this data on January 31, 2020",2009-04-03,,,2019-11-18,2009-04-03,2009-04-07,Estimate,,,,,,,2019-11-18,2019-11-20,Actual,November 2008,Actual,2008-11-30,January 2017,2017-01-31,"August 13, 2015",Actual,2015-08-13,"August 13, 2015",Actual,2015-08-13,,Interventional,,,"Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease","A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,49,Actual,Sangamo Therapeutics,,2,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 18:31:39.651990,2020-02-01 18:31:39.651990,Sangamo Therapeutics,Industry,CERE-110: Adeno-Associated Virus Delivery of NGF,Drug
NCT00911807,"ClinicalTrials.gov processed this data on January 31, 2020",2009-04-07,2009-04-07,,2009-06-04,2009-04-07,2009-06-02,Estimate,2009-04-07,2009-06-02,Estimate,,,,2009-06-04,2009-06-10,Estimate,October 2004,,2004-10-31,June 2009,2009-06-30,April 2008,Actual,2008-04-30,April 2008,Actual,2008-04-30,,Interventional,Combi,,Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease,"A Randomized, Double-Blind, Clinical Trial to Compare the Safety and Efficacy of Cerebrolysin and Aricept (Donepezil) and a Combination Therapy in Patients With Probable Alzheimer's Disease (AD)",Completed,,Phase 2,217,Actual,Ever Neuro Pharma GmbH,,3,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:21:22.041636,2020-02-01 18:21:22.041636,Ever Neuro Pharma GmbH,Industry,Cerebrolysin + donepezil,Drug
NCT00911807,"ClinicalTrials.gov processed this data on January 31, 2020",2009-04-07,2009-04-07,,2009-06-04,2009-04-07,2009-06-02,Estimate,2009-04-07,2009-06-02,Estimate,,,,2009-06-04,2009-06-10,Estimate,October 2004,,2004-10-31,June 2009,2009-06-30,April 2008,Actual,2008-04-30,April 2008,Actual,2008-04-30,,Interventional,Combi,,Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease,"A Randomized, Double-Blind, Clinical Trial to Compare the Safety and Efficacy of Cerebrolysin and Aricept (Donepezil) and a Combination Therapy in Patients With Probable Alzheimer's Disease (AD)",Completed,,Phase 2,217,Actual,Ever Neuro Pharma GmbH,,3,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:21:22.041636,2020-02-01 18:21:22.041636,Ever Neuro Pharma GmbH,Industry,Cerebrolysin + placebo,Drug
NCT01303744,"ClinicalTrials.gov processed this data on January 31, 2020",2011-02-23,2015-10-16,2012-05-18,2015-12-02,2011-02-23,2011-02-25,Estimate,2015-12-02,2016-01-11,Estimate,2012-05-18,2012-05-30,Estimate,2015-12-02,2016-01-11,Estimate,March 2011,,2011-03-31,December 2015,2015-12-31,April 2012,Actual,2012-04-30,April 2012,Actual,2012-04-30,,Interventional,CT04,,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074,"A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment",Completed,,Phase 2,96,Actual,CERESPIR,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:21:56.018097,2020-02-01 16:21:56.018097,CERESPIR,Industry,CHF 5074 1x,Drug
NCT01203384,"ClinicalTrials.gov processed this data on January 31, 2020",2010-09-15,,,2015-02-09,2010-09-15,2010-09-16,Estimate,,,,,,,2015-02-09,2015-02-10,Estimate,September 2010,,2010-09-30,February 2015,2015-02-28,December 2010,Actual,2010-12-31,December 2010,Actual,2010-12-31,,Interventional,CT02,,"Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects","Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects",Completed,,Phase 1,48,Actual,CERESPIR,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:51:33.506485,2020-02-01 16:51:33.506485,CERESPIR,Industry,CHF5074 1x,Drug
NCT01303744,"ClinicalTrials.gov processed this data on January 31, 2020",2011-02-23,2015-10-16,2012-05-18,2015-12-02,2011-02-23,2011-02-25,Estimate,2015-12-02,2016-01-11,Estimate,2012-05-18,2012-05-30,Estimate,2015-12-02,2016-01-11,Estimate,March 2011,,2011-03-31,December 2015,2015-12-31,April 2012,Actual,2012-04-30,April 2012,Actual,2012-04-30,,Interventional,CT04,,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074,"A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment",Completed,,Phase 2,96,Actual,CERESPIR,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:21:56.018097,2020-02-01 16:21:56.018097,CERESPIR,Industry,CHF 5074 2x,Drug
NCT01203384,"ClinicalTrials.gov processed this data on January 31, 2020",2010-09-15,,,2015-02-09,2010-09-15,2010-09-16,Estimate,,,,,,,2015-02-09,2015-02-10,Estimate,September 2010,,2010-09-30,February 2015,2015-02-28,December 2010,Actual,2010-12-31,December 2010,Actual,2010-12-31,,Interventional,CT02,,"Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects","Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects",Completed,,Phase 1,48,Actual,CERESPIR,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:51:33.506485,2020-02-01 16:51:33.506485,CERESPIR,Industry,CHF5074 2x,Drug
NCT01303744,"ClinicalTrials.gov processed this data on January 31, 2020",2011-02-23,2015-10-16,2012-05-18,2015-12-02,2011-02-23,2011-02-25,Estimate,2015-12-02,2016-01-11,Estimate,2012-05-18,2012-05-30,Estimate,2015-12-02,2016-01-11,Estimate,March 2011,,2011-03-31,December 2015,2015-12-31,April 2012,Actual,2012-04-30,April 2012,Actual,2012-04-30,,Interventional,CT04,,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074,"A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment",Completed,,Phase 2,96,Actual,CERESPIR,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:21:56.018097,2020-02-01 16:21:56.018097,CERESPIR,Industry,CHF 5074 3x,Drug
NCT01203384,"ClinicalTrials.gov processed this data on January 31, 2020",2010-09-15,,,2015-02-09,2010-09-15,2010-09-16,Estimate,,,,,,,2015-02-09,2015-02-10,Estimate,September 2010,,2010-09-30,February 2015,2015-02-28,December 2010,Actual,2010-12-31,December 2010,Actual,2010-12-31,,Interventional,CT02,,"Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects","Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects",Completed,,Phase 1,48,Actual,CERESPIR,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:51:33.506485,2020-02-01 16:51:33.506485,CERESPIR,Industry,CHF5074 3x,Drug
NCT02035982,"ClinicalTrials.gov processed this data on January 31, 2020",2013-11-25,,,2017-04-26,2014-01-13,2014-01-14,Estimate,,,,,,,2017-04-26,2017-04-28,Actual,July 2010,,2010-07-31,April 2017,2017-04-30,September 2015,Actual,2015-09-30,May 2014,Actual,2014-05-31,,Interventional,,,Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease,A Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease in Long Term Care Setting,Completed,,Phase 3,40,Actual,Sunnybrook Health Sciences Centre,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:09:43.530864,2020-02-01 13:09:43.530864,Sunnybrook Health Sciences Centre,Other,Cholinesterase Inhibitor,Drug
NCT00940589,"ClinicalTrials.gov processed this data on January 31, 2020",2009-07-15,2018-03-28,,2018-05-29,2009-07-15,2009-07-16,Estimate,2018-05-29,2018-06-01,Actual,,,,2018-05-29,2018-06-01,Actual,September 2009,,2009-09-30,May 2018,2018-05-31,May 2013,Actual,2013-05-31,February 2013,Actual,2013-02-28,,Interventional,,,Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor,"A Double-blind, Parallel Group, Randomized, Placebo Controlled Study of the Efficacy of Circadin® 2mg in Patients With Mild to Moderate Alzheimer Disease (AD) Treated With Acetylcholinesterase (AChE) Inhibitor",Completed,,Phase 2,73,Actual,Neurim Pharmaceuticals Ltd.,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:12:57.684048,2020-02-01 18:12:57.684048,Neurim Pharmaceuticals Ltd.,Industry,Circadin,Drug
NCT00898807,"ClinicalTrials.gov processed this data on January 31, 2020",2009-05-11,2014-03-19,,2014-06-26,2009-05-11,2009-05-12,Estimate,2014-06-26,2014-06-27,Estimate,,,,2014-06-26,2014-06-27,Estimate,July 2009,,2009-07-31,June 2014,2014-06-30,September 2013,Actual,2013-09-30,September 2013,Actual,2013-09-30,,Interventional,CitAD,,Citalopram for Agitation in Alzheimer's Disease,A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease,Completed,,Phase 3,186,Actual,JHSPH Center for Clinical Trials,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:25:13.871439,2020-02-01 18:25:13.871439,JHSPH Center for Clinical Trials,Other,citalopram,Drug
NCT02565511,"ClinicalTrials.gov processed this data on January 31, 2020",2015-09-28,,,2019-10-25,2015-09-29,2015-10-01,Estimate,,,,,,,2019-10-25,2019-10-28,Actual,"November 30, 2015",Actual,2015-11-30,October 2019,2019-10-31,"March 31, 2025",Anticipated,2025-03-31,"December 31, 2024",Anticipated,2024-12-31,,Interventional,Generation S1,,A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease,"A Randomized, Double-blind, Placebo-controlled, Two-cohort, Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease.",Recruiting,,Phase 2/Phase 3,481,Anticipated,Novartis,,4,,,False,,,,True,True,False,,,,,,,,,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2020-02-01 11:06:28.630491,2020-02-01 11:06:28.630491,Novartis Pharmaceuticals,Industry,CNP520,Drug
NCT03131453,"ClinicalTrials.gov processed this data on January 31, 2020",2017-04-05,,,2019-10-03,2017-04-24,2017-04-27,Actual,,,,,,,2019-10-03,2019-10-07,Actual,"August 3, 2017",Actual,2017-08-03,September 2019,2019-09-30,"March 31, 2025",Anticipated,2025-03-31,"July 30, 2024",Anticipated,2024-07-30,,Interventional,Generation S2,,A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease,"A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (AD).","Active, not recruiting",,Phase 2/Phase 3,1145,Actual,Novartis,,3,,,False,,,,True,True,False,,,,,,,,https://www.clinicalstudydatarequest.com,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2020-02-01 09:13:42.422620,2020-02-01 09:13:42.422620,Novartis Pharmaceuticals,Industry,CNP520 15mg,Drug
NCT03131453,"ClinicalTrials.gov processed this data on January 31, 2020",2017-04-05,,,2019-10-03,2017-04-24,2017-04-27,Actual,,,,,,,2019-10-03,2019-10-07,Actual,"August 3, 2017",Actual,2017-08-03,September 2019,2019-09-30,"March 31, 2025",Anticipated,2025-03-31,"July 30, 2024",Anticipated,2024-07-30,,Interventional,Generation S2,,A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease,"A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (AD).","Active, not recruiting",,Phase 2/Phase 3,1145,Actual,Novartis,,3,,,False,,,,True,True,False,,,,,,,,https://www.clinicalstudydatarequest.com,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2020-02-01 09:13:42.422620,2020-02-01 09:13:42.422620,Novartis Pharmaceuticals,Industry,CNP520 50mg,Drug
NCT01883648,"ClinicalTrials.gov processed this data on January 31, 2020",2013-06-11,,,2017-04-26,2013-06-18,2013-06-21,Estimate,,,,,,,2017-04-26,2017-04-28,Actual,June 2013,,2013-06-30,January 2017,2017-01-31,"February 1, 2017",Actual,2017-02-01,"February 1, 2017",Actual,2017-02-01,,Interventional,,,Study to Evaluate Coconut Oil for Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled, 6 Month Cross-Over Study to Evaluate the Efficacy of Coconut Oil (Fuel for Thought™) Treatment for Subjects With Mild to Moderate Alzheimer's Disease",Terminated,,Phase 2/Phase 3,21,Actual,University of South Florida,,2,,Funding limitations and enrollment was too low.,False,,,,True,,,,,,,,,,,No,,2020-02-01 13:49:29.584007,2020-02-01 13:49:29.584007,University of South Florida,Other,Coconut Oil Beverage,Drug
NCT00766363,"ClinicalTrials.gov processed this data on January 31, 2020",2008-10-01,2011-06-16,,2012-04-18,2008-10-02,2008-10-03,Estimate,2011-06-16,2011-07-14,Estimate,,,,2012-04-18,2012-04-20,Estimate,October 2008,,2008-10-31,April 2012,2012-04-30,March 2009,Actual,2009-03-31,March 2009,Actual,2009-03-31,,Interventional,,,"Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1b Safety Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Patients With Mild to Moderate Probable Alzheimer's Disease",Completed,,Phase 1,49,Actual,FORUM Pharmaceuticals Inc,,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:04:53.564244,2020-02-01 19:04:53.564244,FORUM Pharmaceuticals Inc,Industry,Comparator: Placebo,Drug
NCT03418688,"ClinicalTrials.gov processed this data on January 31, 2020",2018-01-26,,,2018-11-05,2018-01-26,2018-02-01,Actual,,,,,,,2018-11-05,2018-11-07,Actual,"March 6, 2018",Actual,2018-03-06,November 2018,2018-11-30,"October 15, 2018",Actual,2018-10-15,"October 15, 2018",Actual,2018-10-15,,Interventional,,,A Multiple Ascending Dose Study of COR388,"A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of COR388 in Older Healthy Volunteers and Patients With Alzheimer's Disease",Completed,,Phase 1,33,Actual,Cortexyme Inc.,,2,,,False,,,,True,True,False,,,,,,,,,No,,2020-02-01 08:23:47.480357,2020-02-01 08:23:47.480357,Cortexyme Inc.,Industry,COR388,Drug
NCT03823404,"ClinicalTrials.gov processed this data on January 31, 2020",2019-01-24,,,2020-01-10,2019-01-29,2019-01-30,Actual,,,,,,,2020-01-10,2020-01-13,Actual,"March 28, 2019",Actual,2019-03-28,December 2019,2019-12-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,,Interventional,,,GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease,"GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease",Recruiting,,Phase 2/Phase 3,573,Anticipated,Cortexyme Inc.,,3,,,False,,,,True,True,False,,,,,,,,,No,,2020-02-01 07:20:47.948947,2020-02-01 07:20:47.948947,Cortexyme Inc.,Industry,COR388 capsule,Drug
NCT02907567,"ClinicalTrials.gov processed this data on January 31, 2020",2016-09-05,,,2018-07-24,2016-09-15,2016-09-20,Estimate,,,,,,,2018-07-24,2018-07-26,Actual,September 2016,Actual,2016-09-30,July 2018,2018-07-31,September 2017,Actual,2017-09-30,"August 24, 2017",Actual,2017-08-24,,Interventional,,,Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled, Phase I Study of the Safety & Pharmacokinetics of Two Doses of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 1/Phase 2,19,Actual,Cognition Therapeutics,,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 09:57:57.979312,2020-02-01 09:57:57.979312,Cognition Therapeutics,Industry,CT1812,Drug
NCT03507790,"ClinicalTrials.gov processed this data on January 31, 2020",2018-04-10,,,2020-01-20,2018-04-16,2018-04-25,Actual,,,,,,,2020-01-20,2020-01-22,Actual,"October 2, 2018",Actual,2018-10-02,January 2020,2020-01-31,"July 31, 2020",Anticipated,2020-07-31,"June 30, 2020",Anticipated,2020-06-30,,Interventional,,,A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.",Recruiting,,Phase 2,120,Anticipated,Cognition Therapeutics,,3,,,,,,,True,True,False,,,,,,,,,No,,2020-02-01 08:09:06.429952,2020-02-01 08:09:06.429952,Cognition Therapeutics,Industry,CT1812,Drug
NCT03522129,"ClinicalTrials.gov processed this data on February 06, 2020",2018-04-30,,,2020-01-30,2018-04-30,2018-05-11,Actual,,,,,,,2020-01-30,2020-02-05,Actual,"May 16, 2018",Actual,2018-05-16,January 2020,2020-01-31,"March 31, 2021",Anticipated,2021-03-31,"January 30, 2021",Anticipated,2021-01-30,,Interventional,,,Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease,A Pilot Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease,Recruiting,,Phase 1,18,Anticipated,Cognition Therapeutics,,4,,,False,,,,True,True,False,,,,,,,,,,,2020-02-07 06:02:33.931340,2020-02-07 06:02:33.931340,Cognition Therapeutics,Industry,CT1812,Drug
NCT03752294,"ClinicalTrials.gov processed this data on January 31, 2020",2018-05-15,,,2018-11-20,2018-11-20,2018-11-23,Actual,,,,,,,2018-11-20,2018-11-23,Actual,November 2018,Anticipated,2018-11-30,November 2018,2018-11-30,December 2021,Anticipated,2021-12-31,November 2021,Anticipated,2021-11-30,,Interventional,,,A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.,"A 24-month, Randomized-control, Double-blind, Multi-center, Delayed-start, Pilot Study Evaluating Thrombin Inhibitions Alzheimer's Disease Using 150mg Dabigatran Daily: A Novel Therapeutic Target for Alzheimer's Disease",Not yet recruiting,,Phase 1,40,Anticipated,University of Rhode Island,,3,,,False,,,,True,False,False,,,False,,,,,,Undecided,,2020-02-01 07:31:02.811291,2020-02-01 07:31:02.811291,University of Rhode Island,Other,Dabigatran,Drug
NCT03752463,"ClinicalTrials.gov processed this data on January 31, 2020",2018-11-21,,,2018-11-21,2018-11-21,2018-11-26,Actual,,,,,,,2018-11-21,2018-11-26,Actual,"May 22, 2015",Actual,2015-05-22,April 2018,2018-04-30,"December 31, 2019",Anticipated,2019-12-31,"December 31, 2019",Anticipated,2019-12-31,,Interventional,,,NMDA Enhancer for the Treatment of Mild Alzheimer's Disease,NMDA Enhancer for the Treatment of Mild Alzheimer's Disease,Recruiting,,Phase 2,160,Anticipated,Chang Gung Memorial Hospital,,4,,,False,,,,,False,False,,,,,,,,,,,2020-02-01 07:31:01.934898,2020-02-01 07:31:01.934898,Chang Gung Memorial Hospital,Other,DAOI-A group,Drug
NCT02103673,"ClinicalTrials.gov processed this data on January 31, 2020",2014-04-01,,,2018-01-23,2014-04-03,2014-04-04,Estimate,,,,,,,2018-01-23,2018-01-24,Actual,February 2014,,2014-02-28,January 2018,2018-01-31,November 2017,Actual,2017-11-30,November 2017,Actual,2017-11-30,,Interventional,,,DAOIB for the Treatment of Cognitive Function and Behavioral and Psychological Symptoms of Dementia,,Completed,,Phase 2,90,Actual,Chang Gung Memorial Hospital,,2,,,False,,,,,,,,,,,,,,,,,2020-02-01 12:53:13.868291,2020-02-01 12:53:13.868291,Chang Gung Memorial Hospital,Other,DAOIB,Drug
NCT01600469,"ClinicalTrials.gov processed this data on January 31, 2020",2012-05-14,,,2013-06-03,2012-05-15,2012-05-17,Estimate,,,,,,,2013-06-03,2013-06-04,Estimate,January 2012,,2012-01-31,April 2011,2011-04-30,May 2013,Actual,2013-05-31,May 2013,Actual,2013-05-31,,Interventional,,,NMDA-enhancing Agent for Treatment of Mild Cognitive Impairment and Mild Alzheimer's Disease,NMDA-enhancing Agent for Treatment of Mild Cognitive Impairment and Mild Alzheimer's Disease,Completed,,Phase 2,86,Actual,Chang Gung Memorial Hospital,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:04:31.673978,2020-02-01 15:04:31.673978,Chang Gung Memorial Hospital,Other,DAOI-B,Drug
NCT03752463,"ClinicalTrials.gov processed this data on January 31, 2020",2018-11-21,,,2018-11-21,2018-11-21,2018-11-26,Actual,,,,,,,2018-11-21,2018-11-26,Actual,"May 22, 2015",Actual,2015-05-22,April 2018,2018-04-30,"December 31, 2019",Anticipated,2019-12-31,"December 31, 2019",Anticipated,2019-12-31,,Interventional,,,NMDA Enhancer for the Treatment of Mild Alzheimer's Disease,NMDA Enhancer for the Treatment of Mild Alzheimer's Disease,Recruiting,,Phase 2,160,Anticipated,Chang Gung Memorial Hospital,,4,,,False,,,,,False,False,,,,,,,,,,,2020-02-01 07:31:01.934898,2020-02-01 07:31:01.934898,Chang Gung Memorial Hospital,Other,DAOI-B group,Drug
NCT03752463,"ClinicalTrials.gov processed this data on January 31, 2020",2018-11-21,,,2018-11-21,2018-11-21,2018-11-26,Actual,,,,,,,2018-11-21,2018-11-26,Actual,"May 22, 2015",Actual,2015-05-22,April 2018,2018-04-30,"December 31, 2019",Anticipated,2019-12-31,"December 31, 2019",Anticipated,2019-12-31,,Interventional,,,NMDA Enhancer for the Treatment of Mild Alzheimer's Disease,NMDA Enhancer for the Treatment of Mild Alzheimer's Disease,Recruiting,,Phase 2,160,Anticipated,Chang Gung Memorial Hospital,,4,,,False,,,,,False,False,,,,,,,,,,,2020-02-01 07:31:01.934898,2020-02-01 07:31:01.934898,Chang Gung Memorial Hospital,Other,DAOI-C group,Drug
NCT03801642,"ClinicalTrials.gov processed this data on January 31, 2020",2018-12-21,,,2019-06-04,2019-01-10,2019-01-11,Actual,,,,,,,2019-06-04,2019-06-05,Actual,"January 29, 2019",Actual,2019-01-29,June 2019,2019-06-30,October 2020,Anticipated,2020-10-31,October 2020,Anticipated,2020-10-31,,Interventional,,,Dapagliflozin In Alzheimer's Disease,Randomized Controlled Pilot Trial Of Dapagliflozin In Alzheimer's Disease,Recruiting,,Phase 1/Phase 2,48,Anticipated,University of Kansas Medical Center,,2,,,False,,,,True,True,False,,,False,,,,,,No,,2020-02-01 07:23:50.433150,2020-02-01 07:23:50.433150,"Jeff Burns, MD",Other,Dapagliflozin,Drug
NCT01608217,"ClinicalTrials.gov processed this data on January 31, 2020",2012-05-25,,,2014-06-26,2012-05-25,2012-05-31,Estimate,,,,,,,2014-06-26,2014-06-30,Estimate,June 2012,,2012-06-30,June 2014,2014-06-30,June 2014,Actual,2014-06-30,June 2014,Actual,2014-06-30,,Interventional,,,Delta-THC in Dementia,Efficacy and Safety of Delta-9-tetrahydrocannabinol (∆9-THC) in Behavioural Disturbances and Pain in Dementia,Completed,,Phase 2,50,Actual,Radboud University,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:02:26.242272,2020-02-01 15:02:26.242272,Radboud University,Other,delta-9-tetrahydrocannabinol (delta-THC),Drug
NCT00440050,"ClinicalTrials.gov processed this data on January 31, 2020",2007-02-22,2010-05-28,,2014-09-15,2007-02-22,2007-02-26,Estimate,2010-07-28,2010-08-30,Estimate,,,,2014-09-15,2014-09-25,Estimate,February 2007,,2007-02-28,September 2014,2014-09-30,May 2009,Actual,2009-05-31,May 2009,Actual,2009-05-31,,Interventional,DHA,,"DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease",A Randomized Double-Blind Placebo-Controlled Trial Of The Effects Of Docosahexaenoic Acid (DHA) In Slowing The Progression Of Alzheimer's Disease,Completed,,Phase 3,402,Actual,Alzheimer's Disease Cooperative Study (ADCS),,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:42:48.181086,2020-02-01 20:42:48.181086,Alzheimer's Disease Cooperative Study (ADCS),Other,DHA (Docosahexaenoic Acid),Drug
NCT03055741,"ClinicalTrials.gov processed this data on January 31, 2020",2017-02-14,,,2019-08-19,2017-02-15,2017-02-16,Actual,,,,,,,2019-08-19,2019-08-20,Actual,"December 28, 2016",Actual,2016-12-28,August 2019,2019-08-31,August 2019,Actual,2019-08-31,February 2019,Actual,2019-02-28,,Interventional,,,Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA),"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIb, Clinical Study to Evaluate the Safety and Efficacy of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA)",Completed,,Phase 2,180,Actual,"Daehwa Pharmaceutical Co., Ltd.",,3,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 09:26:53.735013,2020-02-01 09:26:53.735013,"Daehwa Pharmaceutical Co., Ltd.",Industry,DHP1401,Drug
NCT00831506,"ClinicalTrials.gov processed this data on January 31, 2020",2009-01-27,,,2009-06-09,2009-01-27,2009-01-29,Estimate,,,,,,,2009-06-09,2009-06-12,Estimate,February 2009,,2009-02-28,June 2009,2009-06-30,May 2009,Actual,2009-05-31,May 2009,Actual,2009-05-31,,Interventional,,,Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF-01913539) On The Safety, Tolerability, And Steady-State Pharmacokinetics Of Digoxin In Healthy Subjects",Completed,,Phase 1,12,Actual,Pfizer,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:44:44.911533,2020-02-01 18:44:44.911533,Pfizer,Industry,digoxin,Drug
NCT00831506,"ClinicalTrials.gov processed this data on January 31, 2020",2009-01-27,,,2009-06-09,2009-01-27,2009-01-29,Estimate,,,,,,,2009-06-09,2009-06-12,Estimate,February 2009,,2009-02-28,June 2009,2009-06-30,May 2009,Actual,2009-05-31,May 2009,Actual,2009-05-31,,Interventional,,,Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF-01913539) On The Safety, Tolerability, And Steady-State Pharmacokinetics Of Digoxin In Healthy Subjects",Completed,,Phase 1,12,Actual,Pfizer,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:44:44.911533,2020-02-01 18:44:44.911533,Pfizer,Industry,dimebon,Drug
NCT00377715,"ClinicalTrials.gov processed this data on January 31, 2020",2006-09-15,,,2015-11-09,2006-09-15,2006-09-18,Estimate,,,,,,,2015-11-09,2015-11-11,Estimate,September 2005,,2005-09-30,November 2015,2015-11-30,,,,August 2006,Actual,2006-08-31,,Interventional,,,"Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease","Phase 2, Double-Blind, Placebo-Controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,183,Actual,"Medivation, Inc.",,2,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:03:34.573776,2020-02-01 21:03:34.573776,"Medivation, Inc.",Industry,Dimebon,Drug
NCT00675623,"ClinicalTrials.gov processed this data on January 31, 2020",2008-05-07,,2016-09-24,2016-09-24,2008-05-08,2008-05-09,Estimate,,,,2016-09-24,2016-09-27,Estimate,2016-09-24,2016-09-27,Estimate,May 2008,,2008-05-31,September 2016,2016-09-30,,,,December 2009,Actual,2009-12-31,,Interventional,CONNECTION,,A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease,"A Global Phase 3, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Oral Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease (CONNECTION)",Completed,,Phase 3,598,Actual,"Medivation, Inc.",,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:31:17.244228,2020-02-01 19:31:17.244228,"Medivation, Inc.",Industry,Dimebon,Drug
NCT00829816,"ClinicalTrials.gov processed this data on January 31, 2020",2009-01-12,,,2015-11-06,2009-01-23,2009-01-27,Estimate,,,,,,,2015-11-06,2015-11-10,Estimate,December 2008,,2008-12-31,November 2015,2015-11-30,August 2010,Actual,2010-08-31,April 2009,Actual,2009-04-30,,Interventional,,,"Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil",A Multi-Center Phase 1 Study of the Safety and Tolerability of Dimebon in Alzheimer's Disease Patients on Memantine (Cohort 1) and Memantine Plus Donepezil (Cohort 2),Completed,,Phase 1,46,Actual,"Medivation, Inc.",,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:45:21.480398,2020-02-01 18:45:21.480398,"Medivation, Inc.",Industry,Dimebon,Drug
NCT00235716,"ClinicalTrials.gov processed this data on January 31, 2020",2005-10-06,2013-12-06,,2014-07-14,2005-10-06,2005-10-10,Estimate,2014-01-23,2014-01-29,Estimate,,,,2014-07-14,2014-07-23,Estimate,August 2007,,2007-08-31,July 2014,2014-07-31,October 2012,Actual,2012-10-31,September 2012,Actual,2012-09-30,,Interventional,TEAM-AD,,"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease","CSP #546 - A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease (TEAM-AD)",Completed,,Phase 3,613,Actual,VA Office of Research and Development,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:42:18.318346,2020-02-01 21:42:18.318346,US Department of Veterans Affairs,U.S. Fed,dl-alpha-tocopherol,Drug
NCT00602680,"ClinicalTrials.gov processed this data on January 31, 2020",2008-01-16,,,2009-07-17,2008-01-16,2008-01-28,Estimate,,,,,,,2009-07-17,2009-07-20,Estimate,January 2008,,2008-01-31,July 2009,2009-07-31,July 2008,Actual,2008-07-31,July 2008,Actual,2008-07-31,,Interventional,,,Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease,"A Multicenter, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance and Safety/Tolerability of SSR180711C for 4 Weeks, Using Donepezil as Calibrator, in Patients With Mild Alzheimer's Disease",Terminated,,Phase 2,1,Actual,Sanofi,,5,,Insufficient expected benefit risk,False,,,,True,,,,,,,,,,,,,2020-02-01 19:52:44.951641,2020-02-01 19:52:44.951641,Sanofi,Industry,donepezil,Drug
NCT01018875,"ClinicalTrials.gov processed this data on January 31, 2020",2009-11-20,,2012-02-01,2018-06-01,2009-11-23,2009-11-24,Estimate,,,,2012-02-01,2012-02-03,Estimate,2018-06-01,2018-06-06,Actual,December 2009,,2009-12-31,January 2013,2013-01-31,February 2011,Actual,2011-02-28,February 2011,Actual,2011-02-28,,Interventional,,,Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Active- and Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease",Completed,,Phase 2,242,Actual,AbbVie,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:45:00.201179,2020-02-01 17:45:00.201179,"AbbVie (prior sponsor, Abbott)",Industry,donepezil,Drug
NCT02305836,"ClinicalTrials.gov processed this data on January 31, 2020",2014-11-13,,,2017-05-13,2014-11-28,2014-12-03,Estimate,,,,,,,2017-05-13,2017-05-16,Actual,June 2017,Anticipated,2017-06-30,May 2017,2017-05-31,December 2019,Anticipated,2019-12-31,June 2019,Anticipated,2019-06-30,,Interventional,,,Effect of Electroacupuncture Combined With Donepezil for Treating Alzheimer's Disease,The Effect of Electroacupuncture Combined With Donepezil on Cognitive Function in Alzheimer's Disease Patients: Study Protocol for a Randomized Controlled Trial,Unknown status,Recruiting,Phase 2,334,Anticipated,Guang'anmen Hospital of China Academy of Chinese Medical Sciences,,2,,,False,,,,True,False,False,,,,,,,,,,,2020-02-01 12:05:20.079249,2020-02-01 12:05:20.079249,Guang'anmen Hospital of China Academy of Chinese Medical Sciences,Other,donepezil,Drug
NCT00151398,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-06,,2013-02-07,2013-02-07,2005-09-07,2005-09-08,Estimate,,,,2013-02-07,2013-02-11,Estimate,2013-02-07,2013-02-11,Estimate,September 2005,,2005-09-30,July 2008,2008-07-31,March 2008,Actual,2008-03-31,March 2008,Actual,2008-03-31,,Interventional,,,Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD),"A 3-Month, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Safety, Tolerability, and Efficacy Study Of 3 Doses Of Lecozotan (SRA-333) SR In Outpatients With Mild To Moderate Alzheimer's Disease With Donepezil As Active Control.",Completed,,Phase 2,229,Actual,Wyeth is now a wholly owned subsidiary of Pfizer,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:02:22.166435,2020-02-01 22:02:22.166435,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,Donepezil,Drug
NCT00423228,"ClinicalTrials.gov processed this data on January 31, 2020",2007-01-17,,,2015-01-13,2007-01-17,2007-01-18,Estimate,,,,,,,2015-01-13,2015-01-14,Estimate,February 2007,,2007-02-28,January 2015,2015-01-31,April 2009,Actual,2009-04-30,April 2009,Actual,2009-04-30,,Interventional,BRAINz,,Efficacy Study of a ZT-1 Implant in Patients Suffering From Alzheimer's Disease,"A Randomised, Double-blind, Double-dummy, Oral Donepezil Controlled Study on the Safety and Efficacy of Repeated Monthly Subcutaneous Injections of a Sustained-release Implant of ZT 1 in Patients With Moderate Alzheimer's Disease",Completed,,N/A,228,Actual,Debiopharm International SA,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:48:39.791345,2020-02-01 20:48:39.791345,Debiopharm International SA,Industry,Donepezil,Drug
NCT00501111,"ClinicalTrials.gov processed this data on January 31, 2020",2007-07-12,,,2014-07-22,2007-07-12,2007-07-13,Estimate,,,,,,,2014-07-22,2014-07-23,Estimate,July 2007,,2007-07-31,July 2014,2014-07-31,August 2008,Actual,2008-08-31,August 2008,Actual,2008-08-31,,Interventional,Sirocco,,Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease,"A Multi-centre, Double-blind, Double-dummy, Placebo Controlled Parallel Group Randomized Phase IIb Proof of Concept Study With 3 Oral Dose Groups of AZD3480 or Donepezil During 12 Weeks Treatment in Patients With Alzheimer's Disease",Completed,,Phase 2,659,Actual,AstraZeneca,,3,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:24:11.554357,2020-02-01 20:24:11.554357,AstraZeneca,Industry,Donepezil,Drug
NCT00766363,"ClinicalTrials.gov processed this data on January 31, 2020",2008-10-01,2011-06-16,,2012-04-18,2008-10-02,2008-10-03,Estimate,2011-06-16,2011-07-14,Estimate,,,,2012-04-18,2012-04-20,Estimate,October 2008,,2008-10-31,April 2012,2012-04-30,March 2009,Actual,2009-03-31,March 2009,Actual,2009-03-31,,Interventional,,,"Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1b Safety Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Patients With Mild to Moderate Probable Alzheimer's Disease",Completed,,Phase 1,49,Actual,FORUM Pharmaceuticals Inc,,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:04:53.564244,2020-02-01 19:04:53.564244,FORUM Pharmaceuticals Inc,Industry,Donepezil,Drug
NCT00866060,"ClinicalTrials.gov processed this data on January 31, 2020",2009-03-19,,,2009-03-19,2009-03-19,2009-03-20,Estimate,,,,,,,2009-03-19,2009-03-20,Estimate,February 2008,,2008-02-29,March 2009,2009-03-31,June 2013,Anticipated,2013-06-30,February 2012,Anticipated,2012-02-29,,Interventional,DOMINO-AD,,Donepezil and Memantine in Moderate to Severe Alzheimer's Disease,Donepezil and Memantine in Moderate to Severe Alzheimer's Disease,Unknown status,Recruiting,Phase 4,800,Anticipated,King's College London,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:34:35.920768,2020-02-01 18:34:35.920768,King's College London,Other,Donepezil,Drug
NCT01266525,"ClinicalTrials.gov processed this data on January 31, 2020",2010-12-23,,2016-02-12,2016-02-12,2010-12-23,2010-12-24,Estimate,,,,2016-02-12,2016-03-14,Estimate,2016-02-12,2016-03-14,Estimate,February 2011,,2011-02-28,February 2016,2016-02-29,January 2013,Actual,2013-01-31,January 2013,Actual,2013-01-31,,Interventional,,,Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil,"A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy",Completed,,Phase 2,291,Actual,Sanofi,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:32:09.069267,2020-02-01 16:32:09.069267,Sanofi,Industry,Donepezil,Drug
NCT01466088,"ClinicalTrials.gov processed this data on January 31, 2020",2011-11-02,,2015-05-11,2015-05-11,2011-11-04,2011-11-06,Estimate,,,,2015-05-11,2015-06-03,Estimate,2015-05-11,2015-06-03,Estimate,October 2011,,2011-10-31,July 2014,2014-07-31,May 2014,Actual,2014-05-31,May 2014,Actual,2014-05-31,,Interventional,,,"Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)","Double-Blind, Positive Comparator, Randomized, Parallel Study of Efficacy, Safety, and Tolerability of AZD3480 (TC-1734-226) as Monotherapy in Patients With Mild to Moderate Dementia of the Alzheimer's Type",Completed,,Phase 2,386,Actual,Targacept Inc.,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:38:14.385865,2020-02-01 15:38:14.385865,Targacept Inc.,Industry,Donepezil,Drug
NCT02051335,"ClinicalTrials.gov processed this data on January 31, 2020",2014-01-29,2015-05-17,,2016-12-02,2014-01-29,2014-01-31,Estimate,2015-07-20,2015-08-17,Estimate,,,,2016-12-02,2017-02-01,Estimate,January 2014,,2014-01-31,September 2016,2016-09-30,May 2014,Actual,2014-05-31,May 2014,Actual,2014-05-31,,Interventional,,,Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults,"A Randomized, Double-Blind, Placebo Controlled, 4-Period, Cross-Over Study to Evaluate the Effects of Single Oral Administrations of Roflumilast in Combination With Donepezil on Reversing Scopolamine (Hyoscine) Induced Deficits in Psychomotor and Cognitive Function in Healthy Adults",Completed,,Phase 1,27,Actual,AstraZeneca,,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:05:37.068408,2020-02-01 13:05:37.068408,AstraZeneca,Industry,Donepezil,Drug
NCT02769065,"ClinicalTrials.gov processed this data on January 31, 2020",2016-05-10,2018-05-30,,2019-03-08,2016-05-10,2016-05-11,Estimate,2019-03-08,2019-06-10,Actual,,,,2019-03-08,2019-06-10,Actual,"May 5, 2016",Actual,2016-05-05,March 2019,2019-03-31,"June 8, 2017",Actual,2017-06-08,"June 8, 2017",Actual,2017-06-08,,Interventional,,Safety analysis set (SAS) included all participants who were enrolled and received at least 1 dose of the study drug.,Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants,"A Phase 1 Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Oral Doses of TAK-071 in Healthy Subjects and Subjects With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability and Food Effect of TAK-071 in Healthy Subjects",Terminated,,Phase 1,179,Actual,Takeda,,30,,Terminated prematurely as data from cohort no longer needed due to indication change.,False,,,,False,True,False,,,,,,,,,,,2020-02-01 10:23:19.348529,2020-02-01 10:23:19.348529,Takeda,Industry,Donepezil,Drug
NCT03055741,"ClinicalTrials.gov processed this data on January 31, 2020",2017-02-14,,,2019-08-19,2017-02-15,2017-02-16,Actual,,,,,,,2019-08-19,2019-08-20,Actual,"December 28, 2016",Actual,2016-12-28,August 2019,2019-08-31,August 2019,Actual,2019-08-31,February 2019,Actual,2019-02-28,,Interventional,,,Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA),"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIb, Clinical Study to Evaluate the Safety and Efficacy of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA)",Completed,,Phase 2,180,Actual,"Daehwa Pharmaceutical Co., Ltd.",,3,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 09:26:53.735013,2020-02-01 09:26:53.735013,"Daehwa Pharmaceutical Co., Ltd.",Industry,Donepezil,Drug
NCT03698695,"ClinicalTrials.gov processed this data on January 31, 2020",2018-10-02,,,2020-01-21,2018-10-03,2018-10-09,Actual,,,,,,,2020-01-21,2020-01-22,Actual,"September 27, 2018",Actual,2018-09-27,January 2020,2020-01-31,"December 20, 2019",Actual,2019-12-20,"October 20, 2019",Actual,2019-10-20,,Interventional,,,"A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers","A Double Blind, Placebo-controlled, Randomized, 15-day Treatment, Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil Administered Orally to Healthy Male Volunteers Including a Scopolamine Challenge",Completed,,Phase 1,152,Actual,Theranexus,,3,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 07:39:11.698156,2020-02-01 07:39:11.698156,Theranexus,Industry,Donepezil,Drug
NCT03810794,"ClinicalTrials.gov processed this data on February 06, 2020",2019-01-17,,,2020-02-04,2019-01-17,2019-01-22,Actual,,,,,,,2020-02-04,2020-02-05,Actual,"March 1, 2019",Actual,2019-03-01,February 2020,2020-02-29,"September 30, 2021",Anticipated,2021-09-30,"March 30, 2021",Anticipated,2021-03-30,,Interventional,,,Clinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease,Clinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease: Multicenter Randomized Controlled Trial,Recruiting,,N/A,180,Anticipated,Shanghai University of Traditional Chinese Medicine,,2,,,False,,,,True,False,False,,,False,,,,,,,,2020-02-07 05:57:00.410826,2020-02-07 05:57:00.410826,Shanghai University of Traditional Chinese Medicine,Other,Donepezil,Drug
NCT01255046,"ClinicalTrials.gov processed this data on January 31, 2020",2010-12-03,,,2014-08-19,2010-12-05,2010-12-07,Estimate,,,,,,,2014-08-19,2014-08-20,Estimate,December 2015,,2015-12-31,August 2014,2014-08-31,,,,December 2018,Anticipated,2018-12-31,,Interventional,,,Study of STA-1 as an Add-on Treatment to Donepezil,"A Phase II Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of STA-1 as an Add-on Treatment to Donepezil in Patients With Mild to Moderate Alzheimer's Disease",Unknown status,Not yet recruiting,Phase 2,136,Anticipated,"Sinphar Pharmaceutical Co., Ltd",,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:35:48.924341,2020-02-01 16:35:48.924341,"Sinphar Pharmaceutical Co., Ltd",Other,"Donepezil,",Drug
NCT02051335,"ClinicalTrials.gov processed this data on January 31, 2020",2014-01-29,2015-05-17,,2016-12-02,2014-01-29,2014-01-31,Estimate,2015-07-20,2015-08-17,Estimate,,,,2016-12-02,2017-02-01,Estimate,January 2014,,2014-01-31,September 2016,2016-09-30,May 2014,Actual,2014-05-31,May 2014,Actual,2014-05-31,,Interventional,,,Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults,"A Randomized, Double-Blind, Placebo Controlled, 4-Period, Cross-Over Study to Evaluate the Effects of Single Oral Administrations of Roflumilast in Combination With Donepezil on Reversing Scopolamine (Hyoscine) Induced Deficits in Psychomotor and Cognitive Function in Healthy Adults",Completed,,Phase 1,27,Actual,AstraZeneca,,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:05:37.068408,2020-02-01 13:05:37.068408,AstraZeneca,Industry,Donepezil placebo,Drug
NCT00911807,"ClinicalTrials.gov processed this data on January 31, 2020",2009-04-07,2009-04-07,,2009-06-04,2009-04-07,2009-06-02,Estimate,2009-04-07,2009-06-02,Estimate,,,,2009-06-04,2009-06-10,Estimate,October 2004,,2004-10-31,June 2009,2009-06-30,April 2008,Actual,2008-04-30,April 2008,Actual,2008-04-30,,Interventional,Combi,,Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease,"A Randomized, Double-Blind, Clinical Trial to Compare the Safety and Efficacy of Cerebrolysin and Aricept (Donepezil) and a Combination Therapy in Patients With Probable Alzheimer's Disease (AD)",Completed,,Phase 2,217,Actual,Ever Neuro Pharma GmbH,,3,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:21:22.041636,2020-02-01 18:21:22.041636,Ever Neuro Pharma GmbH,Industry,Donepezil + placebo,Drug
NCT02769065,"ClinicalTrials.gov processed this data on January 31, 2020",2016-05-10,2018-05-30,,2019-03-08,2016-05-10,2016-05-11,Estimate,2019-03-08,2019-06-10,Actual,,,,2019-03-08,2019-06-10,Actual,"May 5, 2016",Actual,2016-05-05,March 2019,2019-03-31,"June 8, 2017",Actual,2017-06-08,"June 8, 2017",Actual,2017-06-08,,Interventional,,Safety analysis set (SAS) included all participants who were enrolled and received at least 1 dose of the study drug.,Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants,"A Phase 1 Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Oral Doses of TAK-071 in Healthy Subjects and Subjects With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability and Food Effect of TAK-071 in Healthy Subjects",Terminated,,Phase 1,179,Actual,Takeda,,30,,Terminated prematurely as data from cohort no longer needed due to indication change.,False,,,,False,True,False,,,,,,,,,,,2020-02-01 10:23:19.348529,2020-02-01 10:23:19.348529,Takeda,Industry,Donepezil Placebo,Drug
NCT00439166,"ClinicalTrials.gov processed this data on January 31, 2020",2007-02-20,,,2018-03-15,2007-02-21,2007-02-23,Estimate,,,,,,,2018-03-15,2018-03-19,Actual,February 2007,,2007-02-28,March 2017,2017-03-31,December 2010,Actual,2010-12-31,April 2010,Actual,2010-04-30,,Interventional,,,Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid,Effects of Treatment With Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid,Completed,,Phase 3,100,Actual,McMaster University,,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:43:09.592414,2020-02-01 20:43:09.592414,Hamilton Health Sciences Corporation,Other,doxycycline,Drug
NCT02792257,"ClinicalTrials.gov processed this data on January 31, 2020",2016-05-26,,,2019-06-25,2016-06-01,2016-06-07,Estimate,,,,,,,2019-06-25,2019-06-27,Actual,"March 1, 2017",Actual,2017-03-01,June 2019,2019-06-30,December 2020,Anticipated,2020-12-31,August 2020,Anticipated,2020-08-31,,Interventional,THC-AD,,Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease (AD) (THC-AD),Pilot Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease (AD) (THC-AD),Recruiting,,Phase 2,160,Anticipated,Johns Hopkins University,,2,,,False,,,,True,True,False,,,,,,,,,Undecided,,2020-02-01 10:18:48.371685,2020-02-01 10:18:48.371685,Johns Hopkins University,Other,Dronabinol (Marinol®),Drug
NCT01294540,"ClinicalTrials.gov processed this data on January 31, 2020",2011-02-10,,,2013-08-28,2011-02-10,2011-02-11,Estimate,,,,,,,2013-08-28,2013-08-29,Estimate,December 2010,,2010-12-31,August 2013,2013-08-31,December 2011,Actual,2011-12-31,October 2011,Actual,2011-10-31,,Interventional,,,"Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort","A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Doses of E2609 in Healthy Subjects and an Elderly Cohort",Completed,,Phase 1,73,Actual,Eisai Inc.,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 16:24:31.268851,2020-02-01 16:24:31.268851,Eisai Inc.,Industry,Drug: E2609,Drug
NCT01969123,"ClinicalTrials.gov processed this data on January 31, 2020",2013-10-21,,,2016-05-02,2013-10-24,2013-10-25,Estimate,,,,,,,2016-05-02,2016-05-03,Estimate,October 2013,,2013-10-31,September 2015,2015-09-30,January 2017,Anticipated,2017-01-31,January 2017,Anticipated,2017-01-31,,Interventional,,,Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease,"A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication",Terminated,,Phase 3,474,Actual,FORUM Pharmaceuticals Inc,,3,,Study has been suspended due to clinical hold.,False,,,,,,,,,,,,,,,,,2020-02-01 13:27:15.310397,2020-02-01 13:27:15.310397,FORUM Pharmaceuticals Inc,Industry,Drug: EVP-6124,Drug
NCT01969136,"ClinicalTrials.gov processed this data on January 31, 2020",2013-10-21,,,2016-05-02,2013-10-24,2013-10-25,Estimate,,,,,,,2016-05-02,2016-05-03,Estimate,October 2013,,2013-10-31,September 2015,2015-09-30,January 2017,Anticipated,2017-01-31,January 2017,Anticipated,2017-01-31,,Interventional,,,Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease,"A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication",Terminated,,Phase 3,403,Actual,FORUM Pharmaceuticals Inc,,3,,Study has been suspended due to clinical hold.,False,,,,,,,,,,,,,,,,,2020-02-01 13:27:15.097847,2020-02-01 13:27:15.097847,FORUM Pharmaceuticals Inc,Industry,Drug: EVP-6124,Drug
NCT01928420,"ClinicalTrials.gov processed this data on January 31, 2020",2012-08-17,,2016-10-07,2016-10-14,2013-08-20,2013-08-26,Estimate,,,,2016-10-14,2016-10-17,Estimate,2016-10-14,2016-10-17,Estimate,April 2007,,2007-04-30,October 2016,2016-10-31,June 2014,Actual,2014-06-30,June 2014,Actual,2014-06-30,,Interventional,,,"A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease","A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease",Completed,,Phase 2,30,Actual,Humanetics Corporation,,2,,,False,,,,True,,,,,,,,,,,Undecided,,2020-02-01 13:38:52.901927,2020-02-01 13:38:52.901927,Humanetics Corporation,Industry,Drug: NIC5-15,Drug
NCT01276353,"ClinicalTrials.gov processed this data on January 31, 2020",2011-01-12,2014-02-24,,2014-08-05,2011-01-12,2011-01-13,Estimate,2014-07-07,2014-08-01,Estimate,,,,2014-08-05,2014-08-08,Estimate,January 2011,,2011-01-31,August 2014,2014-08-31,April 2012,Actual,2012-04-30,April 2012,Actual,2012-04-30,,Interventional,,,A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia,"A Randomized, Double Blind, Parallel-Group Comparison Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia",Completed,,Phase 2,45,Actual,Eisai Inc.,,2,,,False,,,,,,,,,,,,,,,,,2020-02-01 16:29:41.006388,2020-02-01 16:29:41.006388,Eisai Inc.,Industry,E2020,Drug
NCT01404169,"ClinicalTrials.gov processed this data on January 31, 2020",2011-07-26,,,2017-03-07,2011-07-26,2011-07-27,Estimate,,,,,,,2017-03-07,2017-03-08,Actual,September 2011,Actual,2011-09-30,March 2017,2017-03-31,September 2014,Actual,2014-09-30,July 2014,Actual,2014-07-31,,Interventional,,,"A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease","A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease",Completed,,Phase 3,260,Actual,Eisai Inc.,,2,,,False,,,,,,,,,,,,,,,,,2020-02-01 15:54:49.274654,2020-02-01 15:54:49.274654,Eisai Limited,Industry,E2020,Drug
NCT01539031,"ClinicalTrials.gov processed this data on January 31, 2020",2012-02-21,,,2015-09-16,2012-02-24,2012-02-27,Estimate,,,,,,,2015-09-16,2015-09-17,Estimate,March 2012,,2012-03-31,September 2015,2015-09-30,March 2015,Actual,2015-03-31,January 2015,Actual,2015-01-31,,Interventional,,,Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease,"Randomized, Multicenter, Double-blind, Double-dummy, Parallel-Group Study With an Open-label Extension Phase to Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease",Completed,,Phase 3,351,Actual,Eisai Inc.,,2,,,False,,,,,,,,,,,,,,,,,2020-02-01 15:19:37.202868,2020-02-01 15:19:37.202868,"Eisai Co., Ltd.",Industry,E2020,Drug
NCT01221259,"ClinicalTrials.gov processed this data on January 31, 2020",2010-10-13,,,2013-05-20,2010-10-13,2010-10-14,Estimate,,,,,,,2013-05-20,2013-05-22,Estimate,January 2010,,2010-01-31,February 2013,2013-02-28,November 2012,Actual,2012-11-30,October 2011,Actual,2011-10-31,,Interventional,,,"A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects","A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects",Completed,,Phase 1,60,Actual,Eisai Inc.,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 16:46:00.362394,2020-02-01 16:46:00.362394,Eisai Inc.,Industry,E2212,Drug
NCT00500500,"ClinicalTrials.gov processed this data on January 31, 2020",2007-07-11,,,2013-10-10,2007-07-11,2007-07-12,Estimate,,,,,,,2013-10-10,2013-10-11,Estimate,July 2005,,2005-07-31,October 2013,2013-10-31,April 2008,Actual,2008-04-30,April 2008,Actual,2008-04-30,,Interventional,,,Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease,"Effect of EGb 761® on the Ratio of the Isoforms of the Protein Precursor of Beta Amyloid Platelets on Patients With Mild to Moderate Alzheimer's Disease. A Phase II, Randomised, Double-blind Trial, on Parallel Groups Versus Placebo.",Terminated,,Phase 2,40,Actual,Ipsen,,2,,Inability to recruit sufficient number of patients,False,,,,,,,,,,,,,,,,,2020-02-01 20:24:29.403973,2020-02-01 20:24:29.403973,Ipsen,Industry,EGb 761® (Tanakan®),Drug
NCT00880412,"ClinicalTrials.gov processed this data on January 31, 2020",2009-04-10,,,2009-09-18,2009-04-10,2009-04-13,Estimate,,,,,,,2009-09-18,2009-09-21,Estimate,April 2008,,2008-04-30,September 2009,2009-09-30,August 2009,Actual,2009-08-31,June 2009,Actual,2009-06-30,,Interventional,EHT0202/002,,A Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 as Adjunctive Therapy to Acetylcholinesterase Inhibitor in Mild to Moderate Alzheimer's Disease,"A Pilot, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase IIA Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 (40 and 80 mg Bid) as Adjunctive Therapy to Acetylcholinesterase Inhibitor Over a 3-month Period in Ambulatory Patients Suffering From Mild to Moderate Alzheimer's Disease (EHT 0202/002 Protocol)",Completed,,Phase 2,197,Actual,Exonhit,,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:30:27.434852,2020-02-01 18:30:27.434852,Exonhit,Industry,EHT 0202 etazolate,Drug
NCT02322021,"ClinicalTrials.gov processed this data on January 31, 2020",2014-12-17,,2019-06-07,2019-06-07,2014-12-19,2014-12-22,Estimate,,,,2019-06-07,2019-06-10,Actual,2019-06-07,2019-06-10,Actual,"November 26, 2014",Actual,2014-11-26,June 2018,2018-06-30,"July 31, 2022",Anticipated,2022-07-31,"March 27, 2018",Actual,2018-03-27,,Interventional,,,Dose-Finding Study To Evaluate the Safety and Tolerability of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease,"A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Dose-Finding Study To Evaluate the Safety and Tolerability of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease","Active, not recruiting",,Phase 2,71,Actual,Eisai Inc.,,8,,,False,,,,True,True,,,,,,,,,,Undecided,,2020-02-01 12:01:27.666580,2020-02-01 12:01:27.666580,Eisai Inc.,Industry,Elenbecestat (E2609),Drug
NCT02956486,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-03,,,2019-09-18,2016-11-03,2016-11-06,Estimate,,,,,,,2019-09-18,2019-09-19,Actual,"October 20, 2016",Actual,2016-10-20,September 2018,2018-09-30,"November 21, 2023",Anticipated,2023-11-21,"November 21, 2023",Anticipated,2023-11-21,,Interventional,MissionAD1,,A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease,"A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease","Active, not recruiting",,Phase 3,950,Anticipated,Eisai Inc.,,3,,,False,,,,True,True,,,,,,,,,,Undecided,,2020-02-01 09:45:53.235437,2020-02-01 09:45:53.235437,"Eisai Co., Ltd.",Industry,Elenbecestat (E2609),Drug
NCT03036280,"ClinicalTrials.gov processed this data on January 31, 2020",2017-01-26,,,2019-09-18,2017-01-26,2017-01-30,Estimate,,,,,,,2019-09-18,2019-09-19,Actual,"December 29, 2016",Actual,2016-12-29,September 2019,2019-09-30,"November 21, 2023",Anticipated,2023-11-21,"November 21, 2023",Anticipated,2023-11-21,,Interventional,MissionAD2,,A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease_,"A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease","Active, not recruiting",,Phase 3,950,Anticipated,Eisai Inc.,,3,,,False,,,,True,True,,,,,,,,,,Undecided,,2020-02-01 09:30:30.434411,2020-02-01 09:30:30.434411,"Eisai Co., Ltd.",Industry,Elenbecestat (E2609),Drug
NCT00568776,"ClinicalTrials.gov processed this data on January 31, 2020",2007-12-04,2011-09-27,,2019-10-17,2007-12-04,2007-12-06,Estimate,2012-03-01,2012-03-29,Estimate,,,,2019-10-17,2019-11-01,Actual,December 2007,,2007-12-31,October 2019,2019-10-31,May 2010,Actual,2010-05-31,May 2010,Actual,2010-05-31,,Interventional,,,ELND005 in Patients With Mild to Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral ELND005 (AZD-103) in Alzheimer's Disease",Completed,,Phase 2,353,Actual,"OPKO Health, Inc.","The two high dose groups of ELND005 were discontinued before study end, so the efficacy analysis was based only on placebo and ELND005 250 mg bid groups.",4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:01:52.395629,2020-02-01 20:01:52.395629,"OPKO Health, Inc.",Industry,ELND005,Drug
NCT01735630,"ClinicalTrials.gov processed this data on January 31, 2020",2012-11-25,2016-04-07,,2019-10-17,2012-11-27,2012-11-28,Estimate,2016-07-06,2016-08-15,Estimate,,,,2019-10-17,2019-10-21,Actual,November 2012,,2012-11-30,October 2019,2019-10-31,May 2015,Actual,2015-05-31,May 2015,Actual,2015-05-31,,Interventional,,,Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease,"A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease",Completed,,Phase 2,350,Actual,"OPKO Health, Inc.",,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 14:29:01.435468,2020-02-01 14:29:01.435468,"OPKO Health, Inc.",Industry,ELND005,Drug
NCT01047254,"ClinicalTrials.gov processed this data on January 31, 2020",2010-01-11,,,2017-05-08,2010-01-11,2010-01-12,Estimate,,,,,,,2017-05-08,2017-05-09,Actual,January 2010,,2010-01-31,May 2017,2017-05-31,July 2014,Actual,2014-07-31,July 2014,Actual,2014-07-31,,Interventional,APA-AD,,Bupropion for the Treatment of Apathy in Alzheimer's Dementia,"A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Bupropion for the Treatment of Apathy in Alzheimer's Dementia(Apa-AD)",Completed,,Phase 3,110,Actual,"University Hospital, Bonn",,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:37:20.131108,2020-02-01 17:37:20.131108,"University Hospital, Bonn",Other,Elontril,Drug
NCT01614886,"ClinicalTrials.gov processed this data on January 31, 2020",2012-06-06,2015-04-16,,2016-06-30,2012-06-07,2012-06-08,Estimate,2015-04-16,2015-05-12,Estimate,,,,2016-06-30,2016-08-01,Estimate,July 2012,,2012-07-31,June 2015,2015-06-30,May 2014,Actual,2014-05-31,May 2014,Actual,2014-05-31,,Interventional,,"Randomized set (RAN) The RAN consisted of all randomized patients. Patients were analyzed according to the treatment group they were assigned to at randomization. A patient was diagnosed of dementia with Lewy Bodies, different from AD, after randomization and was excluded from all analysis (SAF and FAS).","Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)","A 24-week, Multicenter, Parallel-group, Randomized,Double-blind Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Methods of Rivastigmine Patch (ENA713D/ONO-2540) in Patients With Mild to Moderate Alzheimer's Disease (MMSE 10-20)",Completed,,Phase 3,216,Actual,Novartis,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:00:51.368993,2020-02-01 15:00:51.368993,Novartis Pharmaceuticals,Industry,ENA713,Drug
NCT00580931,"ClinicalTrials.gov processed this data on January 31, 2020",2007-12-24,,,2017-01-23,2007-12-26,2007-12-27,Estimate,,,,,,,2017-01-23,2017-01-25,Estimate,January 2008,Actual,2008-01-31,January 2017,2017-01-31,July 2014,Actual,2014-07-31,July 2014,Actual,2014-07-31,,Interventional,,,Safety Study of Nicotinamide to Treat Alzheimer's Disease,Efficacy of Nicotinamide for the Treatment of Alzheimer's Disease,Completed,,Phase 1/Phase 2,50,Actual,"University of California, Irvine",,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:58:33.890191,2020-02-01 19:58:33.890191,"University of California, Irvine",Other,Enduramide placebo,Drug
NCT00951834,"ClinicalTrials.gov processed this data on January 31, 2020",2009-08-03,,,2018-11-28,2009-08-03,2009-08-04,Estimate,,,,,,,2018-11-28,2018-11-29,Actual,October 2009,,2009-10-31,November 2018,2018-11-30,February 2015,Actual,2015-02-28,February 2015,Actual,2015-02-28,,Interventional,SUN-AK,,Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease,Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease,Completed,,Phase 2/Phase 3,21,Actual,"Charite University, Berlin, Germany",,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:09:10.750449,2020-02-01 18:09:10.750449,"Charite University, Berlin, Germany",Other,Epigallocatechin-Gallate,Drug
NCT00702780,"ClinicalTrials.gov processed this data on January 31, 2020",2008-06-15,2014-04-10,,2014-05-13,2008-06-18,2008-06-20,Estimate,2014-05-13,2014-06-13,Estimate,,,,2014-05-13,2014-06-13,Estimate,November 2008,,2008-11-30,May 2014,2014-05-31,September 2011,Actual,2011-09-30,September 2011,Actual,2011-09-30,,Interventional,ESAD,,Progression Delaying Effect of Escitalopram in Alzheimer's Disease,"Multi-center, Randomized, Placebo-controlled, Double-blind Clinical Trial of Escitalopram on the Progression Delaying Effect in Alzheimer's Disease",Completed,,N/A,74,Actual,Seoul National University Hospital,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:23:05.471913,2020-02-01 19:23:05.471913,Seoul National University Hospital,Other,escitalopram,Drug
NCT01119638,"ClinicalTrials.gov processed this data on January 31, 2020",2010-05-06,,,2015-06-23,2010-05-06,2010-05-07,Estimate,,,,,,,2015-06-23,2015-06-24,Estimate,April 2008,,2008-04-30,June 2015,2015-06-30,May 2010,Actual,2010-05-31,April 2010,Actual,2010-04-30,,Interventional,EscBPSD,,Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone,Post Marketing Study of Escitalopram Versus Risperidone for the Treatment of Behavioral and Psychological Symptoms Amongst Alzheimer's Disease Patients,Completed,,Phase 4,40,Actual,Abarbanel Mental Health Center,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:16:52.586627,2020-02-01 17:16:52.586627,Abarbanel Mental Health Center,Other,Escitalopram,Drug
NCT03108846,"ClinicalTrials.gov processed this data on January 31, 2020",2017-04-06,,,2019-01-16,2017-04-06,2017-04-11,Actual,,,,,,,2019-01-16,2019-01-17,Actual,"January 3, 2018",Actual,2018-01-03,January 2019,2019-01-31,August 2022,Anticipated,2022-08-31,December 2021,Anticipated,2021-12-31,,Interventional,S-CitAD,,Escitalopram for Agitation in Alzheimer's Disease,Escitalopram for Agitation in Alzheimer's Disease,Recruiting,,Phase 3,392,Anticipated,JHSPH Center for Clinical Trials,,2,,,False,,,,True,True,False,,,True,,,,,,No,,2020-02-01 09:17:38.732615,2020-02-01 09:17:38.732615,JHSPH Center for Clinical Trials,Other,Escitalopram,Drug
NCT01661673,"ClinicalTrials.gov processed this data on January 31, 2020",2012-08-03,,,2014-01-10,2012-08-06,2012-08-09,Estimate,,,,,,,2014-01-10,2014-01-13,Estimate,November 2012,,2012-11-30,January 2014,2014-01-31,,,,October 2013,Actual,2013-10-31,,Interventional,,,"Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease","Safety, Tolerability, Pharmacokinetics, and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease",Completed,,Phase 2,52,Actual,FORUM Pharmaceuticals Inc,,5,,,False,,,,False,,,,,,,,,,,,,2020-02-01 14:49:17.382489,2020-02-01 14:49:17.382489,FORUM Pharmaceuticals Inc,Industry,EVP-0962,Drug
NCT01073228,"ClinicalTrials.gov processed this data on January 31, 2020",2010-02-19,,2013-02-19,2014-03-28,2010-02-22,2010-02-23,Estimate,,,,2013-02-19,2013-02-22,Estimate,2014-03-28,2014-04-25,Estimate,April 2010,,2010-04-30,February 2013,2013-02-28,February 2012,Actual,2012-02-29,November 2011,Actual,2011-11-30,,Interventional,,,Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease,"A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease",Completed,,Phase 2,409,Actual,FORUM Pharmaceuticals Inc,,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 17:30:03.549834,2020-02-01 17:30:03.549834,FORUM Pharmaceuticals Inc,Industry,EVP-6124,Drug
NCT02004392,"ClinicalTrials.gov processed this data on January 31, 2020",2013-11-27,,,2016-05-02,2013-12-03,2013-12-09,Estimate,,,,,,,2016-05-02,2016-05-03,Estimate,June 2014,,2014-06-30,September 2015,2015-09-30,August 2017,Anticipated,2017-08-31,August 2017,Anticipated,2017-08-31,,Interventional,,,Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025,A 26-Week Extension Study of the Safety and Clinical Effects of EVP-6124 in Subjects With Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication,Terminated,,Phase 3,348,Actual,FORUM Pharmaceuticals Inc,,2,,Study has been suspended due to clinical hold.,False,,,,True,,,,,,,,,,,,,2020-02-01 13:17:38.089038,2020-02-01 13:17:38.089038,FORUM Pharmaceuticals Inc,Industry,EVP-6124,Drug
NCT02246075,"ClinicalTrials.gov processed this data on January 31, 2020",2014-09-17,,,2015-10-13,2014-09-19,2014-09-22,Estimate,,,,,,,2015-10-13,2015-10-15,Estimate,July 2015,,2015-07-31,October 2015,2015-10-31,,,,October 2016,Anticipated,2016-10-31,,Interventional,,,Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 24-Week, Phase 2 Study of Two Doses of EVP-6124 Hydrochloride or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently Receiving Memantine Medication With or Without Additional Acetylcholinesterase Inhibitor Co-Medication",Withdrawn,,Phase 2,0,Actual,FORUM Pharmaceuticals Inc,,3,,Forum has decided not to proceed with this study at this time.,False,,,,True,,,,,,,,,,,,,2020-02-01 12:18:59.203192,2020-02-01 12:18:59.203192,FORUM Pharmaceuticals Inc,Industry,EVP-6124,Drug
NCT00766363,"ClinicalTrials.gov processed this data on January 31, 2020",2008-10-01,2011-06-16,,2012-04-18,2008-10-02,2008-10-03,Estimate,2011-06-16,2011-07-14,Estimate,,,,2012-04-18,2012-04-20,Estimate,October 2008,,2008-10-31,April 2012,2012-04-30,March 2009,Actual,2009-03-31,March 2009,Actual,2009-03-31,,Interventional,,,"Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1b Safety Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Patients With Mild to Moderate Probable Alzheimer's Disease",Completed,,Phase 1,49,Actual,FORUM Pharmaceuticals Inc,,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:04:53.564244,2020-02-01 19:04:53.564244,FORUM Pharmaceuticals Inc,Industry,EVP-6124 (0.1 mg/day),Drug
NCT00766363,"ClinicalTrials.gov processed this data on January 31, 2020",2008-10-01,2011-06-16,,2012-04-18,2008-10-02,2008-10-03,Estimate,2011-06-16,2011-07-14,Estimate,,,,2012-04-18,2012-04-20,Estimate,October 2008,,2008-10-31,April 2012,2012-04-30,March 2009,Actual,2009-03-31,March 2009,Actual,2009-03-31,,Interventional,,,"Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1b Safety Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Patients With Mild to Moderate Probable Alzheimer's Disease",Completed,,Phase 1,49,Actual,FORUM Pharmaceuticals Inc,,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:04:53.564244,2020-02-01 19:04:53.564244,FORUM Pharmaceuticals Inc,Industry,EVP-6124 (0.3 mg/day),Drug
NCT00766363,"ClinicalTrials.gov processed this data on January 31, 2020",2008-10-01,2011-06-16,,2012-04-18,2008-10-02,2008-10-03,Estimate,2011-06-16,2011-07-14,Estimate,,,,2012-04-18,2012-04-20,Estimate,October 2008,,2008-10-31,April 2012,2012-04-30,March 2009,Actual,2009-03-31,March 2009,Actual,2009-03-31,,Interventional,,,"Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1b Safety Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Patients With Mild to Moderate Probable Alzheimer's Disease",Completed,,Phase 1,49,Actual,FORUM Pharmaceuticals Inc,,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:04:53.564244,2020-02-01 19:04:53.564244,FORUM Pharmaceuticals Inc,Industry,EVP-6124 (1.0 mg/day),Drug
NCT01255163,"ClinicalTrials.gov processed this data on January 31, 2020",2010-12-04,2017-11-08,,2018-01-23,2010-12-04,2010-12-07,Estimate,2018-01-23,2018-02-22,Actual,,,,2018-01-23,2018-02-22,Actual,"November 21, 2010",,2010-11-21,January 2018,2018-01-31,"November 18, 2016",Actual,2016-11-18,"November 18, 2016",Actual,2016-11-18,,Interventional,,"The baseline analysis population includes 27 participants who underwent randomization and received at least one dose of experimental medication. Of those 27, we have at least one outcome measure (i.e. at least the 6 months follow-up data point) for 21 participants. Of those 21, 18 completed the study (i.e. reached 18 months).",A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease,A Pilot Study of Exendin-4 in Alzheimer s Disease,Terminated,,Phase 2,57,Actual,National Institutes of Health Clinical Center (CC),The study was terminated after AstraZeneca withdrew support. Early termination lead to small number of subjects analyzed.,2,,AstraZeneca withdrew support for the study.,False,,,,True,True,False,,,False,,,,,,,,2020-02-01 16:35:47.564810,2020-02-01 16:35:47.564810,National Institute on Aging (NIA),NIH,Exendin-4 SC,Drug
NCT01254773,"ClinicalTrials.gov processed this data on January 31, 2020",2010-12-03,,2014-02-26,2014-04-21,2010-12-03,2010-12-07,Estimate,,,,2014-02-26,2014-03-26,Estimate,2014-04-21,2014-05-09,Estimate,December 2010,,2010-12-31,April 2014,2014-04-30,March 2013,Actual,2013-03-31,January 2013,Actual,2013-01-31,,Interventional,SUMMIT AD,,Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Biomarker, Safety, and Pharmacokinetic Study of Bapineuzumab (AAB-001) Administered Subcutaneously at Monthly Intervals in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,146,Actual,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:35:52.472913,2020-02-01 16:35:52.472913,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Industry,Experimental Bapineuzumab,Drug
NCT04098666,"ClinicalTrials.gov processed this data on January 31, 2020",2019-09-19,,,2019-11-07,2019-09-19,2019-09-23,Actual,,,,,,,2019-11-07,2019-11-12,Actual,"August 1, 2020",Anticipated,2020-08-01,November 2019,2019-11-30,"April 30, 2024",Anticipated,2024-04-30,"March 30, 2024",Anticipated,2024-03-30,,Interventional,MAP,,Metformin in Alzheimer's Dementia Prevention,Metformin in Alzheimer's Dementia Prevention,Not yet recruiting,,Phase 2/Phase 3,370,Anticipated,Columbia University,,2,,,False,,,,True,True,False,,,,,,After reporting of main results,,,Yes,"All datasets used/generated on the project will be made accessible and reusable by qualified individuals other than the original data generators via web-based resources with the capacity to store large and diverse datasets (such as data about clinical phenotypes, genetics, epigenetics, proteomics, and metabolomics) to enable multiple parallel approaches to data analysis and interpretation. All analytical methodologies will be made fully reproducible and transparent so that results can be vetted and existing analysis techniques quickly applied to new application areas. We will comply with the data sharing arrangement decided by NIA.",2020-02-01 06:40:23.267307,2020-02-01 06:40:23.267307,Columbia University,Other,extended release metformin,Drug
NCT02380573,"ClinicalTrials.gov processed this data on January 31, 2020",2015-02-24,,,2019-05-06,2015-02-27,2015-03-05,Estimate,,,,,,,2019-05-06,2019-05-08,Actual,July 2015,,2015-07-31,April 2019,2019-04-30,July 2023,Anticipated,2023-07-31,July 2022,Anticipated,2022-07-31,,Interventional,MB2,,"Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease","Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease",Suspended,,Phase 2,117,Actual,The University of Texas Health Science Center at San Antonio,,8,,Pending enrollment of new subjects if new funding obtained,False,,,,True,,,,,,,,,,,,,2020-02-01 11:48:30.714225,2020-02-01 11:48:30.714225,The University of Texas Health Science Center at San Antonio,Other,FD&C Blue # 2,Drug
NCT02667496,"ClinicalTrials.gov processed this data on January 31, 2020",2016-01-26,,,2017-04-05,2016-01-28,2016-01-29,Estimate,,,,,,,2017-04-05,2017-04-07,Actual,November 2016,,2016-11-30,April 2017,2017-04-30,"March 31, 2017",Actual,2017-03-31,"March 31, 2017",Actual,2017-03-31,,Interventional,,,Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease,A Study Examining the Safety and Activity of Innate Immune System Stimulation With Leukine® (Sargramostim) to Reduce Brain Amyloid Load in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease,Withdrawn,,Phase 2,0,Actual,Sanofi,,2,,Slow recruitment,False,,,,True,,,,,,,,,,,,,2020-02-01 10:44:33.482652,2020-02-01 10:44:33.482652,Sanofi,Industry,Florbetapir F18,Drug
NCT02500784,"ClinicalTrials.gov processed this data on January 31, 2020",2015-05-19,,,2019-04-01,2015-07-15,2015-07-17,Estimate,,,,,,,2019-04-01,2019-04-03,Actual,January 2023,Anticipated,2023-01-31,April 2019,2019-04-30,July 2025,Anticipated,2025-07-31,April 2025,Anticipated,2025-04-30,,Interventional,,,Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease,Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease,Suspended,,Phase 2,60,Anticipated,Palo Alto Veterans Institute for Research,,2,,"Funding ran out before study started, prior PI left institution.",False,,,,False,True,False,,,,,,,,,,,2020-02-01 11:21:41.477120,2020-02-01 11:21:41.477120,Palo Alto Veterans Institute for Research,Other,Formoterol A,Drug
NCT03082755,"ClinicalTrials.gov processed this data on January 31, 2020",2017-03-06,,,2019-10-23,2017-03-10,2017-03-17,Actual,,,,,,,2019-10-23,2019-10-25,Actual,"July 1, 2017",Actual,2017-07-01,October 2019,2019-10-31,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2021",Anticipated,2021-03-31,,Interventional,,,Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease,Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease,Recruiting,,Phase 4,136,Anticipated,University of Texas at Austin,,2,,,False,,,,True,True,False,,,False,,,Data will be made available 6 months after publication of the main study findings and will be available in perpetuity.,IPD will be publicly available via the following url,https://dataverse.tdl.org/dataset.xhtml?persistentId=doi:10.18738/T8/GDSFSQ,Yes,Data have been prepared for sharing with other investigators. All collected individual participant data (IPD) can be accessed at https://dataverse.tdl.org/dataset.xhtml?persistentId=doi:10.18738/T8/GDSFSQ after publication of the main study findings,2020-02-01 09:22:16.586579,2020-02-01 09:22:16.586579,University of Texas at Austin,Other,Gabapentin Enacarbil,Drug
NCT00679627,"ClinicalTrials.gov processed this data on January 31, 2020",2008-05-15,2013-04-23,,2013-09-10,2008-05-15,2008-05-19,Estimate,2013-07-30,2013-09-02,Estimate,,,,2013-09-10,2013-09-19,Estimate,June 2008,,2008-06-30,September 2013,2013-09-30,May 2012,Actual,2012-05-31,April 2012,Actual,2012-04-30,,Interventional,,,A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-controlled Trial of Long-term (2-year) Treatment of Galantamine in Mild to Moderately-Severe Alzheimer's Disease",Terminated,,Phase 3,2051,Actual,"Janssen Research & Development, LLC",,2,,"Due to a pre-specified imbalance of deaths between treatment groups, the DSMB recommended early
    termination of the trial",False,,,,,,,,,,,,,,,,,2020-02-01 19:29:53.904574,2020-02-01 19:29:53.904574,"Janssen Research & Development, LLC",Industry,Galantamine,Drug
NCT01921972,"ClinicalTrials.gov processed this data on January 31, 2020",2013-08-07,,,2013-08-12,2013-08-12,2013-08-14,Estimate,,,,,,,2013-08-12,2013-08-14,Estimate,November 2004,,2004-11-30,August 2013,2013-08-31,May 2009,Actual,2009-05-31,November 2008,Actual,2008-11-30,,Interventional,AD-Combi,,The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease,"Competence Network - Dementia (BMBF) ""Pharmacological and Psychosocial Treatment"" (Modul E.2) Part II: The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease",Completed,,Phase 4,232,Actual,"Charite University, Berlin, Germany",,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:40:38.562936,2020-02-01 13:40:38.562936,"Charite University, Berlin, Germany",Other,Galantamine CR,Drug
NCT01760005,"ClinicalTrials.gov processed this data on January 31, 2020",2012-12-26,,,2019-10-01,2012-12-31,2013-01-03,Estimate,,,,,,,2019-10-01,2019-10-03,Actual,December 2012,,2012-12-31,October 2019,2019-10-31,March 2021,Anticipated,2021-03-31,December 2020,Anticipated,2020-12-31,,Interventional,DIAN-TU,,Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.,"A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease",Recruiting,,Phase 2/Phase 3,490,Anticipated,Washington University School of Medicine,,5,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:23:00.489600,2020-02-01 14:23:00.489600,Washington University School of Medicine,Other,Gantenerumab,Drug
NCT01617577,"ClinicalTrials.gov processed this data on January 31, 2020",2011-11-08,2012-06-29,,2012-11-26,2012-06-11,2012-06-12,Estimate,2012-11-26,2012-12-27,Estimate,,,,2012-11-26,2012-12-27,Estimate,June 2009,,2009-06-30,June 2012,2012-06-30,February 2012,Actual,2012-02-29,February 2012,Actual,2012-02-29,,Interventional,FFAD,,Efficacy and Safety of Filgrastim in Alzheimer's Disease,Efficacy and Safety of Filgrastim as a Pro‐Cognitive Agent in Alzheimer's Disease,Completed,,Phase 1/Phase 2,8,Actual,University of South Florida,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:00:17.017452,2020-02-01 15:00:17.017452,University of South Florida,Other,G-CSF; filgrastim,Drug
NCT03520998,"ClinicalTrials.gov processed this data on January 31, 2020",2018-04-25,,,2019-07-15,2018-05-08,2018-05-11,Actual,,,,,,,2019-07-15,2019-07-16,Actual,"April 16, 2018",Actual,2018-04-16,August 2018,2018-08-31,"May 24, 2019",Actual,2019-05-24,"May 24, 2019",Actual,2019-05-24,,Interventional,,,A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease,"A Prospective, Randomized, Double-Blind, Dose-Comparison Concurrent Control Study to Assess the Safety and Tolerability of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,40,Actual,"Alkahest, Inc.",,2,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 08:06:55.302057,2020-02-01 08:06:55.302057,"Alkahest, Inc.",Industry,GRF6019,Drug
NCT03765762,"ClinicalTrials.gov processed this data on January 31, 2020",2018-11-29,,,2020-01-29,2018-12-04,2018-12-05,Actual,,,,,,,2020-01-29,2020-01-31,Estimate,"January 15, 2019",Actual,2019-01-15,May 2019,2019-05-31,March 2020,Anticipated,2020-03-31,March 2020,Anticipated,2020-03-31,,Interventional,,,A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of Pulsed GRF6019 Infusions in Subjects With Severe Alzheimer's Disease","Active, not recruiting",,Phase 2,20,Anticipated,"Alkahest, Inc.",,2,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-04 05:13:33.658930,2020-02-04 05:13:33.658930,"Alkahest, Inc.",Industry,GRF6019,Drug
NCT01766336,"ClinicalTrials.gov processed this data on January 31, 2020",2013-01-08,2016-04-07,,2019-10-17,2013-01-10,2013-01-11,Estimate,2016-04-07,2016-05-13,Estimate,,,,2019-10-17,2019-10-21,Actual,January 2013,,2013-01-31,October 2019,2019-10-31,August 2015,Actual,2015-08-31,August 2015,Actual,2015-08-31,,Interventional,,,A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease,A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease,Terminated,,Phase 2,296,Actual,"OPKO Health, Inc.",,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 14:21:02.495392,2020-02-01 14:21:02.495392,"OPKO Health, Inc.",Industry,Group 1 ELND005,Drug
NCT01766336,"ClinicalTrials.gov processed this data on January 31, 2020",2013-01-08,2016-04-07,,2019-10-17,2013-01-10,2013-01-11,Estimate,2016-04-07,2016-05-13,Estimate,,,,2019-10-17,2019-10-21,Actual,January 2013,,2013-01-31,October 2019,2019-10-31,August 2015,Actual,2015-08-31,August 2015,Actual,2015-08-31,,Interventional,,,A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease,A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease,Terminated,,Phase 2,296,Actual,"OPKO Health, Inc.",,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 14:21:02.495392,2020-02-01 14:21:02.495392,"OPKO Health, Inc.",Industry,Group 2 ELND005,Drug
NCT00719394,"ClinicalTrials.gov processed this data on January 31, 2020",2008-07-17,,,2009-07-08,2008-07-18,2008-07-21,Estimate,,,,,,,2009-07-08,2009-07-10,Estimate,March 2008,,2008-03-31,July 2009,2009-07-31,August 2008,Actual,2008-08-31,August 2008,Actual,2008-08-31,,Interventional,,,Study Evaluating Safety of GSI 136 in Young and Elderly Japanese Males,"Ascending Single-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-136 Administered Orally to Healthy Japanese Male Subjects and Healthy Japanese Elderly Male Subjects",Completed,,Phase 1,72,Anticipated,Wyeth is now a wholly owned subsidiary of Pfizer,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:17:48.931302,2020-02-01 19:17:48.931302,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,GSI 136,Drug
NCT01009255,"ClinicalTrials.gov processed this data on January 31, 2020",2009-11-05,,,2017-04-11,2009-11-05,2009-11-06,Estimate,,,,,,,2017-04-11,2017-04-13,Actual,"November 2, 2009",Actual,2009-11-02,April 2017,2017-04-30,"November 10, 2010",Actual,2010-11-10,"November 10, 2010",Actual,2010-11-10,,Interventional,,,Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease,"A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of the H3 Receptor Antagonist, GSK239512 in Subjects With Mild to Moderate Alzheimer's Disease.",Completed,,Phase 2,196,Actual,GlaxoSmithKline,,2,,,False,,,,False,False,False,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 17:48:00.502559,2020-02-01 17:48:00.502559,GlaxoSmithKline,Industry,GSK239512,Drug
NCT03959553,"ClinicalTrials.gov processed this data on January 31, 2020",2019-05-08,,,2019-05-23,2019-05-21,2019-05-22,Actual,,,,,,,2019-05-23,2019-05-28,Actual,"September 1, 2019",Anticipated,2019-09-01,May 2019,2019-05-31,"February 28, 2022",Anticipated,2022-02-28,"August 31, 2021",Anticipated,2021-08-31,,Interventional,,,GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, Phase IIa Clinical Trial to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of Moderate Alzheimer's Disease",Not yet recruiting,,Phase 2,90,Anticipated,GemVax & Kael,,3,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 07:00:23.340260,2020-02-01 07:00:23.340260,GemVax & Kael,Industry,GV1001,Drug
NCT03184467,"ClinicalTrials.gov processed this data on January 31, 2020",2017-06-09,,,2017-06-09,2017-06-09,2017-06-12,Actual,,,,,,,2017-06-09,2017-06-12,Actual,June 2017,Anticipated,2017-06-30,June 2017,2017-06-30,June 2019,Anticipated,2019-06-30,June 2019,Anticipated,2019-06-30,,Interventional,,,Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Design, Prospective, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Donepezil and Combined With GV1001 in Alzheimer Patients",Unknown status,Recruiting,Phase 2,90,Anticipated,GemVax & Kael,,3,,,False,,,,False,False,False,,,,,,,,,Undecided,,2020-02-01 09:04:28.719332,2020-02-01 09:04:28.719332,GemVax & Kael,Industry,GV1001 0.56 mg,Drug
NCT03184467,"ClinicalTrials.gov processed this data on January 31, 2020",2017-06-09,,,2017-06-09,2017-06-09,2017-06-12,Actual,,,,,,,2017-06-09,2017-06-12,Actual,June 2017,Anticipated,2017-06-30,June 2017,2017-06-30,June 2019,Anticipated,2019-06-30,June 2019,Anticipated,2019-06-30,,Interventional,,,Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Design, Prospective, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Donepezil and Combined With GV1001 in Alzheimer Patients",Unknown status,Recruiting,Phase 2,90,Anticipated,GemVax & Kael,,3,,,False,,,,False,False,False,,,,,,,,,Undecided,,2020-02-01 09:04:28.719332,2020-02-01 09:04:28.719332,GemVax & Kael,Industry,GV1001 1.12 mg,Drug
NCT00009217,"ClinicalTrials.gov processed this data on January 31, 2020",2001-01-23,,,2016-05-23,2001-01-23,2001-01-24,Estimate,,,,,,,2016-05-23,2016-05-24,Estimate,January 1999,,1999-01-31,February 2012,2012-02-29,December 2004,Actual,2004-12-31,December 2004,Actual,2004-12-31,,Interventional,,,Treatment of Behavioral Symptoms in Alzheimer's Disease,Treatment of Behavioral Symptoms in Alzheimer's Disease,Completed,,Phase 4,44,Actual,New York State Psychiatric Institute,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 22:48:44.873571,2020-02-01 22:48:44.873571,New York State Psychiatric Institute,Other,Haloperidol-Haloperidol,Drug
NCT00009217,"ClinicalTrials.gov processed this data on January 31, 2020",2001-01-23,,,2016-05-23,2001-01-23,2001-01-24,Estimate,,,,,,,2016-05-23,2016-05-24,Estimate,January 1999,,1999-01-31,February 2012,2012-02-29,December 2004,Actual,2004-12-31,December 2004,Actual,2004-12-31,,Interventional,,,Treatment of Behavioral Symptoms in Alzheimer's Disease,Treatment of Behavioral Symptoms in Alzheimer's Disease,Completed,,Phase 4,44,Actual,New York State Psychiatric Institute,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 22:48:44.873571,2020-02-01 22:48:44.873571,New York State Psychiatric Institute,Other,Haloperidol-Placebo,Drug
NCT03790709,"ClinicalTrials.gov processed this data on January 31, 2020",2018-12-24,,,2019-11-17,2018-12-31,2019-01-02,Actual,,,,,,,2019-11-17,2019-11-19,Actual,"July 3, 2018",Actual,2018-07-03,August 2019,2019-08-31,"December 31, 2021",Anticipated,2021-12-31,"September 30, 2021",Anticipated,2021-09-30,,Interventional,,,ANAVEX2-73 for Treatment of Early Alzheimer's Disease,"A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy Trial of ANAVEX2-73 for the Treatment of Early Alzheimer's Disease (AD)",Recruiting,,Phase 2/Phase 3,450,Anticipated,Anavex Life Sciences Corp.,,3,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 07:25:39.943948,2020-02-01 07:25:39.943948,Anavex Life Sciences Corp.,Industry,High dose ANAVEX2-73,Drug
NCT02291783,"ClinicalTrials.gov processed this data on January 31, 2020",2014-10-07,,,2017-06-19,2014-11-11,2014-11-14,Estimate,,,,,,,2017-06-19,2017-06-20,Actual,November 2013,,2013-11-30,June 2017,2017-06-30,July 2014,Actual,2014-07-31,July 2014,Actual,2014-07-31,,Interventional,,,"Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive Impairment","A Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of HTL0009936 in Healthy Subjects",Completed,,Phase 1,108,Actual,Heptares Therapeutics Limited,,2,,,False,,,,False,,,,,,,,,,,No,,2020-02-01 12:08:34.341587,2020-02-01 12:08:34.341587,Heptares Therapeutics Limited,Industry,HTL0009936,Drug
NCT02291783,"ClinicalTrials.gov processed this data on January 31, 2020",2014-10-07,,,2017-06-19,2014-11-11,2014-11-14,Estimate,,,,,,,2017-06-19,2017-06-20,Actual,November 2013,,2013-11-30,June 2017,2017-06-30,July 2014,Actual,2014-07-31,July 2014,Actual,2014-07-31,,Interventional,,,"Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive Impairment","A Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of HTL0009936 in Healthy Subjects",Completed,,Phase 1,108,Actual,Heptares Therapeutics Limited,,2,,,False,,,,False,,,,,,,,,,,No,,2020-02-01 12:08:34.341587,2020-02-01 12:08:34.341587,Heptares Therapeutics Limited,Industry,HTL0009936 placebo,Drug
NCT00385684,"ClinicalTrials.gov processed this data on January 31, 2020",2006-10-06,2014-06-02,,2015-11-18,2006-10-06,2006-10-11,Estimate,2015-11-18,2015-11-20,Estimate,,,,2015-11-18,2015-11-20,Estimate,October 2007,,2007-10-31,November 2015,2015-11-30,June 2014,Actual,2014-06-30,December 2011,Actual,2011-12-31,,Interventional,LDOT,Veterans with severe dementia residing in VA nursing home.,Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT),Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT),Completed,,Phase 4,11,Actual,VA Office of Research and Development,,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:00:50.049144,2020-02-01 21:00:50.049144,VA Office of Research and Development,U.S. Fed,hydrocodone/APAP,Drug
NCT00385684,"ClinicalTrials.gov processed this data on January 31, 2020",2006-10-06,2014-06-02,,2015-11-18,2006-10-06,2006-10-11,Estimate,2015-11-18,2015-11-20,Estimate,,,,2015-11-18,2015-11-20,Estimate,October 2007,,2007-10-31,November 2015,2015-11-30,June 2014,Actual,2014-06-30,December 2011,Actual,2011-12-31,,Interventional,LDOT,Veterans with severe dementia residing in VA nursing home.,Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT),Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT),Completed,,Phase 4,11,Actual,VA Office of Research and Development,,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:00:50.049144,2020-02-01 21:00:50.049144,VA Office of Research and Development,U.S. Fed,hydrocodone/APAP w placebo PRN,Drug
NCT00239746,"ClinicalTrials.gov processed this data on January 31, 2020",2005-10-13,,,2009-04-28,2005-10-13,2005-10-17,Estimate,,,,,,,2009-04-28,2009-04-29,Estimate,October 2005,,2005-10-31,April 2009,2009-04-30,August 2009,Anticipated,2009-08-31,August 2009,Anticipated,2009-08-31,,Interventional,,,BONSAI: Biomarkers of Nonsteroidal Anti-Inflammatories,Biomarkers of Nonsteroidal Anti-Inflammatories,Unknown status,"Active, not recruiting",Phase 1,40,Anticipated,National Institute on Aging (NIA),,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:41:15.228944,2020-02-01 21:41:15.228944,National Institute on Aging (NIA),NIH,Ibuprofen,Drug
NCT01595646,"ClinicalTrials.gov processed this data on January 31, 2020",2012-05-08,2017-04-17,,2018-04-23,2012-05-09,2012-05-10,Estimate,2018-01-05,2018-02-01,Actual,,,,2018-04-23,2018-05-22,Actual,November 2011,Actual,2011-11-30,April 2018,2018-04-30,"March 12, 2015",Actual,2015-03-12,"March 12, 2015",Actual,2015-03-12,,Interventional,SL120,,Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120),Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120),Completed,,Phase 2,37,Actual,Wake Forest University Health Sciences,,3,,,False,,,,True,True,False,,,,,,,,,No,There is no plan to share individual participant data with other researchers.,2020-02-01 15:05:56.020319,2020-02-01 15:05:56.020319,Wake Forest University Health Sciences,Other,Insulin,Drug
NCT02462161,"ClinicalTrials.gov processed this data on January 31, 2020",2015-06-01,,,2019-08-29,2015-06-02,2015-06-03,Estimate,,,,,,,2019-08-29,2019-09-03,Actual,"March 20, 2015",Actual,2015-03-20,August 2019,2019-08-31,"April 16, 2019",Actual,2019-04-16,"April 16, 2019",Actual,2019-04-16,,Interventional,SNIFF-Quick,,Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart,Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart,Completed,,Phase 1,24,Actual,Wake Forest University Health Sciences,,2,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 11:30:11.664980,2020-02-01 11:30:11.664980,Wake Forest University Health Sciences,Other,Insulin aspart,Drug
NCT01547169,"ClinicalTrials.gov processed this data on January 31, 2020",2012-02-07,,,2012-12-17,2012-03-06,2012-03-07,Estimate,,,,,,,2012-12-17,2012-12-18,Estimate,March 2011,,2011-03-31,December 2012,2012-12-31,December 2012,Actual,2012-12-31,December 2012,Actual,2012-12-31,,Interventional,SNIFF-LONG 21,,Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days,Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days,Completed,,Phase 2,60,Actual,University of Washington,,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:17:31.332607,2020-02-01 15:17:31.332607,University of Washington,Other,insulin detemir,Drug
NCT01595646,"ClinicalTrials.gov processed this data on January 31, 2020",2012-05-08,2017-04-17,,2018-04-23,2012-05-09,2012-05-10,Estimate,2018-01-05,2018-02-01,Actual,,,,2018-04-23,2018-05-22,Actual,November 2011,Actual,2011-11-30,April 2018,2018-04-30,"March 12, 2015",Actual,2015-03-12,"March 12, 2015",Actual,2015-03-12,,Interventional,SL120,,Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120),Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120),Completed,,Phase 2,37,Actual,Wake Forest University Health Sciences,,3,,,False,,,,True,True,False,,,,,,,,,No,There is no plan to share individual participant data with other researchers.,2020-02-01 15:05:56.020319,2020-02-01 15:05:56.020319,Wake Forest University Health Sciences,Other,Insulin detemir,Drug
NCT01436045,"ClinicalTrials.gov processed this data on January 31, 2020",2011-09-16,2015-04-09,,2015-09-25,2011-09-16,2011-09-19,Estimate,2015-09-25,2015-10-19,Estimate,,,,2015-09-25,2015-10-19,Estimate,September 2011,,2011-09-30,September 2015,2015-09-30,June 2013,Actual,2013-06-30,June 2013,Actual,2013-06-30,,Interventional,,,Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.,"A Double-Blind, Placebo-Controlled Single Dose Study of the Safety and Efficacy of Glulisine on Cognitive Function and Memory in Individuals Diagnosed With Probable Mild to Moderate Alzheimer's Disease/Intranasal Insulin Study.",Completed,,Phase 2,12,Actual,HealthPartners Institute,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:46:57.736752,2020-02-01 15:46:57.736752,HealthPartners Institute,Other,Insulin glulisine,Drug
NCT02503501,"ClinicalTrials.gov processed this data on January 31, 2020",2015-07-14,,,2020-01-29,2015-07-17,2015-07-21,Estimate,,,,,,,2020-01-29,2020-01-31,Estimate,August 2015,,2015-08-31,January 2020,2020-01-31,February 2020,Anticipated,2020-02-29,February 2020,Anticipated,2020-02-29,,Interventional,,,Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease,"A Phase II, Single Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and the Therapeutic Effectiveness of Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease","Active, not recruiting",,Phase 2,49,Actual,HealthPartners Institute,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-04 05:17:00.541400,2020-02-04 05:17:00.541400,HealthPartners Institute,Other,Insulin glulisine,Drug
NCT01767909,"ClinicalTrials.gov processed this data on January 31, 2020",2013-01-10,,,2019-01-16,2013-01-11,2013-01-15,Estimate,,,,,,,2019-01-16,2019-01-18,Actual,"January 8, 2014",Actual,2014-01-08,January 2019,2019-01-31,"December 11, 2018",Actual,2018-12-11,"December 11, 2018",Actual,2018-12-11,,Interventional,,,The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF),Therapeutic Effects of Intranasally-Administered Insulin in Adults With Amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (AD),Completed,,Phase 2/Phase 3,239,Actual,University of Southern California,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:20:36.780945,2020-02-01 14:20:36.780945,University of Southern California,Other,Insulin (Humulin® R U-100),Drug
NCT02817906,"ClinicalTrials.gov processed this data on January 31, 2020",2016-06-27,,,2018-12-18,2016-06-27,2016-06-29,Estimate,,,,,,,2018-12-18,2018-12-20,Actual,June 2016,Actual,2016-06-30,December 2018,2018-12-31,December 2018,Actual,2018-12-31,December 2018,Actual,2018-12-31,,Interventional,,,"ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 in the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease",Terminated,,Phase 3,177,Actual,"Intra-Cellular Therapies, Inc.",,2,,Pre-specified Interim Analysis Indicated Futility,False,,,,,True,False,,,,,,,,,,,2020-02-01 10:14:10.009879,2020-02-01 10:14:10.009879,"Intra-Cellular Therapies, Inc.",Industry,ITI-007,Drug
NCT03838185,"ClinicalTrials.gov processed this data on January 31, 2020",2019-02-07,,,2019-02-09,2019-02-09,2019-02-12,Actual,,,,,,,2019-02-09,2019-02-12,Actual,"January 22, 2019",Actual,2019-01-22,February 2019,2019-02-28,January 2020,Anticipated,2020-01-31,October 2019,Anticipated,2019-10-31,,Interventional,,,"Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147","A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147 in Healthy Young Volunteers and Healthy Elderly Volunteers",Recruiting,,Phase 1,64,Anticipated,"Abrexa Pharmaceuticals, Inc.",,2,,,False,,,,True,True,False,,,,,,,,,Undecided,,2020-02-01 07:18:39.582788,2020-02-01 07:18:39.582788,"Abrexa Pharmaceuticals, Inc.",Industry,J147,Drug
NCT01137799,"ClinicalTrials.gov processed this data on January 31, 2020",2010-06-03,,,2012-11-07,2010-06-03,2010-06-04,Estimate,,,,,,,2012-11-07,2012-11-08,Estimate,August 2009,,2009-08-31,November 2012,2012-11-30,March 2011,Actual,2011-03-31,,,,,Interventional,,,The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients,"A Double-Blind, Placebo-Controlled, Randomized, Four-Way Cross-Over Study To Investigate Effect Of Single Oral Doses Of JNJ-39393406 On Event-Related Potentials In Subjects With Stable Schizophrenia",Terminated,,Phase 1,47,Actual,"Janssen Pharmaceutica N.V., Belgium",,6,,Efficacy signals were insufficiently strong to justify recruitment of additional patients.,False,,,,False,,,,,,,,,,,,,2020-02-01 17:11:10.402638,2020-02-01 17:11:10.402638,"Janssen Pharmaceutica N.V., Belgium",Industry,JNJ-39393406,Drug
NCT02127476,"ClinicalTrials.gov processed this data on January 31, 2020",2014-04-24,,,2017-05-31,2014-04-28,2014-04-30,Estimate,,,,,,,2017-05-31,2017-06-01,Actual,July 2014,,2014-07-31,May 2017,2017-05-31,May 2017,Actual,2017-05-31,May 2017,Actual,2017-05-31,,Interventional,,,A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease,"A Phase 1 Double-blind, Placebo-controlled, Single- and Multiple-ascending-dose Study of KHK6640 in Alzheimer's Disease",Completed,,Phase 1,57,Actual,"Kyowa Kirin Pharmaceutical Development, Inc.",,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:47:13.721981,2020-02-01 12:47:13.721981,"Kyowa Hakko Kirin Pharma, Inc.",Industry,KHK6640,Drug
NCT01354691,"ClinicalTrials.gov processed this data on January 31, 2020",2011-05-01,,,2013-07-22,2011-05-14,2011-05-17,Estimate,,,,,,,2013-07-22,2013-07-23,Estimate,February 2011,,2011-02-28,July 2013,2013-07-31,March 2013,Actual,2013-03-31,September 2012,Actual,2012-09-30,,Interventional,,,Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease,"A 6-Month Prospective, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Adaptive-Trial-Design Study to Evaluate the Safety and Efficacy of 80mg b.i.d Ladostigil in Patients With Mild to Moderate Probable Alzheimer's Disease With a 6-Month Open Label Follow-Up Period",Completed,,Phase 2,201,Actual,Avraham Pharmaceuticals Ltd,,1,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:07:25.394126,2020-02-01 16:07:25.394126,Avraham Pharmaceuticals Ltd,Industry,ladostigil hemitartrate,Drug
NCT00151398,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-06,,2013-02-07,2013-02-07,2005-09-07,2005-09-08,Estimate,,,,2013-02-07,2013-02-11,Estimate,2013-02-07,2013-02-11,Estimate,September 2005,,2005-09-30,July 2008,2008-07-31,March 2008,Actual,2008-03-31,March 2008,Actual,2008-03-31,,Interventional,,,Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD),"A 3-Month, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Safety, Tolerability, and Efficacy Study Of 3 Doses Of Lecozotan (SRA-333) SR In Outpatients With Mild To Moderate Alzheimer's Disease With Donepezil As Active Control.",Completed,,Phase 2,229,Actual,Wyeth is now a wholly owned subsidiary of Pfizer,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:02:22.166435,2020-02-01 22:02:22.166435,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,lecozotan SR,Drug
NCT03001557,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-16,2020-01-03,2019-07-22,2020-01-03,2016-12-20,2016-12-23,Estimate,2020-01-03,2020-01-14,Actual,2019-07-22,2019-07-29,Actual,2020-01-03,2020-01-14,Actual,"December 20, 2016",Actual,2016-12-20,July 2019,2019-07-31,"April 9, 2020",Anticipated,2020-04-09,"July 26, 2018",Actual,2018-07-26,,Interventional,,The safety analysis set included the group of randomized participants who received at least 1 dose of randomized study drug and had at least 1 postdose safety assessment.,Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia","Active, not recruiting",,Phase 2,63,Actual,Eisai Inc.,,5,,,False,,,,False,True,False,,,,,,,,,,,2020-02-01 09:37:08.757519,2020-02-01 09:37:08.757519,Eisai Inc.,Industry,Lemborexant 10 mg,Drug
NCT03001557,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-16,2020-01-03,2019-07-22,2020-01-03,2016-12-20,2016-12-23,Estimate,2020-01-03,2020-01-14,Actual,2019-07-22,2019-07-29,Actual,2020-01-03,2020-01-14,Actual,"December 20, 2016",Actual,2016-12-20,July 2019,2019-07-31,"April 9, 2020",Anticipated,2020-04-09,"July 26, 2018",Actual,2018-07-26,,Interventional,,The safety analysis set included the group of randomized participants who received at least 1 dose of randomized study drug and had at least 1 postdose safety assessment.,Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia","Active, not recruiting",,Phase 2,63,Actual,Eisai Inc.,,5,,,False,,,,False,True,False,,,,,,,,,,,2020-02-01 09:37:08.757519,2020-02-01 09:37:08.757519,Eisai Inc.,Industry,Lemborexant 15 mg,Drug
NCT03001557,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-16,2020-01-03,2019-07-22,2020-01-03,2016-12-20,2016-12-23,Estimate,2020-01-03,2020-01-14,Actual,2019-07-22,2019-07-29,Actual,2020-01-03,2020-01-14,Actual,"December 20, 2016",Actual,2016-12-20,July 2019,2019-07-31,"April 9, 2020",Anticipated,2020-04-09,"July 26, 2018",Actual,2018-07-26,,Interventional,,The safety analysis set included the group of randomized participants who received at least 1 dose of randomized study drug and had at least 1 postdose safety assessment.,Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia","Active, not recruiting",,Phase 2,63,Actual,Eisai Inc.,,5,,,False,,,,False,True,False,,,,,,,,,,,2020-02-01 09:37:08.757519,2020-02-01 09:37:08.757519,Eisai Inc.,Industry,Lemborexant 2.5 mg,Drug
NCT03001557,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-16,2020-01-03,2019-07-22,2020-01-03,2016-12-20,2016-12-23,Estimate,2020-01-03,2020-01-14,Actual,2019-07-22,2019-07-29,Actual,2020-01-03,2020-01-14,Actual,"December 20, 2016",Actual,2016-12-20,July 2019,2019-07-31,"April 9, 2020",Anticipated,2020-04-09,"July 26, 2018",Actual,2018-07-26,,Interventional,,The safety analysis set included the group of randomized participants who received at least 1 dose of randomized study drug and had at least 1 postdose safety assessment.,Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia","Active, not recruiting",,Phase 2,63,Actual,Eisai Inc.,,5,,,False,,,,False,True,False,,,,,,,,,,,2020-02-01 09:37:08.757519,2020-02-01 09:37:08.757519,Eisai Inc.,Industry,Lemborexant 5 mg,Drug
NCT03001557,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-16,2020-01-03,2019-07-22,2020-01-03,2016-12-20,2016-12-23,Estimate,2020-01-03,2020-01-14,Actual,2019-07-22,2019-07-29,Actual,2020-01-03,2020-01-14,Actual,"December 20, 2016",Actual,2016-12-20,July 2019,2019-07-31,"April 9, 2020",Anticipated,2020-04-09,"July 26, 2018",Actual,2018-07-26,,Interventional,,The safety analysis set included the group of randomized participants who received at least 1 dose of randomized study drug and had at least 1 postdose safety assessment.,Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia","Active, not recruiting",,Phase 2,63,Actual,Eisai Inc.,,5,,,False,,,,False,True,False,,,,,,,,,,,2020-02-01 09:37:08.757519,2020-02-01 09:37:08.757519,Eisai Inc.,Industry,Lemborexant-matched placebo,Drug
NCT03489044,"ClinicalTrials.gov processed this data on January 31, 2020",2018-03-09,,,2018-10-15,2018-03-28,2018-04-05,Actual,,,,,,,2018-10-15,2018-10-16,Actual,November 2018,Anticipated,2018-11-30,March 2018,2018-03-31,January 2020,Anticipated,2020-01-31,"November 1, 2019",Anticipated,2019-11-01,,Interventional,ILiAD,,An Investigation of Levetiracetam in Alzheimer's Disease,An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a Proof of Concept Study,Enrolling by invitation,,Phase 2,30,Anticipated,University of Oxford,,2,,,False,,,,False,False,False,,,,,,,,,Undecided,It is possible that irretrievably anonymised data will be shared with other researchers dependent on securing relevant ethical approval,2020-02-01 08:12:09.213728,2020-02-01 08:12:09.213728,University of Oxford,Other,Levetiracetam,Drug
NCT03875638,"ClinicalTrials.gov processed this data on January 31, 2020",2019-03-13,,,2019-09-09,2019-03-13,2019-03-15,Actual,,,,,,,2019-09-09,2019-09-10,Actual,"August 22, 2019",Actual,2019-08-22,September 2019,2019-09-30,November 2023,Anticipated,2023-11-30,August 2023,Anticipated,2023-08-31,,Interventional,,,Treating Hyperexcitability in AD With Levetiracetam,Treating Hyperexcitability in Alzheimer's Disease With Levetiracetam to Improve Brain Function and Cognition,Recruiting,,Phase 2,85,Anticipated,Beth Israel Deaconess Medical Center,,4,,,False,,,,True,True,False,,,False,,,,,,Undecided,,2020-02-01 07:13:04.175822,2020-02-01 07:13:04.175822,Beth Israel Deaconess Medical Center,Other,Levetiracetam,Drug
NCT01058941,"ClinicalTrials.gov processed this data on January 31, 2020",2010-01-27,2017-03-01,,2017-03-01,2010-01-28,2010-01-29,Estimate,2017-03-01,2017-04-13,Actual,,,,2017-03-01,2017-04-13,Actual,September 2010,,2010-09-30,March 2017,2017-03-31,December 2014,Actual,2014-12-31,December 2014,Actual,2014-12-31,,Interventional,,,Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease,Lipoic Acid and Omega-3 Fatty Acids in Alzheimer's Disease,Completed,,Phase 1/Phase 2,67,Actual,Oregon Health and Science University,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:34:22.620784,2020-02-01 17:34:22.620784,Oregon Health and Science University,Other,Lipoic acid and fish oil concentrate,Drug
NCT01469351,"ClinicalTrials.gov processed this data on January 31, 2020",2011-11-01,,,2013-04-18,2011-11-07,2011-11-10,Estimate,,,,,,,2013-04-18,2013-04-19,Estimate,January 2012,,2012-01-31,April 2013,2013-04-30,April 2013,Actual,2013-04-30,April 2013,Actual,2013-04-30,,Interventional,,,Identifying Potential Effects of Liraglutide on Degenerative Changes,Neurodegenerative Changes in Alzheimer's Disease: Identifying Potential Effects of Liraglutide on Degenerative Changes,Completed,,N/A,34,Actual,University of Aarhus,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:37:03.985693,2020-02-01 15:37:03.985693,University of Aarhus,Other,Liraglutide,Drug
NCT01843075,"ClinicalTrials.gov processed this data on January 31, 2020",2013-04-24,,,2019-06-06,2013-04-26,2013-04-30,Estimate,,,,,,,2019-06-06,2019-06-10,Actual,January 2014,Actual,2014-01-31,June 2019,2019-06-30,December 2019,Anticipated,2019-12-31,December 2019,Anticipated,2019-12-31,,Interventional,ELAD,,Evaluating Liraglutide in Alzheimer's Disease,"Evaluating the Effects of the Novel GLP-1 Analogue, Liraglutide, in Patients With Mild Alzheimer's Disease (ELAD Study)","Active, not recruiting",,Phase 2,204,Actual,Imperial College London,,2,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 14:02:32.425844,2020-02-01 14:02:32.425844,Imperial College London,Other,Liraglutide,Drug
NCT01211782,"ClinicalTrials.gov processed this data on January 31, 2020",2010-09-24,,,2012-12-03,2010-09-28,2010-09-30,Estimate,,,,,,,2012-12-03,2012-12-04,Estimate,,,,December 2012,2012-12-31,,,,,,,,Interventional,ALERT,,AC-1204 Long-term Efficacy Response Trial (ALERT Protocol),"A Phase 2-3, 6-12 Month, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Subjects With Mild to Moderate Alzheimer's Disease Who Are APOE4(-)",Withdrawn,,Phase 2/Phase 3,0,Actual,Cerecin,,2,,Study never started. Study was redesgined.,False,,,,False,,,,,,,,,,,,,2020-02-01 16:49:09.095841,2020-02-01 16:49:09.095841,Cerecin,Industry,long-chain triglyceride,Drug
NCT03062449,"ClinicalTrials.gov processed this data on January 31, 2020",2017-02-20,,,2019-09-06,2017-02-20,2017-02-23,Actual,,,,,,,2019-09-06,2019-09-09,Actual,"March 1, 2017",Actual,2017-03-01,September 2019,2019-09-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,,Interventional,LSPI-2,,Phase IIa L-serine Trial for eAD,"A Phase IIa Proof of Concept, Randomized, Double-blind, Placebo-controlled Study of the Effects of L-serine on Early Stage Alzheimer's Disease Patients",Recruiting,,Phase 2,40,Anticipated,Dartmouth-Hitchcock Medical Center,,2,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 09:25:52.371375,2020-02-01 09:25:52.371375,Aleksandra Stark,Other,L-Serine,Drug
NCT00904683,"ClinicalTrials.gov processed this data on January 31, 2020",2009-05-18,,2012-09-18,2012-12-11,2009-05-18,2009-05-20,Estimate,,,,2012-09-18,2012-09-25,Estimate,2012-12-11,2012-12-13,Estimate,May 2009,,2009-05-31,December 2012,2012-12-31,June 2012,Actual,2012-06-30,June 2012,Actual,2012-06-30,,Interventional,EXPEDITION2,,Effect of LY2062430 on the Progression of Alzheimer's Disease,Effect of Passive Immunization on the Progression of Alzheimer's Disease: LY2062430 Versus Placebo,Completed,,Phase 3,1040,Actual,Eli Lilly and Company,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:23:37.732667,2020-02-01 18:23:37.732667,Eli Lilly and Company,Industry,LY2062430,Drug
NCT00905372,"ClinicalTrials.gov processed this data on January 31, 2020",2009-05-18,,2012-09-18,2012-09-18,2009-05-18,2009-05-20,Estimate,,,,2012-09-18,2012-09-25,Estimate,2012-09-18,2012-09-25,Estimate,May 2009,,2009-05-31,May 2012,2012-05-31,April 2012,Actual,2012-04-30,April 2012,Actual,2012-04-30,,Interventional,EXPEDITION,,Effect of LY2062430 on the Progression of Alzheimer's Disease,"Effect of LY2062430, an Anti-Amyloid Beta Monoclonal Antibody, on the Progression of Alzheimer's Disease as Compared With Placebo",Completed,,Phase 3,1000,Anticipated,Eli Lilly and Company,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:23:26.031400,2020-02-01 18:23:26.031400,Eli Lilly and Company,Industry,LY2062430,Drug
NCT03518073,"ClinicalTrials.gov processed this data on February 06, 2020",2018-04-26,,,2020-02-03,2018-05-01,2018-05-08,Actual,,,,,,,2020-02-03,2020-02-05,Actual,"April 30, 2018",Actual,2018-04-30,February 2020,2020-02-29,"October 22, 2021",Anticipated,2021-10-22,"August 23, 2021",Anticipated,2021-08-23,,Interventional,,,A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease,"Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease","Active, not recruiting",,Phase 2,285,Anticipated,Eli Lilly and Company,,3,,,False,,,,True,True,False,,,,,,,,,Yes,"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.",2020-02-07 06:02:44.436528,2020-02-07 06:02:44.436528,Eli Lilly and Company,Industry,LY3303560,Drug
NCT00594568,"ClinicalTrials.gov processed this data on January 31, 2020",2008-01-11,2013-11-06,2011-08-09,2015-03-13,2008-01-11,2008-01-15,Estimate,2014-09-22,2014-09-25,Estimate,2011-08-09,2011-08-15,Estimate,2015-03-13,2015-03-17,Estimate,March 2008,,2008-03-31,March 2015,2015-03-31,May 2011,Actual,2011-05-31,May 2011,Actual,2011-05-31,,Interventional,,,Effect of LY450139 on the Long Term Progression of Alzheimer's Disease,Effect of γ-Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo,Completed,,Phase 3,1537,Actual,Eli Lilly and Company,Outcomes with 4-week after study drug cessation timeframe=All dosing stopped after protocol-specified interim review showed dose-dependent cognitive/functional worsening for LY450139 participants; followed for 32 weeks; not all assessments were made.,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:55:02.296322,2020-02-01 19:55:02.296322,Eli Lilly and Company,Industry,LY450139,Drug
NCT00762411,"ClinicalTrials.gov processed this data on January 31, 2020",2008-09-26,2013-11-06,2011-08-22,2015-01-28,2008-09-26,2008-09-30,Estimate,2014-09-22,2014-09-25,Estimate,2011-08-22,2011-08-23,Estimate,2015-01-28,2015-02-16,Estimate,September 2008,,2008-09-30,January 2015,2015-01-31,April 2011,Actual,2011-04-30,April 2011,Actual,2011-04-30,,Interventional,IDENTITY-2,,"Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo","Effect of LY450139 a y-Secretase Inhibitor, on the Progression of Alzheimer's Disease as Compared With Placebo",Completed,,Phase 3,1111,Actual,Eli Lilly and Company,All dosing for 4-week post-study drug cessation timeframe outcome measures stopped after protocol-specified interim review showed dose-dependent cognitive/functional worsening for LY450139 participants. No assessments made during 32-week follow up.,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:05:56.411245,2020-02-01 19:05:56.411245,Eli Lilly and Company,Industry,LY450139,Drug
NCT00843518,"ClinicalTrials.gov processed this data on January 31, 2020",2009-02-12,2016-07-07,2011-09-20,2017-10-23,2009-02-12,2009-02-13,Estimate,2017-10-23,2017-11-29,Actual,2011-09-20,2011-09-26,Estimate,2017-10-23,2017-11-29,Actual,February 2009,,2009-02-28,October 2017,2017-10-31,June 2011,Actual,2011-06-30,June 2011,Actual,2011-06-30,,Interventional,,,Treatment for Aggression and Agitation in Patients With Alzheimer's Disease,Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease,Completed,,Phase 2,132,Actual,Eli Lilly and Company,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:41:24.194777,2020-02-01 18:41:24.194777,Eli Lilly and Company,Industry,LY451395,Drug
NCT01872598,"ClinicalTrials.gov processed this data on January 31, 2020",2013-06-05,,,2019-06-13,2013-06-06,2013-06-07,Estimate,,,,,,,2019-06-13,2019-06-17,Actual,January 2012,,2012-01-31,June 2019,2019-06-30,December 2019,Anticipated,2019-12-31,December 2019,Anticipated,2019-12-31,,Interventional,,,Masitinib in Patients With Mild to Moderate Alzheimer's Disease,"A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Phase 3 Study to Evaluate the Safety and Efficacy of Masitinib in Patients With Mild to Moderate Alzheimer's Disease","Active, not recruiting",,Phase 3,721,Actual,AB Science,,5,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:52:27.547176,2020-02-01 13:52:27.547176,AB Science,Industry,Masitinib,Drug
NCT00976118,"ClinicalTrials.gov processed this data on January 31, 2020",2009-09-11,,,2018-12-12,2009-09-11,2009-09-14,Estimate,,,,,,,2018-12-12,2018-12-13,Actual,February 2006,,2006-02-28,December 2018,2018-12-31,February 2009,Actual,2009-02-28,July 2008,Actual,2008-07-31,,Interventional,,,Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease,"A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Efficacy of Oral AB1010 in Adults Patients With Mild to Moderate Alzheimer-type Disease.",Completed,,Phase 2,34,Actual,AB Science,,2,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 18:02:06.818140,2020-02-01 18:02:06.818140,AB Science,Industry,masitinib (AB1010),Drug
NCT02127476,"ClinicalTrials.gov processed this data on January 31, 2020",2014-04-24,,,2017-05-31,2014-04-28,2014-04-30,Estimate,,,,,,,2017-05-31,2017-06-01,Actual,July 2014,,2014-07-31,May 2017,2017-05-31,May 2017,Actual,2017-05-31,May 2017,Actual,2017-05-31,,Interventional,,,A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease,"A Phase 1 Double-blind, Placebo-controlled, Single- and Multiple-ascending-dose Study of KHK6640 in Alzheimer's Disease",Completed,,Phase 1,57,Actual,"Kyowa Kirin Pharmaceutical Development, Inc.",,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:47:13.721981,2020-02-01 12:47:13.721981,"Kyowa Hakko Kirin Pharma, Inc.",Industry,Matching Placebo,Drug
NCT01760005,"ClinicalTrials.gov processed this data on January 31, 2020",2012-12-26,,,2019-10-01,2012-12-31,2013-01-03,Estimate,,,,,,,2019-10-01,2019-10-03,Actual,December 2012,,2012-12-31,October 2019,2019-10-31,March 2021,Anticipated,2021-03-31,December 2020,Anticipated,2020-12-31,,Interventional,DIAN-TU,,Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.,"A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease",Recruiting,,Phase 2/Phase 3,490,Anticipated,Washington University School of Medicine,,5,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:23:00.489600,2020-02-01 14:23:00.489600,Washington University School of Medicine,Other,Matching Placebo (Gantenerumab),Drug
NCT01760005,"ClinicalTrials.gov processed this data on January 31, 2020",2012-12-26,,,2019-10-01,2012-12-31,2013-01-03,Estimate,,,,,,,2019-10-01,2019-10-03,Actual,December 2012,,2012-12-31,October 2019,2019-10-31,March 2021,Anticipated,2021-03-31,December 2020,Anticipated,2020-12-31,,Interventional,DIAN-TU,,Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.,"A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease",Recruiting,,Phase 2/Phase 3,490,Anticipated,Washington University School of Medicine,,5,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:23:00.489600,2020-02-01 14:23:00.489600,Washington University School of Medicine,Other,Matching Placebo (Solanezumab),Drug
NCT00066157,"ClinicalTrials.gov processed this data on January 31, 2020",2003-08-04,,,2018-08-22,2003-08-04,2003-08-05,Estimate,,,,,,,2018-08-22,2018-08-23,Actual,September 2001,,2001-09-30,August 2018,2018-08-31,December 2007,Actual,2007-12-31,December 2007,Actual,2007-12-31,,Interventional,,,Alzheimer's Disease: Therapeutic Potential of Estrogen,Alzheimer's Disease: Therapeutic Potential of Estrogen,Completed,,Phase 2/Phase 3,42,Actual,"University of Wisconsin, Madison",,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:32:28.672051,2020-02-01 22:32:28.672051,"University of Wisconsin, Madison",Other,Medroxyprogesterone,Drug
NCT02033941,"ClinicalTrials.gov processed this data on January 31, 2020",2014-01-09,,,2019-03-12,2014-01-09,2014-01-13,Estimate,,,,,,,2019-03-12,2019-03-13,Actual,November 2014,,2014-11-30,March 2019,2019-03-31,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,,Interventional,,,Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD),Phase II Grape Seed Extract as Anti-Oligomerization Agent in Alzheimer's Disease,Recruiting,,Phase 2,20,Anticipated,Icahn School of Medicine at Mount Sinai,,2,,,False,,,,True,True,False,,,,,,,,,No,,2020-02-01 13:10:17.207831,2020-02-01 13:10:17.207831,Hillel Grossman,Other,Meganatural-Az Grapeseed Extract,Drug
NCT00545974,"ClinicalTrials.gov processed this data on January 31, 2020",2007-10-16,2013-04-22,,2019-10-08,2007-10-17,2007-10-18,Estimate,2013-12-13,2014-02-05,Estimate,,,,2019-10-08,2019-10-17,Actual,October 2007,,2007-10-31,October 2019,2019-10-31,December 2012,Actual,2012-12-31,December 2012,Actual,2012-12-31,,Interventional,,,Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia,"A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia",Completed,,Phase 4,81,Actual,"University of California, San Francisco",Lower enrollment than planned may have limited ability detect a treatment effect; Small size of semantic dementia group limits generalizability of results to FTD syndrome;Newer tools have been developed to better capture FTD-specific behaviors.,2,,,,,,,True,,,,,,,,,,,,,2020-02-01 20:10:00.659080,2020-02-01 20:10:00.659080,"University of California, San Francisco",Other,memantine,Drug
NCT00235716,"ClinicalTrials.gov processed this data on January 31, 2020",2005-10-06,2013-12-06,,2014-07-14,2005-10-06,2005-10-10,Estimate,2014-01-23,2014-01-29,Estimate,,,,2014-07-14,2014-07-23,Estimate,August 2007,,2007-08-31,July 2014,2014-07-31,October 2012,Actual,2012-10-31,September 2012,Actual,2012-09-30,,Interventional,TEAM-AD,,"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease","CSP #546 - A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease (TEAM-AD)",Completed,,Phase 3,613,Actual,VA Office of Research and Development,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:42:18.318346,2020-02-01 21:42:18.318346,US Department of Veterans Affairs,U.S. Fed,Memantine,Drug
NCT00255086,"ClinicalTrials.gov processed this data on January 31, 2020",2005-11-15,2016-08-23,,2017-02-23,2005-11-15,2005-11-17,Estimate,2017-02-23,2017-04-07,Actual,,,,2017-02-23,2017-04-07,Actual,May 2005,,2005-05-31,February 2017,2017-02-28,February 2010,Actual,2010-02-28,June 2009,Actual,2009-06-30,,Interventional,,"Per protocol, only participants who completed the study were evaluable for baseline characteristics.",The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients,"The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients: A Randomized, Placebo-Controlled, 52-Week Clinical Trial",Completed,,Phase 3,17,Actual,Stanford University,,2,,,False,,,,False,,,,,,,,,,,Undecided,,2020-02-01 21:37:34.734231,2020-02-01 21:37:34.734231,Stanford University,Other,Memantine,Drug
NCT00630500,"ClinicalTrials.gov processed this data on January 31, 2020",2008-02-27,,,2015-07-27,2008-03-06,2008-03-07,Estimate,,,,,,,2015-07-27,2015-07-28,Estimate,February 2006,,2006-02-28,February 2009,2009-02-28,March 2009,Actual,2009-03-31,February 2009,Actual,2009-02-28,,Interventional,MEMPDD,,Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB),"A Double-blind, Placebo-controlled Multicentre Trial of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies",Completed,,Phase 2,75,Actual,Helse Stavanger HF,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:44:12.140389,2020-02-01 19:44:12.140389,Helse Stavanger HF,Other,Memantine,Drug
NCT00703430,"ClinicalTrials.gov processed this data on January 31, 2020",2008-06-20,,,2013-01-24,2008-06-20,2008-06-23,Estimate,,,,,,,2013-01-24,2013-01-25,Estimate,March 2008,,2008-03-31,January 2013,2013-01-31,June 2014,Anticipated,2014-06-30,December 2013,Anticipated,2013-12-31,,Interventional,,,Memantine on Aggression and Agitation of Alzheimer's Disease (AD),The Effect of Memantine on Aggression and Agitation and Its Impact on Caregiver Burden of Patients With Alzheimer's Disease: A 12-week Open-label Study,Unknown status,Recruiting,N/A,50,Anticipated,Peking University,,1,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:22:50.758975,2020-02-01 19:22:50.758975,Peking University,Other,Memantine,Drug
NCT00800709,"ClinicalTrials.gov processed this data on January 31, 2020",2008-10-23,,,2010-12-02,2008-12-01,2008-12-02,Estimate,,,,,,,2010-12-02,2010-12-03,Estimate,July 2008,,2008-07-31,December 2010,2010-12-31,October 2010,Actual,2010-10-31,October 2010,Actual,2010-10-31,,Interventional,,,Memantine and Changes of Biological Markers and Brain PET Imaging in Alzheimer's Disease,"Changes of Biological Markers and Brain PET Imaging and Clinical Effects of Memantine for Patients With Moderate to Severe Alzheimer's Disease: a 24 Week Double-blind, Randomized, Placebo-Controlled Study",Completed,,Phase 4,26,Anticipated,Shanghai Mental Health Center,,1,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:54:16.957917,2020-02-01 18:54:16.957917,Shanghai Mental Health Center,Other,Memantine,Drug
NCT00866060,"ClinicalTrials.gov processed this data on January 31, 2020",2009-03-19,,,2009-03-19,2009-03-19,2009-03-20,Estimate,,,,,,,2009-03-19,2009-03-20,Estimate,February 2008,,2008-02-29,March 2009,2009-03-31,June 2013,Anticipated,2013-06-30,February 2012,Anticipated,2012-02-29,,Interventional,DOMINO-AD,,Donepezil and Memantine in Moderate to Severe Alzheimer's Disease,Donepezil and Memantine in Moderate to Severe Alzheimer's Disease,Unknown status,Recruiting,Phase 4,800,Anticipated,King's College London,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:34:35.920768,2020-02-01 18:34:35.920768,King's College London,Other,Memantine,Drug
NCT01409694,"ClinicalTrials.gov processed this data on January 31, 2020",2011-08-02,,,2016-09-21,2011-08-03,2011-08-04,Estimate,,,,,,,2016-09-21,2016-09-22,Estimate,September 2011,,2011-09-30,March 2011,2011-03-31,January 2016,Actual,2016-01-31,January 2016,Actual,2016-01-31,,Interventional,AD-IDEA,,Alzheimer's Disease - Input of Vitamin D With mEmantine Assay,Evaluation d'Une stratégie thérapeutique d'Association médicamenteuse Pour la Prise en Charge de la Maladie d'Alzheimer et Des Maladies apparentées au Stade modéré,Completed,,Phase 3,90,Actual,"University Hospital, Angers",,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:53:36.184745,2020-02-01 15:53:36.184745,"University Hospital, Angers",Other,Memantine,Drug
NCT01921972,"ClinicalTrials.gov processed this data on January 31, 2020",2013-08-07,,,2013-08-12,2013-08-12,2013-08-14,Estimate,,,,,,,2013-08-12,2013-08-14,Estimate,November 2004,,2004-11-30,August 2013,2013-08-31,May 2009,Actual,2009-05-31,November 2008,Actual,2008-11-30,,Interventional,AD-Combi,,The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease,"Competence Network - Dementia (BMBF) ""Pharmacological and Psychosocial Treatment"" (Modul E.2) Part II: The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease",Completed,,Phase 4,232,Actual,"Charite University, Berlin, Germany",,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:40:38.562936,2020-02-01 13:40:38.562936,"Charite University, Berlin, Germany",Other,Memantine,Drug
NCT02288000,"ClinicalTrials.gov processed this data on January 31, 2020",2014-11-06,,,2019-06-25,2014-11-06,2014-11-11,Estimate,,,,,,,2019-06-25,2019-06-27,Actual,"September 14, 2016",Actual,2016-09-14,June 2019,2019-06-30,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,,Interventional,WP3_P002,,Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases,Effect of a 15-day Memantine Treatment on Biomarkers of AD in Healthy Volunteers,Recruiting,,Phase 1,30,Anticipated,"University Hospital, Lille",,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:09:22.892287,2020-02-01 12:09:22.892287,"University Hospital, Lille",Other,Memantine,Drug
NCT03703856,"ClinicalTrials.gov processed this data on January 31, 2020",2018-10-09,,,2020-01-21,2018-10-10,2018-10-12,Actual,,,,,,,2020-01-21,2020-01-23,Actual,"January 31, 2019",Actual,2019-01-31,January 2020,2020-01-31,August 2023,Anticipated,2023-08-31,August 2023,Anticipated,2023-08-31,,Interventional,,,Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease,Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease,Recruiting,,Phase 4,88,Anticipated,"University of California, San Diego",,2,,,False,,,,,True,False,,,True,,,,,,,,2020-02-01 07:38:26.839208,2020-02-01 07:38:26.839208,"University of California, San Diego",Other,Memantine,Drug
NCT00322153,"ClinicalTrials.gov processed this data on January 31, 2020",2006-05-03,2010-07-20,,2010-08-25,2006-05-04,2006-05-05,Estimate,2010-08-25,2010-09-16,Estimate,,,,2010-08-25,2010-09-16,Estimate,June 2005,,2005-06-30,August 2010,2010-08-31,January 2008,Actual,2008-01-31,October 2007,Actual,2007-10-31,,Interventional,,,A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients With Moderate-to-Severe Dementia of the Alzheimer's Type",Completed,,Phase 3,677,Actual,Forest Laboratories,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 21:18:57.061793,2020-02-01 21:18:57.061793,Forest Laboratories,Industry,memantine ER,Drug
NCT03168997,"ClinicalTrials.gov processed this data on January 31, 2020",2017-05-16,,,2017-05-25,2017-05-25,2017-05-30,Actual,,,,,,,2017-05-25,2017-05-30,Actual,"July 15, 2017",Anticipated,2017-07-15,May 2017,2017-05-31,"December 31, 2018",Anticipated,2018-12-31,"September 30, 2018",Anticipated,2018-09-30,,Interventional,,,Memantine Treatment in Alzheimer's Disease Patients,"Memantine Treatment in Alzheimer's Disease Patients Stratified With Behavioral and Psychological Symptoms of Dementia (BPSD) Symptoms and Cognitive Severity: A Multi-center, Open-label, Parallel-group and Prospective Clinical Study",Unknown status,Not yet recruiting,Phase 4,222,Anticipated,"Xuanwu Hospital, Beijing",,3,,,False,,,,,False,False,,,False,,,,,,Undecided,,2020-02-01 09:07:13.556546,2020-02-01 09:07:13.556546,Wei Cuibai,Other,Memantine Hydrochloride,Drug
NCT04044131,"ClinicalTrials.gov processed this data on January 31, 2020",2019-07-17,,,2019-07-31,2019-07-31,2019-08-05,Actual,,,,,,,2019-07-31,2019-08-05,Actual,"September 1, 2019",Anticipated,2019-09-01,July 2019,2019-07-31,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,,Interventional,,,Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients,"A Phase 2, Randomized, Placebo Controlled Study to Evaluate the Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) And Parkinson's Disease (PD) Patients",Not yet recruiting,,Phase 2,120,Anticipated,Istanbul Medipol University Hospital,,2,,,False,,,,,False,False,,,,,,,,,,,2020-02-01 06:48:09.330007,2020-02-01 06:48:09.330007,Istanbul Medipol University Hospital,Other,Metabolic Cofactor Supplementation,Drug
NCT01965756,"ClinicalTrials.gov processed this data on January 31, 2020",2013-10-16,2017-06-06,,2017-08-21,2013-10-16,2013-10-18,Estimate,2017-08-21,2017-09-21,Actual,,,,2017-08-21,2017-09-21,Actual,January 2013,,2013-01-31,August 2017,2017-08-31,April 2017,Actual,2017-04-30,"December 22, 2015",Actual,2015-12-22,,Interventional,,,Effect of Insulin Sensitizer Metformin on AD Biomarkers,"A Phase II Trial to Study the Effect of Metformin on AD Biomarkers: A Randomized Placebo Controlled Crossover Pilot Study of Metformin Effects on Cognitive, Physiological and Biochemical Biomarkers of MCI and Dementia Due to AD",Completed,,Phase 2,20,Actual,University of Pennsylvania,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:28:20.189926,2020-02-01 13:28:20.189926,University of Pennsylvania,Other,Metformin,Drug
NCT02380573,"ClinicalTrials.gov processed this data on January 31, 2020",2015-02-24,,,2019-05-06,2015-02-27,2015-03-05,Estimate,,,,,,,2019-05-06,2019-05-08,Actual,July 2015,,2015-07-31,April 2019,2019-04-30,July 2023,Anticipated,2023-07-31,July 2022,Anticipated,2022-07-31,,Interventional,MB2,,"Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease","Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease",Suspended,,Phase 2,117,Actual,The University of Texas Health Science Center at San Antonio,,8,,Pending enrollment of new subjects if new funding obtained,False,,,,True,,,,,,,,,,,,,2020-02-01 11:48:30.714225,2020-02-01 11:48:30.714225,The University of Texas Health Science Center at San Antonio,Other,Methylene Blue,Drug
NCT00792662,"ClinicalTrials.gov processed this data on January 31, 2020",2008-11-17,,,2018-03-27,2008-11-17,2008-11-18,Estimate,,,,,,,2018-03-27,2018-03-29,Actual,November 2008,Actual,2008-11-30,March 2018,2018-03-31,December 2011,Actual,2011-12-31,December 2011,Actual,2011-12-31,,Interventional,,,"Improving Function, Quality of Life, Glycemia in Diabetics With Dementia","Improving Function, Quality of Life, Glycemia in Diabetics With Dementia",Withdrawn,,Phase 4,0,Actual,University of Nebraska,,2,,No Subjects enrolled,False,,,,True,,,,,,,,,,,,,2020-02-01 18:56:39.297993,2020-02-01 18:56:39.297993,University of Nebraska,Other,Methylphenidate,Drug
NCT01117181,"ClinicalTrials.gov processed this data on January 31, 2020",2010-05-04,2013-02-11,,2018-06-07,2010-05-04,2010-05-05,Estimate,2013-04-01,2013-05-10,Estimate,,,,2018-06-07,2018-06-12,Actual,June 2010,,2010-06-30,June 2018,2018-06-30,August 2012,Actual,2012-08-31,August 2012,Actual,2012-08-31,,Interventional,ADMET,,Apathy in Dementia Methylphenidate Trial (ADMET),Apathy in Dementia Methylphenidate Trial (ADMET),Completed,,Phase 2,60,Actual,Johns Hopkins Bloomberg School of Public Health,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:17:32.212260,2020-02-01 17:17:32.212260,Johns Hopkins Bloomberg School of Public Health,Other,Methylphenidate,Drug
NCT02346201,"ClinicalTrials.gov processed this data on January 31, 2020",2015-01-20,,,2020-01-16,2015-01-20,2015-01-26,Estimate,,,,,,,2020-01-16,2020-01-21,Actual,January 2016,,2016-01-31,January 2020,2020-01-31,June 2020,Anticipated,2020-06-30,May 2020,Anticipated,2020-05-31,,Interventional,ADMET2,,Apathy in Dementia Methylphenidate Trial 2,Apathy in Dementia Methylphenidate Trial 2,"Active, not recruiting",,Phase 3,200,Actual,Johns Hopkins Bloomberg School of Public Health,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:56:10.970719,2020-02-01 11:56:10.970719,Johns Hopkins Bloomberg School of Public Health,Other,Methylphenidate,Drug
NCT03790709,"ClinicalTrials.gov processed this data on January 31, 2020",2018-12-24,,,2019-11-17,2018-12-31,2019-01-02,Actual,,,,,,,2019-11-17,2019-11-19,Actual,"July 3, 2018",Actual,2018-07-03,August 2019,2019-08-31,"December 31, 2021",Anticipated,2021-12-31,"September 30, 2021",Anticipated,2021-09-30,,Interventional,,,ANAVEX2-73 for Treatment of Early Alzheimer's Disease,"A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy Trial of ANAVEX2-73 for the Treatment of Early Alzheimer's Disease (AD)",Recruiting,,Phase 2/Phase 3,450,Anticipated,Anavex Life Sciences Corp.,,3,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 07:25:39.943948,2020-02-01 07:25:39.943948,Anavex Life Sciences Corp.,Industry,Mid dose ANAVEX2-73,Drug
NCT01867775,"ClinicalTrials.gov processed this data on January 31, 2020",2013-05-30,,,2013-06-03,2013-06-03,2013-06-04,Estimate,,,,,,,2013-06-03,2013-06-04,Estimate,May 2012,,2012-05-31,May 2013,2013-05-31,May 2014,Anticipated,2014-05-31,December 2013,Anticipated,2013-12-31,,Interventional,,,Mirtazapine for Sleep Disorders in Alzheimer's Disease,"Mirtazapine for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomized, Double-blind, Placebo-controlled Study",Unknown status,Recruiting,Phase 3,30,Anticipated,Brasilia University Hospital,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:53:58.997628,2020-02-01 13:53:58.997628,Brasilia University Hospital,Other,Mirtazapine,Drug
NCT03038035,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-01,,,2017-01-26,2017-01-26,2017-01-31,Estimate,,,,,,,2017-01-26,2017-01-31,Estimate,December 2016,,2016-12-31,January 2017,2017-01-31,June 2019,Anticipated,2019-06-30,June 2018,Anticipated,2018-06-30,,Interventional,ATHENE,,The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study,"The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study : Assessing the Safety and Efficacy of Neuroaid II (MLC901) in Patients With Mild to Moderate Alzheimer's Disease Stable on Cholinesterase Inhibitors or Memantine: A Randomized, Double Blind, Placebo Controlled Trial",Unknown status,Recruiting,Phase 2,150,Anticipated,"National University Hospital, Singapore",,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 09:30:10.628210,2020-02-01 09:30:10.628210,"National University Hospital, Singapore",Other,MLC901,Drug
NCT01172145,"ClinicalTrials.gov processed this data on January 31, 2020",2010-07-28,2010-08-04,,2011-02-09,2010-07-28,2010-07-29,Estimate,2011-02-09,2011-03-04,Estimate,,,,2011-02-09,2011-03-04,Estimate,July 2005,,2005-07-31,September 2010,2010-09-30,September 2007,Actual,2007-09-30,,,,,Interventional,,,Treatment of Apathy in Alzheimer's Disease With Modafinil,Treatment of Apathy in Alzheimer's Disease With Modafinil,Completed,,Phase 3,22,Actual,Brown University,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 17:01:29.146927,2020-02-01 17:01:29.146927,Brown University,Other,Modafinil,Drug
NCT01374438,"ClinicalTrials.gov processed this data on January 31, 2020",2011-06-14,2014-09-25,,2014-11-05,2011-06-15,2011-06-16,Estimate,2014-11-03,2014-11-05,Estimate,,,,2014-11-05,2014-11-18,Estimate,July 2011,,2011-07-31,November 2014,2014-11-30,May 2013,Actual,2013-05-31,March 2013,Actual,2013-03-31,,Interventional,,All randomized subjects completed the full study and are included in the analysis.,"3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease","A 3-month Randomized, Double-Blind, Placebo-Controlled, Feasibility Study to Evaluate the Effects of MSDC-0160 on Brain Glucose Utilization, Cognition, Safety and Tolerability in Older Persons With Mild Alzheimer's Disease",Completed,,Phase 2,29,Actual,Metabolic Solutions Development Company,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 16:02:10.248730,2020-02-01 16:02:10.248730,Metabolic Solutions Development Company,Industry,MSDC-0160,Drug
NCT01764243,"ClinicalTrials.gov processed this data on January 31, 2020",2012-12-26,,,2015-09-24,2013-01-07,2013-01-09,Estimate,,,,,,,2015-09-24,2015-09-28,Estimate,November 2012,,2012-11-30,September 2015,2015-09-30,July 2015,Actual,2015-07-31,June 2015,Actual,2015-06-30,,Interventional,,,Safety and Efficacy of MT-4666,"A Double-Blind, Placebo-Controlled Phase2 Study of MT-4666 in Patients With Mild to Moderate Probable Alzheimer's Disease.",Completed,,Phase 2,450,Actual,Mitsubishi Tanabe Pharma Corporation,,3,,,False,,,,False,,,,,,,,,,,,,2020-02-01 14:21:47.790249,2020-02-01 14:21:47.790249,Mitsubishi Tanabe Pharma Corporation,Industry,MT-4666,Drug
NCT00056329,"ClinicalTrials.gov processed this data on January 31, 2020",2003-03-10,,,2012-05-02,2003-03-11,2003-03-12,Estimate,,,,,,,2012-05-02,2012-05-04,Estimate,April 2002,,2002-04-30,May 2012,2012-05-31,May 2012,Anticipated,2012-05-31,May 2012,Anticipated,2012-05-31,,Interventional,,,Vitamin E in Aging Persons With Down Syndrome,Multicenter Vitamin E Trial in Aging Persons With Down Syndrome,Unknown status,"Active, not recruiting",Phase 3,350,Actual,New York State Institute for Basic Research,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:35:03.109992,2020-02-01 22:35:03.109992,New York State Institute for Basic Research,Other,multivitamin,Drug
NCT02351882,"ClinicalTrials.gov processed this data on January 31, 2020",2014-11-17,,,2019-04-08,2015-01-27,2015-01-30,Estimate,,,,,,,2019-04-08,2019-04-10,Actual,January 2015,,2015-01-31,April 2019,2019-04-30,March 2019,Actual,2019-03-31,January 2018,Actual,2018-01-31,,Interventional,,,Safety and Efficacy of Nabilone in Alzheimer's Disease,Safety and Efficacy of Nabilone in Alzheimer's Disease: a Pilot Study,Completed,,Phase 2/Phase 3,38,Actual,Sunnybrook Health Sciences Centre,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:54:58.307512,2020-02-01 11:54:58.307512,Sunnybrook Health Sciences Centre,Other,Nabilone,Drug
NCT03298672,"ClinicalTrials.gov processed this data on January 31, 2020",2017-09-21,,,2019-09-06,2017-09-26,2017-10-02,Actual,,,,,,,2019-09-06,2019-09-10,Actual,"October 9, 2017",Actual,2017-10-09,September 2019,2019-09-30,"September 5, 2019",Actual,2019-09-05,"September 5, 2019",Actual,2019-09-05,,Interventional,,,"Safety, Tolerability, and Pharmacokinetics Study of NDX-1017","A Randomized, Placebo-Controlled, Double-Blinded, First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (Part A) and Multiple Ascending Doses (Part B) of NDX-1017 in Healthy Young and Elderly Subjects",Completed,,Phase 1,88,Actual,Athira Pharma,,2,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 08:43:58.167473,2020-02-01 08:43:58.167473,Athira Pharma,Industry,NDX-1017,Drug
NCT03402659,"ClinicalTrials.gov processed this data on January 31, 2020",2018-01-11,,,2019-10-01,2018-01-11,2018-01-18,Actual,,,,,,,2019-10-01,2019-10-03,Actual,"December 29, 2017",Actual,2017-12-29,August 2018,2018-08-31,"July 31, 2019",Actual,2019-07-31,"June 30, 2019",Actual,2019-06-30,,Interventional,REVERSE-SD,,"Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease","A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease",Completed,,Phase 2,161,Actual,EIP Pharma Inc,,2,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 08:26:25.557931,2020-02-01 08:26:25.557931,EIP Pharma Inc,Industry,neflamapimod,Drug
NCT02708186,"ClinicalTrials.gov processed this data on January 31, 2020",2016-03-10,,,2018-10-22,2016-03-14,2016-03-15,Estimate,,,,,,,2018-10-22,2018-10-23,Actual,March 2016,Actual,2016-03-31,April 2018,2018-04-30,May 2018,Actual,2018-05-31,May 2018,Actual,2018-05-31,,Interventional,,,Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD),"A Phase 2, Double-blind, Randomized, Placebo-controlled Study of Nelotanserin Versus Placebo in Subjects With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) Who Have REM Sleep Behavior Disorder (RBD)",Completed,,Phase 2,29,Actual,Axovant Sciences Ltd.,,2,,,False,,,,,,,,,,,,,,,,,2020-02-01 10:35:55.243047,2020-02-01 10:35:55.243047,Axovant Sciences Ltd.,Industry,Nelotanserin,Drug
NCT00470418,"ClinicalTrials.gov processed this data on January 31, 2020",2007-05-04,2014-01-16,,2017-01-05,2007-05-04,2007-05-07,Estimate,2017-01-05,2017-01-09,Estimate,,,,2017-01-05,2017-01-09,Estimate,January 2007,,2007-01-31,January 2017,2017-01-31,March 2010,Actual,2010-03-31,August 2008,Actual,2008-08-31,,Interventional,,,Development of NIC5-15 in the Treatment of Alzheimer's Disease,Development of NIC5-15 in the Treatment of Alzheimer's Disease,Completed,,Phase 2,15,Actual,VA Office of Research and Development,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:33:24.684642,2020-02-01 20:33:24.684642,VA Office of Research and Development,U.S. Fed,NIC5-15,Drug
NCT00580931,"ClinicalTrials.gov processed this data on January 31, 2020",2007-12-24,,,2017-01-23,2007-12-26,2007-12-27,Estimate,,,,,,,2017-01-23,2017-01-25,Estimate,January 2008,Actual,2008-01-31,January 2017,2017-01-31,July 2014,Actual,2014-07-31,July 2014,Actual,2014-07-31,,Interventional,,,Safety Study of Nicotinamide to Treat Alzheimer's Disease,Efficacy of Nicotinamide for the Treatment of Alzheimer's Disease,Completed,,Phase 1/Phase 2,50,Actual,"University of California, Irvine",,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:58:33.890191,2020-02-01 19:58:33.890191,"University of California, Irvine",Other,Nicotinamide,Drug
NCT02947893,"ClinicalTrials.gov processed this data on January 31, 2020",2016-10-21,,,2019-03-12,2016-10-27,2016-10-28,Estimate,,,,,,,2019-03-12,2019-03-13,Actual,January 2017,Actual,2017-01-31,March 2019,2019-03-31,February 2020,Anticipated,2020-02-29,December 2019,Anticipated,2019-12-31,,Interventional,AD,,"Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease","A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib (Tasigna®) on Safety, Biomarkers and Clinical Outcomes in Subjects With Mild to Moderate Alzheimer's Disease","Active, not recruiting",,Phase 2,42,Anticipated,Georgetown University,,2,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 09:47:48.303388,2020-02-01 09:47:48.303388,Georgetown University,Other,Nilotinib Capsule(s) Once a Day by Mouth,Drug
NCT02017340,"ClinicalTrials.gov processed this data on January 31, 2020",2013-12-16,,,2017-03-03,2013-12-16,2013-12-20,Estimate,,,,,,,2017-03-03,2017-03-06,Actual,"April 24, 2013",Actual,2013-04-24,March 2017,2017-03-31,"December 16, 2016",Actual,2016-12-16,"December 16, 2016",Actual,2016-12-16,,Interventional,NILVAD,,A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease,A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease,Completed,,Phase 3,511,Actual,"St. James's Hospital, Ireland",,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:14:04.638889,2020-02-01 13:14:04.638889,Prof Brian Lawlor,Other,Nilvadipine,Drug
NCT04074837,"ClinicalTrials.gov processed this data on January 31, 2020",2019-08-27,,,2019-08-28,2019-08-28,2019-08-30,Actual,,,,,,,2019-08-28,2019-08-30,Actual,"August 1, 2019",Actual,2019-08-01,August 2019,2019-08-31,"April 1, 2020",Anticipated,2020-04-01,"March 1, 2020",Anticipated,2020-03-01,,Interventional,,,"Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers","Phase1a, Randomized Placebo-controlled, Single and Multiple Dose, Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNI-362 in Healthy Aged Volunteers 50 to 72 Years of Age",Recruiting,,Phase 1,56,Anticipated,"Neuronascent, Inc.",,4,,,False,,,,True,True,False,,,,,,,,,No,This clinical trial will be available for peer-reviewed publication.,2020-02-01 06:43:42.295547,2020-02-01 06:43:42.295547,"Neuronascent, Inc.",Industry,NNI-362,Drug
NCT01469351,"ClinicalTrials.gov processed this data on January 31, 2020",2011-11-01,,,2013-04-18,2011-11-07,2011-11-10,Estimate,,,,,,,2013-04-18,2013-04-19,Estimate,January 2012,,2012-01-31,April 2013,2013-04-30,April 2013,Actual,2013-04-30,April 2013,Actual,2013-04-30,,Interventional,,,Identifying Potential Effects of Liraglutide on Degenerative Changes,Neurodegenerative Changes in Alzheimer's Disease: Identifying Potential Effects of Liraglutide on Degenerative Changes,Completed,,N/A,34,Actual,University of Aarhus,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:37:03.985693,2020-02-01 15:37:03.985693,University of Aarhus,Other,non-active study drug,Drug
NCT03959553,"ClinicalTrials.gov processed this data on January 31, 2020",2019-05-08,,,2019-05-23,2019-05-21,2019-05-22,Actual,,,,,,,2019-05-23,2019-05-28,Actual,"September 1, 2019",Anticipated,2019-09-01,May 2019,2019-05-31,"February 28, 2022",Anticipated,2022-02-28,"August 31, 2021",Anticipated,2021-08-31,,Interventional,,,GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, Phase IIa Clinical Trial to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of Moderate Alzheimer's Disease",Not yet recruiting,,Phase 2,90,Anticipated,GemVax & Kael,,3,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 07:00:23.340260,2020-02-01 07:00:23.340260,GemVax & Kael,Industry,Normal saline,Drug
NCT03184467,"ClinicalTrials.gov processed this data on January 31, 2020",2017-06-09,,,2017-06-09,2017-06-09,2017-06-12,Actual,,,,,,,2017-06-09,2017-06-12,Actual,June 2017,Anticipated,2017-06-30,June 2017,2017-06-30,June 2019,Anticipated,2019-06-30,June 2019,Anticipated,2019-06-30,,Interventional,,,Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Design, Prospective, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Donepezil and Combined With GV1001 in Alzheimer Patients",Unknown status,Recruiting,Phase 2,90,Anticipated,GemVax & Kael,,3,,,False,,,,False,False,False,,,,,,,,,Undecided,,2020-02-01 09:04:28.719332,2020-02-01 09:04:28.719332,GemVax & Kael,Industry,Normal Saline 0.9%,Drug
NCT04052737,"ClinicalTrials.gov processed this data on January 31, 2020",2019-08-08,,,2019-08-11,2019-08-09,2019-08-12,Actual,,,,,,,2019-08-11,2019-08-13,Actual,"March 23, 2018",Actual,2018-03-23,August 2019,2019-08-31,July 2020,Anticipated,2020-07-31,December 2019,Anticipated,2019-12-31,,Interventional,,,PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease,"A Prospective, Multicentric, Randomized, Double Blind, Placebo Controlled Phase II Clinical Study to Compare the Safety and Efficacy of PMZ-1620 Therapy Along With Standard Supportive Care in Subjects of Mild to Moderate Alzheimer's Disease",Recruiting,,Phase 2,80,Anticipated,"Pharmazz, Inc.",,2,,,False,,,,True,False,False,,,,,,,,,No,Results will be communicated and published as manuscript,2020-02-01 06:46:51.040091,2020-02-01 06:46:51.040091,"Pharmazz, Inc.",Industry,Normal Saline along with standard treatment,Drug
NCT00205179,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-13,2016-01-26,,2020-01-13,2005-09-13,2005-09-20,Estimate,2020-01-13,2020-01-22,Actual,,,,2020-01-13,2020-01-22,Actual,January 2005,,2005-01-31,January 2020,2020-01-31,December 2009,Actual,2009-12-31,December 2009,Actual,2009-12-31,,Interventional,,Older adults with Alzheimer's disease,Alzheimer's Disease: Potential Benefit of Isoflavones,Alzheimer's Disease: Potential Benefit of Isoflavones,Completed,,Phase 2,72,Actual,"University of Wisconsin, Madison",,2,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 21:48:33.787059,2020-02-01 21:48:33.787059,"University of Wisconsin, Madison",Other,Novasoy,Drug
NCT00948259,"ClinicalTrials.gov processed this data on January 31, 2020",2009-07-27,,,2009-11-10,2009-07-28,2009-07-29,Estimate,,,,,,,2009-11-10,2009-11-11,Estimate,December 2008,,2008-12-31,November 2009,2009-11-30,November 2009,Actual,2009-11-30,November 2009,Actual,2009-11-30,,Interventional,,,Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease,"Phase IIa 20 Week Double-blind, Placebo-controlled, Randomized, Escalating Dose Study to Evaluate the Safety and Tolerability of Four Oral Doses of NP031112, a Novel GSK3 Inhibitor, in Mild to Moderate Alzheimer's Disease Patients With Stable Anticholinesterasic Treatment.",Completed,,Phase 1/Phase 2,30,Actual,Noscira SA,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:10:37.833566,2020-02-01 18:10:37.833566,Noscira SA,Industry,NP031112,Drug
NCT03008161,"ClinicalTrials.gov processed this data on January 31, 2020",2016-12-23,,,2019-08-14,2016-12-29,2017-01-02,Estimate,,,,,,,2019-08-14,2019-08-15,Actual,December 2016,Actual,2016-12-31,August 2019,2019-08-31,"February 6, 2019",Actual,2019-02-06,"February 6, 2019",Actual,2019-02-06,,Interventional,,,Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease,"A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation Study of NPT088 in Patients With Probable Alzheimer's Disease",Completed,,Phase 1,83,Actual,"Proclara Biosciences, Inc.",,4,,,False,,,,True,,,,,,,,,,,Undecided,,2020-02-01 09:35:53.375769,2020-02-01 09:35:53.375769,"Proclara Biosciences, Inc.",Industry,NPT088,Drug
NCT01569516,"ClinicalTrials.gov processed this data on January 31, 2020",2012-03-30,,,2012-04-06,2012-03-30,2012-04-03,Estimate,,,,,,,2012-04-06,2012-04-09,Estimate,June 2011,,2011-06-30,May 2011,2011-05-31,October 2012,Anticipated,2012-10-31,July 2012,Anticipated,2012-07-31,,Interventional,,,Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease,"A Phase II, Double Blind, Placebo-controlled, Randomized, Multi-Center, Parallel Group Dose Exploring Study to Evaluate the Efficacy and Safety of Octohydroaminoacridine Succinate Tablets in Patient With Mild to Moderate Alzheimer's Disease",Unknown status,Recruiting,Phase 2,288,Anticipated,"Changchun Huayang High-tech Co., Ltd",,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:12:18.612653,2020-02-01 15:12:18.612653,"Changchun Huayang High-tech Co., Ltd",Industry,Octohydroaminoacridine succinate Tablets,Drug
NCT01569516,"ClinicalTrials.gov processed this data on January 31, 2020",2012-03-30,,,2012-04-06,2012-03-30,2012-04-03,Estimate,,,,,,,2012-04-06,2012-04-09,Estimate,June 2011,,2011-06-30,May 2011,2011-05-31,October 2012,Anticipated,2012-10-31,July 2012,Anticipated,2012-07-31,,Interventional,,,Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease,"A Phase II, Double Blind, Placebo-controlled, Randomized, Multi-Center, Parallel Group Dose Exploring Study to Evaluate the Efficacy and Safety of Octohydroaminoacridine Succinate Tablets in Patient With Mild to Moderate Alzheimer's Disease",Unknown status,Recruiting,Phase 2,288,Anticipated,"Changchun Huayang High-tech Co., Ltd",,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:12:18.612653,2020-02-01 15:12:18.612653,"Changchun Huayang High-tech Co., Ltd",Industry,Octohydroaminoacridine Succinate Tablets,Drug
NCT01324518,"ClinicalTrials.gov processed this data on January 31, 2020",2011-03-24,,,2014-10-20,2011-03-25,2011-03-29,Estimate,,,,,,,2014-10-20,2014-10-21,Estimate,April 2011,,2011-04-30,October 2014,2014-10-31,October 2012,Actual,2012-10-31,September 2012,Actual,2012-09-30,,Interventional,ALPO,,Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease,Safety and Efficacy of ORM-12741 on Cognitive and Behavioral Symptoms in Patients With Alzheimer's Disease,Completed,,Phase 2,100,Actual,"Orion Corporation, Orion Pharma",,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:16:14.110927,2020-02-01 16:16:14.110927,"Orion Corporation, Orion Pharma",Industry,ORM-12741,Drug
NCT02471196,"ClinicalTrials.gov processed this data on January 31, 2020",2015-06-08,,,2018-02-14,2015-06-12,2015-06-15,Estimate,,,,,,,2018-02-14,2018-02-15,Actual,"August 14, 2015",Actual,2015-08-14,February 2018,2018-02-28,"December 4, 2017",Actual,2017-12-04,"October 9, 2017",Actual,2017-10-09,,Interventional,Nebula,,Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease,"Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Patients With Alzheimer's Disease: A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study of 12 Weeks",Completed,,Phase 2,308,Actual,"Orion Corporation, Orion Pharma",,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:28:13.264712,2020-02-01 11:28:13.264712,"Orion Corporation, Orion Pharma",Industry,ORM-12741,Drug
NCT03867253,"ClinicalTrials.gov processed this data on January 31, 2020",2019-02-20,,,2019-12-02,2019-03-06,2019-03-07,Actual,,,,,,,2019-12-02,2019-12-03,Actual,"May 16, 2019",Actual,2019-05-16,November 2019,2019-11-30,"November 15, 2020",Anticipated,2020-11-15,"November 15, 2020",Anticipated,2020-11-15,,Interventional,ETHERAL-US,,Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease,"A Multicentre,Randomised, Double-blind, Placebo-controlled, 3-arm, 24-week Parallel-group Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ORY-2001 in Patients With Mild-moderate Alzheimer's Disease",Recruiting,,Phase 2,33,Anticipated,Oryzon Genomics S.A.,,3,,,False,,,,True,True,False,,,,,,,,,Undecided,,2020-02-01 07:14:13.743720,2020-02-01 07:14:13.743720,Oryzon Genomics S.A.,Industry,ORY-2001 High dose,Drug
NCT03867253,"ClinicalTrials.gov processed this data on January 31, 2020",2019-02-20,,,2019-12-02,2019-03-06,2019-03-07,Actual,,,,,,,2019-12-02,2019-12-03,Actual,"May 16, 2019",Actual,2019-05-16,November 2019,2019-11-30,"November 15, 2020",Anticipated,2020-11-15,"November 15, 2020",Anticipated,2020-11-15,,Interventional,ETHERAL-US,,Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease,"A Multicentre,Randomised, Double-blind, Placebo-controlled, 3-arm, 24-week Parallel-group Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ORY-2001 in Patients With Mild-moderate Alzheimer's Disease",Recruiting,,Phase 2,33,Anticipated,Oryzon Genomics S.A.,,3,,,False,,,,True,True,False,,,,,,,,,Undecided,,2020-02-01 07:14:13.743720,2020-02-01 07:14:13.743720,Oryzon Genomics S.A.,Industry,ORY-2001 Low dose,Drug
NCT00684710,"ClinicalTrials.gov processed this data on January 31, 2020",2008-05-23,,,2009-01-28,2008-05-27,2008-05-28,Estimate,,,,,,,2009-01-28,2009-01-30,Estimate,April 2008,,2008-04-30,January 2009,2009-01-31,August 2008,Actual,2008-08-31,August 2008,Actual,2008-08-31,,Interventional,,,"Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese Subjects","Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of PAZ 417 Administered Orally to Healthy Young Japanese Male and Healthy Elderly Japanese Male Subjects",Completed,,Phase 1,56,Anticipated,Wyeth is now a wholly owned subsidiary of Pfizer,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:28:29.702780,2020-02-01 19:28:29.702780,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,PAZ-417,Drug
NCT01028911,"ClinicalTrials.gov processed this data on January 31, 2020",2009-12-07,2014-04-09,,2014-05-16,2009-12-08,2009-12-09,Estimate,2014-05-16,2014-06-04,Estimate,,,,2014-05-16,2014-06-04,Estimate,December 2009,,2009-12-31,May 2014,2014-05-31,May 2010,Actual,2010-05-31,May 2010,Actual,2010-05-31,,Interventional,,Safety population included all participants who took at least 1 dose of study drug.,"A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease","A Phase 1, Double-Blind, Placebo-Controlled, Sponsor-Open, Randomized, Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-03654746 in Mild to Moderate Alzheimer's Disease Patients on Stable Donepezil Therapy",Terminated,,Phase 1,9,Actual,Pfizer,The study was terminated early due to slow recruitment and the need to use the existing information to determine dosing for another study.,2,,"This study terminated 27Apr2010 due to slow recruitment and the need to use the existing
    information to determine dosing for another study.",False,,,,False,,,,,,,,,,,,,2020-02-01 17:42:14.368255,2020-02-01 17:42:14.368255,Pfizer,Industry,PF-03654746,Drug
NCT00930059,"ClinicalTrials.gov processed this data on January 31, 2020",2009-06-29,,2013-04-09,2013-04-09,2009-06-29,2009-06-30,Estimate,,,,2013-04-09,2013-04-16,Estimate,2013-04-09,2013-04-16,Estimate,September 2009,,2009-09-30,April 2013,2013-04-30,September 2010,Actual,2010-09-30,September 2010,Actual,2010-09-30,,Interventional,,,A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease,"A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study Of PF-04447943 In Subjects With Mild To Moderate Alzheimer's Disease",Completed,,Phase 2,198,Actual,Pfizer,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:16:09.262269,2020-02-01 18:16:09.262269,Pfizer,Industry,PF-04447943,Drug
NCT00988598,"ClinicalTrials.gov processed this data on January 31, 2020",2009-10-01,,,2010-08-05,2009-10-01,2009-10-02,Estimate,,,,,,,2010-08-05,2010-08-09,Estimate,October 2009,,2009-10-31,August 2010,2010-08-31,July 2010,Actual,2010-07-31,July 2010,Actual,2010-07-31,,Interventional,,,"A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease","A Phase 1, Double-Blind, Placebo-Controlled, Sponsor Open, Randomized, Multiple Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04447943 In Mild To Moderate Alzheimer's Disease Subjects On Stable Donepezil Therapy",Completed,,Phase 1,15,Actual,Pfizer,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 17:55:55.298687,2020-02-01 17:55:55.298687,Pfizer,Industry,PF-04447943,Drug
NCT00566397,"ClinicalTrials.gov processed this data on January 31, 2020",2007-11-29,,2013-03-19,2018-11-28,2007-11-29,2007-12-03,Estimate,,,,2013-03-19,2013-03-25,Estimate,2018-11-28,2018-11-30,Actual,December 2007,,2007-12-31,November 2018,2018-11-30,December 2010,Actual,2010-12-31,December 2010,Actual,2010-12-31,,Interventional,,,A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease,"A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease",Completed,,Phase 2,402,Actual,Pfizer,,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:02:38.629333,2020-02-01 20:02:38.629333,Pfizer,Industry,PF-04494700,Drug
NCT00141661,"ClinicalTrials.gov processed this data on January 31, 2020",2005-08-30,,,2009-08-19,2005-08-30,2005-09-01,Estimate,,,,,,,2009-08-19,2009-08-20,Estimate,October 2005,,2005-10-31,August 2009,2009-08-31,June 2006,Actual,2006-06-30,June 2006,Actual,2006-06-30,,Interventional,,,A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients,"A Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study in Subjects With Mild to Moderate Dementia of the Alzheimer's Type to Evaluate the Safety and Tolerability of Two 10-Week Dose Regimens of Orally-Administered PF-04494700",Completed,,Phase 2,67,Actual,Pfizer,,3,,,False,,,,False,,,,,,,,,,,,,2020-02-01 22:05:05.719845,2020-02-01 22:05:05.719845,Pfizer,Industry,PF-04494700 - High Dose Arm,Drug
NCT00141661,"ClinicalTrials.gov processed this data on January 31, 2020",2005-08-30,,,2009-08-19,2005-08-30,2005-09-01,Estimate,,,,,,,2009-08-19,2009-08-20,Estimate,October 2005,,2005-10-31,August 2009,2009-08-31,June 2006,Actual,2006-06-30,June 2006,Actual,2006-06-30,,Interventional,,,A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients,"A Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study in Subjects With Mild to Moderate Dementia of the Alzheimer's Type to Evaluate the Safety and Tolerability of Two 10-Week Dose Regimens of Orally-Administered PF-04494700",Completed,,Phase 2,67,Actual,Pfizer,,3,,,False,,,,False,,,,,,,,,,,,,2020-02-01 22:05:05.719845,2020-02-01 22:05:05.719845,Pfizer,Industry,PF-04494700 - Low Dose Arm,Drug
NCT01712074,"ClinicalTrials.gov processed this data on January 31, 2020",2012-10-19,2016-08-26,,2017-01-30,2012-10-19,2012-10-23,Estimate,2017-01-30,2017-03-20,Actual,,,,2017-01-30,2017-03-20,Actual,November 2012,,2012-11-30,January 2017,2017-01-31,September 2015,Actual,2015-09-30,September 2015,Actual,2015-09-30,,Interventional,,One (1) of participant randomized but not treated appeared under placebo run-in including his/her discontinued and safety information,Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil,"A Randomized, 18-week, Placebo-controlled, Double-blind, Parallel Group Study Of The Safety And Efficacy Of Pf-05212377 (Sam-760) In Subjects With Mild-to-moderate Alzheimer's Disease With Existing Neuropsychiatric Symptoms On A Stable Daily Dose Of Donepezil",Terminated,,Phase 2,186,Actual,Pfizer,,2,,"The study was terminated October 23, 2015 as pre-specified, interim analysis futility criteria
    were met. The termination was not due to safety concerns.",False,,,,True,,,,,,,,,,,,,2020-02-01 14:35:19.013899,2020-02-01 14:35:19.013899,Pfizer,Industry,PF-05212377 (SAM-760),Drug
NCT02380573,"ClinicalTrials.gov processed this data on January 31, 2020",2015-02-24,,,2019-05-06,2015-02-27,2015-03-05,Estimate,,,,,,,2019-05-06,2019-05-08,Actual,July 2015,,2015-07-31,April 2019,2019-04-30,July 2023,Anticipated,2023-07-31,July 2022,Anticipated,2022-07-31,,Interventional,MB2,,"Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease","Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease",Suspended,,Phase 2,117,Actual,The University of Texas Health Science Center at San Antonio,,8,,Pending enrollment of new subjects if new funding obtained,False,,,,True,,,,,,,,,,,,,2020-02-01 11:48:30.714225,2020-02-01 11:48:30.714225,The University of Texas Health Science Center at San Antonio,Other,Phenazopyridine hydrochloride,Drug
NCT02992132,"ClinicalTrials.gov processed this data on January 31, 2020",2016-12-12,2019-01-25,,2019-03-07,2016-12-13,2016-12-14,Estimate,2019-03-07,2019-03-28,Actual,,,,2019-03-07,2019-03-28,Actual,November 2016,,2016-11-30,March 2019,2019-03-31,"February 16, 2018",Actual,2018-02-16,"January 25, 2018",Actual,2018-01-25,,Interventional,,All patients randomized,Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE),"A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease",Terminated,,Phase 2,111,Actual,ACADIA Pharmaceuticals Inc.,"The original study (n=432) was powered to detect a treatment effect on CMAI, however recruitment was discontinued early for business reasons and amended accordingly The final study (n=111) was no longer adequately powered to detect a treatment effect",3,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 09:38:59.986951,2020-02-01 09:38:59.986951,ACADIA Pharmaceuticals Inc.,Industry,Pimavanserin 20 mg,Drug
NCT02992132,"ClinicalTrials.gov processed this data on January 31, 2020",2016-12-12,2019-01-25,,2019-03-07,2016-12-13,2016-12-14,Estimate,2019-03-07,2019-03-28,Actual,,,,2019-03-07,2019-03-28,Actual,November 2016,,2016-11-30,March 2019,2019-03-31,"February 16, 2018",Actual,2018-02-16,"January 25, 2018",Actual,2018-01-25,,Interventional,,All patients randomized,Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE),"A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease",Terminated,,Phase 2,111,Actual,ACADIA Pharmaceuticals Inc.,"The original study (n=432) was powered to detect a treatment effect on CMAI, however recruitment was discontinued early for business reasons and amended accordingly The final study (n=111) was no longer adequately powered to detect a treatment effect",3,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 09:38:59.986951,2020-02-01 09:38:59.986951,ACADIA Pharmaceuticals Inc.,Industry,Pimavanserin 34 mg,Drug
NCT02035553,"ClinicalTrials.gov processed this data on January 31, 2020",2014-01-13,2017-09-28,,2017-09-28,2014-01-13,2014-01-14,Estimate,2017-09-28,2017-10-25,Actual,,,,2017-09-28,2017-10-25,Actual,November 2013,,2013-11-30,September 2017,2017-09-30,"October 27, 2016",Actual,2016-10-27,"September 28, 2016",Actual,2016-09-28,,Interventional,,,A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis,"A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease",Completed,,Phase 2,181,Actual,ACADIA Pharmaceuticals Inc.,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:09:51.019135,2020-02-01 13:09:51.019135,ACADIA Pharmaceuticals Inc.,Industry,Pimavanserin tartrate,Drug
NCT00982202,"ClinicalTrials.gov processed this data on January 31, 2020",2009-09-22,,,2009-09-22,2009-09-22,2009-09-23,Estimate,,,,,,,2009-09-22,2009-09-23,Estimate,January 2002,,2002-01-31,September 2009,2009-09-30,January 2005,Actual,2005-01-31,January 2005,Actual,2005-01-31,,Interventional,,,Pioglitazone in Alzheimer Disease,Pioglitazone in Alzheimer Disease Progression,Completed,,Phase 2,25,Actual,National Institute on Aging (NIA),,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:59:55.966871,2020-02-01 17:59:55.966871,National Institute on Aging (NIA),NIH,pioglitazone,Drug
NCT01931566,"ClinicalTrials.gov processed this data on January 31, 2020",2013-08-26,2019-07-22,,2019-08-29,2013-08-26,2013-08-29,Estimate,2019-07-22,2019-08-14,Actual,,,,2019-08-29,2019-09-16,Actual,"August 1, 2013",Actual,2013-08-01,August 2019,2019-08-31,"September 6, 2018",Actual,2018-09-06,"July 24, 2018",Actual,2018-07-24,,Interventional,TOMMORROW,Randomized Set included all participants who were randomized in the study.,Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset,"A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects",Terminated,,Phase 3,3494,Actual,Takeda,,3,,Lack of efficacy of the drug; no safety concern,False,,,,True,,,,,,,,,,,Yes,"Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.",2020-02-01 13:37:58.521166,2020-02-01 13:37:58.521166,Takeda,Industry,Pioglitazone,Drug
NCT02284906,"ClinicalTrials.gov processed this data on January 31, 2020",2014-11-04,2019-05-07,,2019-06-11,2014-11-04,2014-11-06,Estimate,2019-06-11,2019-07-02,Actual,,,,2019-06-11,2019-07-02,Actual,"February 12, 2015",Actual,2015-02-12,June 2019,2019-06-30,"May 8, 2018",Actual,2018-05-08,"January 31, 2018",Actual,2018-01-31,,Interventional,,Safety analysis set included all participants who received at least 1 dose of blinded study medication.,AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease,A Blinded Long-term Extension Study to Evaluate the Safety and Efficacy of Pioglitazone (AD-4833 Sustained Release 0.8 mg Daily) to Slow the Progression of Cognitive Decline in Subjects Who Have Completed the AD-4833/TOMM40_301 Study With Diagnosis of Mild Cognitive Impairment Due to Alzheimer Disease,Terminated,,Phase 3,40,Actual,Takeda,,2,,Lack of efficacy of the drug; no safety concern,False,,,,True,True,,,,,,,,,,Yes,"Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.",2020-02-01 12:10:02.597766,2020-02-01 12:10:02.597766,Takeda,Industry,Pioglitazone,Drug
NCT01931566,"ClinicalTrials.gov processed this data on January 31, 2020",2013-08-26,2019-07-22,,2019-08-29,2013-08-26,2013-08-29,Estimate,2019-07-22,2019-08-14,Actual,,,,2019-08-29,2019-09-16,Actual,"August 1, 2013",Actual,2013-08-01,August 2019,2019-08-31,"September 6, 2018",Actual,2018-09-06,"July 24, 2018",Actual,2018-07-24,,Interventional,TOMMORROW,Randomized Set included all participants who were randomized in the study.,Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset,"A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects",Terminated,,Phase 3,3494,Actual,Takeda,,3,,Lack of efficacy of the drug; no safety concern,False,,,,True,,,,,,,,,,,Yes,"Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.",2020-02-01 13:37:58.521166,2020-02-01 13:37:58.521166,Takeda,Industry,Pioglitazone placebo,Drug
NCT02615002,"ClinicalTrials.gov processed this data on January 31, 2020",2015-11-18,,,2019-08-20,2015-11-22,2015-11-25,Estimate,,,,,,,2019-08-20,2019-08-21,Actual,November 2015,,2015-11-30,August 2019,2019-08-31,"November 30, 2019",Anticipated,2019-11-30,November 2019,Anticipated,2019-11-30,,Interventional,,,Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION),"Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Ranging Study of Piromelatine in Patients With Mild Dementia Due to Alzheimer's Disease","Active, not recruiting",,Phase 2,500,Anticipated,Neurim Pharmaceuticals Ltd.,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 10:55:14.266636,2020-02-01 10:55:14.266636,Neurim Pharmaceuticals Ltd.,Industry,Piromelatine,Drug
NCT00555204,"ClinicalTrials.gov processed this data on January 31, 2020",2007-11-07,,2011-08-19,2011-08-19,2007-11-07,2007-11-08,Estimate,,,,2011-08-19,2011-08-23,Estimate,2011-08-19,2011-08-23,Estimate,November 2007,,2007-11-30,August 2011,2011-08-31,,,,June 2009,Actual,2009-06-30,,Interventional,,,Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled Study Using a Bayesian Adaptive Design to Evaluate the Efficacy and Safety of ABT-089 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors",Terminated,,Phase 2,337,Actual,Abbott,,7,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:06:30.241600,2020-02-01 20:06:30.241600,Abbott,Industry,placebo,Drug
NCT00602680,"ClinicalTrials.gov processed this data on January 31, 2020",2008-01-16,,,2009-07-17,2008-01-16,2008-01-28,Estimate,,,,,,,2009-07-17,2009-07-20,Estimate,January 2008,,2008-01-31,July 2009,2009-07-31,July 2008,Actual,2008-07-31,July 2008,Actual,2008-07-31,,Interventional,,,Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease,"A Multicenter, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance and Safety/Tolerability of SSR180711C for 4 Weeks, Using Donepezil as Calibrator, in Patients With Mild Alzheimer's Disease",Terminated,,Phase 2,1,Actual,Sanofi,,5,,Insufficient expected benefit risk,False,,,,True,,,,,,,,,,,,,2020-02-01 19:52:44.951641,2020-02-01 19:52:44.951641,Sanofi,Industry,placebo,Drug
NCT00667810,"ClinicalTrials.gov processed this data on January 31, 2020",2008-04-24,2013-10-22,,2015-12-04,2008-04-25,2008-04-28,Estimate,2015-12-04,2016-01-08,Estimate,,,,2015-12-04,2016-01-08,Estimate,June 2008,,2008-06-30,December 2015,2015-12-31,August 2013,Actual,2013-08-31,October 2012,Actual,2012-10-31,,Interventional,,Safety population included all randomized participants who received at least one infusion or portion of an infusion of study drug.,Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers",Terminated,,Phase 3,901,Actual,Pfizer,"The impact of study termination, the shorter observational periods and the resulting small sample size coupled with not having enough participants with post baseline assessments for various reasons were limiting factors for data interpretation.",3,,"The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical
    benefit. This decision was not based on any new safety concerns.",False,,,,True,,,,,,,,,,,,,2020-02-01 19:33:15.927565,2020-02-01 19:33:15.927565,Pfizer,Industry,placebo,Drug
NCT00676143,"ClinicalTrials.gov processed this data on January 31, 2020",2008-05-02,2013-10-14,,2016-05-03,2008-05-09,2008-05-12,Estimate,2016-05-03,2016-06-10,Estimate,,,,2016-05-03,2016-06-10,Estimate,January 2008,,2008-01-31,May 2016,2016-05-31,November 2012,Actual,2012-11-30,October 2012,Actual,2012-10-31,,Interventional,,Safety population included all randomized participants who received at least one infusion or portion of an infusion of study drug.,Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients,"A Phase Iii, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Efficacy And Safety Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Mild To Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Carriers",Terminated,,Phase 3,1100,Actual,Pfizer,,2,,"The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical
    benefit. This decision was not based on any new safety concerns.",False,,,,True,,,,,,,,,,,,,2020-02-01 19:31:07.517307,2020-02-01 19:31:07.517307,Pfizer,Industry,placebo,Drug
NCT00702780,"ClinicalTrials.gov processed this data on January 31, 2020",2008-06-15,2014-04-10,,2014-05-13,2008-06-18,2008-06-20,Estimate,2014-05-13,2014-06-13,Estimate,,,,2014-05-13,2014-06-13,Estimate,November 2008,,2008-11-30,May 2014,2014-05-31,September 2011,Actual,2011-09-30,September 2011,Actual,2011-09-30,,Interventional,ESAD,,Progression Delaying Effect of Escitalopram in Alzheimer's Disease,"Multi-center, Randomized, Placebo-controlled, Double-blind Clinical Trial of Escitalopram on the Progression Delaying Effect in Alzheimer's Disease",Completed,,N/A,74,Actual,Seoul National University Hospital,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:23:05.471913,2020-02-01 19:23:05.471913,Seoul National University Hospital,Other,placebo,Drug
NCT00719394,"ClinicalTrials.gov processed this data on January 31, 2020",2008-07-17,,,2009-07-08,2008-07-18,2008-07-21,Estimate,,,,,,,2009-07-08,2009-07-10,Estimate,March 2008,,2008-03-31,July 2009,2009-07-31,August 2008,Actual,2008-08-31,August 2008,Actual,2008-08-31,,Interventional,,,Study Evaluating Safety of GSI 136 in Young and Elderly Japanese Males,"Ascending Single-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-136 Administered Orally to Healthy Japanese Male Subjects and Healthy Japanese Elderly Male Subjects",Completed,,Phase 1,72,Anticipated,Wyeth is now a wholly owned subsidiary of Pfizer,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:17:48.931302,2020-02-01 19:17:48.931302,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,placebo,Drug
NCT00898807,"ClinicalTrials.gov processed this data on January 31, 2020",2009-05-11,2014-03-19,,2014-06-26,2009-05-11,2009-05-12,Estimate,2014-06-26,2014-06-27,Estimate,,,,2014-06-26,2014-06-27,Estimate,July 2009,,2009-07-31,June 2014,2014-06-30,September 2013,Actual,2013-09-30,September 2013,Actual,2013-09-30,,Interventional,CitAD,,Citalopram for Agitation in Alzheimer's Disease,A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease,Completed,,Phase 3,186,Actual,JHSPH Center for Clinical Trials,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:25:13.871439,2020-02-01 18:25:13.871439,JHSPH Center for Clinical Trials,Other,placebo,Drug
NCT00976118,"ClinicalTrials.gov processed this data on January 31, 2020",2009-09-11,,,2018-12-12,2009-09-11,2009-09-14,Estimate,,,,,,,2018-12-12,2018-12-13,Actual,February 2006,,2006-02-28,December 2018,2018-12-31,February 2009,Actual,2009-02-28,July 2008,Actual,2008-07-31,,Interventional,,,Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease,"A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Efficacy of Oral AB1010 in Adults Patients With Mild to Moderate Alzheimer-type Disease.",Completed,,Phase 2,34,Actual,AB Science,,2,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 18:02:06.818140,2020-02-01 18:02:06.818140,AB Science,Industry,placebo,Drug
NCT01018875,"ClinicalTrials.gov processed this data on January 31, 2020",2009-11-20,,2012-02-01,2018-06-01,2009-11-23,2009-11-24,Estimate,,,,2012-02-01,2012-02-03,Estimate,2018-06-01,2018-06-06,Actual,December 2009,,2009-12-31,January 2013,2013-01-31,February 2011,Actual,2011-02-28,February 2011,Actual,2011-02-28,,Interventional,,,Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Active- and Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease",Completed,,Phase 2,242,Actual,AbbVie,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:45:00.201179,2020-02-01 17:45:00.201179,"AbbVie (prior sponsor, Abbott)",Industry,placebo,Drug
NCT01047254,"ClinicalTrials.gov processed this data on January 31, 2020",2010-01-11,,,2017-05-08,2010-01-11,2010-01-12,Estimate,,,,,,,2017-05-08,2017-05-09,Actual,January 2010,,2010-01-31,May 2017,2017-05-31,July 2014,Actual,2014-07-31,July 2014,Actual,2014-07-31,,Interventional,APA-AD,,Bupropion for the Treatment of Apathy in Alzheimer's Dementia,"A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Bupropion for the Treatment of Apathy in Alzheimer's Dementia(Apa-AD)",Completed,,Phase 3,110,Actual,"University Hospital, Bonn",,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:37:20.131108,2020-02-01 17:37:20.131108,"University Hospital, Bonn",Other,placebo,Drug
NCT01117181,"ClinicalTrials.gov processed this data on January 31, 2020",2010-05-04,2013-02-11,,2018-06-07,2010-05-04,2010-05-05,Estimate,2013-04-01,2013-05-10,Estimate,,,,2018-06-07,2018-06-12,Actual,June 2010,,2010-06-30,June 2018,2018-06-30,August 2012,Actual,2012-08-31,August 2012,Actual,2012-08-31,,Interventional,ADMET,,Apathy in Dementia Methylphenidate Trial (ADMET),Apathy in Dementia Methylphenidate Trial (ADMET),Completed,,Phase 2,60,Actual,Johns Hopkins Bloomberg School of Public Health,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:17:32.212260,2020-02-01 17:17:32.212260,Johns Hopkins Bloomberg School of Public Health,Other,placebo,Drug
NCT01137799,"ClinicalTrials.gov processed this data on January 31, 2020",2010-06-03,,,2012-11-07,2010-06-03,2010-06-04,Estimate,,,,,,,2012-11-07,2012-11-08,Estimate,August 2009,,2009-08-31,November 2012,2012-11-30,March 2011,Actual,2011-03-31,,,,,Interventional,,,The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients,"A Double-Blind, Placebo-Controlled, Randomized, Four-Way Cross-Over Study To Investigate Effect Of Single Oral Doses Of JNJ-39393406 On Event-Related Potentials In Subjects With Stable Schizophrenia",Terminated,,Phase 1,47,Actual,"Janssen Pharmaceutica N.V., Belgium",,6,,Efficacy signals were insufficiently strong to justify recruitment of additional patients.,False,,,,False,,,,,,,,,,,,,2020-02-01 17:11:10.402638,2020-02-01 17:11:10.402638,"Janssen Pharmaceutica N.V., Belgium",Industry,placebo,Drug
NCT01221259,"ClinicalTrials.gov processed this data on January 31, 2020",2010-10-13,,,2013-05-20,2010-10-13,2010-10-14,Estimate,,,,,,,2013-05-20,2013-05-22,Estimate,January 2010,,2010-01-31,February 2013,2013-02-28,November 2012,Actual,2012-11-30,October 2011,Actual,2011-10-31,,Interventional,,,"A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects","A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects",Completed,,Phase 1,60,Actual,Eisai Inc.,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 16:46:00.362394,2020-02-01 16:46:00.362394,Eisai Inc.,Industry,placebo,Drug
NCT01255046,"ClinicalTrials.gov processed this data on January 31, 2020",2010-12-03,,,2014-08-19,2010-12-05,2010-12-07,Estimate,,,,,,,2014-08-19,2014-08-20,Estimate,December 2015,,2015-12-31,August 2014,2014-08-31,,,,December 2018,Anticipated,2018-12-31,,Interventional,,,Study of STA-1 as an Add-on Treatment to Donepezil,"A Phase II Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of STA-1 as an Add-on Treatment to Donepezil in Patients With Mild to Moderate Alzheimer's Disease",Unknown status,Not yet recruiting,Phase 2,136,Anticipated,"Sinphar Pharmaceutical Co., Ltd",,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:35:48.924341,2020-02-01 16:35:48.924341,"Sinphar Pharmaceutical Co., Ltd",Other,placebo,Drug
NCT02361424,"ClinicalTrials.gov processed this data on January 31, 2020",2014-12-19,,,2016-02-12,2015-02-06,2015-02-11,Estimate,,,,,,,2016-02-12,2016-02-15,Estimate,February 2013,,2013-02-28,October 2015,2015-10-31,June 2015,Actual,2015-06-30,June 2015,Actual,2015-06-30,,Interventional,PLEODIAL-I,,Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD),First Single-blind Sequential Placebo-controlled Prospective Phase IIA Pilot Study Assessing the Effects of PXT00864 in Mild AD Patients,Completed,,Phase 2,47,Actual,Pharnext SA,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:52:50.624085,2020-02-01 11:52:50.624085,Pharnext SA,Other,placebo,Drug
NCT03435861,"ClinicalTrials.gov processed this data on January 31, 2020",2017-12-22,,,2018-11-19,2018-02-09,2018-02-19,Actual,,,,,,,2018-11-19,2018-11-21,Actual,"October 8, 2018",Actual,2018-10-08,November 2018,2018-11-30,"January 30, 2021",Anticipated,2021-01-30,"January 30, 2020",Anticipated,2020-01-30,,Interventional,VIP,,Effect of Neflamapimod on Brain Inflammation in Alzheimer's Disease Patients,Effect of Neflamapimod (VX-745) on Brain Inflammation Using Positron Emission Tomography (PET) Scan in Alzheimer's Disease (AD) Patients,Recruiting,,Phase 2,40,Anticipated,"University Hospital, Toulouse",,2,,,False,,,,False,False,False,,,,,,,,,No,,2020-02-01 08:20:44.789272,2020-02-01 08:20:44.789272,"University Hospital, Toulouse",Other,placebo,Drug
NCT00056329,"ClinicalTrials.gov processed this data on January 31, 2020",2003-03-10,,,2012-05-02,2003-03-11,2003-03-12,Estimate,,,,,,,2012-05-02,2012-05-04,Estimate,April 2002,,2002-04-30,May 2012,2012-05-31,May 2012,Anticipated,2012-05-31,May 2012,Anticipated,2012-05-31,,Interventional,,,Vitamin E in Aging Persons With Down Syndrome,Multicenter Vitamin E Trial in Aging Persons With Down Syndrome,Unknown status,"Active, not recruiting",Phase 3,350,Actual,New York State Institute for Basic Research,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:35:03.109992,2020-02-01 22:35:03.109992,New York State Institute for Basic Research,Other,Placebo,Drug
NCT00066157,"ClinicalTrials.gov processed this data on January 31, 2020",2003-08-04,,,2018-08-22,2003-08-04,2003-08-05,Estimate,,,,,,,2018-08-22,2018-08-23,Actual,September 2001,,2001-09-30,August 2018,2018-08-31,December 2007,Actual,2007-12-31,December 2007,Actual,2007-12-31,,Interventional,,,Alzheimer's Disease: Therapeutic Potential of Estrogen,Alzheimer's Disease: Therapeutic Potential of Estrogen,Completed,,Phase 2/Phase 3,42,Actual,"University of Wisconsin, Madison",,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:32:28.672051,2020-02-01 22:32:28.672051,"University of Wisconsin, Madison",Other,Placebo,Drug
NCT00071721,"ClinicalTrials.gov processed this data on January 31, 2020",2003-10-29,2010-07-06,,2014-09-15,2003-10-30,2003-10-31,Estimate,2010-09-24,2010-10-20,Estimate,,,,2014-09-15,2014-09-25,Estimate,October 2003,,2003-10-31,September 2014,2014-09-30,December 2009,Actual,2009-12-31,February 2009,Actual,2009-02-28,,Interventional,,,Valproate in Dementia (VALID),"A Randomized, Double-Blind, Placebo-Controlled Trial of Valproate to Attenuate the Progression of Alzheimer's Disease (AD)",Completed,,Phase 3,313,Actual,Alzheimer's Disease Cooperative Study (ADCS),,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:30:40.191422,2020-02-01 22:30:40.191422,Alzheimer's Disease Cooperative Study (ADCS),Other,Placebo,Drug
NCT00086138,"ClinicalTrials.gov processed this data on January 31, 2020",2004-06-25,2016-03-08,,2017-02-28,2004-06-25,2004-06-28,Estimate,2017-02-28,2017-04-11,Actual,,,,2017-02-28,2017-04-11,Actual,July 2004,,2004-07-31,February 2017,2017-02-28,July 2009,Actual,2009-07-31,July 2008,Actual,2008-07-31,,Interventional,DIADS-2,,Depression in Alzheimer's Disease-2,Depression in Alzheimer's Disease (DIADS-2),Completed,,Phase 2/Phase 3,131,Actual,Johns Hopkins University,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:24:18.842269,2020-02-01 22:24:18.842269,Johns Hopkins University,Other,Placebo,Drug
NCT00160147,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-08,,2015-01-29,2015-01-29,2005-09-08,2005-09-12,Estimate,,,,2015-01-29,2015-02-09,Estimate,2015-01-29,2015-02-09,Estimate,December 2005,,2005-12-31,June 2009,2009-06-30,January 2008,Actual,2008-01-31,January 2008,Actual,2008-01-31,,Interventional,,,Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type,"A Randomized, Double-Blind, Placebo-controlled, Efficacy, Safety, and Tolerability Study of Bifeprunox in the Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type",Terminated,,Phase 3,60,Actual,Solvay Pharmaceuticals,,2,,The study was discontinued prematurely on 25 February 2008 due to slow enrollment,False,,,,,,,,,,,,,,,,,2020-02-01 21:59:51.819507,2020-02-01 21:59:51.819507,Solvay Pharmaceuticals,Industry,Placebo,Drug
NCT00205179,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-13,2016-01-26,,2020-01-13,2005-09-13,2005-09-20,Estimate,2020-01-13,2020-01-22,Actual,,,,2020-01-13,2020-01-22,Actual,January 2005,,2005-01-31,January 2020,2020-01-31,December 2009,Actual,2009-12-31,December 2009,Actual,2009-12-31,,Interventional,,Older adults with Alzheimer's disease,Alzheimer's Disease: Potential Benefit of Isoflavones,Alzheimer's Disease: Potential Benefit of Isoflavones,Completed,,Phase 2,72,Actual,"University of Wisconsin, Madison",,2,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 21:48:33.787059,2020-02-01 21:48:33.787059,"University of Wisconsin, Madison",Other,Placebo,Drug
NCT00235716,"ClinicalTrials.gov processed this data on January 31, 2020",2005-10-06,2013-12-06,,2014-07-14,2005-10-06,2005-10-10,Estimate,2014-01-23,2014-01-29,Estimate,,,,2014-07-14,2014-07-23,Estimate,August 2007,,2007-08-31,July 2014,2014-07-31,October 2012,Actual,2012-10-31,September 2012,Actual,2012-09-30,,Interventional,TEAM-AD,,"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease","CSP #546 - A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease (TEAM-AD)",Completed,,Phase 3,613,Actual,VA Office of Research and Development,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:42:18.318346,2020-02-01 21:42:18.318346,US Department of Veterans Affairs,U.S. Fed,Placebo,Drug
NCT00239746,"ClinicalTrials.gov processed this data on January 31, 2020",2005-10-13,,,2009-04-28,2005-10-13,2005-10-17,Estimate,,,,,,,2009-04-28,2009-04-29,Estimate,October 2005,,2005-10-31,April 2009,2009-04-30,August 2009,Anticipated,2009-08-31,August 2009,Anticipated,2009-08-31,,Interventional,,,BONSAI: Biomarkers of Nonsteroidal Anti-Inflammatories,Biomarkers of Nonsteroidal Anti-Inflammatories,Unknown status,"Active, not recruiting",Phase 1,40,Anticipated,National Institute on Aging (NIA),,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:41:15.228944,2020-02-01 21:41:15.228944,National Institute on Aging (NIA),NIH,Placebo,Drug
NCT00322153,"ClinicalTrials.gov processed this data on January 31, 2020",2006-05-03,2010-07-20,,2010-08-25,2006-05-04,2006-05-05,Estimate,2010-08-25,2010-09-16,Estimate,,,,2010-08-25,2010-09-16,Estimate,June 2005,,2005-06-30,August 2010,2010-08-31,January 2008,Actual,2008-01-31,October 2007,Actual,2007-10-31,,Interventional,,,A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients With Moderate-to-Severe Dementia of the Alzheimer's Type",Completed,,Phase 3,677,Actual,Forest Laboratories,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 21:18:57.061793,2020-02-01 21:18:57.061793,Forest Laboratories,Industry,Placebo,Drug
NCT00325728,"ClinicalTrials.gov processed this data on January 31, 2020",2006-05-11,,,2017-08-10,2006-05-11,2006-05-15,Estimate,,,,,,,2017-08-10,2017-08-14,Actual,"March 21, 2006",Actual,2006-03-21,August 2017,2017-08-31,"August 20, 2007",Actual,2007-08-20,"August 1, 2007",Actual,2007-08-01,,Interventional,,,Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease,"A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of 8 Week Treatment of Rozerem 8 mg (QHS) in Sleep Disturbed, Mild to Moderately Severe Alzheimer's Disease Subjects",Completed,,Phase 2,74,Actual,Takeda,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 21:17:49.788554,2020-02-01 21:17:49.788554,Takeda,Industry,Placebo,Drug
NCT00368459,"ClinicalTrials.gov processed this data on January 31, 2020",2006-08-22,2015-03-01,,2015-03-20,2006-08-22,2006-08-24,Estimate,2015-03-20,2015-04-02,Estimate,,,,2015-03-20,2015-04-02,Estimate,August 2006,,2006-08-31,March 2015,2015-03-31,January 2012,Actual,2012-01-31,March 2011,Actual,2011-03-31,,Interventional,,Postmenopausal women with Alzheimer's disease of mild to moderate severity,Raloxifene for Women With Alzheimer's Disease,Raloxifene in Women With AD: Randomized Controlled Trial,Completed,,Phase 2,42,Actual,Stanford University,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:06:20.426774,2020-02-01 21:06:20.426774,Stanford University,Other,Placebo,Drug
NCT00377715,"ClinicalTrials.gov processed this data on January 31, 2020",2006-09-15,,,2015-11-09,2006-09-15,2006-09-18,Estimate,,,,,,,2015-11-09,2015-11-11,Estimate,September 2005,,2005-09-30,November 2015,2015-11-30,,,,August 2006,Actual,2006-08-31,,Interventional,,,"Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease","Phase 2, Double-Blind, Placebo-Controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,183,Actual,"Medivation, Inc.",,2,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:03:34.573776,2020-02-01 21:03:34.573776,"Medivation, Inc.",Industry,Placebo,Drug
NCT00411580,"ClinicalTrials.gov processed this data on January 31, 2020",2006-12-13,,,2013-03-27,2006-12-13,2006-12-14,Estimate,,,,,,,2013-03-27,2013-03-29,Estimate,June 2005,,2005-06-30,March 2013,2013-03-31,December 2008,Actual,2008-12-31,December 2008,Actual,2008-12-31,,Interventional,,,Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD),"A 52-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Time-lagged, Parallel Group Study in Patients With Mild to Moderate Alzheimer's Disease (AD) to Investigate the Safety, Tolerability and Aß-specific Antibody Response Following Three Subcutaneous Injections of CAD106",Completed,,Phase 1,58,Actual,Novartis,,2,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:52:37.297594,2020-02-01 20:52:37.297594,Novartis Pharmaceuticals,Industry,Placebo,Drug
NCT00438568,"ClinicalTrials.gov processed this data on January 31, 2020",2007-02-21,,,2012-09-12,2007-02-21,2007-02-22,Estimate,,,,,,,2012-09-12,2012-09-14,Estimate,June 2006,,2006-06-30,September 2012,2012-09-30,December 2011,Actual,2011-12-31,December 2011,Actual,2011-12-31,,Interventional,SNIFF 120,,SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days),Therapeutic Effects of Intranasal Insulin Administration in AD,Completed,,Phase 2,173,Actual,University of Washington,,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:43:16.502687,2020-02-01 20:43:16.502687,University of Washington,Other,Placebo,Drug
NCT00440050,"ClinicalTrials.gov processed this data on January 31, 2020",2007-02-22,2010-05-28,,2014-09-15,2007-02-22,2007-02-26,Estimate,2010-07-28,2010-08-30,Estimate,,,,2014-09-15,2014-09-25,Estimate,February 2007,,2007-02-28,September 2014,2014-09-30,May 2009,Actual,2009-05-31,May 2009,Actual,2009-05-31,,Interventional,DHA,,"DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease",A Randomized Double-Blind Placebo-Controlled Trial Of The Effects Of Docosahexaenoic Acid (DHA) In Slowing The Progression Of Alzheimer's Disease,Completed,,Phase 3,402,Actual,Alzheimer's Disease Cooperative Study (ADCS),,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:42:48.181086,2020-02-01 20:42:48.181086,Alzheimer's Disease Cooperative Study (ADCS),Other,Placebo,Drug
NCT00470418,"ClinicalTrials.gov processed this data on January 31, 2020",2007-05-04,2014-01-16,,2017-01-05,2007-05-04,2007-05-07,Estimate,2017-01-05,2017-01-09,Estimate,,,,2017-01-05,2017-01-09,Estimate,January 2007,,2007-01-31,January 2017,2017-01-31,March 2010,Actual,2010-03-31,August 2008,Actual,2008-08-31,,Interventional,,,Development of NIC5-15 in the Treatment of Alzheimer's Disease,Development of NIC5-15 in the Treatment of Alzheimer's Disease,Completed,,Phase 2,15,Actual,VA Office of Research and Development,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:33:24.684642,2020-02-01 20:33:24.684642,VA Office of Research and Development,U.S. Fed,Placebo,Drug
NCT00515333,"ClinicalTrials.gov processed this data on January 31, 2020",2007-08-10,,,2008-02-19,2007-08-10,2007-08-13,Estimate,,,,,,,2008-02-19,2008-02-20,Estimate,August 2004,,2004-08-31,February 2008,2008-02-29,December 2007,Actual,2007-12-31,December 2007,Actual,2007-12-31,,Interventional,,,TRx0014 in Patients With Mild or Moderate Alzheimer's Disease,"An Exploratory Placebo-Controlled, Dose-Ranging Study of the Effects of TRx0014 30 MG TID, 60 MG TID AND 100 MG TID in Patients With Mild or Moderate Dementia of the Alzheimer Type",Completed,,Phase 2,323,Actual,TauRx Therapeutics Ltd,,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:19:58.910572,2020-02-01 20:19:58.910572,TauRx Therapeutics Ltd,Industry,Placebo,Drug
NCT00566397,"ClinicalTrials.gov processed this data on January 31, 2020",2007-11-29,,2013-03-19,2018-11-28,2007-11-29,2007-12-03,Estimate,,,,2013-03-19,2013-03-25,Estimate,2018-11-28,2018-11-30,Actual,December 2007,,2007-12-31,November 2018,2018-11-30,December 2010,Actual,2010-12-31,December 2010,Actual,2010-12-31,,Interventional,,,A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease,"A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease",Completed,,Phase 2,402,Actual,Pfizer,,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:02:38.629333,2020-02-01 20:02:38.629333,Pfizer,Industry,Placebo,Drug
NCT00594568,"ClinicalTrials.gov processed this data on January 31, 2020",2008-01-11,2013-11-06,2011-08-09,2015-03-13,2008-01-11,2008-01-15,Estimate,2014-09-22,2014-09-25,Estimate,2011-08-09,2011-08-15,Estimate,2015-03-13,2015-03-17,Estimate,March 2008,,2008-03-31,March 2015,2015-03-31,May 2011,Actual,2011-05-31,May 2011,Actual,2011-05-31,,Interventional,,,Effect of LY450139 on the Long Term Progression of Alzheimer's Disease,Effect of γ-Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo,Completed,,Phase 3,1537,Actual,Eli Lilly and Company,Outcomes with 4-week after study drug cessation timeframe=All dosing stopped after protocol-specified interim review showed dose-dependent cognitive/functional worsening for LY450139 participants; followed for 32 weeks; not all assessments were made.,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:55:02.296322,2020-02-01 19:55:02.296322,Eli Lilly and Company,Industry,Placebo,Drug
NCT00606164,"ClinicalTrials.gov processed this data on January 31, 2020",2008-01-21,,,2008-01-21,2008-01-21,2008-02-01,Estimate,,,,,,,2008-01-21,2008-02-01,Estimate,April 2008,,2008-04-30,January 2008,2008-01-31,December 2008,Anticipated,2008-12-31,December 2008,Anticipated,2008-12-31,,Interventional,,,"Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin 1 in Patients With Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Parallel Groups, Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bryostatin 1 in Patients With Mild to Moderate Alzheimer's Disease",Unknown status,Not yet recruiting,Phase 2,9,Anticipated,Blanchette Rockefeller Neurosciences Insitute,,3,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:51:23.445840,2020-02-01 19:51:23.445840,Blanchette Rockefeller Neurosciences Insitute,Other,Placebo,Drug
NCT00630500,"ClinicalTrials.gov processed this data on January 31, 2020",2008-02-27,,,2015-07-27,2008-03-06,2008-03-07,Estimate,,,,,,,2015-07-27,2015-07-28,Estimate,February 2006,,2006-02-28,February 2009,2009-02-28,March 2009,Actual,2009-03-31,February 2009,Actual,2009-02-28,,Interventional,MEMPDD,,Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB),"A Double-blind, Placebo-controlled Multicentre Trial of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies",Completed,,Phase 2,75,Actual,Helse Stavanger HF,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:44:12.140389,2020-02-01 19:44:12.140389,Helse Stavanger HF,Other,Placebo,Drug
NCT00663936,"ClinicalTrials.gov processed this data on January 31, 2020",2008-04-18,,2012-12-09,2013-10-09,2008-04-21,2008-04-22,Estimate,,,,2012-12-10,2012-12-12,Estimate,2013-10-09,2013-11-05,Estimate,April 2008,,2008-04-30,December 2012,2012-12-31,June 2011,Actual,2011-06-30,May 2011,Actual,2011-05-31,,Interventional,,,Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease,"A Phase 2a Multi-center, Randomized, Double Blind, Placebo-controlled Study to Investigate the Efficacy and Safety of T-817MAa in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,373,Actual,"FUJIFILM Toyama Chemical Co., Ltd.",,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:34:29.421057,2020-02-01 19:34:29.421057,"FUJIFILM Toyama Chemical Co., Ltd.",Industry,Placebo,Drug
NCT00675623,"ClinicalTrials.gov processed this data on January 31, 2020",2008-05-07,,2016-09-24,2016-09-24,2008-05-08,2008-05-09,Estimate,,,,2016-09-24,2016-09-27,Estimate,2016-09-24,2016-09-27,Estimate,May 2008,,2008-05-31,September 2016,2016-09-30,,,,December 2009,Actual,2009-12-31,,Interventional,CONNECTION,,A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease,"A Global Phase 3, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Oral Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease (CONNECTION)",Completed,,Phase 3,598,Actual,"Medivation, Inc.",,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:31:17.244228,2020-02-01 19:31:17.244228,"Medivation, Inc.",Industry,Placebo,Drug
NCT00679627,"ClinicalTrials.gov processed this data on January 31, 2020",2008-05-15,2013-04-23,,2013-09-10,2008-05-15,2008-05-19,Estimate,2013-07-30,2013-09-02,Estimate,,,,2013-09-10,2013-09-19,Estimate,June 2008,,2008-06-30,September 2013,2013-09-30,May 2012,Actual,2012-05-31,April 2012,Actual,2012-04-30,,Interventional,,,A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-controlled Trial of Long-term (2-year) Treatment of Galantamine in Mild to Moderately-Severe Alzheimer's Disease",Terminated,,Phase 3,2051,Actual,"Janssen Research & Development, LLC",,2,,"Due to a pre-specified imbalance of deaths between treatment groups, the DSMB recommended early
    termination of the trial",False,,,,,,,,,,,,,,,,,2020-02-01 19:29:53.904574,2020-02-01 19:29:53.904574,"Janssen Research & Development, LLC",Industry,Placebo,Drug
NCT00684710,"ClinicalTrials.gov processed this data on January 31, 2020",2008-05-23,,,2009-01-28,2008-05-27,2008-05-28,Estimate,,,,,,,2009-01-28,2009-01-30,Estimate,April 2008,,2008-04-30,January 2009,2009-01-31,August 2008,Actual,2008-08-31,August 2008,Actual,2008-08-31,,Interventional,,,"Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese Subjects","Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of PAZ 417 Administered Orally to Healthy Young Japanese Male and Healthy Elderly Japanese Male Subjects",Completed,,Phase 1,56,Anticipated,Wyeth is now a wholly owned subsidiary of Pfizer,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:28:29.702780,2020-02-01 19:28:29.702780,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,Placebo,Drug
NCT00762411,"ClinicalTrials.gov processed this data on January 31, 2020",2008-09-26,2013-11-06,2011-08-22,2015-01-28,2008-09-26,2008-09-30,Estimate,2014-09-22,2014-09-25,Estimate,2011-08-22,2011-08-23,Estimate,2015-01-28,2015-02-16,Estimate,September 2008,,2008-09-30,January 2015,2015-01-31,April 2011,Actual,2011-04-30,April 2011,Actual,2011-04-30,,Interventional,IDENTITY-2,,"Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo","Effect of LY450139 a y-Secretase Inhibitor, on the Progression of Alzheimer's Disease as Compared With Placebo",Completed,,Phase 3,1111,Actual,Eli Lilly and Company,All dosing for 4-week post-study drug cessation timeframe outcome measures stopped after protocol-specified interim review showed dose-dependent cognitive/functional worsening for LY450139 participants. No assessments made during 32-week follow up.,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:05:56.411245,2020-02-01 19:05:56.411245,Eli Lilly and Company,Industry,Placebo,Drug
NCT00792662,"ClinicalTrials.gov processed this data on January 31, 2020",2008-11-17,,,2018-03-27,2008-11-17,2008-11-18,Estimate,,,,,,,2018-03-27,2018-03-29,Actual,November 2008,Actual,2008-11-30,March 2018,2018-03-31,December 2011,Actual,2011-12-31,December 2011,Actual,2011-12-31,,Interventional,,,"Improving Function, Quality of Life, Glycemia in Diabetics With Dementia","Improving Function, Quality of Life, Glycemia in Diabetics With Dementia",Withdrawn,,Phase 4,0,Actual,University of Nebraska,,2,,No Subjects enrolled,False,,,,True,,,,,,,,,,,,,2020-02-01 18:56:39.297993,2020-02-01 18:56:39.297993,University of Nebraska,Other,Placebo,Drug
NCT00810147,"ClinicalTrials.gov processed this data on January 31, 2020",2008-12-16,,2012-03-24,2015-09-23,2008-12-16,2008-12-17,Estimate,,,,2015-09-23,2015-10-12,Estimate,2015-09-23,2015-10-12,Estimate,February 2009,,2009-02-28,September 2015,2015-09-30,June 2010,Actual,2010-06-30,June 2010,Actual,2010-06-30,,Interventional,,,"A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease","Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,209,Actual,Bristol-Myers Squibb,,5,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:51:11.554481,2020-02-01 18:51:11.554481,Bristol-Myers Squibb,Industry,Placebo,Drug
NCT00812565,"ClinicalTrials.gov processed this data on January 31, 2020",2008-11-10,2013-12-02,,2014-04-02,2008-12-19,2008-12-22,Estimate,2014-04-02,2014-05-05,Estimate,,,,2014-04-02,2014-05-05,Estimate,February 2009,,2009-02-28,April 2014,2014-04-30,September 2010,Actual,2010-09-30,September 2010,Actual,2010-09-30,,Interventional,,Full analysis set: All randomized patients who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment.,Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease,"Prospective 24-week, Double-blind, Randomised, Placebo-controlled, Multicenter Study Evaluating Safety and Change in Efficacy-related Surrogate Parameters in Patients With Dementia of the Alzheimer's Type Under Treatment With Increasing Dosages of Intravenous Immunoglobulin (Octagam 10%)",Completed,,Phase 2,58,Actual,Octapharma,Small numbers of patients per treatment group (between 5 and 8) and variable total Aβ levels over time.,8,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:50:23.862407,2020-02-01 18:50:23.862407,Octapharma,Industry,Placebo,Drug
NCT00814502,"ClinicalTrials.gov processed this data on January 31, 2020",2008-12-18,2017-02-02,,2017-04-12,2008-12-24,2008-12-25,Estimate,2017-04-12,2017-05-22,Actual,,,,2017-04-12,2017-05-22,Actual,December 2008,,2008-12-31,April 2017,2017-04-30,December 2013,Actual,2013-12-31,December 2013,Actual,2013-12-31,,Interventional,,,Zolpidem CR and Hospitalized Patients With Dementia,Does Zolpidem CR Treatment Change Clinical Outcomes in Elderly Hospitalized Patients With Dementia- A Pilot Study,Completed,,N/A,20,Actual,Massachusetts General Hospital,Small sample size. We were unable to control for different treatments that our subjects received as inpatients.,2,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 18:49:38.034289,2020-02-01 18:49:38.034289,Massachusetts General Hospital,Other,Placebo,Drug
NCT00829816,"ClinicalTrials.gov processed this data on January 31, 2020",2009-01-12,,,2015-11-06,2009-01-23,2009-01-27,Estimate,,,,,,,2015-11-06,2015-11-10,Estimate,December 2008,,2008-12-31,November 2015,2015-11-30,August 2010,Actual,2010-08-31,April 2009,Actual,2009-04-30,,Interventional,,,"Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil",A Multi-Center Phase 1 Study of the Safety and Tolerability of Dimebon in Alzheimer's Disease Patients on Memantine (Cohort 1) and Memantine Plus Donepezil (Cohort 2),Completed,,Phase 1,46,Actual,"Medivation, Inc.",,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:45:21.480398,2020-02-01 18:45:21.480398,"Medivation, Inc.",Industry,Placebo,Drug
NCT00842673,"ClinicalTrials.gov processed this data on January 31, 2020",2009-02-10,,,2012-06-05,2009-02-10,2009-02-12,Estimate,,,,,,,2012-06-05,2012-06-07,Estimate,February 2009,,2009-02-28,June 2012,2012-06-30,September 2010,Actual,2010-09-30,September 2010,Actual,2010-09-30,,Interventional,,,Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease,"A Double-Blind Placebo-Controlled Preliminary Study of the Efficacy, Safety and Tolerability of ST101 Tablets in the Treatment of Alzheimer's Disease",Completed,,Phase 2,168,Actual,"Sonexa Therapeutics, Inc.",,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:41:39.618333,2020-02-01 18:41:39.618333,"Sonexa Therapeutics, Inc.",Industry,Placebo,Drug
NCT00842816,"ClinicalTrials.gov processed this data on January 31, 2020",2009-02-10,,,2012-06-05,2009-02-11,2009-02-12,Estimate,,,,,,,2012-06-05,2012-06-07,Estimate,February 2009,,2009-02-28,June 2012,2012-06-30,May 2011,Actual,2011-05-31,May 2011,Actual,2011-05-31,,Interventional,,,Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease,"A Double-Blind Placebo-Controlled Preliminary Study of the Efficacy, Safety and Tolerability of ST101 Tablets in the Treatment of Alzheimer's Disease in Subjects Concurrently Receiving Donepezil (Aricept®)",Completed,,Phase 2,210,Actual,"Sonexa Therapeutics, Inc.",,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:41:36.501371,2020-02-01 18:41:36.501371,"Sonexa Therapeutics, Inc.",Industry,Placebo,Drug
NCT00843518,"ClinicalTrials.gov processed this data on January 31, 2020",2009-02-12,2016-07-07,2011-09-20,2017-10-23,2009-02-12,2009-02-13,Estimate,2017-10-23,2017-11-29,Actual,2011-09-20,2011-09-26,Estimate,2017-10-23,2017-11-29,Actual,February 2009,,2009-02-28,October 2017,2017-10-31,June 2011,Actual,2011-06-30,June 2011,Actual,2011-06-30,,Interventional,,,Treatment for Aggression and Agitation in Patients With Alzheimer's Disease,Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease,Completed,,Phase 2,132,Actual,Eli Lilly and Company,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:41:24.194777,2020-02-01 18:41:24.194777,Eli Lilly and Company,Industry,Placebo,Drug
NCT00880412,"ClinicalTrials.gov processed this data on January 31, 2020",2009-04-10,,,2009-09-18,2009-04-10,2009-04-13,Estimate,,,,,,,2009-09-18,2009-09-21,Estimate,April 2008,,2008-04-30,September 2009,2009-09-30,August 2009,Actual,2009-08-31,June 2009,Actual,2009-06-30,,Interventional,EHT0202/002,,A Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 as Adjunctive Therapy to Acetylcholinesterase Inhibitor in Mild to Moderate Alzheimer's Disease,"A Pilot, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase IIA Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 (40 and 80 mg Bid) as Adjunctive Therapy to Acetylcholinesterase Inhibitor Over a 3-month Period in Ambulatory Patients Suffering From Mild to Moderate Alzheimer's Disease (EHT 0202/002 Protocol)",Completed,,Phase 2,197,Actual,Exonhit,,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:30:27.434852,2020-02-01 18:30:27.434852,Exonhit,Industry,Placebo,Drug
NCT00890890,"ClinicalTrials.gov processed this data on January 31, 2020",2009-04-29,,2015-09-23,2015-09-23,2009-04-29,2009-04-30,Estimate,,,,2015-09-23,2015-10-12,Estimate,2015-09-23,2015-10-12,Estimate,May 2009,,2009-05-31,September 2015,2015-09-30,July 2013,Actual,2013-07-31,July 2013,Actual,2013-07-31,,Interventional,,,"A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease","Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients With Prodromal Alzheimer's Disease",Terminated,,Phase 2,263,Actual,Bristol-Myers Squibb,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:27:25.082950,2020-02-01 18:27:25.082950,Bristol-Myers Squibb,Industry,Placebo,Drug
NCT00904683,"ClinicalTrials.gov processed this data on January 31, 2020",2009-05-18,,2012-09-18,2012-12-11,2009-05-18,2009-05-20,Estimate,,,,2012-09-18,2012-09-25,Estimate,2012-12-11,2012-12-13,Estimate,May 2009,,2009-05-31,December 2012,2012-12-31,June 2012,Actual,2012-06-30,June 2012,Actual,2012-06-30,,Interventional,EXPEDITION2,,Effect of LY2062430 on the Progression of Alzheimer's Disease,Effect of Passive Immunization on the Progression of Alzheimer's Disease: LY2062430 Versus Placebo,Completed,,Phase 3,1040,Actual,Eli Lilly and Company,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:23:37.732667,2020-02-01 18:23:37.732667,Eli Lilly and Company,Industry,Placebo,Drug
NCT00905372,"ClinicalTrials.gov processed this data on January 31, 2020",2009-05-18,,2012-09-18,2012-09-18,2009-05-18,2009-05-20,Estimate,,,,2012-09-18,2012-09-25,Estimate,2012-09-18,2012-09-25,Estimate,May 2009,,2009-05-31,May 2012,2012-05-31,April 2012,Actual,2012-04-30,April 2012,Actual,2012-04-30,,Interventional,EXPEDITION,,Effect of LY2062430 on the Progression of Alzheimer's Disease,"Effect of LY2062430, an Anti-Amyloid Beta Monoclonal Antibody, on the Progression of Alzheimer's Disease as Compared With Placebo",Completed,,Phase 3,1000,Anticipated,Eli Lilly and Company,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:23:26.031400,2020-02-01 18:23:26.031400,Eli Lilly and Company,Industry,Placebo,Drug
NCT00930059,"ClinicalTrials.gov processed this data on January 31, 2020",2009-06-29,,2013-04-09,2013-04-09,2009-06-29,2009-06-30,Estimate,,,,2013-04-09,2013-04-16,Estimate,2013-04-09,2013-04-16,Estimate,September 2009,,2009-09-30,April 2013,2013-04-30,September 2010,Actual,2010-09-30,September 2010,Actual,2010-09-30,,Interventional,,,A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease,"A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study Of PF-04447943 In Subjects With Mild To Moderate Alzheimer's Disease",Completed,,Phase 2,198,Actual,Pfizer,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:16:09.262269,2020-02-01 18:16:09.262269,Pfizer,Industry,Placebo,Drug
NCT00940589,"ClinicalTrials.gov processed this data on January 31, 2020",2009-07-15,2018-03-28,,2018-05-29,2009-07-15,2009-07-16,Estimate,2018-05-29,2018-06-01,Actual,,,,2018-05-29,2018-06-01,Actual,September 2009,,2009-09-30,May 2018,2018-05-31,May 2013,Actual,2013-05-31,February 2013,Actual,2013-02-28,,Interventional,,,Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor,"A Double-blind, Parallel Group, Randomized, Placebo Controlled Study of the Efficacy of Circadin® 2mg in Patients With Mild to Moderate Alzheimer Disease (AD) Treated With Acetylcholinesterase (AChE) Inhibitor",Completed,,Phase 2,73,Actual,Neurim Pharmaceuticals Ltd.,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:12:57.684048,2020-02-01 18:12:57.684048,Neurim Pharmaceuticals Ltd.,Industry,Placebo,Drug
NCT00948259,"ClinicalTrials.gov processed this data on January 31, 2020",2009-07-27,,,2009-11-10,2009-07-28,2009-07-29,Estimate,,,,,,,2009-11-10,2009-11-11,Estimate,December 2008,,2008-12-31,November 2009,2009-11-30,November 2009,Actual,2009-11-30,November 2009,Actual,2009-11-30,,Interventional,,,Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease,"Phase IIa 20 Week Double-blind, Placebo-controlled, Randomized, Escalating Dose Study to Evaluate the Safety and Tolerability of Four Oral Doses of NP031112, a Novel GSK3 Inhibitor, in Mild to Moderate Alzheimer's Disease Patients With Stable Anticholinesterasic Treatment.",Completed,,Phase 1/Phase 2,30,Actual,Noscira SA,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:10:37.833566,2020-02-01 18:10:37.833566,Noscira SA,Industry,Placebo,Drug
NCT00948766,"ClinicalTrials.gov processed this data on January 31, 2020",2009-07-28,2013-01-08,,2013-08-19,2009-07-28,2009-07-29,Estimate,2013-01-08,2013-02-11,Estimate,,,,2013-08-19,2013-08-28,Estimate,July 2009,,2009-07-31,August 2013,2013-08-31,June 2012,Actual,2012-06-30,January 2012,Actual,2012-01-31,,Interventional,ACTION,,"Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44","A 24 Week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study (ENA713DUS44) Comparing the Effects of Rivastigmine Patch 15 cm^2 vs. Rivastigmine Patch 5 cm^2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION) and a 24-week Open-label Extension to Study ENA713DUS44",Completed,,Phase 4,716,Actual,Novartis,,2,,,False,,,,,,,,,,,,,,,,,2020-02-01 18:10:30.542059,2020-02-01 18:10:30.542059,Novartis,Industry,Placebo,Drug
NCT00951834,"ClinicalTrials.gov processed this data on January 31, 2020",2009-08-03,,,2018-11-28,2009-08-03,2009-08-04,Estimate,,,,,,,2018-11-28,2018-11-29,Actual,October 2009,,2009-10-31,November 2018,2018-11-30,February 2015,Actual,2015-02-28,February 2015,Actual,2015-02-28,,Interventional,SUN-AK,,Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease,Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease,Completed,,Phase 2/Phase 3,21,Actual,"Charite University, Berlin, Germany",,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:09:10.750449,2020-02-01 18:09:10.750449,"Charite University, Berlin, Germany",Other,Placebo,Drug
NCT00982202,"ClinicalTrials.gov processed this data on January 31, 2020",2009-09-22,,,2009-09-22,2009-09-22,2009-09-23,Estimate,,,,,,,2009-09-22,2009-09-23,Estimate,January 2002,,2002-01-31,September 2009,2009-09-30,January 2005,Actual,2005-01-31,January 2005,Actual,2005-01-31,,Interventional,,,Pioglitazone in Alzheimer Disease,Pioglitazone in Alzheimer Disease Progression,Completed,,Phase 2,25,Actual,National Institute on Aging (NIA),,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:59:55.966871,2020-02-01 17:59:55.966871,National Institute on Aging (NIA),NIH,Placebo,Drug
NCT00988598,"ClinicalTrials.gov processed this data on January 31, 2020",2009-10-01,,,2010-08-05,2009-10-01,2009-10-02,Estimate,,,,,,,2010-08-05,2010-08-09,Estimate,October 2009,,2009-10-31,August 2010,2010-08-31,July 2010,Actual,2010-07-31,July 2010,Actual,2010-07-31,,Interventional,,,"A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease","A Phase 1, Double-Blind, Placebo-Controlled, Sponsor Open, Randomized, Multiple Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04447943 In Mild To Moderate Alzheimer's Disease Subjects On Stable Donepezil Therapy",Completed,,Phase 1,15,Actual,Pfizer,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 17:55:55.298687,2020-02-01 17:55:55.298687,Pfizer,Industry,Placebo,Drug
NCT01009255,"ClinicalTrials.gov processed this data on January 31, 2020",2009-11-05,,,2017-04-11,2009-11-05,2009-11-06,Estimate,,,,,,,2017-04-11,2017-04-13,Actual,"November 2, 2009",Actual,2009-11-02,April 2017,2017-04-30,"November 10, 2010",Actual,2010-11-10,"November 10, 2010",Actual,2010-11-10,,Interventional,,,Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease,"A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of the H3 Receptor Antagonist, GSK239512 in Subjects With Mild to Moderate Alzheimer's Disease.",Completed,,Phase 2,196,Actual,GlaxoSmithKline,,2,,,False,,,,False,False,False,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 17:48:00.502559,2020-02-01 17:48:00.502559,GlaxoSmithKline,Industry,Placebo,Drug
NCT01028911,"ClinicalTrials.gov processed this data on January 31, 2020",2009-12-07,2014-04-09,,2014-05-16,2009-12-08,2009-12-09,Estimate,2014-05-16,2014-06-04,Estimate,,,,2014-05-16,2014-06-04,Estimate,December 2009,,2009-12-31,May 2014,2014-05-31,May 2010,Actual,2010-05-31,May 2010,Actual,2010-05-31,,Interventional,,Safety population included all participants who took at least 1 dose of study drug.,"A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease","A Phase 1, Double-Blind, Placebo-Controlled, Sponsor-Open, Randomized, Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-03654746 in Mild to Moderate Alzheimer's Disease Patients on Stable Donepezil Therapy",Terminated,,Phase 1,9,Actual,Pfizer,The study was terminated early due to slow recruitment and the need to use the existing information to determine dosing for another study.,2,,"This study terminated 27Apr2010 due to slow recruitment and the need to use the existing
    information to determine dosing for another study.",False,,,,False,,,,,,,,,,,,,2020-02-01 17:42:14.368255,2020-02-01 17:42:14.368255,Pfizer,Industry,Placebo,Drug
NCT01058941,"ClinicalTrials.gov processed this data on January 31, 2020",2010-01-27,2017-03-01,,2017-03-01,2010-01-28,2010-01-29,Estimate,2017-03-01,2017-04-13,Actual,,,,2017-03-01,2017-04-13,Actual,September 2010,,2010-09-30,March 2017,2017-03-31,December 2014,Actual,2014-12-31,December 2014,Actual,2014-12-31,,Interventional,,,Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease,Lipoic Acid and Omega-3 Fatty Acids in Alzheimer's Disease,Completed,,Phase 1/Phase 2,67,Actual,Oregon Health and Science University,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:34:22.620784,2020-02-01 17:34:22.620784,Oregon Health and Science University,Other,Placebo,Drug
NCT01073228,"ClinicalTrials.gov processed this data on January 31, 2020",2010-02-19,,2013-02-19,2014-03-28,2010-02-22,2010-02-23,Estimate,,,,2013-02-19,2013-02-22,Estimate,2014-03-28,2014-04-25,Estimate,April 2010,,2010-04-30,February 2013,2013-02-28,February 2012,Actual,2012-02-29,November 2011,Actual,2011-11-30,,Interventional,,,Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease,"A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease",Completed,,Phase 2,409,Actual,FORUM Pharmaceuticals Inc,,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 17:30:03.549834,2020-02-01 17:30:03.549834,FORUM Pharmaceuticals Inc,Industry,Placebo,Drug
NCT01120002,"ClinicalTrials.gov processed this data on January 31, 2020",2010-04-30,,,2011-07-21,2010-05-07,2010-05-10,Estimate,,,,,,,2011-07-21,2011-07-22,Estimate,May 2010,,2010-05-31,July 2011,2011-07-31,December 2012,Anticipated,2012-12-31,December 2012,Anticipated,2012-12-31,,Interventional,,,Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's Disease,,Unknown status,Recruiting,Phase 2,50,Anticipated,Osaka City University,,2,,,False,,,,,,,,,,,,,,,,,2020-02-01 17:16:39.773727,2020-02-01 17:16:39.773727,Osaka City University,Other,Placebo,Drug
NCT01125631,"ClinicalTrials.gov processed this data on January 31, 2020",2010-05-17,,,2011-08-11,2010-05-17,2010-05-18,Estimate,,,,,,,2011-08-11,2011-08-12,Estimate,May 2010,,2010-05-31,August 2011,2011-08-31,August 2011,Actual,2011-08-31,August 2011,Actual,2011-08-31,,Interventional,,,Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease,"A Phase 1, Randomized, Placebo-Controlled, Double Blind, Multicenter Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenous Doses Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease",Completed,,Phase 1,8,Actual,Pfizer,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:14:51.996100,2020-02-01 17:14:51.996100,Pfizer,Industry,Placebo,Drug
NCT01126099,"ClinicalTrials.gov processed this data on January 31, 2020",2010-05-17,2014-07-15,,2015-05-19,2010-05-18,2010-05-19,Estimate,2015-05-19,2015-05-21,Estimate,,,,2015-05-19,2015-05-21,Estimate,March 2010,,2010-03-31,May 2015,2015-05-31,March 2014,Actual,2014-03-31,March 2014,Actual,2014-03-31,,Interventional,,,Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease,Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease,Completed,,N/A,20,Actual,Seattle Institute for Biomedical and Clinical Research,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:14:44.218519,2020-02-01 17:14:44.218519,Seattle Institute for Biomedical and Clinical Research,Other,Placebo,Drug
NCT01172145,"ClinicalTrials.gov processed this data on January 31, 2020",2010-07-28,2010-08-04,,2011-02-09,2010-07-28,2010-07-29,Estimate,2011-02-09,2011-03-04,Estimate,,,,2011-02-09,2011-03-04,Estimate,July 2005,,2005-07-31,September 2010,2010-09-30,September 2007,Actual,2007-09-30,,,,,Interventional,,,Treatment of Apathy in Alzheimer's Disease With Modafinil,Treatment of Apathy in Alzheimer's Disease With Modafinil,Completed,,Phase 3,22,Actual,Brown University,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 17:01:29.146927,2020-02-01 17:01:29.146927,Brown University,Other,Placebo,Drug
NCT01203384,"ClinicalTrials.gov processed this data on January 31, 2020",2010-09-15,,,2015-02-09,2010-09-15,2010-09-16,Estimate,,,,,,,2015-02-09,2015-02-10,Estimate,September 2010,,2010-09-30,February 2015,2015-02-28,December 2010,Actual,2010-12-31,December 2010,Actual,2010-12-31,,Interventional,CT02,,"Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects","Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects",Completed,,Phase 1,48,Actual,CERESPIR,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:51:33.506485,2020-02-01 16:51:33.506485,CERESPIR,Industry,Placebo,Drug
NCT01294540,"ClinicalTrials.gov processed this data on January 31, 2020",2011-02-10,,,2013-08-28,2011-02-10,2011-02-11,Estimate,,,,,,,2013-08-28,2013-08-29,Estimate,December 2010,,2010-12-31,August 2013,2013-08-31,December 2011,Actual,2011-12-31,October 2011,Actual,2011-10-31,,Interventional,,,"Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort","A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Doses of E2609 in Healthy Subjects and an Elderly Cohort",Completed,,Phase 1,73,Actual,Eisai Inc.,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 16:24:31.268851,2020-02-01 16:24:31.268851,Eisai Inc.,Industry,Placebo,Drug
NCT01303744,"ClinicalTrials.gov processed this data on January 31, 2020",2011-02-23,2015-10-16,2012-05-18,2015-12-02,2011-02-23,2011-02-25,Estimate,2015-12-02,2016-01-11,Estimate,2012-05-18,2012-05-30,Estimate,2015-12-02,2016-01-11,Estimate,March 2011,,2011-03-31,December 2015,2015-12-31,April 2012,Actual,2012-04-30,April 2012,Actual,2012-04-30,,Interventional,CT04,,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074,"A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment",Completed,,Phase 2,96,Actual,CERESPIR,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:21:56.018097,2020-02-01 16:21:56.018097,CERESPIR,Industry,Placebo,Drug
NCT01350362,"ClinicalTrials.gov processed this data on January 31, 2020",2011-05-06,,,2012-10-01,2011-05-06,2011-05-09,Estimate,,,,,,,2012-10-01,2012-10-02,Estimate,April 2011,,2011-04-30,October 2012,2012-10-31,October 2012,Actual,2012-10-31,July 2012,Actual,2012-07-31,,Interventional,ARGO,,"Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients","A Multicenter, Randomized, Double-blind, Placebo-controlled, 4-arm, 26 Week Parallel-Group Study to Evaluate Efficacy, Safety and Tolerability of 2 Oral Doses and 2 Regimes of Tideglusib vs Placebo in Mild-to-Moderate AD Patients",Completed,,Phase 2,306,Actual,Noscira SA,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:08:35.589262,2020-02-01 16:08:35.589262,Noscira SA,Industry,Placebo,Drug
NCT01374438,"ClinicalTrials.gov processed this data on January 31, 2020",2011-06-14,2014-09-25,,2014-11-05,2011-06-15,2011-06-16,Estimate,2014-11-03,2014-11-05,Estimate,,,,2014-11-05,2014-11-18,Estimate,July 2011,,2011-07-31,November 2014,2014-11-30,May 2013,Actual,2013-05-31,March 2013,Actual,2013-03-31,,Interventional,,All randomized subjects completed the full study and are included in the analysis.,"3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease","A 3-month Randomized, Double-Blind, Placebo-Controlled, Feasibility Study to Evaluate the Effects of MSDC-0160 on Brain Glucose Utilization, Cognition, Safety and Tolerability in Older Persons With Mild Alzheimer's Disease",Completed,,Phase 2,29,Actual,Metabolic Solutions Development Company,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 16:02:10.248730,2020-02-01 16:02:10.248730,Metabolic Solutions Development Company,Industry,Placebo,Drug
NCT01404169,"ClinicalTrials.gov processed this data on January 31, 2020",2011-07-26,,,2017-03-07,2011-07-26,2011-07-27,Estimate,,,,,,,2017-03-07,2017-03-08,Actual,September 2011,Actual,2011-09-30,March 2017,2017-03-31,September 2014,Actual,2014-09-30,July 2014,Actual,2014-07-31,,Interventional,,,"A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease","A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease",Completed,,Phase 3,260,Actual,Eisai Inc.,,2,,,False,,,,,,,,,,,,,,,,,2020-02-01 15:54:49.274654,2020-02-01 15:54:49.274654,Eisai Limited,Industry,Placebo,Drug
NCT01406145,"ClinicalTrials.gov processed this data on January 31, 2020",2011-07-06,,,2019-01-28,2011-07-28,2011-08-01,Estimate,,,,,,,2019-01-28,2019-01-30,Actual,"June 16, 2011",Actual,2011-06-16,January 2019,2019-01-31,"November 4, 2011",Actual,2011-11-04,"November 4, 2011",Actual,2011-11-04,,Interventional,,,A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil,"A Phase 1b, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Sequential Dose Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease on Donepezil",Completed,,Phase 1,60,Actual,Astellas Pharma Inc,,4,,,False,,,,False,,,,,,,,Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.,"Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.",https://www.clinicalstudydatarequest.com/,Yes,"Access to anonymized individual participant level data collected during the trial, in addition to study-related supporting documentation, is planned for trials conducted with approved product indications and formulations, as well as compounds terminated during development. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.",2020-02-01 15:54:20.292494,2020-02-01 15:54:20.292494,Astellas Pharma Inc,Industry,Placebo,Drug
NCT01428362,"ClinicalTrials.gov processed this data on January 31, 2020",2011-08-31,,2013-10-23,2013-11-15,2011-08-31,2011-09-05,Estimate,,,,2013-10-23,2013-11-15,Estimate,2013-11-15,2013-12-11,Estimate,August 2011,,2011-08-31,November 2013,2013-11-30,August 2013,Actual,2013-08-31,August 2013,Actual,2013-08-31,,Interventional,AD-201,,VI-1121 for the Treatment Alzheimer's Disease,"A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease",Completed,,Phase 2,61,Actual,"VIVUS, Inc.",,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:49:01.052351,2020-02-01 15:49:01.052351,"VIVUS, Inc.",Industry,Placebo,Drug
NCT01438060,"ClinicalTrials.gov processed this data on January 31, 2020",2011-09-02,2012-02-01,,2013-11-07,2011-09-20,2011-09-21,Estimate,2012-02-01,2012-03-05,Estimate,,,,2013-11-07,2013-12-02,Estimate,August 2000,,2000-08-31,November 2013,2013-11-30,July 2010,Actual,2010-07-31,July 2010,Actual,2010-07-31,,Interventional,,,Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type,"A Multicenter, Randomized, Double-Blind, Placebo Controlled Flexible Dose Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type",Completed,,Phase 3,232,Actual,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Limitations of the study, such as early termination leading to small numbers of subjects analyzed and technical problems with measurement leading to unreliable or uninterpretable data",2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:46:23.659143,2020-02-01 15:46:23.659143,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Industry,Placebo,Drug
NCT01504854,"ClinicalTrials.gov processed this data on January 31, 2020",2011-12-23,2016-01-28,,2016-05-06,2012-01-03,2012-01-06,Estimate,2016-05-06,2016-06-14,Estimate,,,,2016-05-06,2016-06-14,Estimate,May 2012,,2012-05-31,April 2016,2016-04-30,March 2014,Actual,2014-03-31,March 2014,Actual,2014-03-31,,Interventional,,,Resveratrol for Alzheimer's Disease,Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease,Completed,,Phase 2,119,Actual,Alzheimer's Disease Cooperative Study (ADCS),This phase 2 study has limitations. A larger study is required to determine whether resveratrol may be beneficial. More potent and bioavailable SIRT1 activators are also in development.,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:28:15.052585,2020-02-01 15:28:15.052585,Alzheimer's Disease Cooperative Study (ADCS),Other,Placebo,Drug
NCT01569516,"ClinicalTrials.gov processed this data on January 31, 2020",2012-03-30,,,2012-04-06,2012-03-30,2012-04-03,Estimate,,,,,,,2012-04-06,2012-04-09,Estimate,June 2011,,2011-06-30,May 2011,2011-05-31,October 2012,Anticipated,2012-10-31,July 2012,Anticipated,2012-07-31,,Interventional,,,Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease,"A Phase II, Double Blind, Placebo-controlled, Randomized, Multi-Center, Parallel Group Dose Exploring Study to Evaluate the Efficacy and Safety of Octohydroaminoacridine Succinate Tablets in Patient With Mild to Moderate Alzheimer's Disease",Unknown status,Recruiting,Phase 2,288,Anticipated,"Changchun Huayang High-tech Co., Ltd",,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:12:18.612653,2020-02-01 15:12:18.612653,"Changchun Huayang High-tech Co., Ltd",Industry,Placebo,Drug
NCT01584440,"ClinicalTrials.gov processed this data on January 31, 2020",2012-04-23,,2018-01-08,2018-01-08,2012-04-24,2012-04-25,Estimate,,,,2018-01-08,2018-01-11,Actual,2018-01-08,2018-01-11,Actual,June 2012,,2012-06-30,January 2018,2018-01-31,September 2014,Actual,2014-09-30,July 2014,Actual,2014-07-31,,Interventional,,,"Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients","A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.",Completed,,Phase 2,220,Actual,Avanir Pharmaceuticals,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:08:45.066700,2020-02-01 15:08:45.066700,Avanir Pharmaceuticals,Industry,Placebo,Drug
NCT01608217,"ClinicalTrials.gov processed this data on January 31, 2020",2012-05-25,,,2014-06-26,2012-05-25,2012-05-31,Estimate,,,,,,,2014-06-26,2014-06-30,Estimate,June 2012,,2012-06-30,June 2014,2014-06-30,June 2014,Actual,2014-06-30,June 2014,Actual,2014-06-30,,Interventional,,,Delta-THC in Dementia,Efficacy and Safety of Delta-9-tetrahydrocannabinol (∆9-THC) in Behavioural Disturbances and Pain in Dementia,Completed,,Phase 2,50,Actual,Radboud University,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:02:26.242272,2020-02-01 15:02:26.242272,Radboud University,Other,Placebo,Drug
NCT01617577,"ClinicalTrials.gov processed this data on January 31, 2020",2011-11-08,2012-06-29,,2012-11-26,2012-06-11,2012-06-12,Estimate,2012-11-26,2012-12-27,Estimate,,,,2012-11-26,2012-12-27,Estimate,June 2009,,2009-06-30,June 2012,2012-06-30,February 2012,Actual,2012-02-29,February 2012,Actual,2012-02-29,,Interventional,FFAD,,Efficacy and Safety of Filgrastim in Alzheimer's Disease,Efficacy and Safety of Filgrastim as a Pro‐Cognitive Agent in Alzheimer's Disease,Completed,,Phase 1/Phase 2,8,Actual,University of South Florida,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:00:17.017452,2020-02-01 15:00:17.017452,University of South Florida,Other,Placebo,Drug
NCT01626391,"ClinicalTrials.gov processed this data on January 31, 2020",2012-06-20,2014-04-28,,2014-06-10,2012-06-20,2012-06-22,Estimate,2014-06-10,2014-07-11,Estimate,,,,2014-06-10,2014-07-11,Estimate,September 2012,,2012-09-30,June 2014,2014-06-30,March 2013,Actual,2013-03-31,March 2013,Actual,2013-03-31,,Interventional,,Safety Population,Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease,"A Double-Blind, Placebo-Controlled, Randomised, 4-Week Safety and Tolerability Study of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease on Pre-Existing Stable Acetylcholinesterase Inhibitor and/or Memantine Therapy",Terminated,,Phase 2,9,Actual,TauRx Therapeutics Ltd,Early termination leading to small numbers of subjects analyzed,2,,This study has been terminated for administrative reasons only.,False,,,,True,,,,,,,,,,,,,2020-02-01 14:58:05.465796,2020-02-01 14:58:05.465796,TauRx Therapeutics Ltd,Industry,Placebo,Drug
NCT01661673,"ClinicalTrials.gov processed this data on January 31, 2020",2012-08-03,,,2014-01-10,2012-08-06,2012-08-09,Estimate,,,,,,,2014-01-10,2014-01-13,Estimate,November 2012,,2012-11-30,January 2014,2014-01-31,,,,October 2013,Actual,2013-10-31,,Interventional,,,"Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease","Safety, Tolerability, Pharmacokinetics, and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease",Completed,,Phase 2,52,Actual,FORUM Pharmaceuticals Inc,,5,,,False,,,,False,,,,,,,,,,,,,2020-02-01 14:49:17.382489,2020-02-01 14:49:17.382489,FORUM Pharmaceuticals Inc,Industry,Placebo,Drug
NCT01689233,"ClinicalTrials.gov processed this data on January 31, 2020",2012-09-14,,2018-03-12,2018-03-12,2012-09-20,2012-09-21,Estimate,,,,2018-03-12,2018-03-14,Actual,2018-03-12,2018-03-14,Actual,October 2012,,2012-10-31,March 2018,2018-03-31,May 2016,Actual,2016-05-31,May 2016,Actual,2016-05-31,,Interventional,,,Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of TRx0237 in Subjects With Mild Alzheimer's Disease",Completed,,Phase 3,800,Actual,TauRx Therapeutics Ltd,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:41:34.512210,2020-02-01 14:41:34.512210,TauRx Therapeutics Ltd,Industry,Placebo,Drug
NCT01689246,"ClinicalTrials.gov processed this data on January 31, 2020",2012-09-14,,2018-03-12,2018-03-12,2012-09-20,2012-09-21,Estimate,,,,2018-03-12,2018-03-14,Actual,2018-03-12,2018-03-14,Actual,January 2013,,2013-01-31,March 2018,2018-03-31,November 2015,Actual,2015-11-30,November 2015,Actual,2015-11-30,,Interventional,,,Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 3,891,Actual,TauRx Therapeutics Ltd,,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:41:34.220277,2020-02-01 14:41:34.220277,TauRx Therapeutics Ltd,Industry,Placebo,Drug
NCT01715350,"ClinicalTrials.gov processed this data on January 31, 2020",2012-10-24,,,2016-04-15,2012-10-25,2012-10-26,Estimate,,,,,,,2016-04-15,2016-04-18,Estimate,May 2012,,2012-05-31,April 2016,2016-04-30,June 2015,Actual,2015-06-30,September 2014,Actual,2014-09-30,,Interventional,ADD,,Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease,"A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease: Double-Blind, Randomized Between Placebo Control Group and Dose Groups, Parallel-Design, Multicenter Study",Completed,,Phase 2,151,Actual,"GMP BIO Co., LTD.",,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:34:17.112760,2020-02-01 14:34:17.112760,"GMP BIO Co., LTD.",Industry,Placebo,Drug
NCT01735630,"ClinicalTrials.gov processed this data on January 31, 2020",2012-11-25,2016-04-07,,2019-10-17,2012-11-27,2012-11-28,Estimate,2016-07-06,2016-08-15,Estimate,,,,2019-10-17,2019-10-21,Actual,November 2012,,2012-11-30,October 2019,2019-10-31,May 2015,Actual,2015-05-31,May 2015,Actual,2015-05-31,,Interventional,,,Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease,"A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease",Completed,,Phase 2,350,Actual,"OPKO Health, Inc.",,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 14:29:01.435468,2020-02-01 14:29:01.435468,"OPKO Health, Inc.",Industry,Placebo,Drug
NCT01764243,"ClinicalTrials.gov processed this data on January 31, 2020",2012-12-26,,,2015-09-24,2013-01-07,2013-01-09,Estimate,,,,,,,2015-09-24,2015-09-28,Estimate,November 2012,,2012-11-30,September 2015,2015-09-30,July 2015,Actual,2015-07-31,June 2015,Actual,2015-06-30,,Interventional,,,Safety and Efficacy of MT-4666,"A Double-Blind, Placebo-Controlled Phase2 Study of MT-4666 in Patients With Mild to Moderate Probable Alzheimer's Disease.",Completed,,Phase 2,450,Actual,Mitsubishi Tanabe Pharma Corporation,,3,,,False,,,,False,,,,,,,,,,,,,2020-02-01 14:21:47.790249,2020-02-01 14:21:47.790249,Mitsubishi Tanabe Pharma Corporation,Industry,Placebo,Drug
NCT01767909,"ClinicalTrials.gov processed this data on January 31, 2020",2013-01-10,,,2019-01-16,2013-01-11,2013-01-15,Estimate,,,,,,,2019-01-16,2019-01-18,Actual,"January 8, 2014",Actual,2014-01-08,January 2019,2019-01-31,"December 11, 2018",Actual,2018-12-11,"December 11, 2018",Actual,2018-12-11,,Interventional,,,The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF),Therapeutic Effects of Intranasally-Administered Insulin in Adults With Amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (AD),Completed,,Phase 2/Phase 3,239,Actual,University of Southern California,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:20:36.780945,2020-02-01 14:20:36.780945,University of Southern California,Other,Placebo,Drug
NCT01843075,"ClinicalTrials.gov processed this data on January 31, 2020",2013-04-24,,,2019-06-06,2013-04-26,2013-04-30,Estimate,,,,,,,2019-06-06,2019-06-10,Actual,January 2014,Actual,2014-01-31,June 2019,2019-06-30,December 2019,Anticipated,2019-12-31,December 2019,Anticipated,2019-12-31,,Interventional,ELAD,,Evaluating Liraglutide in Alzheimer's Disease,"Evaluating the Effects of the Novel GLP-1 Analogue, Liraglutide, in Patients With Mild Alzheimer's Disease (ELAD Study)","Active, not recruiting",,Phase 2,204,Actual,Imperial College London,,2,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 14:02:32.425844,2020-02-01 14:02:32.425844,Imperial College London,Other,Placebo,Drug
NCT01864655,"ClinicalTrials.gov processed this data on January 31, 2020",2013-05-08,,,2014-06-12,2013-05-28,2013-05-29,Estimate,,,,,,,2014-06-12,2014-06-13,Estimate,July 2013,,2013-07-31,June 2014,2014-06-30,,,,March 2014,Actual,2014-03-31,,Interventional,,,Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease,"A Phase Ib Multiple Ascending Dose Study of the Safety, Tolerability, and CNS Availability of AZD0530 in Alzheimer's Disease",Completed,,Phase 1,24,Actual,Yale University,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:55:28.062074,2020-02-01 13:55:28.062074,Stephen M. Strittmatter,Other,Placebo,Drug
NCT01872598,"ClinicalTrials.gov processed this data on January 31, 2020",2013-06-05,,,2019-06-13,2013-06-06,2013-06-07,Estimate,,,,,,,2019-06-13,2019-06-17,Actual,January 2012,,2012-01-31,June 2019,2019-06-30,December 2019,Anticipated,2019-12-31,December 2019,Anticipated,2019-12-31,,Interventional,,,Masitinib in Patients With Mild to Moderate Alzheimer's Disease,"A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Phase 3 Study to Evaluate the Safety and Efficacy of Masitinib in Patients With Mild to Moderate Alzheimer's Disease","Active, not recruiting",,Phase 3,721,Actual,AB Science,,5,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:52:27.547176,2020-02-01 13:52:27.547176,AB Science,Industry,Placebo,Drug
NCT01900665,"ClinicalTrials.gov processed this data on January 31, 2020",2013-07-12,2018-02-16,2016-12-21,2019-09-25,2013-07-12,2013-07-16,Estimate,2018-02-16,2018-03-14,Actual,2016-12-21,2016-12-23,Estimate,2019-09-25,2019-10-09,Actual,July 2013,,2013-07-31,September 2019,2019-09-30,February 2017,Actual,2017-02-28,October 2016,Actual,2016-10-31,,Interventional,EXPEDITION 3,All randomized participants.,Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo,Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo,Terminated,,Phase 3,2129,Actual,Eli Lilly and Company,,2,,Solanezumab did not meet the study's primary endpoint.,False,,,,True,,,,,,,,"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.",A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.,https://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.,2020-02-01 13:45:21.891307,2020-02-01 13:45:21.891307,Eli Lilly and Company,Industry,Placebo,Drug
NCT01921972,"ClinicalTrials.gov processed this data on January 31, 2020",2013-08-07,,,2013-08-12,2013-08-12,2013-08-14,Estimate,,,,,,,2013-08-12,2013-08-14,Estimate,November 2004,,2004-11-30,August 2013,2013-08-31,May 2009,Actual,2009-05-31,November 2008,Actual,2008-11-30,,Interventional,AD-Combi,,The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease,"Competence Network - Dementia (BMBF) ""Pharmacological and Psychosocial Treatment"" (Modul E.2) Part II: The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease",Completed,,Phase 4,232,Actual,"Charite University, Berlin, Germany",,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:40:38.562936,2020-02-01 13:40:38.562936,"Charite University, Berlin, Germany",Other,Placebo,Drug
NCT01928420,"ClinicalTrials.gov processed this data on January 31, 2020",2012-08-17,,2016-10-07,2016-10-14,2013-08-20,2013-08-26,Estimate,,,,2016-10-14,2016-10-17,Estimate,2016-10-14,2016-10-17,Estimate,April 2007,,2007-04-30,October 2016,2016-10-31,June 2014,Actual,2014-06-30,June 2014,Actual,2014-06-30,,Interventional,,,"A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease","A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease",Completed,,Phase 2,30,Actual,Humanetics Corporation,,2,,,False,,,,True,,,,,,,,,,,Undecided,,2020-02-01 13:38:52.901927,2020-02-01 13:38:52.901927,Humanetics Corporation,Industry,Placebo,Drug
NCT01969123,"ClinicalTrials.gov processed this data on January 31, 2020",2013-10-21,,,2016-05-02,2013-10-24,2013-10-25,Estimate,,,,,,,2016-05-02,2016-05-03,Estimate,October 2013,,2013-10-31,September 2015,2015-09-30,January 2017,Anticipated,2017-01-31,January 2017,Anticipated,2017-01-31,,Interventional,,,Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease,"A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication",Terminated,,Phase 3,474,Actual,FORUM Pharmaceuticals Inc,,3,,Study has been suspended due to clinical hold.,False,,,,,,,,,,,,,,,,,2020-02-01 13:27:15.310397,2020-02-01 13:27:15.310397,FORUM Pharmaceuticals Inc,Industry,Placebo,Drug
NCT01969136,"ClinicalTrials.gov processed this data on January 31, 2020",2013-10-21,,,2016-05-02,2013-10-24,2013-10-25,Estimate,,,,,,,2016-05-02,2016-05-03,Estimate,October 2013,,2013-10-31,September 2015,2015-09-30,January 2017,Anticipated,2017-01-31,January 2017,Anticipated,2017-01-31,,Interventional,,,Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease,"A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication",Terminated,,Phase 3,403,Actual,FORUM Pharmaceuticals Inc,,3,,Study has been suspended due to clinical hold.,False,,,,,,,,,,,,,,,,,2020-02-01 13:27:15.097847,2020-02-01 13:27:15.097847,FORUM Pharmaceuticals Inc,Industry,Placebo,Drug
NCT02017340,"ClinicalTrials.gov processed this data on January 31, 2020",2013-12-16,,,2017-03-03,2013-12-16,2013-12-20,Estimate,,,,,,,2017-03-03,2017-03-06,Actual,"April 24, 2013",Actual,2013-04-24,March 2017,2017-03-31,"December 16, 2016",Actual,2016-12-16,"December 16, 2016",Actual,2016-12-16,,Interventional,NILVAD,,A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease,A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease,Completed,,Phase 3,511,Actual,"St. James's Hospital, Ireland",,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:14:04.638889,2020-02-01 13:14:04.638889,Prof Brian Lawlor,Other,Placebo,Drug
NCT02033941,"ClinicalTrials.gov processed this data on January 31, 2020",2014-01-09,,,2019-03-12,2014-01-09,2014-01-13,Estimate,,,,,,,2019-03-12,2019-03-13,Actual,November 2014,,2014-11-30,March 2019,2019-03-31,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,,Interventional,,,Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD),Phase II Grape Seed Extract as Anti-Oligomerization Agent in Alzheimer's Disease,Recruiting,,Phase 2,20,Anticipated,Icahn School of Medicine at Mount Sinai,,2,,,False,,,,True,True,False,,,,,,,,,No,,2020-02-01 13:10:17.207831,2020-02-01 13:10:17.207831,Hillel Grossman,Other,Placebo,Drug
NCT02035553,"ClinicalTrials.gov processed this data on January 31, 2020",2014-01-13,2017-09-28,,2017-09-28,2014-01-13,2014-01-14,Estimate,2017-09-28,2017-10-25,Actual,,,,2017-09-28,2017-10-25,Actual,November 2013,,2013-11-30,September 2017,2017-09-30,"October 27, 2016",Actual,2016-10-27,"September 28, 2016",Actual,2016-09-28,,Interventional,,,A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis,"A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease",Completed,,Phase 2,181,Actual,ACADIA Pharmaceuticals Inc.,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:09:51.019135,2020-02-01 13:09:51.019135,ACADIA Pharmaceuticals Inc.,Industry,Placebo,Drug
NCT02035982,"ClinicalTrials.gov processed this data on January 31, 2020",2013-11-25,,,2017-04-26,2014-01-13,2014-01-14,Estimate,,,,,,,2017-04-26,2017-04-28,Actual,July 2010,,2010-07-31,April 2017,2017-04-30,September 2015,Actual,2015-09-30,May 2014,Actual,2014-05-31,,Interventional,,,Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease,A Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease in Long Term Care Setting,Completed,,Phase 3,40,Actual,Sunnybrook Health Sciences Centre,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:09:43.530864,2020-02-01 13:09:43.530864,Sunnybrook Health Sciences Centre,Other,Placebo,Drug
NCT02079909,"ClinicalTrials.gov processed this data on January 31, 2020",2014-03-04,2018-05-07,2016-02-23,2019-02-12,2014-03-04,2014-03-06,Estimate,2018-07-12,2018-08-09,Actual,2016-06-22,2016-06-27,Estimate,2019-02-12,2019-02-26,Actual,March 2014,,2014-03-31,February 2019,2019-02-28,"May 5, 2017",Actual,2017-05-05,"May 5, 2017",Actual,2017-05-05,,Interventional,,"The overall numbers of baseline participants display patient numbers in the mITT population, the primary analysis population. The mITT population excludes patients who did not take any study drug or did not perform any efficacy evaluation post-baseline. Thus, the numbers are slightly difference from the ones in the participant flow.",Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202),"A Phase 2 Multi-center, Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,482,Actual,"FUJIFILM Toyama Chemical Co., Ltd.",,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:58:33.435431,2020-02-01 12:58:33.435431,"FUJIFILM Toyama Chemical Co., Ltd.",Industry,Placebo,Drug
NCT02080364,"ClinicalTrials.gov processed this data on January 31, 2020",2014-02-25,,2019-05-08,2019-05-13,2014-03-04,2014-03-06,Estimate,,,,2019-05-13,2019-05-17,Actual,2019-05-13,2019-05-17,Actual,April 2015,Actual,2015-04-30,May 2019,2019-05-31,"June 1, 2018",Actual,2018-06-01,"June 1, 2018",Actual,2018-06-01,,Interventional,STEADFAST,,Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease,"Randomized, Double-blind, Placebo Controlled, Multi-center Registration Trial to Evaluate the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine",Terminated,,Phase 3,880,Actual,vTv Therapeutics,,2,,Not due to safety but due to a lack of efficacy at the 5 mg azeliragon dose.,False,,,,True,True,False,,,,,,,,,,,2020-02-01 12:58:28.399182,2020-02-01 12:58:28.399182,vTv Therapeutics,Industry,Placebo,Drug
NCT02103673,"ClinicalTrials.gov processed this data on January 31, 2020",2014-04-01,,,2018-01-23,2014-04-03,2014-04-04,Estimate,,,,,,,2018-01-23,2018-01-24,Actual,February 2014,,2014-02-28,January 2018,2018-01-31,November 2017,Actual,2017-11-30,November 2017,Actual,2017-11-30,,Interventional,,,DAOIB for the Treatment of Cognitive Function and Behavioral and Psychological Symptoms of Dementia,,Completed,,Phase 2,90,Actual,Chang Gung Memorial Hospital,,2,,,False,,,,,,,,,,,,,,,,,2020-02-01 12:53:13.868291,2020-02-01 12:53:13.868291,Chang Gung Memorial Hospital,Other,Placebo,Drug
NCT02167256,"ClinicalTrials.gov processed this data on January 31, 2020",2014-06-12,2019-06-19,,2019-07-25,2014-06-16,2014-06-19,Estimate,2019-07-25,2019-08-14,Actual,,,,2019-07-25,2019-08-14,Actual,December 2014,Actual,2014-12-31,July 2019,2019-07-31,"February 27, 2018",Actual,2018-02-27,"February 27, 2018",Actual,2018-02-27,,Interventional,,,"A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease","A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease",Completed,,Phase 2,159,Actual,Yale University,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:37:40.784913,2020-02-01 12:37:40.784913,Yale University,Other,Placebo,Drug
NCT02221947,"ClinicalTrials.gov processed this data on January 31, 2020",2014-07-02,2016-03-21,,2017-10-03,2014-08-20,2014-08-21,Estimate,2016-03-21,2016-04-21,Estimate,,,,2017-10-03,2017-11-06,Actual,June 2014,,2014-06-30,October 2017,2017-10-31,December 2014,Actual,2014-12-31,December 2014,Actual,2014-12-31,,Interventional,,,"Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Preliminary Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bryostatin 1 in Patients With Alzheimer's Disease",Terminated,,Phase 1/Phase 2,9,Actual,"Neurotrope Bioscience, Inc.",,2,,"Part 2 of study replaced by NTRP-101-202, assessing 3 doses of bryostatin.",False,,,,False,,,,,,,,,,,No,,2020-02-01 12:24:20.790879,2020-02-01 12:24:20.790879,"Neurotrope Bioscience, Inc.",Industry,Placebo,Drug
NCT02284906,"ClinicalTrials.gov processed this data on January 31, 2020",2014-11-04,2019-05-07,,2019-06-11,2014-11-04,2014-11-06,Estimate,2019-06-11,2019-07-02,Actual,,,,2019-06-11,2019-07-02,Actual,"February 12, 2015",Actual,2015-02-12,June 2019,2019-06-30,"May 8, 2018",Actual,2018-05-08,"January 31, 2018",Actual,2018-01-31,,Interventional,,Safety analysis set included all participants who received at least 1 dose of blinded study medication.,AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease,A Blinded Long-term Extension Study to Evaluate the Safety and Efficacy of Pioglitazone (AD-4833 Sustained Release 0.8 mg Daily) to Slow the Progression of Cognitive Decline in Subjects Who Have Completed the AD-4833/TOMM40_301 Study With Diagnosis of Mild Cognitive Impairment Due to Alzheimer Disease,Terminated,,Phase 3,40,Actual,Takeda,,2,,Lack of efficacy of the drug; no safety concern,False,,,,True,True,,,,,,,,,,Yes,"Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.",2020-02-01 12:10:02.597766,2020-02-01 12:10:02.597766,Takeda,Industry,Placebo,Drug
NCT02288000,"ClinicalTrials.gov processed this data on January 31, 2020",2014-11-06,,,2019-06-25,2014-11-06,2014-11-11,Estimate,,,,,,,2019-06-25,2019-06-27,Actual,"September 14, 2016",Actual,2016-09-14,June 2019,2019-06-30,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,,Interventional,WP3_P002,,Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases,Effect of a 15-day Memantine Treatment on Biomarkers of AD in Healthy Volunteers,Recruiting,,Phase 1,30,Anticipated,"University Hospital, Lille",,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:09:22.892287,2020-02-01 12:09:22.892287,"University Hospital, Lille",Other,Placebo,Drug
NCT02322021,"ClinicalTrials.gov processed this data on January 31, 2020",2014-12-17,,2019-06-07,2019-06-07,2014-12-19,2014-12-22,Estimate,,,,2019-06-07,2019-06-10,Actual,2019-06-07,2019-06-10,Actual,"November 26, 2014",Actual,2014-11-26,June 2018,2018-06-30,"July 31, 2022",Anticipated,2022-07-31,"March 27, 2018",Actual,2018-03-27,,Interventional,,,Dose-Finding Study To Evaluate the Safety and Tolerability of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease,"A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Dose-Finding Study To Evaluate the Safety and Tolerability of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease","Active, not recruiting",,Phase 2,71,Actual,Eisai Inc.,,8,,,False,,,,True,True,,,,,,,,,,Undecided,,2020-02-01 12:01:27.666580,2020-02-01 12:01:27.666580,Eisai Inc.,Industry,Placebo,Drug
NCT02346201,"ClinicalTrials.gov processed this data on January 31, 2020",2015-01-20,,,2020-01-16,2015-01-20,2015-01-26,Estimate,,,,,,,2020-01-16,2020-01-21,Actual,January 2016,,2016-01-31,January 2020,2020-01-31,June 2020,Anticipated,2020-06-30,May 2020,Anticipated,2020-05-31,,Interventional,ADMET2,,Apathy in Dementia Methylphenidate Trial 2,Apathy in Dementia Methylphenidate Trial 2,"Active, not recruiting",,Phase 3,200,Actual,Johns Hopkins Bloomberg School of Public Health,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:56:10.970719,2020-02-01 11:56:10.970719,Johns Hopkins Bloomberg School of Public Health,Other,Placebo,Drug
NCT02351882,"ClinicalTrials.gov processed this data on January 31, 2020",2014-11-17,,,2019-04-08,2015-01-27,2015-01-30,Estimate,,,,,,,2019-04-08,2019-04-10,Actual,January 2015,,2015-01-31,April 2019,2019-04-30,March 2019,Actual,2019-03-31,January 2018,Actual,2018-01-31,,Interventional,,,Safety and Efficacy of Nabilone in Alzheimer's Disease,Safety and Efficacy of Nabilone in Alzheimer's Disease: a Pilot Study,Completed,,Phase 2/Phase 3,38,Actual,Sunnybrook Health Sciences Centre,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:54:58.307512,2020-02-01 11:54:58.307512,Sunnybrook Health Sciences Centre,Other,Placebo,Drug
NCT02442765,"ClinicalTrials.gov processed this data on January 31, 2020",2015-05-11,,,2019-03-04,2015-05-11,2015-05-13,Estimate,,,,,,,2019-03-04,2019-03-06,Actual,September 2015,,2015-09-30,March 2019,2019-03-31,"February 27, 2019",Actual,2019-02-27,"January 30, 2019",Actual,2019-01-30,,Interventional,,,"Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",Completed,,Phase 3,410,Actual,Avanir Pharmaceuticals,,3,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 11:35:00.526050,2020-02-01 11:35:00.526050,Avanir Pharmaceuticals,Industry,Placebo,Drug
NCT02442778,"ClinicalTrials.gov processed this data on January 31, 2020",2015-05-11,,,2019-10-13,2015-05-11,2015-05-13,Estimate,,,,,,,2019-10-13,2019-10-15,Actual,September 2015,,2015-09-30,October 2019,2019-10-31,"September 9, 2019",Actual,2019-09-09,"August 14, 2019",Actual,2019-08-14,,Interventional,,,"Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type.",Completed,,Phase 3,522,Actual,Avanir Pharmaceuticals,,3,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 11:34:59.205605,2020-02-01 11:34:59.205605,Avanir Pharmaceuticals,Industry,Placebo,Drug
NCT02462161,"ClinicalTrials.gov processed this data on January 31, 2020",2015-06-01,,,2019-08-29,2015-06-02,2015-06-03,Estimate,,,,,,,2019-08-29,2019-09-03,Actual,"March 20, 2015",Actual,2015-03-20,August 2019,2019-08-31,"April 16, 2019",Actual,2019-04-16,"April 16, 2019",Actual,2019-04-16,,Interventional,SNIFF-Quick,,Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart,Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart,Completed,,Phase 1,24,Actual,Wake Forest University Health Sciences,,2,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 11:30:11.664980,2020-02-01 11:30:11.664980,Wake Forest University Health Sciences,Other,Placebo,Drug
NCT02471196,"ClinicalTrials.gov processed this data on January 31, 2020",2015-06-08,,,2018-02-14,2015-06-12,2015-06-15,Estimate,,,,,,,2018-02-14,2018-02-15,Actual,"August 14, 2015",Actual,2015-08-14,February 2018,2018-02-28,"December 4, 2017",Actual,2017-12-04,"October 9, 2017",Actual,2017-10-09,,Interventional,Nebula,,Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease,"Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Patients With Alzheimer's Disease: A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study of 12 Weeks",Completed,,Phase 2,308,Actual,"Orion Corporation, Orion Pharma",,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:28:13.264712,2020-02-01 11:28:13.264712,"Orion Corporation, Orion Pharma",Industry,Placebo,Drug
NCT02477800,"ClinicalTrials.gov processed this data on January 31, 2020",2015-06-18,,,2019-11-07,2015-06-18,2015-06-23,Estimate,,,,,,,2019-11-07,2019-11-12,Actual,"August 31, 2015",Actual,2015-08-31,November 2019,2019-11-30,"August 8, 2019",Actual,2019-08-08,"August 8, 2019",Actual,2019-08-08,,Interventional,ENGAGE,,221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease",Terminated,,Phase 3,1647,Actual,Biogen,,2,,"Study was discontinued based on futility analysis done and not based on safety concerns.
    Follow-up visits and closing out study activities are completed",False,,,,True,,,,,,,,,,,,,2020-02-01 11:26:54.149156,2020-02-01 11:26:54.149156,Biogen,Industry,Placebo,Drug
NCT02484547,"ClinicalTrials.gov processed this data on January 31, 2020",2015-06-18,,,2019-11-07,2015-06-26,2015-06-29,Estimate,,,,,,,2019-11-07,2019-11-12,Actual,"September 30, 2015",Actual,2015-09-30,November 2019,2019-11-30,"August 5, 2019",Actual,2019-08-05,"August 5, 2019",Actual,2019-08-05,,Interventional,EMERGE,,221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease",Terminated,,Phase 3,1638,Actual,Biogen,,2,,"Study was discontinued based on futility analysis done and not based on safety concerns.
    Follow-up visits and closing out study activities are completed",False,,,,True,,,,,,,,,,,,,2020-02-01 11:25:35.474212,2020-02-01 11:25:35.474212,Biogen,Industry,Placebo,Drug
NCT02503501,"ClinicalTrials.gov processed this data on January 31, 2020",2015-07-14,,,2020-01-29,2015-07-17,2015-07-21,Estimate,,,,,,,2020-01-29,2020-01-31,Estimate,August 2015,,2015-08-31,January 2020,2020-01-31,February 2020,Anticipated,2020-02-29,February 2020,Anticipated,2020-02-29,,Interventional,,,Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease,"A Phase II, Single Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and the Therapeutic Effectiveness of Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease","Active, not recruiting",,Phase 2,49,Actual,HealthPartners Institute,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-04 05:17:00.541400,2020-02-04 05:17:00.541400,HealthPartners Institute,Other,Placebo,Drug
NCT02579252,"ClinicalTrials.gov processed this data on January 31, 2020",2015-10-09,,,2019-11-13,2015-10-15,2015-10-19,Estimate,,,,,,,2019-11-13,2019-11-14,Actual,March 2016,,2016-03-31,November 2019,2019-11-30,June 2019,Actual,2019-06-30,June 2019,Actual,2019-06-30,,Interventional,ADAMANT,,24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease,"A 24 Months Randomised, Placebo-controlled, Parallel Group, Double Blinded, Multi Centre, Phase 2 Study to Assess Safety and Efficacy of AADvac1 Applied to Patients With Mild Alzheimer's Disease",Completed,,Phase 2,208,Actual,Axon Neuroscience SE,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:03:14.453391,2020-02-01 11:03:14.453391,Axon Neuroscience SE,Industry,Placebo,Drug
NCT02580305,"ClinicalTrials.gov processed this data on January 31, 2020",2015-10-17,,,2019-11-15,2015-10-17,2015-10-20,Estimate,,,,,,,2019-11-15,2019-11-18,Actual,September 2015,,2015-09-30,November 2019,2019-11-30,"November 7, 2019",Actual,2019-11-07,"November 5, 2019",Actual,2019-11-05,,Interventional,,,SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study,"A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride",Completed,,Phase 2,563,Actual,Suven Life Sciences Limited,,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:02:59.952283,2020-02-01 11:02:59.952283,Suven Life Sciences Limited,Industry,Placebo,Drug
NCT02585934,"ClinicalTrials.gov processed this data on January 31, 2020",2015-10-22,2018-09-30,,2018-11-08,2015-10-22,2015-10-26,Estimate,2018-11-08,2018-12-05,Actual,,,,2018-11-08,2018-12-05,Actual,October 2015,Actual,2015-10-31,November 2018,2018-11-30,September 2017,Actual,2017-09-30,September 2017,Actual,2017-09-30,,Interventional,,ITT population,Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study,"A Phase 3, Double-blind, Randomized Study of RVT-101 Versus Placebo When Added to Existing Stable Donepezil Treatment in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 3,1315,Actual,Axovant Sciences Ltd.,,2,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 11:01:27.758831,2020-02-01 11:01:27.758831,Axovant Sciences Ltd.,Industry,Placebo,Drug
NCT02615002,"ClinicalTrials.gov processed this data on January 31, 2020",2015-11-18,,,2019-08-20,2015-11-22,2015-11-25,Estimate,,,,,,,2019-08-20,2019-08-21,Actual,November 2015,,2015-11-30,August 2019,2019-08-31,"November 30, 2019",Anticipated,2019-11-30,November 2019,Anticipated,2019-11-30,,Interventional,,,Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION),"Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Ranging Study of Piromelatine in Patients With Mild Dementia Due to Alzheimer's Disease","Active, not recruiting",,Phase 2,500,Anticipated,Neurim Pharmaceuticals Ltd.,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 10:55:14.266636,2020-02-01 10:55:14.266636,Neurim Pharmaceuticals Ltd.,Industry,Placebo,Drug
NCT02626572,"ClinicalTrials.gov processed this data on January 31, 2020",2015-11-04,,,2018-08-13,2015-12-07,2015-12-10,Estimate,,,,,,,2018-08-13,2018-08-15,Actual,February 2015,,2015-02-28,August 2018,2018-08-31,September 2017,Actual,2017-09-30,September 2017,Actual,2017-09-30,,Interventional,,,Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms,"Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms. A 24-week International, Multi-centre, Randomized, Double-blind, Placebo-controlled Phase II Study in Monotherapy Followed by an Optional 28-week Extension Period in Co-administration With Donepezil.",Completed,,Phase 2,500,Anticipated,Servier,,4,,,False,,,,True,,,,,,,,After Marketing Authorisation in EEA or US if the study is used for the approval.,Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.,http://clinicaltrials.servier.com,Yes,"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).
They can ask all interventional clinical studies:
submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope.",2020-02-01 10:52:59.050457,2020-02-01 10:52:59.050457,Institut de Recherches Internationales Servier,Other,Placebo,Drug
NCT02646982,"ClinicalTrials.gov processed this data on January 31, 2020",2016-01-04,,,2019-02-15,2016-01-04,2016-01-06,Estimate,,,,,,,2019-02-15,2019-02-18,Actual,June 2016,,2016-06-30,February 2019,2019-02-28,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,,Interventional,CEDAR,,Candesartan's Effects on Alzheimer's Disease And Related Biomarkers,Candesartan's Effects on Alzheimer's Disease And Related Biomarkers,Recruiting,,Phase 2,72,Anticipated,Emory University,,2,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 10:48:22.473223,2020-02-01 10:48:22.473223,Emory University,Other,Placebo,Drug
NCT02667496,"ClinicalTrials.gov processed this data on January 31, 2020",2016-01-26,,,2017-04-05,2016-01-28,2016-01-29,Estimate,,,,,,,2017-04-05,2017-04-07,Actual,November 2016,,2016-11-30,April 2017,2017-04-30,"March 31, 2017",Actual,2017-03-31,"March 31, 2017",Actual,2017-03-31,,Interventional,,,Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease,A Study Examining the Safety and Activity of Innate Immune System Stimulation With Leukine® (Sargramostim) to Reduce Brain Amyloid Load in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease,Withdrawn,,Phase 2,0,Actual,Sanofi,,2,,Slow recruitment,False,,,,True,,,,,,,,,,,,,2020-02-01 10:44:33.482652,2020-02-01 10:44:33.482652,Sanofi,Industry,Placebo,Drug
NCT02708186,"ClinicalTrials.gov processed this data on January 31, 2020",2016-03-10,,,2018-10-22,2016-03-14,2016-03-15,Estimate,,,,,,,2018-10-22,2018-10-23,Actual,March 2016,Actual,2016-03-31,April 2018,2018-04-30,May 2018,Actual,2018-05-31,May 2018,Actual,2018-05-31,,Interventional,,,Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD),"A Phase 2, Double-blind, Randomized, Placebo-controlled Study of Nelotanserin Versus Placebo in Subjects With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) Who Have REM Sleep Behavior Disorder (RBD)",Completed,,Phase 2,29,Actual,Axovant Sciences Ltd.,,2,,,False,,,,,,,,,,,,,,,,,2020-02-01 10:35:55.243047,2020-02-01 10:35:55.243047,Axovant Sciences Ltd.,Industry,Placebo,Drug
NCT02792257,"ClinicalTrials.gov processed this data on January 31, 2020",2016-05-26,,,2019-06-25,2016-06-01,2016-06-07,Estimate,,,,,,,2019-06-25,2019-06-27,Actual,"March 1, 2017",Actual,2017-03-01,June 2019,2019-06-30,December 2020,Anticipated,2020-12-31,August 2020,Anticipated,2020-08-31,,Interventional,THC-AD,,Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease (AD) (THC-AD),Pilot Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease (AD) (THC-AD),Recruiting,,Phase 2,160,Anticipated,Johns Hopkins University,,2,,,False,,,,True,True,False,,,,,,,,,Undecided,,2020-02-01 10:18:48.371685,2020-02-01 10:18:48.371685,Johns Hopkins University,Other,Placebo,Drug
NCT02817906,"ClinicalTrials.gov processed this data on January 31, 2020",2016-06-27,,,2018-12-18,2016-06-27,2016-06-29,Estimate,,,,,,,2018-12-18,2018-12-20,Actual,June 2016,Actual,2016-06-30,December 2018,2018-12-31,December 2018,Actual,2018-12-31,December 2018,Actual,2018-12-31,,Interventional,,,"ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 in the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease",Terminated,,Phase 3,177,Actual,"Intra-Cellular Therapies, Inc.",,2,,Pre-specified Interim Analysis Indicated Futility,False,,,,,True,False,,,,,,,,,,,2020-02-01 10:14:10.009879,2020-02-01 10:14:10.009879,"Intra-Cellular Therapies, Inc.",Industry,Placebo,Drug
NCT02907567,"ClinicalTrials.gov processed this data on January 31, 2020",2016-09-05,,,2018-07-24,2016-09-15,2016-09-20,Estimate,,,,,,,2018-07-24,2018-07-26,Actual,September 2016,Actual,2016-09-30,July 2018,2018-07-31,September 2017,Actual,2017-09-30,"August 24, 2017",Actual,2017-08-24,,Interventional,,,Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled, Phase I Study of the Safety & Pharmacokinetics of Two Doses of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 1/Phase 2,19,Actual,Cognition Therapeutics,,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 09:57:57.979312,2020-02-01 09:57:57.979312,Cognition Therapeutics,Industry,Placebo,Drug
NCT02910102,"ClinicalTrials.gov processed this data on January 31, 2020",2016-09-16,,,2017-12-22,2016-09-19,2016-09-21,Estimate,,,,,,,2017-12-22,2017-12-27,Actual,October 2016,Actual,2016-10-31,December 2017,2017-12-31,November 2017,Actual,2017-11-30,November 2017,Actual,2017-11-30,,Interventional,,,Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia,"A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia",Completed,,Phase 2,38,Actual,Axovant Sciences Ltd.,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 09:57:01.127041,2020-02-01 09:57:01.127041,Axovant Sciences Ltd.,Industry,Placebo,Drug
NCT02925650,"ClinicalTrials.gov processed this data on January 31, 2020",2016-09-29,,,2020-01-18,2016-10-04,2016-10-06,Estimate,,,,,,,2020-01-18,2020-01-22,Actual,"March 2, 2017",Actual,2017-03-02,January 2020,2020-01-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,,Interventional,DISCOVER,,"Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects of Posiphen® in Subjects With Early Alzheimer's Disease (AD)",Recruiting,,Phase 1/Phase 2,24,Anticipated,QR Pharma Inc.,,4,,,False,,,,True,True,False,,,,,,,,,Yes,"Data from this research will be shared with other researchers pursuant to the 02/26/2003 ""NIH Final Statement on Sharing Research Data"".",2020-02-01 09:52:28.469882,2020-02-01 09:52:28.469882,QR Pharma Inc.,Industry,Placebo,Drug
NCT02956486,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-03,,,2019-09-18,2016-11-03,2016-11-06,Estimate,,,,,,,2019-09-18,2019-09-19,Actual,"October 20, 2016",Actual,2016-10-20,September 2018,2018-09-30,"November 21, 2023",Anticipated,2023-11-21,"November 21, 2023",Anticipated,2023-11-21,,Interventional,MissionAD1,,A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease,"A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease","Active, not recruiting",,Phase 3,950,Anticipated,Eisai Inc.,,3,,,False,,,,True,True,,,,,,,,,,Undecided,,2020-02-01 09:45:53.235437,2020-02-01 09:45:53.235437,"Eisai Co., Ltd.",Industry,Placebo,Drug
NCT03008161,"ClinicalTrials.gov processed this data on January 31, 2020",2016-12-23,,,2019-08-14,2016-12-29,2017-01-02,Estimate,,,,,,,2019-08-14,2019-08-15,Actual,December 2016,Actual,2016-12-31,August 2019,2019-08-31,"February 6, 2019",Actual,2019-02-06,"February 6, 2019",Actual,2019-02-06,,Interventional,,,Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease,"A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation Study of NPT088 in Patients With Probable Alzheimer's Disease",Completed,,Phase 1,83,Actual,"Proclara Biosciences, Inc.",,4,,,False,,,,True,,,,,,,,,,,Undecided,,2020-02-01 09:35:53.375769,2020-02-01 09:35:53.375769,"Proclara Biosciences, Inc.",Industry,Placebo,Drug
NCT03036280,"ClinicalTrials.gov processed this data on January 31, 2020",2017-01-26,,,2019-09-18,2017-01-26,2017-01-30,Estimate,,,,,,,2019-09-18,2019-09-19,Actual,"December 29, 2016",Actual,2016-12-29,September 2019,2019-09-30,"November 21, 2023",Anticipated,2023-11-21,"November 21, 2023",Anticipated,2023-11-21,,Interventional,MissionAD2,,A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease_,"A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease","Active, not recruiting",,Phase 3,950,Anticipated,Eisai Inc.,,3,,,False,,,,True,True,,,,,,,,,,Undecided,,2020-02-01 09:30:30.434411,2020-02-01 09:30:30.434411,"Eisai Co., Ltd.",Industry,Placebo,Drug
NCT03038035,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-01,,,2017-01-26,2017-01-26,2017-01-31,Estimate,,,,,,,2017-01-26,2017-01-31,Estimate,December 2016,,2016-12-31,January 2017,2017-01-31,June 2019,Anticipated,2019-06-30,June 2018,Anticipated,2018-06-30,,Interventional,ATHENE,,The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study,"The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study : Assessing the Safety and Efficacy of Neuroaid II (MLC901) in Patients With Mild to Moderate Alzheimer's Disease Stable on Cholinesterase Inhibitors or Memantine: A Randomized, Double Blind, Placebo Controlled Trial",Unknown status,Recruiting,Phase 2,150,Anticipated,"National University Hospital, Singapore",,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 09:30:10.628210,2020-02-01 09:30:10.628210,"National University Hospital, Singapore",Other,Placebo,Drug
NCT03055741,"ClinicalTrials.gov processed this data on January 31, 2020",2017-02-14,,,2019-08-19,2017-02-15,2017-02-16,Actual,,,,,,,2019-08-19,2019-08-20,Actual,"December 28, 2016",Actual,2016-12-28,August 2019,2019-08-31,August 2019,Actual,2019-08-31,February 2019,Actual,2019-02-28,,Interventional,,,Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA),"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIb, Clinical Study to Evaluate the Safety and Efficacy of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA)",Completed,,Phase 2,180,Actual,"Daehwa Pharmaceutical Co., Ltd.",,3,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 09:26:53.735013,2020-02-01 09:26:53.735013,"Daehwa Pharmaceutical Co., Ltd.",Industry,Placebo,Drug
NCT03108846,"ClinicalTrials.gov processed this data on January 31, 2020",2017-04-06,,,2019-01-16,2017-04-06,2017-04-11,Actual,,,,,,,2019-01-16,2019-01-17,Actual,"January 3, 2018",Actual,2018-01-03,January 2019,2019-01-31,August 2022,Anticipated,2022-08-31,December 2021,Anticipated,2021-12-31,,Interventional,S-CitAD,,Escitalopram for Agitation in Alzheimer's Disease,Escitalopram for Agitation in Alzheimer's Disease,Recruiting,,Phase 3,392,Anticipated,JHSPH Center for Clinical Trials,,2,,,False,,,,True,True,False,,,True,,,,,,No,,2020-02-01 09:17:38.732615,2020-02-01 09:17:38.732615,JHSPH Center for Clinical Trials,Other,Placebo,Drug
NCT03113812,"ClinicalTrials.gov processed this data on January 31, 2020",2017-04-04,,,2017-04-10,2017-04-10,2017-04-14,Actual,,,,,,,2017-04-10,2017-04-14,Actual,"January 1, 2014",Actual,2014-01-01,April 2017,2017-04-30,"July 30, 2015",Actual,2015-07-30,"July 30, 2015",Actual,2015-07-30,,Interventional,,,Repeated Subcutaneous Administration of ABvac40 in Mild to Moderate Alzheimer's Disease Patients,"A Randomized, Placebo-controlled, Parallel Group, Double-blinded, Single-center Phase-I, Pilot Study to Assess Tolerability and Safety of Repeated Subcutaneous Administration of ABvac40 in Patients With Mild to Moderate Alzheimer's Disease.",Completed,,Phase 1,24,Actual,Araclon Biotech S.L.,,2,,,False,,,,True,False,False,,,,,,,,,No,,2020-02-01 09:16:52.146443,2020-02-01 09:16:52.146443,Araclon Biotech S.L.,Industry,Placebo,Drug
NCT03289143,"ClinicalTrials.gov processed this data on January 31, 2020",2017-09-18,,,2020-01-06,2017-09-18,2017-09-20,Actual,,,,,,,2020-01-06,2020-01-09,Actual,"October 4, 2017",Actual,2017-10-04,January 2020,2020-01-31,"September 20, 2022",Anticipated,2022-09-20,"June 24, 2020",Anticipated,2020-06-24,,Interventional,,,A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease,"A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Prodromal to Mild Alzheimer's Disease","Active, not recruiting",,Phase 2,457,Actual,"Genentech, Inc.",,4,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:45:33.720811,2020-02-01 08:45:33.720811,"Genentech, Inc.",Industry,Placebo,Drug
NCT03298672,"ClinicalTrials.gov processed this data on January 31, 2020",2017-09-21,,,2019-09-06,2017-09-26,2017-10-02,Actual,,,,,,,2019-09-06,2019-09-10,Actual,"October 9, 2017",Actual,2017-10-09,September 2019,2019-09-30,"September 5, 2019",Actual,2019-09-05,"September 5, 2019",Actual,2019-09-05,,Interventional,,,"Safety, Tolerability, and Pharmacokinetics Study of NDX-1017","A Randomized, Placebo-Controlled, Double-Blinded, First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (Part A) and Multiple Ascending Doses (Part B) of NDX-1017 in Healthy Young and Elderly Subjects",Completed,,Phase 1,88,Actual,Athira Pharma,,2,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 08:43:58.167473,2020-02-01 08:43:58.167473,Athira Pharma,Industry,Placebo,Drug
NCT03352557,"ClinicalTrials.gov processed this data on January 31, 2020",2017-11-21,,,2020-01-20,2017-11-21,2017-11-24,Actual,,,,,,,2020-01-20,2020-01-22,Actual,"May 3, 2018",Actual,2018-05-03,January 2020,2020-01-31,"March 26, 2024",Anticipated,2024-03-26,"March 26, 2024",Anticipated,2024-03-26,,Interventional,TANGO,,Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease","Active, not recruiting",,Phase 2,654,Actual,Biogen,,4,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:34:31.539157,2020-02-01 08:34:31.539157,Biogen,Industry,Placebo,Drug
NCT03393520,"ClinicalTrials.gov processed this data on January 31, 2020",2018-01-03,,,2020-01-24,2018-01-03,2018-01-08,Actual,,,,,,,2020-01-24,2020-01-27,Actual,"October 13, 2017",Actual,2017-10-13,January 2020,2020-01-31,June 2021,Anticipated,2021-06-30,June 2021,Anticipated,2021-06-30,,Interventional,,,"Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",Recruiting,,Phase 3,412,Anticipated,Avanir Pharmaceuticals,,3,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:27:50.083519,2020-02-01 08:27:50.083519,Avanir Pharmaceuticals,Industry,Placebo,Drug
NCT03418688,"ClinicalTrials.gov processed this data on January 31, 2020",2018-01-26,,,2018-11-05,2018-01-26,2018-02-01,Actual,,,,,,,2018-11-05,2018-11-07,Actual,"March 6, 2018",Actual,2018-03-06,November 2018,2018-11-30,"October 15, 2018",Actual,2018-10-15,"October 15, 2018",Actual,2018-10-15,,Interventional,,,A Multiple Ascending Dose Study of COR388,"A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of COR388 in Older Healthy Volunteers and Patients With Alzheimer's Disease",Completed,,Phase 1,33,Actual,Cortexyme Inc.,,2,,,False,,,,True,True,False,,,,,,,,,No,,2020-02-01 08:23:47.480357,2020-02-01 08:23:47.480357,Cortexyme Inc.,Industry,Placebo,Drug
NCT03446001,"ClinicalTrials.gov processed this data on January 31, 2020",2018-02-08,,,2020-01-22,2018-02-20,2018-02-26,Actual,,,,,,,2020-01-22,2020-01-23,Actual,"January 10, 2018",Actual,2018-01-10,January 2020,2020-01-31,December 2022,Anticipated,2022-12-31,December 2021,Anticipated,2021-12-31,,Interventional,,,Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment,"Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of TRx0237 Monotherapy in Subjects With Alzheimer's Disease Followed by a 12-Month Open-Label Treatment",Recruiting,,Phase 3,450,Anticipated,TauRx Therapeutics Ltd,,3,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:18:55.846673,2020-02-01 08:18:55.846673,TauRx Therapeutics Ltd,Industry,Placebo,Drug
NCT03493282,"ClinicalTrials.gov processed this data on February 06, 2020",2018-02-14,,,2020-01-30,2018-04-03,2018-04-10,Actual,,,,,,,2020-01-30,2020-02-05,Actual,"April 20, 2018",Actual,2018-04-20,January 2020,2020-01-31,"March 1, 2021",Anticipated,2021-03-01,"January 31, 2021",Anticipated,2021-01-31,,Interventional,,,Effect of CT1812 Treatment on Brain Synaptic Density,A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants With Mild to Moderate Alzheimer's Disease,"Active, not recruiting",,Phase 1/Phase 2,23,Actual,Cognition Therapeutics,,3,,,,,,,True,True,False,,,,,,,,,Undecided,,2020-02-07 06:03:03.394019,2020-02-07 06:03:03.394019,Cognition Therapeutics,Industry,Placebo,Drug
NCT03507790,"ClinicalTrials.gov processed this data on January 31, 2020",2018-04-10,,,2020-01-20,2018-04-16,2018-04-25,Actual,,,,,,,2020-01-20,2020-01-22,Actual,"October 2, 2018",Actual,2018-10-02,January 2020,2020-01-31,"July 31, 2020",Anticipated,2020-07-31,"June 30, 2020",Anticipated,2020-06-30,,Interventional,,,A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.",Recruiting,,Phase 2,120,Anticipated,Cognition Therapeutics,,3,,,,,,,True,True,False,,,,,,,,,No,,2020-02-01 08:09:06.429952,2020-02-01 08:09:06.429952,Cognition Therapeutics,Industry,Placebo,Drug
NCT03518073,"ClinicalTrials.gov processed this data on February 06, 2020",2018-04-26,,,2020-02-03,2018-05-01,2018-05-08,Actual,,,,,,,2020-02-03,2020-02-05,Actual,"April 30, 2018",Actual,2018-04-30,February 2020,2020-02-29,"October 22, 2021",Anticipated,2021-10-22,"August 23, 2021",Anticipated,2021-08-23,,Interventional,,,A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease,"Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease","Active, not recruiting",,Phase 2,285,Anticipated,Eli Lilly and Company,,3,,,False,,,,True,True,False,,,,,,,,,Yes,"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.",2020-02-07 06:02:44.436528,2020-02-07 06:02:44.436528,Eli Lilly and Company,Industry,Placebo,Drug
NCT03522129,"ClinicalTrials.gov processed this data on February 06, 2020",2018-04-30,,,2020-01-30,2018-04-30,2018-05-11,Actual,,,,,,,2020-01-30,2020-02-05,Actual,"May 16, 2018",Actual,2018-05-16,January 2020,2020-01-31,"March 31, 2021",Anticipated,2021-03-31,"January 30, 2021",Anticipated,2021-01-30,,Interventional,,,Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease,A Pilot Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease,Recruiting,,Phase 1,18,Anticipated,Cognition Therapeutics,,4,,,False,,,,True,True,False,,,,,,,,,,,2020-02-07 06:02:33.931340,2020-02-07 06:02:33.931340,Cognition Therapeutics,Industry,Placebo,Drug
NCT03533257,"ClinicalTrials.gov processed this data on January 31, 2020",2018-04-30,,,2020-01-15,2018-05-10,2018-05-23,Actual,,,,,,,2020-01-15,2020-01-18,Actual,"August 27, 2018",Actual,2018-08-27,January 2020,2020-01-31,"September 1, 2020",Anticipated,2020-09-01,"July 1, 2020",Anticipated,2020-07-01,,Interventional,PEGASUS,,Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease,"Phase II Study to Assess the Safety, Tolerability, and Target Engagement of AMX0035, a Fixed Combination of Sodium Phenylbutyrate and Tauroursodeoxycholic Acid for the Treatment of Alzheimer's Disease",Recruiting,,Phase 2,100,Anticipated,Amylyx Pharmaceuticals Inc.,,2,,,,,,,False,True,False,,,,,,,,,Undecided,,2020-02-01 08:04:53.807069,2020-02-01 08:04:53.807069,Amylyx Pharmaceuticals Inc.,Industry,Placebo,Drug
NCT03620981,"ClinicalTrials.gov processed this data on January 31, 2020",2018-08-05,,,2019-07-09,2018-08-05,2018-08-08,Actual,,,,,,,2019-07-09,2019-07-11,Actual,"August 20, 2018",Actual,2018-08-20,July 2019,2019-07-31,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,,Interventional,,,Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type,"A Phase 2/3 Multicenter, Placebo-controlled, Randomized, Double-blind, Parallel-group Comparison Trial to Evaluate the Efficacy and Safety of Brexpiprazole (OPC-34712) in the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type",Recruiting,,Phase 2/Phase 3,407,Anticipated,"Otsuka Pharmaceutical Co., Ltd.",,3,,,False,,,,True,False,False,,,,,,,,,Undecided,,2020-02-01 07:51:00.823260,2020-02-01 07:51:00.823260,"Otsuka Pharmaceutical Co., Ltd.",Industry,Placebo,Drug
NCT03625622,"ClinicalTrials.gov processed this data on January 31, 2020",2018-08-08,,,2019-03-28,2018-08-08,2018-08-10,Actual,,,,,,,2019-03-28,2019-04-01,Actual,"January 15, 2019",Actual,2019-01-15,March 2019,2019-03-31,"August 1, 2020",Anticipated,2020-08-01,"June 1, 2020",Anticipated,2020-06-01,,Interventional,,,Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease,"A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease",Recruiting,,Phase 2,210,Anticipated,"AriBio Co., Ltd.",,3,,,,,,,False,True,False,,,,,,,,,,,2020-02-01 07:50:16.488873,2020-02-01 07:50:16.488873,"AriBio Co., Ltd.",Industry,Placebo,Drug
NCT03639987,"ClinicalTrials.gov processed this data on January 31, 2020",2018-08-17,,,2019-11-07,2018-08-17,2018-08-21,Actual,,,,,,,2019-11-07,2019-11-12,Actual,"December 20, 2018",Actual,2018-12-20,November 2019,2019-11-30,"July 30, 2019",Actual,2019-07-30,"July 30, 2019",Actual,2019-07-30,,Interventional,EVOLVE,,A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities,"A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Blind, Controlled Study of Aducanumab (BIIB037) in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Subjects With Asymptomatic Amyloid-Related Imaging Abnormalities",Terminated,,Phase 2,500,Actual,Biogen,,2,,"Study was discontinued based on futility analysis conducted on Phase 3 trials (NCT02477800 and
    NCT02484547) and not based on safety concerns.",False,,,,True,True,False,,,,,,,,,,,2020-02-01 07:47:53.971667,2020-02-01 07:47:53.971667,Biogen,Industry,Placebo,Drug
NCT03698695,"ClinicalTrials.gov processed this data on January 31, 2020",2018-10-02,,,2020-01-21,2018-10-03,2018-10-09,Actual,,,,,,,2020-01-21,2020-01-22,Actual,"September 27, 2018",Actual,2018-09-27,January 2020,2020-01-31,"December 20, 2019",Actual,2019-12-20,"October 20, 2019",Actual,2019-10-20,,Interventional,,,"A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers","A Double Blind, Placebo-controlled, Randomized, 15-day Treatment, Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil Administered Orally to Healthy Male Volunteers Including a Scopolamine Challenge",Completed,,Phase 1,152,Actual,Theranexus,,3,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 07:39:11.698156,2020-02-01 07:39:11.698156,Theranexus,Industry,Placebo,Drug
NCT03703856,"ClinicalTrials.gov processed this data on January 31, 2020",2018-10-09,,,2020-01-21,2018-10-10,2018-10-12,Actual,,,,,,,2020-01-21,2020-01-23,Actual,"January 31, 2019",Actual,2019-01-31,January 2020,2020-01-31,August 2023,Anticipated,2023-08-31,August 2023,Anticipated,2023-08-31,,Interventional,,,Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease,Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease,Recruiting,,Phase 4,88,Anticipated,"University of California, San Diego",,2,,,False,,,,,True,False,,,True,,,,,,,,2020-02-01 07:38:26.839208,2020-02-01 07:38:26.839208,"University of California, San Diego",Other,Placebo,Drug
NCT03817684,"ClinicalTrials.gov processed this data on January 31, 2020",2019-01-18,,,2019-10-30,2019-01-23,2019-01-25,Actual,,,,,,,2019-10-30,2019-10-31,Actual,"April 30, 2019",Actual,2019-04-30,October 2019,2019-10-31,February 2020,Anticipated,2020-02-29,February 2020,Anticipated,2020-02-29,,Interventional,,,Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects,"A Randomized , Double Blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients With Early Stage Alzheimer's Disease","Active, not recruiting",,Phase 2,255,Actual,Tetra Discovery Partners,,3,,,False,,,,True,True,False,,,,,,,,,No,,2020-02-01 07:21:36.297810,2020-02-01 07:21:36.297810,Tetra Discovery Partners,Industry,Placebo,Drug
NCT03828747,"ClinicalTrials.gov processed this data on February 06, 2020",2019-01-29,,,2020-02-04,2019-01-31,2019-02-04,Actual,,,,,,,2020-02-04,2020-02-06,Estimate,"January 30, 2019",Actual,2019-01-30,February 2020,2020-02-29,"June 2, 2023",Anticipated,2023-06-02,"May 7, 2021",Anticipated,2021-05-07,,Interventional,,,A Study of Semorinemab in Patients With Moderate Alzheimer's Disease,"A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Moderate Alzheimer's Disease",Recruiting,,Phase 2,260,Anticipated,"Genentech, Inc.",,2,,,False,,,,True,True,False,,,,,,,,,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)",2020-02-07 05:56:24.743317,2020-02-07 05:56:24.743317,"Genentech, Inc.",Industry,Placebo,Drug
NCT03838185,"ClinicalTrials.gov processed this data on January 31, 2020",2019-02-07,,,2019-02-09,2019-02-09,2019-02-12,Actual,,,,,,,2019-02-09,2019-02-12,Actual,"January 22, 2019",Actual,2019-01-22,February 2019,2019-02-28,January 2020,Anticipated,2020-01-31,October 2019,Anticipated,2019-10-31,,Interventional,,,"Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147","A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147 in Healthy Young Volunteers and Healthy Elderly Volunteers",Recruiting,,Phase 1,64,Anticipated,"Abrexa Pharmaceuticals, Inc.",,2,,,False,,,,True,True,False,,,,,,,,,Undecided,,2020-02-01 07:18:39.582788,2020-02-01 07:18:39.582788,"Abrexa Pharmaceuticals, Inc.",Industry,Placebo,Drug
NCT03867253,"ClinicalTrials.gov processed this data on January 31, 2020",2019-02-20,,,2019-12-02,2019-03-06,2019-03-07,Actual,,,,,,,2019-12-02,2019-12-03,Actual,"May 16, 2019",Actual,2019-05-16,November 2019,2019-11-30,"November 15, 2020",Anticipated,2020-11-15,"November 15, 2020",Anticipated,2020-11-15,,Interventional,ETHERAL-US,,Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease,"A Multicentre,Randomised, Double-blind, Placebo-controlled, 3-arm, 24-week Parallel-group Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ORY-2001 in Patients With Mild-moderate Alzheimer's Disease",Recruiting,,Phase 2,33,Anticipated,Oryzon Genomics S.A.,,3,,,False,,,,True,True,False,,,,,,,,,Undecided,,2020-02-01 07:14:13.743720,2020-02-01 07:14:13.743720,Oryzon Genomics S.A.,Industry,Placebo,Drug
NCT03887455,"ClinicalTrials.gov processed this data on January 31, 2020",2019-03-21,,,2019-07-10,2019-03-21,2019-03-25,Actual,,,,,,,2019-07-10,2019-07-12,Actual,"March 27, 2019",Actual,2019-03-27,March 2019,2019-03-31,"March 7, 2024",Anticipated,2024-03-07,"February 24, 2022",Anticipated,2022-02-24,,Interventional,Clarity AD,,A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer's Disease,"A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease",Recruiting,,Phase 3,1566,Anticipated,Eisai Inc.,,3,,,False,,,,True,True,False,,,False,,,,,,Yes,Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.,2020-02-01 07:11:13.548680,2020-02-01 07:11:13.548680,Eisai Inc.,Industry,Placebo,Drug
NCT03980730,"ClinicalTrials.gov processed this data on January 31, 2020",2019-05-31,,,2020-01-13,2019-06-06,2019-06-10,Actual,,,,,,,2020-01-13,2020-01-14,Actual,"June 27, 2019",Actual,2019-06-27,January 2020,2020-01-31,July 2023,Anticipated,2023-07-31,April 2023,Anticipated,2023-04-30,,Interventional,Elevage,,Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance,"Randomized, Double-blind, Placebo-controlled, Multicenter Studies to Evaluate the Safety and Efficacy of Azeliragon as a Treatment for Subjects With Mild Alzheimer's Disease and Impaired Glucose Tolerance",Recruiting,,Phase 2/Phase 3,300,Anticipated,vTv Therapeutics,,2,,,False,,,,True,True,False,,,,,,,,,No,,2020-02-01 06:57:16.531793,2020-02-01 06:57:16.531793,vTv Therapeutics,Industry,Placebo,Drug
NCT04074837,"ClinicalTrials.gov processed this data on January 31, 2020",2019-08-27,,,2019-08-28,2019-08-28,2019-08-30,Actual,,,,,,,2019-08-28,2019-08-30,Actual,"August 1, 2019",Actual,2019-08-01,August 2019,2019-08-31,"April 1, 2020",Anticipated,2020-04-01,"March 1, 2020",Anticipated,2020-03-01,,Interventional,,,"Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers","Phase1a, Randomized Placebo-controlled, Single and Multiple Dose, Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNI-362 in Healthy Aged Volunteers 50 to 72 Years of Age",Recruiting,,Phase 1,56,Anticipated,"Neuronascent, Inc.",,4,,,False,,,,True,True,False,,,,,,,,,No,This clinical trial will be available for peer-reviewed publication.,2020-02-01 06:43:42.295547,2020-02-01 06:43:42.295547,"Neuronascent, Inc.",Industry,Placebo,Drug
NCT04187547,"ClinicalTrials.gov processed this data on February 06, 2020",2019-11-29,,,2020-02-04,2019-12-03,2019-12-05,Actual,,,,,,,2020-02-04,2020-02-06,Estimate,"July 31, 2020",Anticipated,2020-07-31,February 2020,2020-02-29,"December 31, 2022",Anticipated,2022-12-31,"September 30, 2022",Anticipated,2022-09-30,,Interventional,,,A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension,"A 20-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Trial to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin as AC-SD-03 in Subjects With Mild to Moderately Severe Probable Alzheimer's Disease and Who Are Non-carriers of the APOE4 Allele With an Optional 30-Week Open Label Extension",Not yet recruiting,,Phase 3,300,Anticipated,Cerecin,,2,,,False,,,,True,True,False,,,,,,,,,,,2020-02-07 05:47:57.344149,2020-02-07 05:47:57.344149,Cerecin,Industry,Placebo,Drug
NCT04191486,"ClinicalTrials.gov processed this data on February 06, 2020",2019-11-26,,,2020-02-05,2019-12-05,2019-12-09,Actual,,,,,,,2020-02-05,2020-02-06,Estimate,"December 24, 2019",Actual,2019-12-24,February 2020,2020-02-29,October 2022,Anticipated,2022-10-31,September 2022,Anticipated,2022-09-30,,Interventional,,,Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD,"A Phase 2 Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease",Recruiting,,Phase 2,200,Anticipated,"FUJIFILM Toyama Chemical Co., Ltd.",,2,,,False,,,,True,False,False,,,,,,,,,Undecided,Details for sharing data have not been decided yet.,2020-02-07 05:47:54.530500,2020-02-07 05:47:54.530500,"FUJIFILM Toyama Chemical Co., Ltd.",Industry,Placebo,Drug
NCT02168920,"ClinicalTrials.gov processed this data on January 31, 2020",2014-06-18,,,2017-10-13,2014-06-18,2014-06-20,Estimate,,,,,,,2017-10-13,2017-10-16,Actual,"June 11, 2014",Actual,2014-06-11,October 2017,2017-10-31,"March 18, 2016",Actual,2016-03-18,"March 18, 2016",Actual,2016-03-18,,Interventional,,,Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole in the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type",Terminated,,Phase 3,150,Actual,"Otsuka Pharmaceutical Co., Ltd.",,4,,It was difficult to secure enrollment of the targeted number of subjects.,False,,,,True,,,,,,,,,,,,,2020-02-01 12:37:21.845361,2020-02-01 12:37:21.845361,"Otsuka Pharmaceutical Co., Ltd.",Industry,Placebo (0 mg/day),Drug
NCT03752294,"ClinicalTrials.gov processed this data on January 31, 2020",2018-05-15,,,2018-11-20,2018-11-20,2018-11-23,Actual,,,,,,,2018-11-20,2018-11-23,Actual,November 2018,Anticipated,2018-11-30,November 2018,2018-11-30,December 2021,Anticipated,2021-12-31,November 2021,Anticipated,2021-11-30,,Interventional,,,A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.,"A 24-month, Randomized-control, Double-blind, Multi-center, Delayed-start, Pilot Study Evaluating Thrombin Inhibitions Alzheimer's Disease Using 150mg Dabigatran Daily: A Novel Therapeutic Target for Alzheimer's Disease",Not yet recruiting,,Phase 1,40,Anticipated,University of Rhode Island,,3,,,False,,,,True,False,False,,,False,,,,,,Undecided,,2020-02-01 07:31:02.811291,2020-02-01 07:31:02.811291,University of Rhode Island,Other,Placebo - Cap,Drug
NCT03823404,"ClinicalTrials.gov processed this data on January 31, 2020",2019-01-24,,,2020-01-10,2019-01-29,2019-01-30,Actual,,,,,,,2020-01-10,2020-01-13,Actual,"March 28, 2019",Actual,2019-03-28,December 2019,2019-12-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,,Interventional,,,GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease,"GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease",Recruiting,,Phase 2/Phase 3,573,Anticipated,Cortexyme Inc.,,3,,,False,,,,True,True,False,,,,,,,,,No,,2020-02-01 07:20:47.948947,2020-02-01 07:20:47.948947,Cortexyme Inc.,Industry,Placebo capsule,Drug
NCT02947893,"ClinicalTrials.gov processed this data on January 31, 2020",2016-10-21,,,2019-03-12,2016-10-27,2016-10-28,Estimate,,,,,,,2019-03-12,2019-03-13,Actual,January 2017,Actual,2017-01-31,March 2019,2019-03-31,February 2020,Anticipated,2020-02-29,December 2019,Anticipated,2019-12-31,,Interventional,AD,,"Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease","A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib (Tasigna®) on Safety, Biomarkers and Clinical Outcomes in Subjects With Mild to Moderate Alzheimer's Disease","Active, not recruiting",,Phase 2,42,Anticipated,Georgetown University,,2,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 09:47:48.303388,2020-02-01 09:47:48.303388,Georgetown University,Other,Placebo Capsule(s) Once a Day by Mouth,Drug
NCT00141661,"ClinicalTrials.gov processed this data on January 31, 2020",2005-08-30,,,2009-08-19,2005-08-30,2005-09-01,Estimate,,,,,,,2009-08-19,2009-08-20,Estimate,October 2005,,2005-10-31,August 2009,2009-08-31,June 2006,Actual,2006-06-30,June 2006,Actual,2006-06-30,,Interventional,,,A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients,"A Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study in Subjects With Mild to Moderate Dementia of the Alzheimer's Type to Evaluate the Safety and Tolerability of Two 10-Week Dose Regimens of Orally-Administered PF-04494700",Completed,,Phase 2,67,Actual,Pfizer,,3,,,False,,,,False,,,,,,,,,,,,,2020-02-01 22:05:05.719845,2020-02-01 22:05:05.719845,Pfizer,Industry,Placebo Comparator,Drug
NCT01547169,"ClinicalTrials.gov processed this data on January 31, 2020",2012-02-07,,,2012-12-17,2012-03-06,2012-03-07,Estimate,,,,,,,2012-12-17,2012-12-18,Estimate,March 2011,,2011-03-31,December 2012,2012-12-31,December 2012,Actual,2012-12-31,December 2012,Actual,2012-12-31,,Interventional,SNIFF-LONG 21,,Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days,Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days,Completed,,Phase 2,60,Actual,University of Washington,,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:17:31.332607,2020-02-01 15:17:31.332607,University of Washington,Other,Placebo Comparator,Drug
NCT01230853,"ClinicalTrials.gov processed this data on January 31, 2020",2010-10-27,,,2013-05-20,2010-10-28,2010-10-29,Estimate,,,,,,,2013-05-20,2013-05-22,Estimate,August 2010,,2010-08-31,February 2013,2013-02-28,February 2013,Actual,2013-02-28,October 2012,Actual,2012-10-31,,Interventional,,,"A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study","A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacodynamic Response, and Pharmacokinetics of Intravenous Infusions of BAN2401 in Subjects With Mild to Moderate Alzheimer?s Disease",Completed,,Phase 1,80,Actual,Eisai Inc.,,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 16:43:04.642093,2020-02-01 16:43:04.642093,Eisai Inc.,Industry,Placebo Comparator A,Drug
NCT01230853,"ClinicalTrials.gov processed this data on January 31, 2020",2010-10-27,,,2013-05-20,2010-10-28,2010-10-29,Estimate,,,,,,,2013-05-20,2013-05-22,Estimate,August 2010,,2010-08-31,February 2013,2013-02-28,February 2013,Actual,2013-02-28,October 2012,Actual,2012-10-31,,Interventional,,,"A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study","A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacodynamic Response, and Pharmacokinetics of Intravenous Infusions of BAN2401 in Subjects With Mild to Moderate Alzheimer?s Disease",Completed,,Phase 1,80,Actual,Eisai Inc.,,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 16:43:04.642093,2020-02-01 16:43:04.642093,Eisai Inc.,Industry,Placebo Comparator B,Drug
NCT00568776,"ClinicalTrials.gov processed this data on January 31, 2020",2007-12-04,2011-09-27,,2019-10-17,2007-12-04,2007-12-06,Estimate,2012-03-01,2012-03-29,Estimate,,,,2019-10-17,2019-11-01,Actual,December 2007,,2007-12-31,October 2019,2019-10-31,May 2010,Actual,2010-05-31,May 2010,Actual,2010-05-31,,Interventional,,,ELND005 in Patients With Mild to Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral ELND005 (AZD-103) in Alzheimer's Disease",Completed,,Phase 2,353,Actual,"OPKO Health, Inc.","The two high dose groups of ELND005 were discontinued before study end, so the efficacy analysis was based only on placebo and ELND005 250 mg bid groups.",4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:01:52.395629,2020-02-01 20:01:52.395629,"OPKO Health, Inc.",Industry,Placebo Control,Drug
NCT00574132,"ClinicalTrials.gov processed this data on January 31, 2020",2007-12-10,,2013-09-27,2013-10-30,2007-12-13,2007-12-17,Estimate,,,,2013-09-27,2013-10-28,Estimate,2013-10-30,2013-11-25,Estimate,December 2007,,2007-12-31,October 2013,2013-10-31,June 2012,Actual,2012-06-30,June 2012,Actual,2012-06-30,,Interventional,,,Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier),"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Non- Carriers.",Completed,,Phase 3,1331,Actual,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",,3,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:00:25.535905,2020-02-01 20:00:25.535905,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Industry,Placebo Control,Drug
NCT00575055,"ClinicalTrials.gov processed this data on January 31, 2020",2007-12-10,,2013-09-27,2013-10-30,2007-12-13,2007-12-17,Estimate,,,,2013-09-27,2013-10-28,Estimate,2013-10-30,2013-11-25,Estimate,December 2007,,2007-12-31,October 2013,2013-10-31,April 2012,Actual,2012-04-30,April 2012,Actual,2012-04-30,,Interventional,,,Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier),"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Carriers.",Completed,,Phase 3,1121,Actual,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",,3,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:00:04.969013,2020-02-01 20:00:04.969013,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Industry,Placebo Control,Drug
NCT00866060,"ClinicalTrials.gov processed this data on January 31, 2020",2009-03-19,,,2009-03-19,2009-03-19,2009-03-20,Estimate,,,,,,,2009-03-19,2009-03-20,Estimate,February 2008,,2008-02-29,March 2009,2009-03-31,June 2013,Anticipated,2013-06-30,February 2012,Anticipated,2012-02-29,,Interventional,DOMINO-AD,,Donepezil and Memantine in Moderate to Severe Alzheimer's Disease,Donepezil and Memantine in Moderate to Severe Alzheimer's Disease,Unknown status,Recruiting,Phase 4,800,Anticipated,King's College London,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:34:35.920768,2020-02-01 18:34:35.920768,King's College London,Other,Placebo donepezil,Drug
NCT01940952,"ClinicalTrials.gov processed this data on January 31, 2020",2013-09-09,,,2013-09-09,2013-09-09,2013-09-12,Estimate,,,,,,,2013-09-09,2013-09-12,Estimate,September 2013,,2013-09-30,September 2013,2013-09-30,,,,August 2015,Anticipated,2015-08-31,,Interventional,,,Zydena on Cognitive Function of Alzheimer's Disease Patients,"Efficacy of Zydena (Udenafil) on Cognitive Function of Alzheimer's Disease Patients: A Randomized, Double Blind, Placebo-controlled Multicenter Study",Unknown status,Not yet recruiting,Phase 3,210,Anticipated,Samsung Medical Center,,3,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:35:04.954668,2020-02-01 13:35:04.954668,Samsung Medical Center,Other,Placebo + Donepezil 5mg or 10mg,Drug
NCT02880956,"ClinicalTrials.gov processed this data on January 31, 2020",2016-08-24,,,2020-01-14,2016-08-24,2016-08-26,Estimate,,,,,,,2020-01-14,2020-01-18,Actual,"October 17, 2016",Actual,2016-10-17,January 2020,2020-01-31,"July 28, 2021",Anticipated,2021-07-28,"April 30, 2021",Anticipated,2021-04-30,,Interventional,,,A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease,"A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease","Active, not recruiting",,Phase 2,453,Actual,AbbVie,,4,,,True,,,,True,True,False,,,False,,,"Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.","Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.",https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html,Yes,"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.",2020-02-01 10:02:59.856443,2020-02-01 10:02:59.856443,AbbVie,Industry,placebo for ABBV-8E12,Drug
NCT01324518,"ClinicalTrials.gov processed this data on January 31, 2020",2011-03-24,,,2014-10-20,2011-03-25,2011-03-29,Estimate,,,,,,,2014-10-20,2014-10-21,Estimate,April 2011,,2011-04-30,October 2014,2014-10-31,October 2012,Actual,2012-10-31,September 2012,Actual,2012-09-30,,Interventional,ALPO,,Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease,Safety and Efficacy of ORM-12741 on Cognitive and Behavioral Symptoms in Patients With Alzheimer's Disease,Completed,,Phase 2,100,Actual,"Orion Corporation, Orion Pharma",,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:16:14.110927,2020-02-01 16:16:14.110927,"Orion Corporation, Orion Pharma",Industry,Placebo for ORM-12741,Drug
NCT01266525,"ClinicalTrials.gov processed this data on January 31, 2020",2010-12-23,,2016-02-12,2016-02-12,2010-12-23,2010-12-24,Estimate,,,,2016-02-12,2016-03-14,Estimate,2016-02-12,2016-03-14,Estimate,February 2011,,2011-02-28,February 2016,2016-02-29,January 2013,Actual,2013-01-31,January 2013,Actual,2013-01-31,,Interventional,,,Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil,"A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy",Completed,,Phase 2,291,Actual,Sanofi,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:32:09.069267,2020-02-01 16:32:09.069267,Sanofi,Industry,placebo (for SAR110894),Drug
NCT00539305,"ClinicalTrials.gov processed this data on January 31, 2020",2007-10-03,2013-03-15,,2014-07-10,2007-10-03,2007-10-04,Estimate,2014-07-10,2014-07-14,Estimate,,,,2014-07-10,2014-07-14,Estimate,July 2009,,2009-07-31,July 2014,2014-07-31,May 2012,Actual,2012-05-31,July 2011,Actual,2011-07-31,,Interventional,HIP,,Hormone and Information Processing Study,Testosterone Supplementation in Men With MCI,Completed,,Phase 3,22,Actual,University of Washington,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:12:13.088046,2020-02-01 20:12:13.088046,University of Washington,Other,placebo gel,Drug
NCT00161473,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-08,2012-02-24,,2012-06-26,2005-09-08,2005-09-12,Estimate,2012-06-26,2012-08-02,Estimate,,,,2012-06-26,2012-08-02,Estimate,January 2001,,2001-01-31,June 2012,2012-06-30,September 2009,Actual,2009-09-30,September 2009,Actual,2009-09-30,,Interventional,,,Alzheimer's in Long-Term Care--Treatment for Agitation,Alzheimer's in Long-Term Care--Treatment for Agitation,Completed,,N/A,24,Actual,University of Washington,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:59:31.636454,2020-02-01 21:59:31.636454,University of Washington,Other,placebo (inert substance),Drug
NCT02221622,"ClinicalTrials.gov processed this data on January 31, 2020",2014-07-02,,,2019-07-02,2014-08-18,2014-08-20,Estimate,,,,,,,2019-07-02,2019-07-05,Actual,August 2014,,2014-08-31,May 2018,2018-05-31,February 2018,Actual,2018-02-28,February 2018,Actual,2018-02-28,,Interventional,Allo,,Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD,Allopregnanolone Regenerative Therapeutic for MCI/AD: Dose Finding Phase 1,Completed,,Phase 1,24,Actual,University of Southern California,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:24:27.622064,2020-02-01 12:24:27.622064,University of Southern California,Other,Placebo injection (intravenous solution),Drug
NCT00439166,"ClinicalTrials.gov processed this data on January 31, 2020",2007-02-20,,,2018-03-15,2007-02-21,2007-02-23,Estimate,,,,,,,2018-03-15,2018-03-19,Actual,February 2007,,2007-02-28,March 2017,2017-03-31,December 2010,Actual,2010-12-31,April 2010,Actual,2010-04-30,,Interventional,,,Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid,Effects of Treatment With Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid,Completed,,Phase 3,100,Actual,McMaster University,,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:43:09.592414,2020-02-01 20:43:09.592414,Hamilton Health Sciences Corporation,Other,Placebo matched to doxycycline,Drug
NCT00439166,"ClinicalTrials.gov processed this data on January 31, 2020",2007-02-20,,,2018-03-15,2007-02-21,2007-02-23,Estimate,,,,,,,2018-03-15,2018-03-19,Actual,February 2007,,2007-02-28,March 2017,2017-03-31,December 2010,Actual,2010-12-31,April 2010,Actual,2010-04-30,,Interventional,,,Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid,Effects of Treatment With Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid,Completed,,Phase 3,100,Actual,McMaster University,,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:43:09.592414,2020-02-01 20:43:09.592414,Hamilton Health Sciences Corporation,Other,Placebo matched to Rifampin,Drug
NCT01492374,"ClinicalTrials.gov processed this data on January 31, 2020",2011-12-13,,,2014-07-23,2011-12-13,2011-12-15,Estimate,,,,,,,2014-07-23,2014-07-24,Estimate,February 2012,,2012-02-29,October 2013,2013-10-31,October 2013,Actual,2013-10-31,October 2013,Actual,2013-10-31,,Interventional,,,"Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease","A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease",Completed,,Phase 1,40,Actual,Bristol-Myers Squibb,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:31:09.583952,2020-02-01 15:31:09.583952,Bristol-Myers Squibb,Industry,Placebo matching BMS-241027,Drug
NCT00866060,"ClinicalTrials.gov processed this data on January 31, 2020",2009-03-19,,,2009-03-19,2009-03-19,2009-03-20,Estimate,,,,,,,2009-03-19,2009-03-20,Estimate,February 2008,,2008-02-29,March 2009,2009-03-31,June 2013,Anticipated,2013-06-30,February 2012,Anticipated,2012-02-29,,Interventional,DOMINO-AD,,Donepezil and Memantine in Moderate to Severe Alzheimer's Disease,Donepezil and Memantine in Moderate to Severe Alzheimer's Disease,Unknown status,Recruiting,Phase 4,800,Anticipated,King's College London,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:34:35.920768,2020-02-01 18:34:35.920768,King's College London,Other,Placebo memantine,Drug
NCT03710642,"ClinicalTrials.gov processed this data on January 31, 2020",2018-10-09,,,2019-06-24,2018-10-16,2018-10-18,Actual,,,,,,,2019-06-24,2019-06-26,Actual,"July 30, 2019",Anticipated,2019-07-30,February 2019,2019-02-28,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,,Interventional,,,Prazosin for Agitation in Alzheimer's Disease,Prazosin for Disruptive Agitation in Alzheimer's Disease (AD) (PEACE-AD),Recruiting,,Phase 2,186,Anticipated,Alzheimer's Disease Cooperative Study (ADCS),,2,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 07:37:23.070907,2020-02-01 07:37:23.070907,Alzheimer's Disease Cooperative Study (ADCS),Other,Placebo oral capsule,Drug
NCT03752463,"ClinicalTrials.gov processed this data on January 31, 2020",2018-11-21,,,2018-11-21,2018-11-21,2018-11-26,Actual,,,,,,,2018-11-21,2018-11-26,Actual,"May 22, 2015",Actual,2015-05-22,April 2018,2018-04-30,"December 31, 2019",Anticipated,2019-12-31,"December 31, 2019",Anticipated,2019-12-31,,Interventional,,,NMDA Enhancer for the Treatment of Mild Alzheimer's Disease,NMDA Enhancer for the Treatment of Mild Alzheimer's Disease,Recruiting,,Phase 2,160,Anticipated,Chang Gung Memorial Hospital,,4,,,False,,,,,False,False,,,,,,,,,,,2020-02-01 07:31:01.934898,2020-02-01 07:31:01.934898,Chang Gung Memorial Hospital,Other,Placebo oral capsule,Drug
NCT03790709,"ClinicalTrials.gov processed this data on January 31, 2020",2018-12-24,,,2019-11-17,2018-12-31,2019-01-02,Actual,,,,,,,2019-11-17,2019-11-19,Actual,"July 3, 2018",Actual,2018-07-03,August 2019,2019-08-31,"December 31, 2021",Anticipated,2021-12-31,"September 30, 2021",Anticipated,2021-09-30,,Interventional,,,ANAVEX2-73 for Treatment of Early Alzheimer's Disease,"A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy Trial of ANAVEX2-73 for the Treatment of Early Alzheimer's Disease (AD)",Recruiting,,Phase 2/Phase 3,450,Anticipated,Anavex Life Sciences Corp.,,3,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 07:25:39.943948,2020-02-01 07:25:39.943948,Anavex Life Sciences Corp.,Industry,Placebo oral capsule,Drug
NCT03875638,"ClinicalTrials.gov processed this data on January 31, 2020",2019-03-13,,,2019-09-09,2019-03-13,2019-03-15,Actual,,,,,,,2019-09-09,2019-09-10,Actual,"August 22, 2019",Actual,2019-08-22,September 2019,2019-09-30,November 2023,Anticipated,2023-11-30,August 2023,Anticipated,2023-08-31,,Interventional,,,Treating Hyperexcitability in AD With Levetiracetam,Treating Hyperexcitability in Alzheimer's Disease With Levetiracetam to Improve Brain Function and Cognition,Recruiting,,Phase 2,85,Anticipated,Beth Israel Deaconess Medical Center,,4,,,False,,,,True,True,False,,,False,,,,,,Undecided,,2020-02-01 07:13:04.175822,2020-02-01 07:13:04.175822,Beth Israel Deaconess Medical Center,Other,Placebo oral capsule,Drug
NCT04079803,"ClinicalTrials.gov processed this data on January 31, 2020",2019-08-26,,,2019-09-04,2019-09-04,2019-09-06,Actual,,,,,,,2019-09-04,2019-09-06,Actual,"August 15, 2019",Actual,2019-08-15,August 2019,2019-08-31,"April 15, 2020",Anticipated,2020-04-15,"January 15, 2020",Anticipated,2020-01-15,,Interventional,,,PTI-125 for Mild-to-moderate Alzheimer's Disease Patients,"A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Biomarker and Safety Study of PTI-125 in Mild-to-moderate Alzheimer's Disease Patients",Recruiting,,Phase 2,60,Anticipated,"Cassava Sciences, Inc.",,3,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 06:43:02.419451,2020-02-01 06:43:02.419451,"Cassava Sciences, Inc.",Industry,Placebo oral tablet,Drug
NCT04098666,"ClinicalTrials.gov processed this data on January 31, 2020",2019-09-19,,,2019-11-07,2019-09-19,2019-09-23,Actual,,,,,,,2019-11-07,2019-11-12,Actual,"August 1, 2020",Anticipated,2020-08-01,November 2019,2019-11-30,"April 30, 2024",Anticipated,2024-04-30,"March 30, 2024",Anticipated,2024-03-30,,Interventional,MAP,,Metformin in Alzheimer's Dementia Prevention,Metformin in Alzheimer's Dementia Prevention,Not yet recruiting,,Phase 2/Phase 3,370,Anticipated,Columbia University,,2,,,False,,,,True,True,False,,,,,,After reporting of main results,,,Yes,"All datasets used/generated on the project will be made accessible and reusable by qualified individuals other than the original data generators via web-based resources with the capacity to store large and diverse datasets (such as data about clinical phenotypes, genetics, epigenetics, proteomics, and metabolomics) to enable multiple parallel approaches to data analysis and interpretation. All analytical methodologies will be made fully reproducible and transparent so that results can be vetted and existing analysis techniques quickly applied to new application areas. We will comply with the data sharing arrangement decided by NIA.",2020-02-01 06:40:23.267307,2020-02-01 06:40:23.267307,Columbia University,Other,Placebo oral tablet,Drug
NCT01862640,"ClinicalTrials.gov processed this data on January 31, 2020",2013-05-22,,2018-01-22,2019-03-11,2013-05-22,2013-05-24,Estimate,,,,2018-01-22,2018-01-26,Actual,2019-03-11,2019-03-14,Actual,July 2013,,2013-07-31,March 2019,2019-03-31,March 2017,Actual,2017-03-31,March 2017,Actual,2017-03-31,,Interventional,,,Safety and Tolerability Study of Two Fixed-doses of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type,"A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type",Completed,,Phase 3,433,Actual,"Otsuka Pharmaceutical Development & Commercialization, Inc.",,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:56:29.292305,2020-02-01 13:56:29.292305,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Industry,Placebo Oral Tablet,Drug
NCT03082755,"ClinicalTrials.gov processed this data on January 31, 2020",2017-03-06,,,2019-10-23,2017-03-10,2017-03-17,Actual,,,,,,,2019-10-23,2019-10-25,Actual,"July 1, 2017",Actual,2017-07-01,October 2019,2019-10-31,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2021",Anticipated,2021-03-31,,Interventional,,,Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease,Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease,Recruiting,,Phase 4,136,Anticipated,University of Texas at Austin,,2,,,False,,,,True,True,False,,,False,,,Data will be made available 6 months after publication of the main study findings and will be available in perpetuity.,IPD will be publicly available via the following url,https://dataverse.tdl.org/dataset.xhtml?persistentId=doi:10.18738/T8/GDSFSQ,Yes,Data have been prepared for sharing with other investigators. All collected individual participant data (IPD) can be accessed at https://dataverse.tdl.org/dataset.xhtml?persistentId=doi:10.18738/T8/GDSFSQ after publication of the main study findings,2020-02-01 09:22:16.586579,2020-02-01 09:22:16.586579,University of Texas at Austin,Other,Placebo Oral Tablet,Drug
NCT03486938,"ClinicalTrials.gov processed this data on February 06, 2020",2018-03-28,,,2020-01-31,2018-04-02,2018-04-03,Actual,,,,,,,2020-01-31,2020-02-05,Actual,"January 15, 2019",Actual,2019-01-15,January 2020,2020-01-31,November 2022,Anticipated,2022-11-30,November 2021,Anticipated,2021-11-30,,Interventional,HOPE4MCI,,Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease",Recruiting,,Phase 3,830,Anticipated,AgeneBio,,2,,,False,,,,True,True,False,,,,,,,,,No,,2020-02-07 06:03:07.574413,2020-02-07 06:03:07.574413,AgeneBio,Industry,Placebo Oral Tablet,Drug
NCT03489044,"ClinicalTrials.gov processed this data on January 31, 2020",2018-03-09,,,2018-10-15,2018-03-28,2018-04-05,Actual,,,,,,,2018-10-15,2018-10-16,Actual,November 2018,Anticipated,2018-11-30,March 2018,2018-03-31,January 2020,Anticipated,2020-01-31,"November 1, 2019",Anticipated,2019-11-01,,Interventional,ILiAD,,An Investigation of Levetiracetam in Alzheimer's Disease,An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a Proof of Concept Study,Enrolling by invitation,,Phase 2,30,Anticipated,University of Oxford,,2,,,False,,,,False,False,False,,,,,,,,,Undecided,It is possible that irretrievably anonymised data will be shared with other researchers dependent on securing relevant ethical approval,2020-02-01 08:12:09.213728,2020-02-01 08:12:09.213728,University of Oxford,Other,Placebo Oral Tablet,Drug
NCT00066157,"ClinicalTrials.gov processed this data on January 31, 2020",2003-08-04,,,2018-08-22,2003-08-04,2003-08-05,Estimate,,,,,,,2018-08-22,2018-08-23,Actual,September 2001,,2001-09-30,August 2018,2018-08-31,December 2007,Actual,2007-12-31,December 2007,Actual,2007-12-31,,Interventional,,,Alzheimer's Disease: Therapeutic Potential of Estrogen,Alzheimer's Disease: Therapeutic Potential of Estrogen,Completed,,Phase 2/Phase 3,42,Actual,"University of Wisconsin, Madison",,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:32:28.672051,2020-02-01 22:32:28.672051,"University of Wisconsin, Madison",Other,Placebo Patch,Drug
NCT00479557,"ClinicalTrials.gov processed this data on January 31, 2020",2007-05-24,2014-05-06,,2015-11-30,2007-05-24,2007-05-28,Estimate,2015-11-30,2016-01-01,Estimate,,,,2015-11-30,2016-01-01,Estimate,May 2007,,2007-05-31,November 2015,2015-11-30,January 2013,Actual,2013-01-31,January 2013,Actual,2013-01-31,,Interventional,,245 participants were randomized in both studies (86 participants in 3134K1-200-EU [B2571004] and 159 participants in 3134K1-2201-US [B2571005]) and included in the analysis below. One participant of the randomized participants did not receive treatment.,"Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease","A Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer's Disease",Completed,,Phase 2,86,Actual,Pfizer,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:30:37.798575,2020-02-01 20:30:37.798575,Pfizer,Industry,Placebo: Phosphate buffered saline,Drug
NCT00255086,"ClinicalTrials.gov processed this data on January 31, 2020",2005-11-15,2016-08-23,,2017-02-23,2005-11-15,2005-11-17,Estimate,2017-02-23,2017-04-07,Actual,,,,2017-02-23,2017-04-07,Actual,May 2005,,2005-05-31,February 2017,2017-02-28,February 2010,Actual,2010-02-28,June 2009,Actual,2009-06-30,,Interventional,,"Per protocol, only participants who completed the study were evaluable for baseline characteristics.",The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients,"The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients: A Randomized, Placebo-Controlled, 52-Week Clinical Trial",Completed,,Phase 3,17,Actual,Stanford University,,2,,,False,,,,False,,,,,,,,,,,Undecided,,2020-02-01 21:37:34.734231,2020-02-01 21:37:34.734231,Stanford University,Other,Placebo pill,Drug
NCT00545974,"ClinicalTrials.gov processed this data on January 31, 2020",2007-10-16,2013-04-22,,2019-10-08,2007-10-17,2007-10-18,Estimate,2013-12-13,2014-02-05,Estimate,,,,2019-10-08,2019-10-17,Actual,October 2007,,2007-10-31,October 2019,2019-10-31,December 2012,Actual,2012-12-31,December 2012,Actual,2012-12-31,,Interventional,,,Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia,"A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia",Completed,,Phase 4,81,Actual,"University of California, San Francisco",Lower enrollment than planned may have limited ability detect a treatment effect; Small size of semantic dementia group limits generalizability of results to FTD syndrome;Newer tools have been developed to better capture FTD-specific behaviors.,2,,,,,,,True,,,,,,,,,,,,,2020-02-01 20:10:00.659080,2020-02-01 20:10:00.659080,"University of California, San Francisco",Other,Placebo pill,Drug
NCT01965756,"ClinicalTrials.gov processed this data on January 31, 2020",2013-10-16,2017-06-06,,2017-08-21,2013-10-16,2013-10-18,Estimate,2017-08-21,2017-09-21,Actual,,,,2017-08-21,2017-09-21,Actual,January 2013,,2013-01-31,August 2017,2017-08-31,April 2017,Actual,2017-04-30,"December 22, 2015",Actual,2015-12-22,,Interventional,,,Effect of Insulin Sensitizer Metformin on AD Biomarkers,"A Phase II Trial to Study the Effect of Metformin on AD Biomarkers: A Randomized Placebo Controlled Crossover Pilot Study of Metformin Effects on Cognitive, Physiological and Biochemical Biomarkers of MCI and Dementia Due to AD",Completed,,Phase 2,20,Actual,University of Pennsylvania,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:28:20.189926,2020-02-01 13:28:20.189926,University of Pennsylvania,Other,Placebos,Drug
NCT04251182,"ClinicalTrials.gov processed this data on January 31, 2020",2020-01-24,,,2020-01-29,2020-01-29,2020-01-31,Estimate,,,,,,,2020-01-29,2020-01-31,Estimate,"February 5, 2020",Anticipated,2020-02-05,January 2020,2020-01-31,"August 13, 2021",Anticipated,2021-08-13,"August 13, 2021",Anticipated,2021-08-13,,Interventional,,,Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects,"A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease",Not yet recruiting,,Phase 2,256,Anticipated,"T3D Therapeutics, Inc.",,4,,,,,,,True,True,False,,,,,,,,,No,A Clinical Study Report (CSR) will be generated within 9 months after database lock. Aggregate study data will be made available in this report.,2020-02-04 05:09:35.057386,2020-02-04 05:09:35.057386,"T3D Therapeutics, Inc.",Industry,Placebos,Drug
NCT01255163,"ClinicalTrials.gov processed this data on January 31, 2020",2010-12-04,2017-11-08,,2018-01-23,2010-12-04,2010-12-07,Estimate,2018-01-23,2018-02-22,Actual,,,,2018-01-23,2018-02-22,Actual,"November 21, 2010",,2010-11-21,January 2018,2018-01-31,"November 18, 2016",Actual,2016-11-18,"November 18, 2016",Actual,2016-11-18,,Interventional,,"The baseline analysis population includes 27 participants who underwent randomization and received at least one dose of experimental medication. Of those 27, we have at least one outcome measure (i.e. at least the 6 months follow-up data point) for 21 participants. Of those 21, 18 completed the study (i.e. reached 18 months).",A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease,A Pilot Study of Exendin-4 in Alzheimer s Disease,Terminated,,Phase 2,57,Actual,National Institutes of Health Clinical Center (CC),The study was terminated after AstraZeneca withdrew support. Early termination lead to small number of subjects analyzed.,2,,AstraZeneca withdrew support for the study.,False,,,,True,True,False,,,False,,,,,,,,2020-02-01 16:35:47.564810,2020-02-01 16:35:47.564810,National Institute on Aging (NIA),NIH,Placebo SC,Drug
NCT01399125,"ClinicalTrials.gov processed this data on January 31, 2020",2011-07-19,2014-05-05,,2014-07-10,2011-07-20,2011-07-21,Estimate,2014-07-10,2014-08-04,Estimate,,,,2014-07-10,2014-08-04,Estimate,July 2011,,2011-07-31,July 2014,2014-07-31,May 2013,Actual,2013-05-31,May 2013,Actual,2013-05-31,,Interventional,,,"A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease","A 24-Week, Randomized, Double-blind, Double-dummy, Parallel-group, Active-controlled Study to Assess the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (Mini-Mental State Examination (MMSE) 10-20)",Completed,,Phase 3,501,Actual,Novartis,,2,,,False,,,,,,,,,,,,,,,,,2020-02-01 15:55:55.772860,2020-02-01 15:55:55.772860,Novartis Pharmaceuticals,Industry,Placebo to Rivastigmine capsules,Drug
NCT01399125,"ClinicalTrials.gov processed this data on January 31, 2020",2011-07-19,2014-05-05,,2014-07-10,2011-07-20,2011-07-21,Estimate,2014-07-10,2014-08-04,Estimate,,,,2014-07-10,2014-08-04,Estimate,July 2011,,2011-07-31,July 2014,2014-07-31,May 2013,Actual,2013-05-31,May 2013,Actual,2013-05-31,,Interventional,,,"A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease","A 24-Week, Randomized, Double-blind, Double-dummy, Parallel-group, Active-controlled Study to Assess the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (Mini-Mental State Examination (MMSE) 10-20)",Completed,,Phase 3,501,Actual,Novartis,,2,,,False,,,,,,,,,,,,,,,,,2020-02-01 15:55:55.772860,2020-02-01 15:55:55.772860,Novartis Pharmaceuticals,Industry,Placebo to Rivastigmine patch,Drug
NCT00385684,"ClinicalTrials.gov processed this data on January 31, 2020",2006-10-06,2014-06-02,,2015-11-18,2006-10-06,2006-10-11,Estimate,2015-11-18,2015-11-20,Estimate,,,,2015-11-18,2015-11-20,Estimate,October 2007,,2007-10-31,November 2015,2015-11-30,June 2014,Actual,2014-06-30,December 2011,Actual,2011-12-31,,Interventional,LDOT,Veterans with severe dementia residing in VA nursing home.,Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT),Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT),Completed,,Phase 4,11,Actual,VA Office of Research and Development,,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:00:50.049144,2020-02-01 21:00:50.049144,VA Office of Research and Development,U.S. Fed,placebo with hydrocodone/APAP PRN,Drug
NCT01715350,"ClinicalTrials.gov processed this data on January 31, 2020",2012-10-24,,,2016-04-15,2012-10-25,2012-10-26,Estimate,,,,,,,2016-04-15,2016-04-18,Estimate,May 2012,,2012-05-31,April 2016,2016-04-30,June 2015,Actual,2015-06-30,September 2014,Actual,2014-09-30,,Interventional,ADD,,Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease,"A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease: Double-Blind, Randomized Between Placebo Control Group and Dose Groups, Parallel-Design, Multicenter Study",Completed,,Phase 2,151,Actual,"GMP BIO Co., LTD.",,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:34:17.112760,2020-02-01 14:34:17.112760,"GMP BIO Co., LTD.",Industry,PM012,Drug
NCT04052737,"ClinicalTrials.gov processed this data on January 31, 2020",2019-08-08,,,2019-08-11,2019-08-09,2019-08-12,Actual,,,,,,,2019-08-11,2019-08-13,Actual,"March 23, 2018",Actual,2018-03-23,August 2019,2019-08-31,July 2020,Anticipated,2020-07-31,December 2019,Anticipated,2019-12-31,,Interventional,,,PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease,"A Prospective, Multicentric, Randomized, Double Blind, Placebo Controlled Phase II Clinical Study to Compare the Safety and Efficacy of PMZ-1620 Therapy Along With Standard Supportive Care in Subjects of Mild to Moderate Alzheimer's Disease",Recruiting,,Phase 2,80,Anticipated,"Pharmazz, Inc.",,2,,,False,,,,True,False,False,,,,,,,,,No,Results will be communicated and published as manuscript,2020-02-01 06:46:51.040091,2020-02-01 06:46:51.040091,"Pharmazz, Inc.",Industry,PMZ-1620 (sovateltide) along with standard treatment,Drug
NCT02925650,"ClinicalTrials.gov processed this data on January 31, 2020",2016-09-29,,,2020-01-18,2016-10-04,2016-10-06,Estimate,,,,,,,2020-01-18,2020-01-22,Actual,"March 2, 2017",Actual,2017-03-02,January 2020,2020-01-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,,Interventional,DISCOVER,,"Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects of Posiphen® in Subjects With Early Alzheimer's Disease (AD)",Recruiting,,Phase 1/Phase 2,24,Anticipated,QR Pharma Inc.,,4,,,False,,,,True,True,False,,,,,,,,,Yes,"Data from this research will be shared with other researchers pursuant to the 02/26/2003 ""NIH Final Statement on Sharing Research Data"".",2020-02-01 09:52:28.469882,2020-02-01 09:52:28.469882,QR Pharma Inc.,Industry,Posiphen,Drug
NCT02389413,"ClinicalTrials.gov processed this data on January 31, 2020",2015-03-05,,,2017-05-31,2015-03-16,2015-03-17,Estimate,,,,,,,2017-05-31,2017-06-01,Actual,March 2015,,2015-03-31,January 2017,2017-01-31,April 2017,Actual,2017-04-30,April 2017,Actual,2017-04-30,,Interventional,SAPHIR,,Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease,"A Phase 2A Multicentre, Randomised, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Study of PQ912 in Subjects With Early Alzheimer's Disease",Completed,,Phase 2,120,Actual,Vivoryon Therapeutics AG,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:46:50.270362,2020-02-01 11:46:50.270362,Vivoryon Therapeutics AG,Industry,PQ912 oral,Drug
NCT00161473,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-08,2012-02-24,,2012-06-26,2005-09-08,2005-09-12,Estimate,2012-06-26,2012-08-02,Estimate,,,,2012-06-26,2012-08-02,Estimate,January 2001,,2001-01-31,June 2012,2012-06-30,September 2009,Actual,2009-09-30,September 2009,Actual,2009-09-30,,Interventional,,,Alzheimer's in Long-Term Care--Treatment for Agitation,Alzheimer's in Long-Term Care--Treatment for Agitation,Completed,,N/A,24,Actual,University of Washington,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:59:31.636454,2020-02-01 21:59:31.636454,University of Washington,Other,prazosin,Drug
NCT01126099,"ClinicalTrials.gov processed this data on January 31, 2020",2010-05-17,2014-07-15,,2015-05-19,2010-05-18,2010-05-19,Estimate,2015-05-19,2015-05-21,Estimate,,,,2015-05-19,2015-05-21,Estimate,March 2010,,2010-03-31,May 2015,2015-05-31,March 2014,Actual,2014-03-31,March 2014,Actual,2014-03-31,,Interventional,,,Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease,Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease,Completed,,N/A,20,Actual,Seattle Institute for Biomedical and Clinical Research,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:14:44.218519,2020-02-01 17:14:44.218519,Seattle Institute for Biomedical and Clinical Research,Other,Prazosin,Drug
NCT03710642,"ClinicalTrials.gov processed this data on January 31, 2020",2018-10-09,,,2019-06-24,2018-10-16,2018-10-18,Actual,,,,,,,2019-06-24,2019-06-26,Actual,"July 30, 2019",Anticipated,2019-07-30,February 2019,2019-02-28,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,,Interventional,,,Prazosin for Agitation in Alzheimer's Disease,Prazosin for Disruptive Agitation in Alzheimer's Disease (AD) (PEACE-AD),Recruiting,,Phase 2,186,Anticipated,Alzheimer's Disease Cooperative Study (ADCS),,2,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 07:37:23.070907,2020-02-01 07:37:23.070907,Alzheimer's Disease Cooperative Study (ADCS),Other,Prazosin,Drug
NCT04079803,"ClinicalTrials.gov processed this data on January 31, 2020",2019-08-26,,,2019-09-04,2019-09-04,2019-09-06,Actual,,,,,,,2019-09-04,2019-09-06,Actual,"August 15, 2019",Actual,2019-08-15,August 2019,2019-08-31,"April 15, 2020",Anticipated,2020-04-15,"January 15, 2020",Anticipated,2020-01-15,,Interventional,,,PTI-125 for Mild-to-moderate Alzheimer's Disease Patients,"A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Biomarker and Safety Study of PTI-125 in Mild-to-moderate Alzheimer's Disease Patients",Recruiting,,Phase 2,60,Anticipated,"Cassava Sciences, Inc.",,3,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 06:43:02.419451,2020-02-01 06:43:02.419451,"Cassava Sciences, Inc.",Industry,PTI-125 100 mg oral tablet,Drug
NCT04079803,"ClinicalTrials.gov processed this data on January 31, 2020",2019-08-26,,,2019-09-04,2019-09-04,2019-09-06,Actual,,,,,,,2019-09-04,2019-09-06,Actual,"August 15, 2019",Actual,2019-08-15,August 2019,2019-08-31,"April 15, 2020",Anticipated,2020-04-15,"January 15, 2020",Anticipated,2020-01-15,,Interventional,,,PTI-125 for Mild-to-moderate Alzheimer's Disease Patients,"A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Biomarker and Safety Study of PTI-125 in Mild-to-moderate Alzheimer's Disease Patients",Recruiting,,Phase 2,60,Anticipated,"Cassava Sciences, Inc.",,3,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 06:43:02.419451,2020-02-01 06:43:02.419451,"Cassava Sciences, Inc.",Industry,PTI-125 50 mg tablet,Drug
NCT02361424,"ClinicalTrials.gov processed this data on January 31, 2020",2014-12-19,,,2016-02-12,2015-02-06,2015-02-11,Estimate,,,,,,,2016-02-12,2016-02-15,Estimate,February 2013,,2013-02-28,October 2015,2015-10-31,June 2015,Actual,2015-06-30,June 2015,Actual,2015-06-30,,Interventional,PLEODIAL-I,,Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD),First Single-blind Sequential Placebo-controlled Prospective Phase IIA Pilot Study Assessing the Effects of PXT00864 in Mild AD Patients,Completed,,Phase 2,47,Actual,Pharnext SA,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:52:50.624085,2020-02-01 11:52:50.624085,Pharnext SA,Other,PXT00864,Drug
NCT00368459,"ClinicalTrials.gov processed this data on January 31, 2020",2006-08-22,2015-03-01,,2015-03-20,2006-08-22,2006-08-24,Estimate,2015-03-20,2015-04-02,Estimate,,,,2015-03-20,2015-04-02,Estimate,August 2006,,2006-08-31,March 2015,2015-03-31,January 2012,Actual,2012-01-31,March 2011,Actual,2011-03-31,,Interventional,,Postmenopausal women with Alzheimer's disease of mild to moderate severity,Raloxifene for Women With Alzheimer's Disease,Raloxifene in Women With AD: Randomized Controlled Trial,Completed,,Phase 2,42,Actual,Stanford University,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:06:20.426774,2020-02-01 21:06:20.426774,Stanford University,Other,raloxifene,Drug
NCT00325728,"ClinicalTrials.gov processed this data on January 31, 2020",2006-05-11,,,2017-08-10,2006-05-11,2006-05-15,Estimate,,,,,,,2017-08-10,2017-08-14,Actual,"March 21, 2006",Actual,2006-03-21,August 2017,2017-08-31,"August 20, 2007",Actual,2007-08-20,"August 1, 2007",Actual,2007-08-01,,Interventional,,,Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease,"A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of 8 Week Treatment of Rozerem 8 mg (QHS) in Sleep Disturbed, Mild to Moderately Severe Alzheimer's Disease Subjects",Completed,,Phase 2,74,Actual,Takeda,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 21:17:49.788554,2020-02-01 21:17:49.788554,Takeda,Industry,Ramelteon,Drug
NCT00438568,"ClinicalTrials.gov processed this data on January 31, 2020",2007-02-21,,,2012-09-12,2007-02-21,2007-02-22,Estimate,,,,,,,2012-09-12,2012-09-14,Estimate,June 2006,,2006-06-30,September 2012,2012-09-30,December 2011,Actual,2011-12-31,December 2011,Actual,2011-12-31,,Interventional,SNIFF 120,,SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days),Therapeutic Effects of Intranasal Insulin Administration in AD,Completed,,Phase 2,173,Actual,University of Washington,,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:43:16.502687,2020-02-01 20:43:16.502687,University of Washington,Other,Regular Insulin,Drug
NCT01504854,"ClinicalTrials.gov processed this data on January 31, 2020",2011-12-23,2016-01-28,,2016-05-06,2012-01-03,2012-01-06,Estimate,2016-05-06,2016-06-14,Estimate,,,,2016-05-06,2016-06-14,Estimate,May 2012,,2012-05-31,April 2016,2016-04-30,March 2014,Actual,2014-03-31,March 2014,Actual,2014-03-31,,Interventional,,,Resveratrol for Alzheimer's Disease,Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease,Completed,,Phase 2,119,Actual,Alzheimer's Disease Cooperative Study (ADCS),This phase 2 study has limitations. A larger study is required to determine whether resveratrol may be beneficial. More potent and bioavailable SIRT1 activators are also in development.,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:28:15.052585,2020-02-01 15:28:15.052585,Alzheimer's Disease Cooperative Study (ADCS),Other,Resveratrol,Drug
NCT00439166,"ClinicalTrials.gov processed this data on January 31, 2020",2007-02-20,,,2018-03-15,2007-02-21,2007-02-23,Estimate,,,,,,,2018-03-15,2018-03-19,Actual,February 2007,,2007-02-28,March 2017,2017-03-31,December 2010,Actual,2010-12-31,April 2010,Actual,2010-04-30,,Interventional,,,Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid,Effects of Treatment With Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid,Completed,,Phase 3,100,Actual,McMaster University,,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:43:09.592414,2020-02-01 20:43:09.592414,Hamilton Health Sciences Corporation,Other,rifampicin,Drug
NCT00417482,"ClinicalTrials.gov processed this data on January 31, 2020",2006-12-28,2013-02-11,,2013-03-14,2006-12-28,2007-01-01,Estimate,2013-03-14,2013-04-24,Estimate,,,,2013-03-14,2013-04-24,Estimate,August 2004,,2004-08-31,March 2013,2013-03-31,April 2011,Actual,2011-04-30,April 2011,Actual,2011-04-30,,Interventional,ADAD,,Antipsychotic Discontinuation in Alzheimer's Disease,Antipsychotic Discontinuation in Alzheimer's Disease,Completed,,Phase 4,180,Actual,New York State Psychiatric Institute,Comparisons of adverse events in Phase B were limited by the small sample & the truncated observation period for relapsed subjects. Identification of predictors of relapse after discontinuation of treatment was limited by the small sample.,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:50:35.722713,2020-02-01 20:50:35.722713,New York State Psychiatric Institute,Other,risperidone,Drug
NCT01119638,"ClinicalTrials.gov processed this data on January 31, 2020",2010-05-06,,,2015-06-23,2010-05-06,2010-05-07,Estimate,,,,,,,2015-06-23,2015-06-24,Estimate,April 2008,,2008-04-30,June 2015,2015-06-30,May 2010,Actual,2010-05-31,April 2010,Actual,2010-04-30,,Interventional,EscBPSD,,Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone,Post Marketing Study of Escitalopram Versus Risperidone for the Treatment of Behavioral and Psychological Symptoms Amongst Alzheimer's Disease Patients,Completed,,Phase 4,40,Actual,Abarbanel Mental Health Center,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:16:52.586627,2020-02-01 17:16:52.586627,Abarbanel Mental Health Center,Other,Risperidone,Drug
NCT00766363,"ClinicalTrials.gov processed this data on January 31, 2020",2008-10-01,2011-06-16,,2012-04-18,2008-10-02,2008-10-03,Estimate,2011-06-16,2011-07-14,Estimate,,,,2012-04-18,2012-04-20,Estimate,October 2008,,2008-10-31,April 2012,2012-04-30,March 2009,Actual,2009-03-31,March 2009,Actual,2009-03-31,,Interventional,,,"Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1b Safety Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Patients With Mild to Moderate Probable Alzheimer's Disease",Completed,,Phase 1,49,Actual,FORUM Pharmaceuticals Inc,,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:04:53.564244,2020-02-01 19:04:53.564244,FORUM Pharmaceuticals Inc,Industry,Rivastigmine,Drug
NCT01183806,"ClinicalTrials.gov processed this data on January 31, 2020",2010-08-16,,,2012-03-19,2010-08-17,2010-08-18,Estimate,,,,,,,2012-03-19,2012-03-20,Estimate,July 2010,,2010-07-31,March 2012,2012-03-31,March 2012,Actual,2012-03-31,January 2012,Actual,2012-01-31,,Interventional,,,Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients,Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients,Completed,,Phase 3,40,Actual,Federal University of Bahia,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 16:57:58.023663,2020-02-01 16:57:58.023663,Federal University of Bahia,Other,Rivastigmine,Drug
NCT00948766,"ClinicalTrials.gov processed this data on January 31, 2020",2009-07-28,2013-01-08,,2013-08-19,2009-07-28,2009-07-29,Estimate,2013-01-08,2013-02-11,Estimate,,,,2013-08-19,2013-08-28,Estimate,July 2009,,2009-07-31,August 2013,2013-08-31,June 2012,Actual,2012-06-30,January 2012,Actual,2012-01-31,,Interventional,ACTION,,"Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44","A 24 Week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study (ENA713DUS44) Comparing the Effects of Rivastigmine Patch 15 cm^2 vs. Rivastigmine Patch 5 cm^2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION) and a 24-week Open-label Extension to Study ENA713DUS44",Completed,,Phase 4,716,Actual,Novartis,,2,,,False,,,,,,,,,,,,,,,,,2020-02-01 18:10:30.542059,2020-02-01 18:10:30.542059,Novartis,Industry,Rivastigmine 13.3 mg/24 h (15 cm^2),Drug
NCT00948766,"ClinicalTrials.gov processed this data on January 31, 2020",2009-07-28,2013-01-08,,2013-08-19,2009-07-28,2009-07-29,Estimate,2013-01-08,2013-02-11,Estimate,,,,2013-08-19,2013-08-28,Estimate,July 2009,,2009-07-31,August 2013,2013-08-31,June 2012,Actual,2012-06-30,January 2012,Actual,2012-01-31,,Interventional,ACTION,,"Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44","A 24 Week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study (ENA713DUS44) Comparing the Effects of Rivastigmine Patch 15 cm^2 vs. Rivastigmine Patch 5 cm^2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION) and a 24-week Open-label Extension to Study ENA713DUS44",Completed,,Phase 4,716,Actual,Novartis,,2,,,False,,,,,,,,,,,,,,,,,2020-02-01 18:10:30.542059,2020-02-01 18:10:30.542059,Novartis,Industry,Rivastigmine 4.6 mg/24 h (5 cm^2),Drug
NCT00948766,"ClinicalTrials.gov processed this data on January 31, 2020",2009-07-28,2013-01-08,,2013-08-19,2009-07-28,2009-07-29,Estimate,2013-01-08,2013-02-11,Estimate,,,,2013-08-19,2013-08-28,Estimate,July 2009,,2009-07-31,August 2013,2013-08-31,June 2012,Actual,2012-06-30,January 2012,Actual,2012-01-31,,Interventional,ACTION,,"Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44","A 24 Week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study (ENA713DUS44) Comparing the Effects of Rivastigmine Patch 15 cm^2 vs. Rivastigmine Patch 5 cm^2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION) and a 24-week Open-label Extension to Study ENA713DUS44",Completed,,Phase 4,716,Actual,Novartis,,2,,,False,,,,,,,,,,,,,,,,,2020-02-01 18:10:30.542059,2020-02-01 18:10:30.542059,Novartis,Industry,Rivastigmine 9.5 mg/24 h (10 cm^2),Drug
NCT01399125,"ClinicalTrials.gov processed this data on January 31, 2020",2011-07-19,2014-05-05,,2014-07-10,2011-07-20,2011-07-21,Estimate,2014-07-10,2014-08-04,Estimate,,,,2014-07-10,2014-08-04,Estimate,July 2011,,2011-07-31,July 2014,2014-07-31,May 2013,Actual,2013-05-31,May 2013,Actual,2013-05-31,,Interventional,,,"A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease","A 24-Week, Randomized, Double-blind, Double-dummy, Parallel-group, Active-controlled Study to Assess the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (Mini-Mental State Examination (MMSE) 10-20)",Completed,,Phase 3,501,Actual,Novartis,,2,,,False,,,,,,,,,,,,,,,,,2020-02-01 15:55:55.772860,2020-02-01 15:55:55.772860,Novartis Pharmaceuticals,Industry,Rivastigmine Capsules,Drug
NCT01399125,"ClinicalTrials.gov processed this data on January 31, 2020",2011-07-19,2014-05-05,,2014-07-10,2011-07-20,2011-07-21,Estimate,2014-07-10,2014-08-04,Estimate,,,,2014-07-10,2014-08-04,Estimate,July 2011,,2011-07-31,July 2014,2014-07-31,May 2013,Actual,2013-05-31,May 2013,Actual,2013-05-31,,Interventional,,,"A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease","A 24-Week, Randomized, Double-blind, Double-dummy, Parallel-group, Active-controlled Study to Assess the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (Mini-Mental State Examination (MMSE) 10-20)",Completed,,Phase 3,501,Actual,Novartis,,2,,,False,,,,,,,,,,,,,,,,,2020-02-01 15:55:55.772860,2020-02-01 15:55:55.772860,Novartis Pharmaceuticals,Industry,Rivastigmine Patch,Drug
NCT02051335,"ClinicalTrials.gov processed this data on January 31, 2020",2014-01-29,2015-05-17,,2016-12-02,2014-01-29,2014-01-31,Estimate,2015-07-20,2015-08-17,Estimate,,,,2016-12-02,2017-02-01,Estimate,January 2014,,2014-01-31,September 2016,2016-09-30,May 2014,Actual,2014-05-31,May 2014,Actual,2014-05-31,,Interventional,,,Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults,"A Randomized, Double-Blind, Placebo Controlled, 4-Period, Cross-Over Study to Evaluate the Effects of Single Oral Administrations of Roflumilast in Combination With Donepezil on Reversing Scopolamine (Hyoscine) Induced Deficits in Psychomotor and Cognitive Function in Healthy Adults",Completed,,Phase 1,27,Actual,AstraZeneca,,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:05:37.068408,2020-02-01 13:05:37.068408,AstraZeneca,Industry,Roflumilast,Drug
NCT02051335,"ClinicalTrials.gov processed this data on January 31, 2020",2014-01-29,2015-05-17,,2016-12-02,2014-01-29,2014-01-31,Estimate,2015-07-20,2015-08-17,Estimate,,,,2016-12-02,2017-02-01,Estimate,January 2014,,2014-01-31,September 2016,2016-09-30,May 2014,Actual,2014-05-31,May 2014,Actual,2014-05-31,,Interventional,,,Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults,"A Randomized, Double-Blind, Placebo Controlled, 4-Period, Cross-Over Study to Evaluate the Effects of Single Oral Administrations of Roflumilast in Combination With Donepezil on Reversing Scopolamine (Hyoscine) Induced Deficits in Psychomotor and Cognitive Function in Healthy Adults",Completed,,Phase 1,27,Actual,AstraZeneca,,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:05:37.068408,2020-02-01 13:05:37.068408,AstraZeneca,Industry,Roflumilast placebo,Drug
NCT00348140,"ClinicalTrials.gov processed this data on January 31, 2020",2006-06-30,2017-04-21,2010-03-29,2017-08-03,2006-06-30,2006-07-04,Estimate,2017-08-03,2017-09-05,Actual,2010-04-22,2010-05-03,Estimate,2017-08-03,2017-09-05,Actual,"July 12, 2006",Actual,2006-07-12,August 2017,2017-08-31,"March 20, 2009",Actual,2009-03-20,"March 20, 2009",Actual,2009-03-20,,Interventional,REFLECT-3,,Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease,"A 54 Week, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Acetylcholinesterase Inhibitors on Cognition and Overall Clinical Response in APOE4-stratified Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 3,1468,Actual,GlaxoSmithKline,,3,,,False,,,,True,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 21:12:00.421890,2020-02-01 21:12:00.421890,GlaxoSmithKline,Industry,Rosiglitazone Extended Release 2mg,Drug
NCT00348309,"ClinicalTrials.gov processed this data on January 31, 2020",2006-06-30,2017-04-21,2010-03-29,2017-10-23,2006-06-30,2006-07-04,Estimate,2017-10-23,2017-11-28,Actual,2010-04-22,2010-05-03,Estimate,2017-10-23,2017-11-28,Actual,"July 6, 2006",,2006-07-06,September 2017,2017-09-30,"January 28, 2009",Actual,2009-01-28,"January 1, 2009",Actual,2009-01-01,,Interventional,REFLECT-2,,Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease,"A 54-week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Donepezil on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects With Mild to Moderate Alzheimer's Disease.",Completed,,N/A,1496,Actual,GlaxoSmithKline,,3,,,False,,,,True,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 21:11:56.425754,2020-02-01 21:11:56.425754,GlaxoSmithKline,Industry,Rosiglitazone Extended Release 2mg,Drug
NCT00348140,"ClinicalTrials.gov processed this data on January 31, 2020",2006-06-30,2017-04-21,2010-03-29,2017-08-03,2006-06-30,2006-07-04,Estimate,2017-08-03,2017-09-05,Actual,2010-04-22,2010-05-03,Estimate,2017-08-03,2017-09-05,Actual,"July 12, 2006",Actual,2006-07-12,August 2017,2017-08-31,"March 20, 2009",Actual,2009-03-20,"March 20, 2009",Actual,2009-03-20,,Interventional,REFLECT-3,,Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease,"A 54 Week, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Acetylcholinesterase Inhibitors on Cognition and Overall Clinical Response in APOE4-stratified Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 3,1468,Actual,GlaxoSmithKline,,3,,,False,,,,True,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 21:12:00.421890,2020-02-01 21:12:00.421890,GlaxoSmithKline,Industry,Rosiglitazone Extended Release 8mg,Drug
NCT00348309,"ClinicalTrials.gov processed this data on January 31, 2020",2006-06-30,2017-04-21,2010-03-29,2017-10-23,2006-06-30,2006-07-04,Estimate,2017-10-23,2017-11-28,Actual,2010-04-22,2010-05-03,Estimate,2017-10-23,2017-11-28,Actual,"July 6, 2006",,2006-07-06,September 2017,2017-09-30,"January 28, 2009",Actual,2009-01-28,"January 1, 2009",Actual,2009-01-01,,Interventional,REFLECT-2,,Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease,"A 54-week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Donepezil on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects With Mild to Moderate Alzheimer's Disease.",Completed,,N/A,1496,Actual,GlaxoSmithKline,,3,,,False,,,,True,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 21:11:56.425754,2020-02-01 21:11:56.425754,GlaxoSmithKline,Industry,Rosiglitazone Extended Release 8mg,Drug
NCT03250741,"ClinicalTrials.gov processed this data on January 31, 2020",2017-08-11,,,2018-12-14,2017-08-11,2017-08-16,Actual,,,,,,,2018-12-14,2018-12-17,Actual,June 2016,Actual,2016-06-30,December 2018,2018-12-31,November 2018,Actual,2018-11-30,November 2018,Actual,2018-11-30,,Interventional,DOPAD,,Effects of Dopaminergic Therapy in Patients With Alzheimer's Disease,"Effects of Dopaminergic Therapy in Patients With Alzheimer's Disease: a Phase II 24-week, Randomized, Double-blind Placebo Controlled Study.",Completed,,Phase 2,94,Actual,I.R.C.C.S. Fondazione Santa Lucia,,2,,,False,,,,False,False,,,,False,,,,,,Undecided,,2020-02-01 08:52:51.999359,2020-02-01 08:52:51.999359,I.R.C.C.S. Fondazione Santa Lucia,Other,Rotigotine transdermal patch,Drug
NCT03462121,"ClinicalTrials.gov processed this data on January 31, 2020",2018-02-16,,,2019-06-13,2018-03-08,2018-03-12,Actual,,,,,,,2019-06-13,2019-06-14,Actual,"March 1, 2018",Actual,2018-03-01,June 2019,2019-06-30,"July 30, 2020",Anticipated,2020-07-30,"December 28, 2019",Anticipated,2019-12-28,,Interventional,,,A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease,"A 6-Month, Double-Blind, Phase 2 Study and 6-Month Open- Label Extension Evaluating the Safety, Tolerability, and Clinical Benefit of RPh201 in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease",Recruiting,,Phase 2,81,Anticipated,Regenera Pharma Ltd,,2,,,False,,,,,False,False,,,,,,,,,Undecided,,2020-02-01 08:16:25.807860,2020-02-01 08:16:25.807860,Regenera Pharma Ltd,Industry,RPh201,Drug
NCT02585934,"ClinicalTrials.gov processed this data on January 31, 2020",2015-10-22,2018-09-30,,2018-11-08,2015-10-22,2015-10-26,Estimate,2018-11-08,2018-12-05,Actual,,,,2018-11-08,2018-12-05,Actual,October 2015,Actual,2015-10-31,November 2018,2018-11-30,September 2017,Actual,2017-09-30,September 2017,Actual,2017-09-30,,Interventional,,ITT population,Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study,"A Phase 3, Double-blind, Randomized Study of RVT-101 Versus Placebo When Added to Existing Stable Donepezil Treatment in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 3,1315,Actual,Axovant Sciences Ltd.,,2,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 11:01:27.758831,2020-02-01 11:01:27.758831,Axovant Sciences Ltd.,Industry,RVT-101,Drug
NCT02910102,"ClinicalTrials.gov processed this data on January 31, 2020",2016-09-16,,,2017-12-22,2016-09-19,2016-09-21,Estimate,,,,,,,2017-12-22,2017-12-27,Actual,October 2016,Actual,2016-10-31,December 2017,2017-12-31,November 2017,Actual,2017-11-30,November 2017,Actual,2017-11-30,,Interventional,,,Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia,"A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia",Completed,,Phase 2,38,Actual,Axovant Sciences Ltd.,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 09:57:01.127041,2020-02-01 09:57:01.127041,Axovant Sciences Ltd.,Industry,RVT-101 35 mg,Drug
NCT02626572,"ClinicalTrials.gov processed this data on January 31, 2020",2015-11-04,,,2018-08-13,2015-12-07,2015-12-10,Estimate,,,,,,,2018-08-13,2018-08-15,Actual,February 2015,,2015-02-28,August 2018,2018-08-31,September 2017,Actual,2017-09-30,September 2017,Actual,2017-09-30,,Interventional,,,Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms,"Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms. A 24-week International, Multi-centre, Randomized, Double-blind, Placebo-controlled Phase II Study in Monotherapy Followed by an Optional 28-week Extension Period in Co-administration With Donepezil.",Completed,,Phase 2,500,Anticipated,Servier,,4,,,False,,,,True,,,,,,,,After Marketing Authorisation in EEA or US if the study is used for the approval.,Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.,http://clinicaltrials.servier.com,Yes,"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).
They can ask all interventional clinical studies:
submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope.",2020-02-01 10:52:59.050457,2020-02-01 10:52:59.050457,Institut de Recherches Internationales Servier,Other,S47445 15mg,Drug
NCT02626572,"ClinicalTrials.gov processed this data on January 31, 2020",2015-11-04,,,2018-08-13,2015-12-07,2015-12-10,Estimate,,,,,,,2018-08-13,2018-08-15,Actual,February 2015,,2015-02-28,August 2018,2018-08-31,September 2017,Actual,2017-09-30,September 2017,Actual,2017-09-30,,Interventional,,,Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms,"Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms. A 24-week International, Multi-centre, Randomized, Double-blind, Placebo-controlled Phase II Study in Monotherapy Followed by an Optional 28-week Extension Period in Co-administration With Donepezil.",Completed,,Phase 2,500,Anticipated,Servier,,4,,,False,,,,True,,,,,,,,After Marketing Authorisation in EEA or US if the study is used for the approval.,Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.,http://clinicaltrials.servier.com,Yes,"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).
They can ask all interventional clinical studies:
submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope.",2020-02-01 10:52:59.050457,2020-02-01 10:52:59.050457,Institut de Recherches Internationales Servier,Other,S47445 50mg,Drug
NCT02626572,"ClinicalTrials.gov processed this data on January 31, 2020",2015-11-04,,,2018-08-13,2015-12-07,2015-12-10,Estimate,,,,,,,2018-08-13,2018-08-15,Actual,February 2015,,2015-02-28,August 2018,2018-08-31,September 2017,Actual,2017-09-30,September 2017,Actual,2017-09-30,,Interventional,,,Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms,"Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms. A 24-week International, Multi-centre, Randomized, Double-blind, Placebo-controlled Phase II Study in Monotherapy Followed by an Optional 28-week Extension Period in Co-administration With Donepezil.",Completed,,Phase 2,500,Anticipated,Servier,,4,,,False,,,,True,,,,,,,,After Marketing Authorisation in EEA or US if the study is used for the approval.,Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.,http://clinicaltrials.servier.com,Yes,"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).
They can ask all interventional clinical studies:
submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope.",2020-02-01 10:52:59.050457,2020-02-01 10:52:59.050457,Institut de Recherches Internationales Servier,Other,S47445 5mg,Drug
NCT01436045,"ClinicalTrials.gov processed this data on January 31, 2020",2011-09-16,2015-04-09,,2015-09-25,2011-09-16,2011-09-19,Estimate,2015-09-25,2015-10-19,Estimate,,,,2015-09-25,2015-10-19,Estimate,September 2011,,2011-09-30,September 2015,2015-09-30,June 2013,Actual,2013-06-30,June 2013,Actual,2013-06-30,,Interventional,,,Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.,"A Double-Blind, Placebo-Controlled Single Dose Study of the Safety and Efficacy of Glulisine on Cognitive Function and Memory in Individuals Diagnosed With Probable Mild to Moderate Alzheimer's Disease/Intranasal Insulin Study.",Completed,,Phase 2,12,Actual,HealthPartners Institute,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:46:57.736752,2020-02-01 15:46:57.736752,HealthPartners Institute,Other,Saline,Drug
NCT01595646,"ClinicalTrials.gov processed this data on January 31, 2020",2012-05-08,2017-04-17,,2018-04-23,2012-05-09,2012-05-10,Estimate,2018-01-05,2018-02-01,Actual,,,,2018-04-23,2018-05-22,Actual,November 2011,Actual,2011-11-30,April 2018,2018-04-30,"March 12, 2015",Actual,2015-03-12,"March 12, 2015",Actual,2015-03-12,,Interventional,SL120,,Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120),Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120),Completed,,Phase 2,37,Actual,Wake Forest University Health Sciences,,3,,,False,,,,True,True,False,,,,,,,,,No,There is no plan to share individual participant data with other researchers.,2020-02-01 15:05:56.020319,2020-02-01 15:05:56.020319,Wake Forest University Health Sciences,Other,Saline,Drug
NCT00110552,"ClinicalTrials.gov processed this data on January 31, 2020",2005-05-10,,,2014-10-27,2005-05-10,2005-05-11,Estimate,,,,,,,2014-10-27,2014-10-29,Estimate,July 2005,,2005-07-31,October 2014,2014-10-31,October 2014,Actual,2014-10-31,December 2012,Actual,2012-12-31,,Interventional,,,Effects of Sage on Memory and Mental Performance in Alzheimer's Disease Patients,Effects of a Cognitive Enhancer on Memory and Cognitive Performance,Completed,,Phase 1,111,Actual,Oregon Health and Science University,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:14:39.997030,2020-02-01 22:14:39.997030,Oregon Health and Science University,Other,Salvia officinalis (sage),Drug
NCT01266525,"ClinicalTrials.gov processed this data on January 31, 2020",2010-12-23,,2016-02-12,2016-02-12,2010-12-23,2010-12-24,Estimate,,,,2016-02-12,2016-03-14,Estimate,2016-02-12,2016-03-14,Estimate,February 2011,,2011-02-28,February 2016,2016-02-29,January 2013,Actual,2013-01-31,January 2013,Actual,2013-01-31,,Interventional,,,Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil,"A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy",Completed,,Phase 2,291,Actual,Sanofi,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:32:09.069267,2020-02-01 16:32:09.069267,Sanofi,Industry,SAR110894,Drug
NCT01864655,"ClinicalTrials.gov processed this data on January 31, 2020",2013-05-08,,,2014-06-12,2013-05-28,2013-05-29,Estimate,,,,,,,2014-06-12,2014-06-13,Estimate,July 2013,,2013-07-31,June 2014,2014-06-30,,,,March 2014,Actual,2014-03-31,,Interventional,,,Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease,"A Phase Ib Multiple Ascending Dose Study of the Safety, Tolerability, and CNS Availability of AZD0530 in Alzheimer's Disease",Completed,,Phase 1,24,Actual,Yale University,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:55:28.062074,2020-02-01 13:55:28.062074,Stephen M. Strittmatter,Other,saracatinib,Drug
NCT02667496,"ClinicalTrials.gov processed this data on January 31, 2020",2016-01-26,,,2017-04-05,2016-01-28,2016-01-29,Estimate,,,,,,,2017-04-05,2017-04-07,Actual,November 2016,,2016-11-30,April 2017,2017-04-30,"March 31, 2017",Actual,2017-03-31,"March 31, 2017",Actual,2017-03-31,,Interventional,,,Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease,A Study Examining the Safety and Activity of Innate Immune System Stimulation With Leukine® (Sargramostim) to Reduce Brain Amyloid Load in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease,Withdrawn,,Phase 2,0,Actual,Sanofi,,2,,Slow recruitment,False,,,,True,,,,,,,,,,,,,2020-02-01 10:44:33.482652,2020-02-01 10:44:33.482652,Sanofi,Industry,Sargramostim GZ402664,Drug
NCT02051335,"ClinicalTrials.gov processed this data on January 31, 2020",2014-01-29,2015-05-17,,2016-12-02,2014-01-29,2014-01-31,Estimate,2015-07-20,2015-08-17,Estimate,,,,2016-12-02,2017-02-01,Estimate,January 2014,,2014-01-31,September 2016,2016-09-30,May 2014,Actual,2014-05-31,May 2014,Actual,2014-05-31,,Interventional,,,Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults,"A Randomized, Double-Blind, Placebo Controlled, 4-Period, Cross-Over Study to Evaluate the Effects of Single Oral Administrations of Roflumilast in Combination With Donepezil on Reversing Scopolamine (Hyoscine) Induced Deficits in Psychomotor and Cognitive Function in Healthy Adults",Completed,,Phase 1,27,Actual,AstraZeneca,,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:05:37.068408,2020-02-01 13:05:37.068408,AstraZeneca,Industry,Scopolamine,Drug
NCT03289143,"ClinicalTrials.gov processed this data on January 31, 2020",2017-09-18,,,2020-01-06,2017-09-18,2017-09-20,Actual,,,,,,,2020-01-06,2020-01-09,Actual,"October 4, 2017",Actual,2017-10-04,January 2020,2020-01-31,"September 20, 2022",Anticipated,2022-09-20,"June 24, 2020",Anticipated,2020-06-24,,Interventional,,,A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease,"A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Prodromal to Mild Alzheimer's Disease","Active, not recruiting",,Phase 2,457,Actual,"Genentech, Inc.",,4,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:45:33.720811,2020-02-01 08:45:33.720811,"Genentech, Inc.",Industry,Semorinemab,Drug
NCT03828747,"ClinicalTrials.gov processed this data on February 06, 2020",2019-01-29,,,2020-02-04,2019-01-31,2019-02-04,Actual,,,,,,,2020-02-04,2020-02-06,Estimate,"January 30, 2019",Actual,2019-01-30,February 2020,2020-02-29,"June 2, 2023",Anticipated,2023-06-02,"May 7, 2021",Anticipated,2021-05-07,,Interventional,,,A Study of Semorinemab in Patients With Moderate Alzheimer's Disease,"A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Moderate Alzheimer's Disease",Recruiting,,Phase 2,260,Anticipated,"Genentech, Inc.",,2,,,False,,,,True,True,False,,,,,,,,,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)",2020-02-07 05:56:24.743317,2020-02-07 05:56:24.743317,"Genentech, Inc.",Industry,Semorinemab,Drug
NCT00086138,"ClinicalTrials.gov processed this data on January 31, 2020",2004-06-25,2016-03-08,,2017-02-28,2004-06-25,2004-06-28,Estimate,2017-02-28,2017-04-11,Actual,,,,2017-02-28,2017-04-11,Actual,July 2004,,2004-07-31,February 2017,2017-02-28,July 2009,Actual,2009-07-31,July 2008,Actual,2008-07-31,,Interventional,DIADS-2,,Depression in Alzheimer's Disease-2,Depression in Alzheimer's Disease (DIADS-2),Completed,,Phase 2/Phase 3,131,Actual,Johns Hopkins University,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:24:18.842269,2020-02-01 22:24:18.842269,Johns Hopkins University,Other,Sertraline (Zoloft),Drug
NCT00443417,"ClinicalTrials.gov processed this data on January 31, 2020",2007-03-05,,,2009-12-08,2007-03-05,2007-03-06,Estimate,,,,,,,2009-12-08,2009-12-09,Estimate,April 2007,,2007-04-30,January 2008,2008-01-31,January 2009,Actual,2009-01-31,January 2009,Actual,2009-01-31,,Interventional,,,A Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease,Dose Finding Study to Assess the Efficacy and Safety of SK-PC-B70M in Patients With Mild to Moderate Alzheimer's Disease,Completed,,Phase 2,188,Anticipated,"SK Chemicals Co., Ltd.",,4,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:41:35.760128,2020-02-01 20:41:35.760128,"SK Chemicals Co., Ltd.",Industry,SK-PC-B70M,Drug
NCT01249196,"ClinicalTrials.gov processed this data on January 31, 2020",2010-11-23,,,2013-11-25,2010-11-24,2010-11-29,Estimate,,,,,,,2013-11-25,2013-11-26,Estimate,May 2010,,2010-05-31,November 2010,2010-11-30,,,,August 2013,Actual,2013-08-31,,Interventional,,,A Confirmatory Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease,,Completed,,Phase 3,256,Anticipated,"SK Chemicals Co., Ltd.",,4,,,False,,,,,,,,,,,,,,,,,2020-02-01 16:37:39.761131,2020-02-01 16:37:39.761131,"SK Chemicals Co., Ltd.",Industry,SK-PC-B70M,Drug
NCT01760005,"ClinicalTrials.gov processed this data on January 31, 2020",2012-12-26,,,2019-10-01,2012-12-31,2013-01-03,Estimate,,,,,,,2019-10-01,2019-10-03,Actual,December 2012,,2012-12-31,October 2019,2019-10-31,March 2021,Anticipated,2021-03-31,December 2020,Anticipated,2020-12-31,,Interventional,DIAN-TU,,Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.,"A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease",Recruiting,,Phase 2/Phase 3,490,Anticipated,Washington University School of Medicine,,5,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:23:00.489600,2020-02-01 14:23:00.489600,Washington University School of Medicine,Other,Solanezumab,Drug
NCT01900665,"ClinicalTrials.gov processed this data on January 31, 2020",2013-07-12,2018-02-16,2016-12-21,2019-09-25,2013-07-12,2013-07-16,Estimate,2018-02-16,2018-03-14,Actual,2016-12-21,2016-12-23,Estimate,2019-09-25,2019-10-09,Actual,July 2013,,2013-07-31,September 2019,2019-09-30,February 2017,Actual,2017-02-28,October 2016,Actual,2016-10-31,,Interventional,EXPEDITION 3,All randomized participants.,Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo,Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo,Terminated,,Phase 3,2129,Actual,Eli Lilly and Company,,2,,Solanezumab did not meet the study's primary endpoint.,False,,,,True,,,,,,,,"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.",A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.,https://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.,2020-02-01 13:45:21.891307,2020-02-01 13:45:21.891307,Eli Lilly and Company,Industry,Solanezumab,Drug
NCT04044131,"ClinicalTrials.gov processed this data on January 31, 2020",2019-07-17,,,2019-07-31,2019-07-31,2019-08-05,Actual,,,,,,,2019-07-31,2019-08-05,Actual,"September 1, 2019",Anticipated,2019-09-01,July 2019,2019-07-31,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,,Interventional,,,Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients,"A Phase 2, Randomized, Placebo Controlled Study to Evaluate the Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) And Parkinson's Disease (PD) Patients",Not yet recruiting,,Phase 2,120,Anticipated,Istanbul Medipol University Hospital,,2,,,False,,,,,False,False,,,,,,,,,,,2020-02-01 06:48:09.330007,2020-02-01 06:48:09.330007,Istanbul Medipol University Hospital,Other,Sorbitol,Drug
NCT00602680,"ClinicalTrials.gov processed this data on January 31, 2020",2008-01-16,,,2009-07-17,2008-01-16,2008-01-28,Estimate,,,,,,,2009-07-17,2009-07-20,Estimate,January 2008,,2008-01-31,July 2009,2009-07-31,July 2008,Actual,2008-07-31,July 2008,Actual,2008-07-31,,Interventional,,,Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease,"A Multicenter, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance and Safety/Tolerability of SSR180711C for 4 Weeks, Using Donepezil as Calibrator, in Patients With Mild Alzheimer's Disease",Terminated,,Phase 2,1,Actual,Sanofi,,5,,Insufficient expected benefit risk,False,,,,True,,,,,,,,,,,,,2020-02-01 19:52:44.951641,2020-02-01 19:52:44.951641,Sanofi,Industry,SSR180711C,Drug
NCT00842673,"ClinicalTrials.gov processed this data on January 31, 2020",2009-02-10,,,2012-06-05,2009-02-10,2009-02-12,Estimate,,,,,,,2012-06-05,2012-06-07,Estimate,February 2009,,2009-02-28,June 2012,2012-06-30,September 2010,Actual,2010-09-30,September 2010,Actual,2010-09-30,,Interventional,,,Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease,"A Double-Blind Placebo-Controlled Preliminary Study of the Efficacy, Safety and Tolerability of ST101 Tablets in the Treatment of Alzheimer's Disease",Completed,,Phase 2,168,Actual,"Sonexa Therapeutics, Inc.",,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:41:39.618333,2020-02-01 18:41:39.618333,"Sonexa Therapeutics, Inc.",Industry,ST101,Drug
NCT00842816,"ClinicalTrials.gov processed this data on January 31, 2020",2009-02-10,,,2012-06-05,2009-02-11,2009-02-12,Estimate,,,,,,,2012-06-05,2012-06-07,Estimate,February 2009,,2009-02-28,June 2012,2012-06-30,May 2011,Actual,2011-05-31,May 2011,Actual,2011-05-31,,Interventional,,,Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease,"A Double-Blind Placebo-Controlled Preliminary Study of the Efficacy, Safety and Tolerability of ST101 Tablets in the Treatment of Alzheimer's Disease in Subjects Concurrently Receiving Donepezil (Aricept®)",Completed,,Phase 2,210,Actual,"Sonexa Therapeutics, Inc.",,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:41:36.501371,2020-02-01 18:41:36.501371,"Sonexa Therapeutics, Inc.",Industry,ST101,Drug
NCT01255046,"ClinicalTrials.gov processed this data on January 31, 2020",2010-12-03,,,2014-08-19,2010-12-05,2010-12-07,Estimate,,,,,,,2014-08-19,2014-08-20,Estimate,December 2015,,2015-12-31,August 2014,2014-08-31,,,,December 2018,Anticipated,2018-12-31,,Interventional,,,Study of STA-1 as an Add-on Treatment to Donepezil,"A Phase II Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of STA-1 as an Add-on Treatment to Donepezil in Patients With Mild to Moderate Alzheimer's Disease",Unknown status,Not yet recruiting,Phase 2,136,Anticipated,"Sinphar Pharmaceutical Co., Ltd",,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:35:48.924341,2020-02-01 16:35:48.924341,"Sinphar Pharmaceutical Co., Ltd",Other,STA-1,Drug
NCT02580305,"ClinicalTrials.gov processed this data on January 31, 2020",2015-10-17,,,2019-11-15,2015-10-17,2015-10-20,Estimate,,,,,,,2019-11-15,2019-11-18,Actual,September 2015,,2015-09-30,November 2019,2019-11-30,"November 7, 2019",Actual,2019-11-07,"November 5, 2019",Actual,2019-11-05,,Interventional,,,SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study,"A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride",Completed,,Phase 2,563,Actual,Suven Life Sciences Limited,,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:02:59.952283,2020-02-01 11:02:59.952283,Suven Life Sciences Limited,Industry,SUVN-502,Drug
NCT00663936,"ClinicalTrials.gov processed this data on January 31, 2020",2008-04-18,,2012-12-09,2013-10-09,2008-04-21,2008-04-22,Estimate,,,,2012-12-10,2012-12-12,Estimate,2013-10-09,2013-11-05,Estimate,April 2008,,2008-04-30,December 2012,2012-12-31,June 2011,Actual,2011-06-30,May 2011,Actual,2011-05-31,,Interventional,,,Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease,"A Phase 2a Multi-center, Randomized, Double Blind, Placebo-controlled Study to Investigate the Efficacy and Safety of T-817MAa in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,373,Actual,"FUJIFILM Toyama Chemical Co., Ltd.",,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:34:29.421057,2020-02-01 19:34:29.421057,"FUJIFILM Toyama Chemical Co., Ltd.",Industry,T-817MA,Drug
NCT04191486,"ClinicalTrials.gov processed this data on February 06, 2020",2019-11-26,,,2020-02-05,2019-12-05,2019-12-09,Actual,,,,,,,2020-02-05,2020-02-06,Estimate,"December 24, 2019",Actual,2019-12-24,February 2020,2020-02-29,October 2022,Anticipated,2022-10-31,September 2022,Anticipated,2022-09-30,,Interventional,,,Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD,"A Phase 2 Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease",Recruiting,,Phase 2,200,Anticipated,"FUJIFILM Toyama Chemical Co., Ltd.",,2,,,False,,,,True,False,False,,,,,,,,,Undecided,Details for sharing data have not been decided yet.,2020-02-07 05:47:54.530500,2020-02-07 05:47:54.530500,"FUJIFILM Toyama Chemical Co., Ltd.",Industry,T-817MA,Drug
NCT02079909,"ClinicalTrials.gov processed this data on January 31, 2020",2014-03-04,2018-05-07,2016-02-23,2019-02-12,2014-03-04,2014-03-06,Estimate,2018-07-12,2018-08-09,Actual,2016-06-22,2016-06-27,Estimate,2019-02-12,2019-02-26,Actual,March 2014,,2014-03-31,February 2019,2019-02-28,"May 5, 2017",Actual,2017-05-05,"May 5, 2017",Actual,2017-05-05,,Interventional,,"The overall numbers of baseline participants display patient numbers in the mITT population, the primary analysis population. The mITT population excludes patients who did not take any study drug or did not perform any efficacy evaluation post-baseline. Thus, the numbers are slightly difference from the ones in the participant flow.",Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202),"A Phase 2 Multi-center, Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,482,Actual,"FUJIFILM Toyama Chemical Co., Ltd.",,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:58:33.435431,2020-02-01 12:58:33.435431,"FUJIFILM Toyama Chemical Co., Ltd.",Industry,T-817MA-H,Drug
NCT02079909,"ClinicalTrials.gov processed this data on January 31, 2020",2014-03-04,2018-05-07,2016-02-23,2019-02-12,2014-03-04,2014-03-06,Estimate,2018-07-12,2018-08-09,Actual,2016-06-22,2016-06-27,Estimate,2019-02-12,2019-02-26,Actual,March 2014,,2014-03-31,February 2019,2019-02-28,"May 5, 2017",Actual,2017-05-05,"May 5, 2017",Actual,2017-05-05,,Interventional,,"The overall numbers of baseline participants display patient numbers in the mITT population, the primary analysis population. The mITT population excludes patients who did not take any study drug or did not perform any efficacy evaluation post-baseline. Thus, the numbers are slightly difference from the ones in the participant flow.",Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202),"A Phase 2 Multi-center, Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,482,Actual,"FUJIFILM Toyama Chemical Co., Ltd.",,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:58:33.435431,2020-02-01 12:58:33.435431,"FUJIFILM Toyama Chemical Co., Ltd.",Industry,T-817MA-L,Drug
NCT02769065,"ClinicalTrials.gov processed this data on January 31, 2020",2016-05-10,2018-05-30,,2019-03-08,2016-05-10,2016-05-11,Estimate,2019-03-08,2019-06-10,Actual,,,,2019-03-08,2019-06-10,Actual,"May 5, 2016",Actual,2016-05-05,March 2019,2019-03-31,"June 8, 2017",Actual,2017-06-08,"June 8, 2017",Actual,2017-06-08,,Interventional,,Safety analysis set (SAS) included all participants who were enrolled and received at least 1 dose of the study drug.,Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants,"A Phase 1 Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Oral Doses of TAK-071 in Healthy Subjects and Subjects With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability and Food Effect of TAK-071 in Healthy Subjects",Terminated,,Phase 1,179,Actual,Takeda,,30,,Terminated prematurely as data from cohort no longer needed due to indication change.,False,,,,False,True,False,,,,,,,,,,,2020-02-01 10:23:19.348529,2020-02-01 10:23:19.348529,Takeda,Industry,TAK-071,Drug
NCT02769065,"ClinicalTrials.gov processed this data on January 31, 2020",2016-05-10,2018-05-30,,2019-03-08,2016-05-10,2016-05-11,Estimate,2019-03-08,2019-06-10,Actual,,,,2019-03-08,2019-06-10,Actual,"May 5, 2016",Actual,2016-05-05,March 2019,2019-03-31,"June 8, 2017",Actual,2017-06-08,"June 8, 2017",Actual,2017-06-08,,Interventional,,Safety analysis set (SAS) included all participants who were enrolled and received at least 1 dose of the study drug.,Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants,"A Phase 1 Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Oral Doses of TAK-071 in Healthy Subjects and Subjects With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability and Food Effect of TAK-071 in Healthy Subjects",Terminated,,Phase 1,179,Actual,Takeda,,30,,Terminated prematurely as data from cohort no longer needed due to indication change.,False,,,,False,True,False,,,,,,,,,,,2020-02-01 10:23:19.348529,2020-02-01 10:23:19.348529,Takeda,Industry,TAK-071 Placebo,Drug
NCT01120002,"ClinicalTrials.gov processed this data on January 31, 2020",2010-04-30,,,2011-07-21,2010-05-07,2010-05-10,Estimate,,,,,,,2011-07-21,2011-07-22,Estimate,May 2010,,2010-05-31,July 2011,2011-07-31,December 2012,Anticipated,2012-12-31,December 2012,Anticipated,2012-12-31,,Interventional,,,Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's Disease,,Unknown status,Recruiting,Phase 2,50,Anticipated,Osaka City University,,2,,,False,,,,,,,,,,,,,,,,,2020-02-01 17:16:39.773727,2020-02-01 17:16:39.773727,Osaka City University,Other,Tamibarotene,Drug
NCT00539305,"ClinicalTrials.gov processed this data on January 31, 2020",2007-10-03,2013-03-15,,2014-07-10,2007-10-03,2007-10-04,Estimate,2014-07-10,2014-07-14,Estimate,,,,2014-07-10,2014-07-14,Estimate,July 2009,,2009-07-31,July 2014,2014-07-31,May 2012,Actual,2012-05-31,July 2011,Actual,2011-07-31,,Interventional,HIP,,Hormone and Information Processing Study,Testosterone Supplementation in Men With MCI,Completed,,Phase 3,22,Actual,University of Washington,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:12:13.088046,2020-02-01 20:12:13.088046,University of Washington,Other,testosterone gel,Drug
NCT03698695,"ClinicalTrials.gov processed this data on January 31, 2020",2018-10-02,,,2020-01-21,2018-10-03,2018-10-09,Actual,,,,,,,2020-01-21,2020-01-22,Actual,"September 27, 2018",Actual,2018-09-27,January 2020,2020-01-31,"December 20, 2019",Actual,2019-12-20,"October 20, 2019",Actual,2019-10-20,,Interventional,,,"A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers","A Double Blind, Placebo-controlled, Randomized, 15-day Treatment, Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil Administered Orally to Healthy Male Volunteers Including a Scopolamine Challenge",Completed,,Phase 1,152,Actual,Theranexus,,3,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 07:39:11.698156,2020-02-01 07:39:11.698156,Theranexus,Industry,THN 201,Drug
NCT01350362,"ClinicalTrials.gov processed this data on January 31, 2020",2011-05-06,,,2012-10-01,2011-05-06,2011-05-09,Estimate,,,,,,,2012-10-01,2012-10-02,Estimate,April 2011,,2011-04-30,October 2012,2012-10-31,October 2012,Actual,2012-10-31,July 2012,Actual,2012-07-31,,Interventional,ARGO,,"Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients","A Multicenter, Randomized, Double-blind, Placebo-controlled, 4-arm, 26 Week Parallel-Group Study to Evaluate Efficacy, Safety and Tolerability of 2 Oral Doses and 2 Regimes of Tideglusib vs Placebo in Mild-to-Moderate AD Patients",Completed,,Phase 2,306,Actual,Noscira SA,,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:08:35.589262,2020-02-01 16:08:35.589262,Noscira SA,Industry,tideglusib,Drug
NCT00066157,"ClinicalTrials.gov processed this data on January 31, 2020",2003-08-04,,,2018-08-22,2003-08-04,2003-08-05,Estimate,,,,,,,2018-08-22,2018-08-23,Actual,September 2001,,2001-09-30,August 2018,2018-08-31,December 2007,Actual,2007-12-31,December 2007,Actual,2007-12-31,,Interventional,,,Alzheimer's Disease: Therapeutic Potential of Estrogen,Alzheimer's Disease: Therapeutic Potential of Estrogen,Completed,,Phase 2/Phase 3,42,Actual,"University of Wisconsin, Madison",,4,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:32:28.672051,2020-02-01 22:32:28.672051,"University of Wisconsin, Madison",Other,Transdermal estradiol,Drug
NCT04187547,"ClinicalTrials.gov processed this data on February 06, 2020",2019-11-29,,,2020-02-04,2019-12-03,2019-12-05,Actual,,,,,,,2020-02-04,2020-02-06,Estimate,"July 31, 2020",Anticipated,2020-07-31,February 2020,2020-02-29,"December 31, 2022",Anticipated,2022-12-31,"September 30, 2022",Anticipated,2022-09-30,,Interventional,,,A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension,"A 20-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Trial to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin as AC-SD-03 in Subjects With Mild to Moderately Severe Probable Alzheimer's Disease and Who Are Non-carriers of the APOE4 Allele With an Optional 30-Week Open Label Extension",Not yet recruiting,,Phase 3,300,Anticipated,Cerecin,,2,,,False,,,,True,True,False,,,,,,,,,,,2020-02-07 05:47:57.344149,2020-02-07 05:47:57.344149,Cerecin,Industry,Tricaprilin,Drug
NCT00515333,"ClinicalTrials.gov processed this data on January 31, 2020",2007-08-10,,,2008-02-19,2007-08-10,2007-08-13,Estimate,,,,,,,2008-02-19,2008-02-20,Estimate,August 2004,,2004-08-31,February 2008,2008-02-29,December 2007,Actual,2007-12-31,December 2007,Actual,2007-12-31,,Interventional,,,TRx0014 in Patients With Mild or Moderate Alzheimer's Disease,"An Exploratory Placebo-Controlled, Dose-Ranging Study of the Effects of TRx0014 30 MG TID, 60 MG TID AND 100 MG TID in Patients With Mild or Moderate Dementia of the Alzheimer Type",Completed,,Phase 2,323,Actual,TauRx Therapeutics Ltd,,4,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:19:58.910572,2020-02-01 20:19:58.910572,TauRx Therapeutics Ltd,Industry,TRx0014,Drug
NCT01626391,"ClinicalTrials.gov processed this data on January 31, 2020",2012-06-20,2014-04-28,,2014-06-10,2012-06-20,2012-06-22,Estimate,2014-06-10,2014-07-11,Estimate,,,,2014-06-10,2014-07-11,Estimate,September 2012,,2012-09-30,June 2014,2014-06-30,March 2013,Actual,2013-03-31,March 2013,Actual,2013-03-31,,Interventional,,Safety Population,Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease,"A Double-Blind, Placebo-Controlled, Randomised, 4-Week Safety and Tolerability Study of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease on Pre-Existing Stable Acetylcholinesterase Inhibitor and/or Memantine Therapy",Terminated,,Phase 2,9,Actual,TauRx Therapeutics Ltd,Early termination leading to small numbers of subjects analyzed,2,,This study has been terminated for administrative reasons only.,False,,,,True,,,,,,,,,,,,,2020-02-01 14:58:05.465796,2020-02-01 14:58:05.465796,TauRx Therapeutics Ltd,Industry,TRx0237,Drug
NCT01689246,"ClinicalTrials.gov processed this data on January 31, 2020",2012-09-14,,2018-03-12,2018-03-12,2012-09-20,2012-09-21,Estimate,,,,2018-03-12,2018-03-14,Actual,2018-03-12,2018-03-14,Actual,January 2013,,2013-01-31,March 2018,2018-03-31,November 2015,Actual,2015-11-30,November 2015,Actual,2015-11-30,,Interventional,,,Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 3,891,Actual,TauRx Therapeutics Ltd,,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:41:34.220277,2020-02-01 14:41:34.220277,TauRx Therapeutics Ltd,Industry,TRx0237 150 mg/day,Drug
NCT03446001,"ClinicalTrials.gov processed this data on January 31, 2020",2018-02-08,,,2020-01-22,2018-02-20,2018-02-26,Actual,,,,,,,2020-01-22,2020-01-23,Actual,"January 10, 2018",Actual,2018-01-10,January 2020,2020-01-31,December 2022,Anticipated,2022-12-31,December 2021,Anticipated,2021-12-31,,Interventional,,,Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment,"Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of TRx0237 Monotherapy in Subjects With Alzheimer's Disease Followed by a 12-Month Open-Label Treatment",Recruiting,,Phase 3,450,Anticipated,TauRx Therapeutics Ltd,,3,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:18:55.846673,2020-02-01 08:18:55.846673,TauRx Therapeutics Ltd,Industry,TRx0237 16 mg/day,Drug
NCT01689233,"ClinicalTrials.gov processed this data on January 31, 2020",2012-09-14,,2018-03-12,2018-03-12,2012-09-20,2012-09-21,Estimate,,,,2018-03-12,2018-03-14,Actual,2018-03-12,2018-03-14,Actual,October 2012,,2012-10-31,March 2018,2018-03-31,May 2016,Actual,2016-05-31,May 2016,Actual,2016-05-31,,Interventional,,,Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of TRx0237 in Subjects With Mild Alzheimer's Disease",Completed,,Phase 3,800,Actual,TauRx Therapeutics Ltd,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:41:34.512210,2020-02-01 14:41:34.512210,TauRx Therapeutics Ltd,Industry,TRx0237 200 mg/day,Drug
NCT01689246,"ClinicalTrials.gov processed this data on January 31, 2020",2012-09-14,,2018-03-12,2018-03-12,2012-09-20,2012-09-21,Estimate,,,,2018-03-12,2018-03-14,Actual,2018-03-12,2018-03-14,Actual,January 2013,,2013-01-31,March 2018,2018-03-31,November 2015,Actual,2015-11-30,November 2015,Actual,2015-11-30,,Interventional,,,Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 3,891,Actual,TauRx Therapeutics Ltd,,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:41:34.220277,2020-02-01 14:41:34.220277,TauRx Therapeutics Ltd,Industry,TRx0237 250 mg/day,Drug
NCT03446001,"ClinicalTrials.gov processed this data on January 31, 2020",2018-02-08,,,2020-01-22,2018-02-20,2018-02-26,Actual,,,,,,,2020-01-22,2020-01-23,Actual,"January 10, 2018",Actual,2018-01-10,January 2020,2020-01-31,December 2022,Anticipated,2022-12-31,December 2021,Anticipated,2021-12-31,,Interventional,,,Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment,"Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of TRx0237 Monotherapy in Subjects With Alzheimer's Disease Followed by a 12-Month Open-Label Treatment",Recruiting,,Phase 3,450,Anticipated,TauRx Therapeutics Ltd,,3,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:18:55.846673,2020-02-01 08:18:55.846673,TauRx Therapeutics Ltd,Industry,TRx0237 8 mg/day,Drug
NCT00071721,"ClinicalTrials.gov processed this data on January 31, 2020",2003-10-29,2010-07-06,,2014-09-15,2003-10-30,2003-10-31,Estimate,2010-09-24,2010-10-20,Estimate,,,,2014-09-15,2014-09-25,Estimate,October 2003,,2003-10-31,September 2014,2014-09-30,December 2009,Actual,2009-12-31,February 2009,Actual,2009-02-28,,Interventional,,,Valproate in Dementia (VALID),"A Randomized, Double-Blind, Placebo-Controlled Trial of Valproate to Attenuate the Progression of Alzheimer's Disease (AD)",Completed,,Phase 3,313,Actual,Alzheimer's Disease Cooperative Study (ADCS),,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:30:40.191422,2020-02-01 22:30:40.191422,Alzheimer's Disease Cooperative Study (ADCS),Other,Valproate,Drug
NCT01953601,"ClinicalTrials.gov processed this data on January 31, 2020",2013-09-25,2019-04-15,,2019-05-15,2013-09-25,2013-10-01,Estimate,2019-05-15,2019-05-17,Actual,,,,2019-05-15,2019-05-17,Actual,"November 5, 2013",Actual,2013-11-05,May 2019,2019-05-31,"April 17, 2018",Actual,2018-04-17,"April 17, 2018",Actual,2018-04-17,,Interventional,APECS,,Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019),"A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects With Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD)",Terminated,,Phase 3,1454,Actual,Merck Sharp & Dohme Corp.,,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:31:39.225008,2020-02-01 13:31:39.225008,Merck Sharp & Dohme Corp.,Industry,Verubecestat 12 mg (Parts 1 and 2),Drug
NCT01953601,"ClinicalTrials.gov processed this data on January 31, 2020",2013-09-25,2019-04-15,,2019-05-15,2013-09-25,2013-10-01,Estimate,2019-05-15,2019-05-17,Actual,,,,2019-05-15,2019-05-17,Actual,"November 5, 2013",Actual,2013-11-05,May 2019,2019-05-31,"April 17, 2018",Actual,2018-04-17,"April 17, 2018",Actual,2018-04-17,,Interventional,APECS,,Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019),"A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects With Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD)",Terminated,,Phase 3,1454,Actual,Merck Sharp & Dohme Corp.,,3,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:31:39.225008,2020-02-01 13:31:39.225008,Merck Sharp & Dohme Corp.,Industry,Verubecestat 40 mg (Parts 1 and 2),Drug
NCT01428362,"ClinicalTrials.gov processed this data on January 31, 2020",2011-08-31,,2013-10-23,2013-11-15,2011-08-31,2011-09-05,Estimate,,,,2013-10-23,2013-11-15,Estimate,2013-11-15,2013-12-11,Estimate,August 2011,,2011-08-31,November 2013,2013-11-30,August 2013,Actual,2013-08-31,August 2013,Actual,2013-08-31,,Interventional,AD-201,,VI-1121 for the Treatment Alzheimer's Disease,"A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease",Completed,,Phase 2,61,Actual,"VIVUS, Inc.",,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:49:01.052351,2020-02-01 15:49:01.052351,"VIVUS, Inc.",Industry,VI-1121,Drug
NCT01409694,"ClinicalTrials.gov processed this data on January 31, 2020",2011-08-02,,,2016-09-21,2011-08-03,2011-08-04,Estimate,,,,,,,2016-09-21,2016-09-22,Estimate,September 2011,,2011-09-30,March 2011,2011-03-31,January 2016,Actual,2016-01-31,January 2016,Actual,2016-01-31,,Interventional,AD-IDEA,,Alzheimer's Disease - Input of Vitamin D With mEmantine Assay,Evaluation d'Une stratégie thérapeutique d'Association médicamenteuse Pour la Prise en Charge de la Maladie d'Alzheimer et Des Maladies apparentées au Stade modéré,Completed,,Phase 3,90,Actual,"University Hospital, Angers",,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:53:36.184745,2020-02-01 15:53:36.184745,"University Hospital, Angers",Other,Vitamin D,Drug
NCT01409694,"ClinicalTrials.gov processed this data on January 31, 2020",2011-08-02,,,2016-09-21,2011-08-03,2011-08-04,Estimate,,,,,,,2016-09-21,2016-09-22,Estimate,September 2011,,2011-09-30,March 2011,2011-03-31,January 2016,Actual,2016-01-31,January 2016,Actual,2016-01-31,,Interventional,AD-IDEA,,Alzheimer's Disease - Input of Vitamin D With mEmantine Assay,Evaluation d'Une stratégie thérapeutique d'Association médicamenteuse Pour la Prise en Charge de la Maladie d'Alzheimer et Des Maladies apparentées au Stade modéré,Completed,,Phase 3,90,Actual,"University Hospital, Angers",,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:53:36.184745,2020-02-01 15:53:36.184745,"University Hospital, Angers",Other,Vitamin D placebo,Drug
NCT00056329,"ClinicalTrials.gov processed this data on January 31, 2020",2003-03-10,,,2012-05-02,2003-03-11,2003-03-12,Estimate,,,,,,,2012-05-02,2012-05-04,Estimate,April 2002,,2002-04-30,May 2012,2012-05-31,May 2012,Anticipated,2012-05-31,May 2012,Anticipated,2012-05-31,,Interventional,,,Vitamin E in Aging Persons With Down Syndrome,Multicenter Vitamin E Trial in Aging Persons With Down Syndrome,Unknown status,"Active, not recruiting",Phase 3,350,Actual,New York State Institute for Basic Research,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:35:03.109992,2020-02-01 22:35:03.109992,New York State Institute for Basic Research,Other,Vitamin E,Drug
NCT02423122,"ClinicalTrials.gov processed this data on January 31, 2020",2015-04-14,2018-01-04,,2019-03-13,2015-04-17,2015-04-22,Estimate,2019-03-13,2019-06-14,Actual,,,,2019-03-13,2019-06-14,Actual,April 2015,,2015-04-30,January 2018,2018-01-31,September 2016,Actual,2016-09-30,July 2016,Actual,2016-07-31,,Interventional,,,"A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)","A Clinical Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745, to Evaluate the Effects of 12-Week Oral Twice-Daily Dosing on Amyloid Plaque Load as Assessed by Quantitative Dynamic 11C-PiB Positive Emission Tomography (PET) Amyloid Scanning",Completed,,Phase 2,16,Actual,EIP Pharma Inc,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 11:39:15.660589,2020-02-01 11:39:15.660589,EIP Pharma Inc,Industry,VX-745,Drug
NCT02423200,"ClinicalTrials.gov processed this data on January 31, 2020",2015-04-03,2018-01-02,,2018-04-02,2015-04-17,2015-04-22,Estimate,2018-04-02,2018-04-03,Actual,,,,2018-04-02,2018-04-03,Actual,April 2015,,2015-04-30,April 2018,2018-04-30,November 2016,Actual,2016-11-30,September 2016,Actual,2016-09-30,,Interventional,,,"Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD","A Randomized, Open-Label, Multiple Dose Clinical Pharmacology Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745 in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) or With Mild AD",Completed,,Phase 2,16,Actual,EIP Pharma Inc,,2,,,False,,,,False,,,,,,,,,,,,,2020-02-01 11:39:14.967409,2020-02-01 11:39:14.967409,EIP Pharma Inc,Industry,VX-745,Drug
NCT03435861,"ClinicalTrials.gov processed this data on January 31, 2020",2017-12-22,,,2018-11-19,2018-02-09,2018-02-19,Actual,,,,,,,2018-11-19,2018-11-21,Actual,"October 8, 2018",Actual,2018-10-08,November 2018,2018-11-30,"January 30, 2021",Anticipated,2021-01-30,"January 30, 2020",Anticipated,2020-01-30,,Interventional,VIP,,Effect of Neflamapimod on Brain Inflammation in Alzheimer's Disease Patients,Effect of Neflamapimod (VX-745) on Brain Inflammation Using Positron Emission Tomography (PET) Scan in Alzheimer's Disease (AD) Patients,Recruiting,,Phase 2,40,Anticipated,"University Hospital, Toulouse",,2,,,False,,,,False,False,False,,,,,,,,,No,,2020-02-01 08:20:44.789272,2020-02-01 08:20:44.789272,"University Hospital, Toulouse",Other,VX-745,Drug
NCT00814502,"ClinicalTrials.gov processed this data on January 31, 2020",2008-12-18,2017-02-02,,2017-04-12,2008-12-24,2008-12-25,Estimate,2017-04-12,2017-05-22,Actual,,,,2017-04-12,2017-05-22,Actual,December 2008,,2008-12-31,April 2017,2017-04-30,December 2013,Actual,2013-12-31,December 2013,Actual,2013-12-31,,Interventional,,,Zolpidem CR and Hospitalized Patients With Dementia,Does Zolpidem CR Treatment Change Clinical Outcomes in Elderly Hospitalized Patients With Dementia- A Pilot Study,Completed,,N/A,20,Actual,Massachusetts General Hospital,Small sample size. We were unable to control for different treatments that our subjects received as inpatients.,2,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 18:49:38.034289,2020-02-01 18:49:38.034289,Massachusetts General Hospital,Other,Zolpidem CR,Drug
NCT00423228,"ClinicalTrials.gov processed this data on January 31, 2020",2007-01-17,,,2015-01-13,2007-01-17,2007-01-18,Estimate,,,,,,,2015-01-13,2015-01-14,Estimate,February 2007,,2007-02-28,January 2015,2015-01-31,April 2009,Actual,2009-04-30,April 2009,Actual,2009-04-30,,Interventional,BRAINz,,Efficacy Study of a ZT-1 Implant in Patients Suffering From Alzheimer's Disease,"A Randomised, Double-blind, Double-dummy, Oral Donepezil Controlled Study on the Safety and Efficacy of Repeated Monthly Subcutaneous Injections of a Sustained-release Implant of ZT 1 in Patients With Moderate Alzheimer's Disease",Completed,,N/A,228,Actual,Debiopharm International SA,,2,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:48:39.791345,2020-02-01 20:48:39.791345,Debiopharm International SA,Industry,ZT-1,Drug
NCT01940952,"ClinicalTrials.gov processed this data on January 31, 2020",2013-09-09,,,2013-09-09,2013-09-09,2013-09-12,Estimate,,,,,,,2013-09-09,2013-09-12,Estimate,September 2013,,2013-09-30,September 2013,2013-09-30,,,,August 2015,Anticipated,2015-08-31,,Interventional,,,Zydena on Cognitive Function of Alzheimer's Disease Patients,"Efficacy of Zydena (Udenafil) on Cognitive Function of Alzheimer's Disease Patients: A Randomized, Double Blind, Placebo-controlled Multicenter Study",Unknown status,Not yet recruiting,Phase 3,210,Anticipated,Samsung Medical Center,,3,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:35:04.954668,2020-02-01 13:35:04.954668,Samsung Medical Center,Other,Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg,Drug
NCT01940952,"ClinicalTrials.gov processed this data on January 31, 2020",2013-09-09,,,2013-09-09,2013-09-09,2013-09-12,Estimate,,,,,,,2013-09-09,2013-09-12,Estimate,September 2013,,2013-09-30,September 2013,2013-09-30,,,,August 2015,Anticipated,2015-08-31,,Interventional,,,Zydena on Cognitive Function of Alzheimer's Disease Patients,"Efficacy of Zydena (Udenafil) on Cognitive Function of Alzheimer's Disease Patients: A Randomized, Double Blind, Placebo-controlled Multicenter Study",Unknown status,Not yet recruiting,Phase 3,210,Anticipated,Samsung Medical Center,,3,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:35:04.954668,2020-02-01 13:35:04.954668,Samsung Medical Center,Other,Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg,Drug
